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ABSTRACT OF DISSERTATION RESEARCH

DEVELOPMENT OF ZAFIRLUKAST DERIVATIVES AGAINST
PORPHYROMONAS GINGIVALIS
Periodontal diseases are inflammatory diseases that can lead to damage of the soft tissue
and bone supporting the teeth. Gingivitis is the reversible early stage of gum disease, which
consist of gums that bleed when brushing or flossing teeth. When left untreated, the
preventable but irreversible late stage of periodontal disease, periodontitis, can lead teeth
to loosen or even fall out. Oral bacterial species, such as the Gram-negative anaerobic
pathogen Porphyromonas gingivalis trigger these inflammatory diseases through oral
dysbiosis. P. gingivalis is a keystone pathogen, meaning that the damage caused by P.
gingivalis is not proportional to its abundance. Treatment options for periodontitis includes
scaling and root planing with an antibacterial agent as adjunct treatment to better improve
patient outcomes. The use of broad-spectrum antibacterial agents that do not specially
target pathogenic oral bacterial species has led to bacteria that are less susceptible or even
resistant to the antibiotics currently used. Therefore, we set out to develop novel
antibacterial agents to selectively combat P. gingivalis without disrupting the beneficial
commensal oral bacterial species. The FDA-approved drug zafirlukast (ZAF), used for the
treatment of asthma, was shown to display antibacterial activity against P. gingivalis. In a
previous study, novel 1st generation ZAF derivatives were synthesized and biologically
evaluated and were found to display increased activity against P. gingivalis compared to
the parent compound ZAF. Through structure-activity relationship (SAR) studies we
rationally designed, synthesized, and biologically evaluated novel 2nd and 3rd generation
ZAF derivatives that (i) displayed superior antibacterial activity against P. gingivalis 381
or ATCC 33277 and selective activity with little to no growth inhibition of other oral
bacterial species, (ii) displayed bactericidal activity with the most active compounds
against P. gingivalis, (iii) displayed an increased safety profile with less cytotoxicity
against mammalian cells than ZAF, and (iv) displayed the ability to inhibit P. gingivalis
biofilm growth. These insights lay the foundation for future studies to test their potential
for preventing and treating P. gingivalis-induced periodontal diseases.
KEYWORDS: Oral microbiome species, gum inflammation, oral dysbiosis, periodontal
disease, biofilm, toxicity.
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PREFACE
The following dissertation consists of 6 chapters highlighting the most important projects
of my Ph.D. studies in this dissertation cover the development of novel antimicrobial agents
covering both antibacterial and antifungal agents. These studies aimed at exploring the
derivatization and biological evaluation of ZAF derivatives for use as potential
antibacterial agents (Chapters 1-3) as well as fluconazole (FLC) and piperazine derivatives
for use as potential antifungal agents (Chapters 4-5). The first 5 chapters are adapted or
partially adapted from my previous publications. Chapter 1 provides an in-depth
exploration of oral bacterial species, their interactions with one another, as well as the novel
antibacterial agents used to target P. gingivalis and other pathogenic oral bacterial species.
(Howard, K. C., Gonzalez, O. A., & Garneau-Tsodikova, S.* (2021). Porphyromonas
gingivalis: where do we stand in our battle against this oral pathogen? RSC Med. Chem.,
12, 666-704.) Chapter 2 presents the successful synthesis and improvement of antibacterial
activity of 2nd generation ZAF derivatives against P. gingivalis 381. (Howard, K. C.,
Gonzalez, O. A., & Garneau-Tsodikova, S.* (2020). Second generation of zafirlukast
derivatives with improved activity against the oral pathogen Porphyromonas gingivalis.
ACS Med. Chem. Lett., 11(10), 1905-1912.) Chapter 3 presents the increased selective
antibacterial activity of the 3rd generation ZAF derivatives along with two of the most
active 2nd generation compounds against P. gingivalis ATCC 33277, their increased safety
profile against mammalian cells, and their ability to inhibit P. gingivalis biofilm formation.
(Howard, K. C., & Garneau-Tsodikova, S.* (2022). Third generation zafirlukast
derivatives with the ability to inhibit biofilm growth of Porphyromonas gingivalis.
Manuscript submitted to J. Med. Chem. on September 8th, 2022.) Chapters 4 and 5 cover

xlii

the research performed during the Summer Undergraduate Research program at the UK
College of Pharmacy as well as the research performed during my first two years in
graduate school at UK. As I am a chemist that performs multidisciplinary research, my
researched focused on many areas of science, including the development of antimicrobial
agents that target various bacterial and fungal species. Therefore, Chapters 4 and 5 are
presented to represent the diverse knowledge I obtained during my Ph.D. journey. Chapter
4 covers the synthesis and biological evaluation of novel fluconazole derivatives as
antifungal agents. (Thamban Chandrika, N., Shrestha, S. K., Ngo, H. X., Howard, K. C.,
& Garneau-Tsodikova, S.* (2018). Novel fluconazole derivatives with promising
antifungal activity. Bioorg. Med. Chem., 26(3), 573-580.) Chapter 5 describes the synthesis
and biological evaluation of novel piperazine derivatives as antifungal agents. (Thamban
Chandrika, N., Shrestha, S. K., Ngo, H. X., Howard, K. C., & Garneau-Tsodikova, S.*
(2018). Alkylated piperazines and piperazine-azole hybrids as antifungal agents. J. Med.
Chem., 61(1), 158-173.) Chapter 6 provides the conclusion and future directions to the ZAF
projects discussed in this dissertation.
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Chapter 1
Porphyromonas gingivalis: where do we stand in our battle against this oral
pathogen?

1.1. ABSTRACT
Periodontal diseases, such as gingivitis and periodontitis, are inflammatory diseases
triggered by pathogenic bacteria that lead to damage of the soft tissue and bone supporting
the teeth. Amongst the identified oral periodontopathogenic bacteria, Porphyromonas
gingivalis is able to enhance oral dysbiosis, which is an imbalance in the beneficial
commensal and periodontal pathogenic bacteria that induces chronic inflammation. Given
the critical role of oral pathogenic bacteria like P. gingivalis in the pathogenesis of
periodontitis, local and/or systemic antibacterial therapy has been suggested to treat this
disease, especially in its severe or refractory forms. Nevertheless, the majority of the
antibacterial agents currently used for the treatment of periodontal diseases are broadspectrum, which harms beneficial bacterial species that are critical in health, inhibit the
growth of pathogenic bacteria, contribute in protecting the periodontal tissues to damage
and aid in its healing. Thus, the development of more effective and specific antibacterial
agents is needed to control oral pathogens in a polymicrobial environment. The strategies
for the development of novel antibacterial agents include natural product isolation as well
as synthetic and semi-synthetic methodologies. This review presents an overview of the
periodontal diseases gingivitis and periodontitis along with current antibacterial treatment
options (i.e., classes of antibacterial agents and the mechanism(s) of resistance that hinder
their usage) used in periodontal diseases that specifically target oral pathogens such as P.
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gingivalis. In addition, to help medicinal chemists gain a better understanding of potentially
promising scaffolds, this review provides an in-depth coverage of the various families of
small molecules that have been investigated as potential anti-P. gingivalis agents, including
novel families of compounds, repositioned drugs, as well as natural products.

1.2. INTRODUCTION
1.2.1. Periodontal diseases: gingivitis and periodontitis
Periodontal diseases, also known as gum diseases, are inflammatory diseases initiated by
oral pathogenic bacteria, which results in the destruction of the bone and tissue supporting
the tooth (e.g., gingiva, alveolar bone, and periodontal ligament).1-3 Periodontal diseases
comprise the early reversible stage of gum disease, gingivitis, which causes red and swollen
gums that bleed when brushing or flossing teeth. When left untreated, this can lead to the
severe form of gum disease, periodontitis, which can cause irreversible damage potentially
leading to tooth loss. In the United States, 64.7 million adults over the age of 30 have
periodontitis.4-6 There are treatment options for periodontitis such as removal/debridement
of subgingival dental plaque, surgery to remove the infected tissue and antibiotics, but the
lack of clear guidelines for choosing an antibiotic that selectively targets pathogenic
bacteria can lead to the development of antibiotic resistance by some bacterial species (see
sections 1.3.1-1.3.2). In general, there is an increasing interest in expanding the knowledge
and arsenal of antibacterial agents, as demonstrated by the steady increase in publications
related to antibacterial research in the last 80 years (Figure 1.1).
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Figure 1.1. Graph displaying the number of publications related to antibacterial research published per year
from 1905 to January 2020.

Additionally, there are some interesting reviews that discuss current antibacterial agents
clinically used to treat periodontal diseases such as periodontitis along with a few novel
non-approved molecules (Figure 1.2). However, few of them discuss the drug discovery
and development of novel antibacterial agents used to target specific periodontal pathogens
along with where treatment is heading in the future. The goal of the current review is to fill
that gap. In order to combat antibacterial resistance, the future of medicine should head
towards the discovery of novel antibiotics, which target specific pathogenic bacteria
causing the diseases, without significantly perturbing the presence of commensal bacteria
critical for health and homeostasis. The periodontopathogenic Gram-negative anaerobic
bacterium Porphyromonas gingivalis is a major keystone pathogen associated with
periodontitis capable of causing tissue damage and invading the weakened epithelial cell
layers leading to systemic diseases in the same way as other pathogenic bacteria, such as
Aggregatibacter actinomycetemcomitans, Tannerella forsythia, Prevotella intermedia, and
Fusobacterium nucleatum.7, 8 Of note, these bacterial species along with other oral bacteria
have been associated with diabetes, Alzheimer’s disease, cardiovascular diseases,
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polycystic ovary syndrome, and rheumatoid arthritis.9-15 Therefore, it is of interest for
researchers to develop novel antibacterial agents that specifically target P. gingivalis. In
order to design and synthesize an antibacterial agent that specifically targets P. gingivalis,
it is critical to understand how this oral pathogen colonizes the oral cavity and interacts
with other pathogenic bacteria in a biofilm (Figure 1.3). In addition, having a deep
knowledge of the breadth of antibacterial agents used to treat periodontal diseases currently
on the market as well as their mechanism(s) of action and bacterial mode(s) of resistance
is important. This review will summarize the copious amount of research articles related
to the discovery and development of novel antibacterial agents used to target P. gingivalis
as treatment options for chronic periodontitis. To provide a thorough overview of where
we stand in our quest for the discovery and development of novel anti-P. gingivalis agents,
in addition to emerging active potential antibacterial agents, this review will discuss
scaffolds found to be inactive against P. gingivalis as well as discuss where future treatment
options are heading. (Note: As most of the studies presented in this review covering the use
of antibacterial agents for the treatment of periodontal diseases were published before the
new classification of periodontal diseases, the terms chronic and aggressive periodontitis,
now simply referred to as one all-encompassing term called “periodontitis”, will be used
in this review).16
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Figure 1.2. Graph displaying the number of reviews published per year from 2010-2019. The various
combination of terms displayed below the graph were searched in PubMed.

1.2.2. Oral biofilms: formation of oral biofilms, oral bacterial species within oral
biofilms, and their organization within oral biofilms
There are over 700 bacterial species found in the oral cavity (including cocci, spirilla,
bacilli, spirochaetes, and vibrios), with only a small number of those bacterial species being
pathogenic leading to inflammation and bone destruction (Table 1.1 and Figure 1.3A).1, 7,
17

Periodontal diseases are caused by the shift of bacterial species in dental plaque from

mostly Gram-positive bacteria, such as Actinomyces and Streptococcus spp., in healthy
gingival to predominantly Gram-negative pathogenic species in periodontal diseases.2
Dental plaque, also known as an oral biofilm, consists of polymicrobial communities
embedded on a tooth surface encased in an extracellular matrix (ECM).17 Oral biofilms
form on the surface of the tooth due to their non-shedding nature that provides microbes,
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such as bacteria, with a favorable environment where they will not be disturbed and can
mature. The volume of oral biofilms is composed of about 20% microorganisms and 80%
ECM (Figure 1.3B). The two main types of oral biofilms are supragingival, above the
gingival margin line associated with dental caries, or subgingival biofilms, below the
gingival margin line associated with periodontal diseases. This review will focus on
pathogenic bacteria, such as P. gingivalis, that reside in subgingival plaque frequently
found in patients with periodontal diseases.

Oral biofilm development begins with association of planktonic bacterial species near the
surface of the tooth (Figure 1.3B). The next stage of development, attachment, is initiated
by the acquired pellicle that is made up of salivary glycoproteins (e.g., phosphate-rich
proteins, proline-rich proteins, mucins, enzymes, etc.)18 adsorbed to the dental surface and
acts as a receptor for early colonizers (Figure 1.3A). Studies show that within as little as
four hours, biofilm formation occurs. These biofilms mainly contain the primary early
colonizers such as Streptococcus spp. (e.g., S. gordonii, S. intermedius, S. mitis, S. oralis,
and S. sanguinis). Streptococcus spp. attach to the acquired pellicle due to their ability to
bind to specific receptors of the acquired pellicle and thrive in aerobic conditions. Oral
bacteria, such as S. sanguinis, have a unique ability to colonize the tooth surface first due
to fimbriae that mediate attachment to the tooth surface along with pili that bind to salivary
components to initiate biofilm formation.19 Once attachment of the early colonizing
Streptococcus spp. occurs with weak binding, they produce an ECM that contains proteins,
nucleic acids, lipids, extracellular DNA, and polysaccharides. The ECM proteins protect
the bacteria and allow them to strongly attach to the acquired pellicle due to their ability to
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mediate cell-cell and cell-surface adhesions to form a structured ECM (Figure 1.3B).19, 20
The components of the ECM are produced by bacteria themselves in addition to saliva and
gingival crevicular fluid. The ECM contains water channels or open areas that carry
nutrients and other agents to the bacteria and carries waste out of the biofilm.1, 21 ECM
proteins allow the biofilm to maintain its structure, protect the bacteria from external
forces, and maintain its integrity. Polysaccharides produced by bacteria colonizing the
biofilm enable the bacteria to adhere to surfaces and other bacterial species.20 The ECM
also allows bacteria to resist antibiotics in various ways: (i) ECM proteins that prevent
antibiotics from reaching bacteria within biofilms, and (ii) transfer of resistance genes (e.g.,
β-lactamase discussed in section 1.3.2) by bacteria that are in close proximity to one
another.

Beneficial commensal oral bacteria along with pathogenic bacteria are seen in healthy and
diseased sites of the oral cavity; the main difference being the proportion of beneficial and
pathogenic bacteria.22 In periodontal health, the Gram-negative pathogenic bacteria are
kept at low concentrations due to the balance of beneficial bacteria controlling the growth
of pathogenic bacteria through antagonistic interactions. A primary example of a
commensal Gram-positive aerobic species prevalent in periodontal health that
counterbalances a pathogenic Gram-negative bacterium is S. sanguinis. Excess O2 is
expelled from S. sanguinis in the form of hydrogen peroxide (H2O2), which acts as an
antimicrobial agent by inhibiting glycolysis or protein synthesis. Increased concentration
of H2O2 results in the growth inhibition of Actinomyces naeslundii, pathogenic/cariogenic
bacteria such as Streptococcus mutans, and the Gram-negative anaerobic pathogenic
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species A. actinomycetemcomitans frequently found in the formerly called localized
aggressive periodontitis.17,

23

Antagonistic interactions by the excretion of H2O2 is

additionally exemplified by S. gordonii inhibiting the growth of A. naeslundii and S.
mutans. S. mutans is not depicted in Figure 1.3A due to the presence of bacterial species S.
oralis that grows rapidly and inhibits the growth of S. mutans and because it is mostly
found in supragingival plaque. There are synergistic interactions where pathogenic
bacterial species protect other bacteria from H2O2 by its consumption through protein
oxidation.17 When cultured without A. actinomycetemcomitans, S. sanguinis inhibits the
growth of the pathogenic bacteria P. gingivalis by secreting H2O2. However, P. gingivalis
is able to grow in the presence of A. actinomycetemcomitans that reduces H2O2 due to
production of the enzyme cytoplasmic catalase by expression of the katA gene.3
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Figure 1.3. A. An overview of the location of commensal and pathogenic bacterial species found in oral
biofilms as early or late Gram-positive and Gram-negative colonizers along with the B. stages of oral biofilm
formation.

Periodontal diseases are initiated by the increase in proportion of pathogenic bacteria where
the level cannot be maintained through antagonistic interactions. Once the disease starts,
the level of pathogenic bacteria can increase due to the positive interactions they have with
each other (i.e., synergism, mutualism, and commensalism), further enhancing progression
of the disease. Synergism is seen with early colonizers of oral biofilms such as Streptococci
and Actinomyces species that are generally non-pathogenic and consume oxygen (Figure
1.3B).7 As the biofilm matures, the environment becomes favorable to more anaerobic
pathogenic bacteria with an oxygen gradient and a flow of nutrients along with horizontal
gene transfer including genes for antibiotic resistance (mechanisms of resistance discussed
in section 1.3.2). The survival of pathogenic bacteria could be enhanced by synergistic
interactions between P. gingivalis and Treponema denticola, which is a motile bacterial
species that can create pores within the biofilm allowing nutrients to flow to P. gingivalis.24
Many of the pathogenic bacteria (e.g., the pairs of P. gingivalis and T. denticola as well as
Tannerella forsythia and Fusobacterium nucleatum) grow better together than they do
apart, which is a relationship known as mutualism. Additionally, the by-product of one
bacterial species can increase the survival of the other bacterial species without affecting
the first bacterial species in the case of P. gingivalis and Campylobacter rectus.

Despite a high and diverse number of oral bacterial species in the oral microbiome, there
are a small number of bacterial species (mainly late colonizers) predominantly found to be
associated with the various forms of periodontal diseases (Table 1.1). Additionally, there
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are a number of factors that can influence the type of bacterial species seen with high
frequency in periodontitis, a major factor being age. In the formerly called localized
aggressive periodontitis (now referred to as periodontitis), found in young children, there
is a high level of A. actinomycetemcomitans. In the generalized form of aggressive
periodontitis, found in individuals younger than 30 years of age, there is however a lower
level of A. actinomycetemcomitans and an increased level of P. gingivalis along with other
species including Campylobacter, Prevotella, Tannerella, and Treponema. In the formerly
called chronic periodontitis (now referred to as periodontitis), the focus of this review,
which develops over a long period of time and is often seen in adults 30 years and older,
the predominant pathogenic bacterial species include Aggregatibacter, Campylobacter,
Eikenella, Fusobacterium, Parvimonas, Porphyromonas, Prevotella, Selenomonas,
Tannerella, and Treponema.1

The concentration of bacterial species in saliva during periodontal diseases are 108 to 109
bacteria/mL compared to a concentration of 103 during periodontal health.1,

25

In the

subgingival plaque, the major bacterial species found in patients with periodontitis seem to
co-exist in six major complexes: yellow, blue, green, purple, orange, and red.26 Early
colonizers such as Streptococcus spp. are Gram-positive commensal beneficial bacteria
that make up the majority of the bacterial species found in supragingival and subgingival
plaque of healthy periodontal patients and comprise the yellow complex.19 Additional early
colonizers include the Gram-positive facultative anaerobic Actinomyces spp. that are a part
of the blue complex along with the green complex, which contains Eikenella corrodens,
Capnocytophaga ochracea, Capnocytophaga gingivalis, Capnocytophaga sputigena, and
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Campylobacter concisus, as well as the purple complex comprising Actinomyces
odontolyticus and Veillonella parvula.26 Once the members of the yellow, blue, green, and
purple complexes colonize the oral biofilm, the orange complex species (e.g., F.
nucleatum, Eubacterium nodatum, P. intermedia, Prevotella nigrescens, C. rectus,
Campylobacter showae, Peptostreptococcus micros, Campylobacter gracilis, and
Streptococcus constellatus) colonize the biofilm.26 As the environment becomes favorable
to more anaerobic pathogenic bacteria, the red complex comprising P. gingivalis, T.
forsythia, and T. denticola can attach.

Orange and red complexes are closely associated together and facilitate the progression of
periodontal diseases through synergistic interactions. The red complex bacteria are usually
found with those in the orange complex and it is rare to see them without one another in
periodontal pockets associated with periodontal diseases. When the concentration of
orange complex species increases, the amount of red complex species also increases in the
oral biofilm. F. nucleatum is a Gram-negative anaerobic bacterium that acts as a bridge
between early and late colonizers of oral biofilms. Although there may be an increased
presence of oxygen that would normally inhibit the growth of anaerobic bacteria, F.
nucleatum provides a microenvironment with high concentrations of carbon dioxide (CO2)
that facilitates the growth of P. gingivalis by providing a CO2 rich, or capnophilic,
environment for P. gingivalis to thrive in.17, 27 P. gingivalis in culture can survive at O2
levels of 3% and 6%, but if the O2 levels are 10% or more, then P. gingivalis is unable to
grow unless co-cultured with F. nucleatum that creates a CO2 rich environment that P.
gingivalis can survive in even at O2 levels of 10% and 20%.27
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When bacteria colonize a biofilm, changes in their gene expression occur to facilitate gene
transfer, nutritional cooperation, and cell-cell signaling. As the bacterial cell density within
the oral biofilm increases, bacteria communicate through quorum sensing systems where
they release chemical signaling molecules called autoinducers. Once the level of
autoinducers is above a certain threshold, this causes changes in gene expression of the
bacteria within the biofilm (e.g., expression of virulence factors).1 Gram-negative bacteria
in the orange and red complexes are considered pathogenic due to the virulence factors that
destroy the surrounding tissue and aid in invasion of gingival tissue.25 In periodontal health,
the ECM components (e.g., fibronectin, vitronectin, elastin, type I collagen, etc.) that make
up the oral biofilm, are essential for the maintenance and repair of gingival tissues and
periodontal ligament cells damaged by pathogenic bacteria. In particular, the ECM
glycoproteins fibronectin and vitronectin bind to integrins, which are transmembrane
receptor proteins that promote cell-ECM adhesion. This causes cellular signal transduction
that results in the promotion of healing gingival tissues and periodontal ligament cells.
Fibronectin is essential for periodontal ligament cells in terms of rapid reproduction, known
as proliferation, as well as the migration of cells in response to an increase or decrease in
concentration of certain extracellular signals, known as chemotaxis. Vitronectin is involved
in cell adhesion and spreading by protecting gingival connective tissue.28

After the initial attachment of Streptococcus spp. and Actinomyces spp., the development
of the ECM allows these bacterial species to adhere to the acquired pellicle and act as
substrates or binding sites for other early colonizers. Attachment of subsequent bacterial
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species is a highly organized process where specific interactions occur between each
individual cell type. The bacteria within a biofilm not only have to be close together to
form a mature biofilm, they also need to have specific interactions (e.g., exchange of
metabolites and genetic material, physical interactions, and communication through
signaling). Interactions between bacterial species include co-adhesion and co-aggregation.
Co-adhesion includes interactions between bacterial cells attached to a surface recognizing
planktonic cells of a different strain or species. Co-aggregation is a term used to describe
the interactions of planktonic cells recognizing and binding to planktonic cells of a different
strain or species.18, 29, 30 The bacterial species S. oralis and S. sanguinis contain receptors
on their cell surface that bind to adhesion proteins on the surface of other early colonizers,
such as Actinomyces spp. (e.g., A. naeslundii), Veillonella spp. (e.g., Veillonella atypica),
Haemophilus spp. (e.g., Haemophilus parainfluenzae), Prevotella spp. (e.g., Prevotella
loescheii), Eikenella spp. (e.g., E. corrodens), Fusobacterium spp. (e.g., F. nucleatum) and
Capnocytophaga spp. (e.g., C. ochracea) (Figure 1.3A).18, 29, 30 With the initial attachment
of bacterial species to streptococci, more receptors and adhesion proteins are available for
other bacterial species to interact with, which increases the diversity of the biofilm. These
specific interactions have been shown to yield co-aggregation partners. A stepwise
formation of the oral biofilm based on co-aggregation partners depicts the interactions of
bacterial species leading to the formation of a mature biofilm in Figure 1.3A. Each
sequential partner attaches to the next bacterial species starting with Streptococcus spp.
that attaches to A. naeslundii, which itself attaches to C. ochracea, followed by
Actinomyces israelii, which then attaches to C. gingivalis. As the biofilm matures there is
a decrease in abundance of Streptococcus spp. (e.g., S. oralis, S. gordonii, and S.
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sanguinis), Actinomyces spp. (e.g., A. naeslundii), Rothia dentocariosa, and Veillonella
spp. (e.g., Veillonella dispar) as well as an increase in abundance of bacterial species
associated with periodontal diseases such as Aggregatibacter, Prevotella, Porphyromonas,
Treponema, Tannerella, and Fusobacterium spp.22 Additional bacterial species with
increased abundance in diseased sites include Porphyromonas endodontalis, P. nigrescens,
Treponema medium, and Parvimonas micra. F. nucleatum is an interesting early colonizer
that interacts with early and late colonizers as a result of its cell wall containing adhesion
proteins rather than receptors. This bacterial species can interact with many different
species including early colonizers such as V. parvula in addition to late colonizers such as
A. actinomycetemcomitans, C. sputigena, P. gingivalis, Prevotella denticola, P.
intermedia, Selenomonas flueggei, and T. denticola.29 The co-aggregation partners P.
gingivalis and T. denticola in the red complex help facilitate the growth of one another and
facilitate the maturation of the oral biofilm by producing growth factors (i.e., succinic acid
in T. denticola and isobutyric acid in P. gingivalis).1, 31 Once the biofilm reaches the stage
of maturation, depending on the available attachment site, nutrient level, and other factors,
the bacteria can disperse to resume planktonic life or form another biofilm.

The pathogenic bacteria P. gingivalis is a black pigmented Gram-negative anaerobe found
in both healthy and diseased periodontal pockets. The ability of P. gingivalis to be the
etiological agent and keystone pathogen of periodontal diseases relies on the slight increase
in abundance of P. gingivalis within the periodontal pocket along with its serotype (Note:
different strains of P. gingivalis have lower or higher levels of pathogenicity). Keystone
pathogen is a term used to describe the ability of a low-abundance pathogenic bacterial
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species to cause a large amount of damage through organizing the commensal microbial
community into a dysbiotic community that progresses an inflammatory disease, such as
periodontal diseases.32, 33 P. gingivalis has been shown to communicate with subgingival
oral bacteria within the biofilm deploying a pathogenic influence that elevates the
pathogenicity of the biofilm community.24 Different strains of P. gingivalis express various
virulence factors (e.g., fimbriae, collagenase, hemolysins, proteases, fatty acids, and
endotoxins) that aid in its ability to trigger inflammation and the progression of
periodontitis.34-36 Fimbriae on the surface of more virulent strains of P. gingivalis are used
to adhere to and invade host cells.34, 37 The fimbriae are required for specific cell-cell
interactions, cell-surface interactions, and cell-ECM protein interactions.34 ECM proteins
have shown specific affinities towards P. gingivalis fimbriae. The ability of P. gingivalis
fimbriae to bind to ECM proteins such as fibronectin and vitronectin could hinder gingival
tissue repair.28, 37 As a late colonizer that requires an anaerobic environment within the oral
biofilm, the location of P. gingivalis deep in the periodontal pocket allows P. gingivalis to
be situated closer to sulcular epithelium rather than the tooth itself.30 Not only can the P.
gingivalis fimbriae bind to ECM proteins, the fimbriae can also competitively inhibit the
binding of ECM proteins to specific integrins (i.e., αvβ3 and α5β1) on the surface of
gingival tissue. Healing of the gingival tissue could be delayed and P. gingivalis could
invade the damaged tissue. For more information regarding common virulent strains of P.
gingivalis associated with periodontal disease based on their subunits of fimbriae the reader
is referred to a previous in-depth review.34
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Overall, the development of an oral biofilm is not random, it is specific and follows a
stepwise formation process (Figure 1.3B). Planktonic bacteria begin the first stage called
association, where they begin to come closer together. As the biofilm matures the number
of different genera and species of oral bacteria increases to form a diverse community.
When the environment becomes favorable (i.e., when formation of the acquired pellicle
occurs) the bacteria attach to the surface of the tooth allowing for various bacterial species
to attach to them to form a mature biofilm. When the environment becomes unfavorable
(i.e., lack of proper nutrients) the bacteria can disperse and detach from the mature biofilm
and resume planktonic life or form a new biofilm. Mature oral biofilms contain
predominantly oral bacterial species, which are the cause of periodontal diseases, but can
additionally be colonized by other microbial species (e.g., viruses, yeasts, and archaea).25

Table 1.1: Major early colonizers and late colonizers of oral biofilms associated with
periodontal diseases.
Early colonizers
Bacterial species (in Shape
alphabetical order of
Gram-positive
and
Gram-negative)
Actinomyces israelii
Bacillus

GramAerobic/Anaer Symbiotic/Antagonisti Complex Found in type Ref.
positive/Gram- obic
c interaction
of periodontal
negative
diseases
+

§

Actinomyces naeslundii Bacillus +

§

Streptococcus gordonii Coccus +

*

Streptococcus
intermedius
Streptococcus mitis

Coccus +

§

Coccus +

*

Streptococcus mutans

Coccus +

§

Competitive interaction
with P. gingivalis
× S. sanguinis
× S. gordonii
Competitive interaction
with P. gingivalis
× A. naeslundii
× S. mutans
× S. sanguinis
 S. gordonii
N/A

Blue

Chronic
periodontitis
Chronic
periodontitis

7, 26, 38

Yellow

Commensal

17

Yellow

Chronic
periodontitis
Commensal

39

Dental caries

7, 17

Blue

Competitive interaction Yellow
with P. gingivalis
×
A. None
actinomycetemcomitan
s and competitive
interaction with P.
gingivalis
× S. gordonii
× S. oralis
× S. sanguinis
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7, 17, 26
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Table 1.1 continued
Streptococcus oralis
Coccus +
Streptococcus sanguinis Coccus +

Yellow
× S. mutans
×
A. Yellow
actinomycetemcomitan
s
× A. naeslundii
× P. gingivalis
× S. mutans
× S. gordonii
N/A
Green

*
*

Commensal
Commensal

17

Periodontitis

26, 40
1, 7, 26, 40

7, 17

Campylobacter
concisus
Campylobacter rectus

Spirilla -

§

Bacillus -

§

 P. gingivalis

Orange

Capnocytophaga
gingivalis
Capnocytophaga
ochracea
Capnocytophaga
sputigena
Eikenella corrodens

Bacillus -

§

N/A

Green

Bacillus -

§

N/A

Green

Chronic
periodontitis
Chronic
periodontitis
Periodontitis

Bacillus -

§

N/A

Green

Periodontitis

26, 42

Bacillus -

§

× P. gingivalis

Green

1, 26, 43

Fusobacterium
nucleatum

Bacillus -

§

 P. gingivalis
 T. forsythia

Orange

Veillonella atypica

Coccus -

§

 S. gordonii

None

Veillonella parvula

Coccus -

§

 F. nucleatum

Purple

Chronic
periodontitis
Chronic
and
aggressive
periodontitis
Early
childhood
caries
and
chronic
periodontitis
Generally
commensal,
but was found
in
early
childhood
caries
and
chronic
periodontitis

Late colonizers
Bacterial species (in Shape
alphabetical order of
Gram-positive
and
Gram-negative)
Eubacterium nodatum Bacillus
Filifactor alocis

Bacillus

Aggregatibacter
Bacillus
actinomycetemcomitans

Porphyromonas
gingivalis

Bacillus

Prevotella denticola

Bacillus

Prevotella intermedia

Bacillus

26
26, 41

7, 17, 19, 23, 26,
27
44-46

26

GramAerobic/Anaer Symbiotic/Antagonisti Complex Periodontal
Ref.
positive/Gram- obic
c interaction
diseases
negative
associated
with
§
17, 23, 26, 27
+
 Red complex species Orange Chronic
periodontitis
§
47-49
+
 P. gingivalis
None
Localized
aggressive and
refractory
periodontitis
§
23
None
Chronic,
× S. mutans
localized
× S. sanguinis
aggressive, and
generalized
aggressive
periodontitis
§
1, 7, 17, 23, 24,
Red
Chronic,
× S. sanguinis
26, 27, 31
localized

A.
aggressive,
and
actinomycetemcomitan
generalized
s
aggressive
 C. rectus
periodontitis
 F. nucleatum
 T. denticola
§
N/A
None
Chronic
and 23
aggressive
periodontitis
§
1, 17, 23, 26, 27
 Red complex species Orange Chronic,
localized
aggressive, and
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Table 1.1 continued
generalized
aggressive
periodontitis
§
Prevotella nigrescens Bacillus  Red complex species Orange Chronic
and 1, 17, 26, 27
aggressive
periodontitis
§
1
Selenomonas flueggei Bacillus N/A
None
Chronic
periodontitis
§
1, 7, 23, 26
Tannerella forsythia
Bacillus  F. nucleatum
Red
Chronic,
localized
aggressive, and
generalized
aggressive
periodontitis
§
Treponema denticola
Spiral
 P. gingivalis
Red
Chronic
and 1, 7, 19, 23, 26,
31
generalized
aggressive
periodontitis
*
= aerobic, § = anaerobic, + = Gram-positive, - = Gram-negative,  = synergistic interactions, × = antagonistic interactions, N/A = no
clear synergistic or antagonistic interactions.

1.3. CURRENT TREATMENT OPTIONS USED TO TARGET PORPHYROMONAS
GINGIVALIS
1.3.1. Classes of antibacterial agents used to treat periodontal diseases and their
mechanisms of action
For the treatment of periodontal diseases, there are noninvasive (e.g., scaling, root planing
alone or combined with antibiotics) and invasive (e.g., flap surgery, bone grafting, soft
tissue grafts, guided tissue regeneration, and tissue-stimulating proteins) techniques.50-59 In
the early stages of periodontal diseases, the noninvasive techniques can be used. However,
if left untreated, the more aggressive and expensive surgical options must be utilized as the
diseases progress.50 Gingivitis can be managed with good plaque control through brushing
and flossing teeth along with antiseptic (e.g., chlorhexidine) oral mouth rinses.
Chlorhexidine inhibits the growth of biofilm forming bacteria such as P. gingivalis, but it
does not eradicate the biofilm.50,

60

As periodontal diseases progress in severity and

extension, other forms of treatment are needed to eradicate periodontopathogenic bacteria
to stop the progression. For example, antibiotics are used as an adjunctive therapy to
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mechanical debridement such as scaling and root planing in severe and refractory forms of
periodontitis.50,

60

Mechanical debridement is not always sufficient to remove/reduce

subgingival pathogenic bacteria that becomes clinically inaccessible in deep periodontal
pockets and is already likely invading soft gingival tissues. Thus, the use of antibiotics
could contribute to lower the number or completely eradicate pathogenic bacteria, which
as a consequence reduce and control pathologic inflammation-induced tissue destruction.
Given the polymicrobial and chronic nature of periodontal diseases, the prolonged use of
antibiotics brings disadvantages such as side effects, poor efficacy and poor specificity
against oral pathogenic bacteria, as well as development of drug-resistant bacteria.61-63
Several classes of antibiotics used for the treatment of periodontal diseases have as their
main mechanisms of action to inhibit (i) cell wall, (ii) protein, and (iii) DNA synthesis
(Figure 1.4). Interestingly, folate synthesis inhibitors seem to be a group of antibacterial
compounds that could be used in the future as a safer and pathogen-specific adjunctive
therapy for periodontal disease (Figure 1.5). In the following sections, the main examples
for each of these antimicrobials used to control periodontal diseases and their effect in oral
pathogens such as P. gingivalis will be presented.
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Figure 1.4. Classes of antibacterial agents commonly used to treat periodontal diseases and their year of
introduction.

1.3.1.1. Cell wall synthesis inhibitors
The most clinically relevant target for antibiotics is bacterial cell wall biosynthesis. In the
clinic, the classes of cell wall synthesis inhibitors more commonly used are the penicillins
(e.g., amoxicillin (AMX))50, 60 and cephalosporins (e.g., cephalexin and cephradine),64
followed by the monobactams (e.g., aztreonam).65 The naturally occurring penicillin,
cephalosporin, and monobactam classes of antibiotics are β-lactams, which contain a fourmembered β-lactam ring (Figure 1.4). The β-lactam antibiotics were introduced into the
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market in 1942. They have a broad-spectrum of activity and are used to treat localized and
generalized aggressive periodontitis by inhibiting the last step in peptidoglycan synthesis.
The monobactam aztreonam is used for root canal irrigation. However, aztreonam is not as
commonly utilized as the other β-lactam antibiotics for the treatment of periodontal
diseases, because Gram-positive bacteria have become resistant to it and it is not active
against Gram-negative anaerobic bacteria.

1.3.1.2. Protein synthesis inhibitors
For the treatment of periodontal diseases, there are three main classes of antibiotics used
to block bacterial protein synthesis. These classes comprise the bacteriostatic tetracyclines
(marketed in 1948), macrolides (1952), and lincosamides (1968) (Figure 1.4). The broadspectrum natural product tetracycline (TET) along with its semi-synthetic derivatives
minocycline (MIN) and doxycycline (DOX) contain four fused cyclic six-membered rings
in their structures. The TET class of antibacterial agents displays activity against Gramnegative anaerobic bacteria such as A. actinomycetemcomitans, C. rectus, E. corrodens,
and Capnocytophaga spp.66 Although TET is used for many common bacterial infections,
it causes adverse effects such as staining of the teeth, nausea, and diarrhea.64 MIN is used
for the treatment of localized aggressive periodontitis normally occurring in children. For
the treatment of chronic periodontitis, DOX is used as an adjunctive therapy to scaling and
root planing, as it has been found to be highly effective at inhibiting P. gingivalis and A.
actinomycetemcomitans growth when isolated from periodontal pockets. The systemic use
of DOX does not completely eradicate P. gingivalis from the oral cavity, as the amount of
P. gingivalis found in the gingival crevicular fluid is not reduced.36 Gingival crevicular
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fluid is found in the gingival sulcus and it is an inflammatory exudate that comprises serum,
inflammatory mediators, antibodies, proteins, various cells, and bacteria from adjacent
plaque.67 Therefore, once a mature biofilm is re-established P. gingivalis can re-colonize
the biofilm.

The broad-spectrum naturally occurring polyketide class of antibiotics, macrolides, inhibits
protein synthesis by interfering with translation (Figure 1.4). Macrolides comprise the
natural products spiramycin and erythromycin (ERY).50, 60, 64 The poor bioavailability of
ERY led to the development of its semi-synthetic derivatives clarithromycin (CLR) and
azithromycin (AZM). Spiramycin is a systemic antibiotic used as an effective treatment
option for periodontitis, but it is active against Gram-positive bacterial species, which
could lead to oral dysbiosis. The less commonly used macrolide, CLR, is prescribed for
patients allergic to penicillin and has been studied in a clinical trial for the treatment of
chronic periodontitis.68 The clinical trial revealed that CLR can be used as an adjunctive
therapy to scaling and root planing, as it reduced probing depth and enhanced clinical
attachment level. Gram-negative anaerobic bacilli are the primary target of AZM used for
the treatment of aggressive/severe forms of periodontitis. In addition to macrolides,
lincosamides are natural products with the same mechanism of action, but lincosamides are
only active against Gram-positive bacterial species. The semi-synthetic derivative of
lincomycin, clindamycin, is a lincosamide used for patients allergic to penicillin to treat
acute periodontal abscesses. Clindamycin is less commonly used as it can lead to an
increased risk of intestinal Clostridium difficile infections.69
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1.3.1.3. DNA synthesis inhibitors
Two classes of synthetic broad-spectrum antibacterial agents, the bactericidal
fluoroquinolones (marketed in 1967) and nitroimidazoles (1960) have been shown to
inhibit DNA synthesis (Figure 1.4).50, 60, 64 For the treatment of aggressive periodontitis,
the fluoroquinolone, ciprofloxacin (CIP), is active against all strains of A.
actinomycetemcomitans and has been shown to help facilitate growth of beneficial
commensal Streptococcus spp.70 CIP inhibits DNA replication, but because of an increase
in CIP bacterial resistance, it is commonly used in combination with metronidazole (MTZ),
which is a nitroimidazole used for the treatment of localized aggressive periodontitis that
inhibits bacterial nucleic acid synthesis. When tested against planktonic P. gingivalis and
F. nucleatum, MTZ inhibited growth with minimum inhibitory concentration (MIC) values
of 0.125 µg/mL and 1 µg/mL, respectively.71 However, MTZ is normally used in
combination with either AMX, for advanced periodontitis, or CIP, for advanced chronic
periodontitis due to its inactivity when tested alone against preformed biofilms of P.
gingivalis.72

1.3.1.4. Folate synthesis inhibitors
Although not currently used in the clinic for the treatment of periodontal diseases, folate
synthesis inhibitors such as the sulfonamides (put on the market in 1965) show great
potential as antibacterial agents against P. gingivalis (Figure 1.5). Sulfonamides, also
known as sulfa drugs, are synthetic antibacterial agents that contain a sulfur double bonded
to two oxygen atoms and single bonded to one nitrogen, and one carbon. Sulfonamides
inhibit tetrahydrofolate biosynthesis by targeting a key biosynthetic enzyme,
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dihydropteroate synthase. Common sulfonamides used in the clinic to treat bacterial
infections include sulfadiazine and sulfamethoxazole (Figure 1.5).73 For the treatment of
periodontal diseases, the sulfonamide anti-asthma drug, zafirlukast (ZAF), which has been
shown to be active against P. gingivalis, could be a promising molecule warranting further
investigation (see section 1.4.1.4).

Figure 1.5. Representative structures of two sulfonamide antimicrobial agents.

1.3.2. Periodontal pathogens modes of resistance to various classes of antibacterial
agents
There are four common modes of resistance to the antibacterial agents used to treat
periodontal diseases: (i) enzymatic inactivation of antibacterial agents, (ii) limiting access
of the antibacterial agent to its target, (iii) modification of the antibacterial agents’ targets,
and (iv) failure to activate the antibacterial agent. Understanding the modes of resistance
provides a basis to discuss the future direction of rational development of novel
antibacterial agents that can overcome these resistance mechanisms. As this review is
primarily focused on the development of novel antibacterial agents active against P.
gingivalis, this section will not go into all of the details, but instead will provide a brief
overview of these antibacterial resistance mechanisms (for in-depth reviews, readers are
directed to refs 74-77).

1.3.2.1. Enzymatic inactivation of antibacterial agents
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The inappropriate and excessive use of antibacterial agents over the years has been the
major cause of bacterial resistance.78 Within five years of widespread penicillin use, the
first case of bacterial resistance to this antibiotic was observed.79 The ability of Gramnegative oral bacterial species to produce β-lactamase, an enzyme that cleaves the β-lactam
ring and makes the antibacterial agent inactive, has led to an increase in resistance to the
penicillin, cephalosporin, and monobactam classes of antibiotics. Oral bacterial species
with increased resistance to β-lactam antibacterial agents include the pathogenic Prevotella
spp., Porphyromonas spp., and Fusobacterium spp.80 Bacterial resistance to the TET class
of antibiotics occurs through oxidation of TET by TET destructase enzymes, which are
class A flavin-monooxygenases.75

1.3.2.2. Limiting access of the antibacterial agent to its target(s)
Due to the lack of a lipopolysaccharide (LPS) outer membrane, it is less common for Grampositive bacteria to limit access of antibacterial agents to their target compared to Gramnegative bacteria.74 Gram-negative bacteria are harder to kill because their cell walls
contain an LPS outer membrane that acts as a barrier to prevent antibacterial agents from
entering the cell and efflux pumps that prevent accumulation of high concentrations of the
drug within the cell. Classes of antibacterial agents (e.g., tetracyclines, macrolides, and
fluoroquinolones) with vastly different structures are exported from the cell by efflux
pumps, which has led to multidrug-resistant bacteria.

1.3.2.3. Modification of the antibacterial agents’ targets
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To interfere with the ability of antibacterial agents to bind to their target(s), bacteria have
developed resistance by modifying these targets. This can occur in two ways: (i)
spontaneous mutations in the target that impede binding and (ii) chemical modifications
that still allow the target to function normally, while inhibiting binding of the antibacterial
agent to the target. Spontaneous mutations in the enzyme dihydropteroate synthase leads
to resistance to the sulfonamide class of antibacterial agents.81 In Gram-negative bacterial
species, the most common mechanism of resistance to β-lactam antibacterial agents is
through enzymatic inactivation by the production of β-lactamases. In Gram-positive
bacteria, the most common mechanism of resistance consists of preventing the antibacterial
agents from binding to their β-lactams target, the penicillin binding protein, by its
mutation.77 Bacterial resistance to the TET class of antibacterial agents is by the
tetracycline binding protein Tet(O), which is a ribosomal protection protein that promotes
the release of TET from the ribosome.82 Resistance to TET through ribosomal protection
has been observed in P. intermedia and P. nigrescens.83 Methylation of the adenine
residues in 23S rRNA by RNA methyltransferases causes antibacterial resistance to
macrolides and lincosamides. Resistance to macrolides due to 23S rRNA methylation has
been observed in the pathogenic bacteria T. denticola and Prevotella spp., while resistance
to lincosamides has been observed in Treponema pallidum.84-86

1.3.2.4. Failure to activate the antibacterial agents
In order for the nitroimidazole class of antibacterial agents to inhibit bacterial DNA
synthesis, they must first be activated by flavodoxins, which are electron-transport
proteins. Bacterial species develop resistance to nitroimidazoles by decreasing the
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expression of flavodoxins. MTZ resistance has been observed in the oral bacterial species
A. actinomycetemcomitans, and in some Porphyromonas spp., Actinomyces spp., and
Parvimonas spp.87

Although there are several periodontal pathogens that have been associated with
periodontal diseases, such as A. actinomycetemcomitans, T. denticola, T. forsythia, F.
nucleatum, P. intermedia, C. rectus, E. corrodens, P. micros, and Selenomas spp., this
review focuses on the advantages and disadvantages of the antimicrobials used to treat
periodontitis with particular emphasis on the pathogen P. gingivalis as a major contributor
to the pathogenesis of periodontal diseases and its association with other systemic diseases.
Many of the currently used antibiotics are broad-spectrum, which leads to poor efficacy
and the development of drug-resistant bacteria. More pathogen targeted therapy should be
used to treat periodontal diseases that would allow the control of pathogenic bacteria (e.g.,
P. gingivalis), without significantly affecting the normal oral microbiota critical for health.

Table 1.2: Classes of antibacterial agents with the various oral diseases they treat, oral
bacteria they target, and their disadvantages.
Classes
antibiotics
β-lactams

Tetracyclines
Macrolides
Nitroimidazoles
Fluoroquinolones

of Diseases targeted

Oral bacteria against
antibiotics are active
Localized and generalized aggressive A. actinomycetemcomitans
periodontitis

which Associated problems

Due to bacterial resistance
they should be used in
combination
with
βlactamase inhibitors
Localized aggressive periodontitis
A.
actinomycetemcomitans,
P. Adverse effect of metal
gingivalis,
P.
intermedia,
E. chelation
corrodens, F. nucleatum, and P. micra
Aggressive and chronic periodontitis P. gingivalis
Not as effective as MTZ +
AMX combination therapy
Localized aggressive periodontitis Active against most Gram-negative Only
active
against
(when used in combination therapy species, including P. gingivalis, F. planktonic species of P.
with other antibiotics)
nucleatum, and P. intermedia
gingivalis
Chronic periodontitis
Active against all strains of A. Active against Gramactinomycetemcomitans
negative bacteria, but little
activity against anaerobic
bacteria
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Table 1.2 continued
Lincosamides

Chronic periodontitis

P. gingivalis and P. intermedia

A. actinomycetemcomitans
displays
resistance
to
lincosamides

89

1.4. DISCOVERY AND DEVELOPMENT OF NEW COMPOUNDS ACTIVE
AGAINST P. GINGIVALIS
In the following sections (1.4.1-1.4.3), several identified compounds will be compared
either to molecules they are derived from or to antibacterial agents that are already used to
treat periodontal diseases in terms of activity against bacterial growth, activity as inhibitors
of bacterial virulence factors, and/or improvement in properties (e.g., solubility,
cytotoxicity, etc.).

In oral subgingival biofilms, increased P. gingivalis numbers favor the expression of many
virulence factors (e.g., proteases, fimbriae, gingipains, LPS, collagenase, capsule, GroEL,
etc.) by P. gingivalis, which contribute to the development of periodontal diseases by
promoting biofilm formation, adhesion, anaerobic growth, invasion, tissue degradation,
intracellular survival in gingival epithelial cells, etc. These virulence factors therefore offer
a wide range of targets for the development of anti-P. gingivalis agents.

When developing a compound to combat P. gingivalis, most researchers will first look at
inhibiting the growth of P. gingivalis by MIC or percent growth inhibition testing. If the
compounds are inactive against P. gingivalis, most groups would not continue on to biofilm
testing. For some of the seemingly inactive compounds in the following studies throughout
the review, not performing biofilm studies would be a mistake as the compounds may have
surprising activity. As described in section 1.2.2, P. gingivalis has the ability to express
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virulence factors, such as fimbriae, which aid in its ability to further progress periodontitis.
Some compounds may be able to stop the progression of periodontal diseases by inhibiting
the ability of P. gingivalis to express fimbriae, which would inhibit its ability to bind to the
early colonizers in a mature biofilm. Researchers should make sure to always include
cytotoxicity studies in their experiments as there may be an increased concentration needed
to inhibit biofilm formation.

In order to control P. gingivalis by inhibiting its bacterial growth, biofilm growth, and the
expression of virulence factors, researchers have utilized three main strategies:
development of novel compounds through new scaffolds or with derivatives of FDAapproved drugs (section 1.4.1), repositioning of FDA-approved drugs (section 1.4.2), and
isolation and derivatization of natural products (section 1.4.3).

1.4.1. Novel compounds
1.4.1.1. Triazole derivatives
The azole class of drugs has traditionally been used in the clinic as antifungal agents. The
azoles have also been investigated against oral bacterial species. In order for colonization
and re-colonization of P. gingivalis within a biofilm to occur, it must first adhere to early
colonizers such as Streptococcus spp. Preventing the colonization of an oral biofilm by
periodontal pathogens, such as P. gingivalis, helps reduce the virulence of the bacterial
species and slows the progression of periodontal diseases. In an investigation with
expansive structure-activity relationship (SAR) studies, small molecules containing 1,2,3triazoles were designed to be structurally similar to the natural peptide substrate that is
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recognized by the minor fimbrial antigen (Mfa) of P. gingivalis (Figure 1.6).90 Binding of
these small molecules to Mfa inhibits the protein-protein interaction that occurs between
the Mfa of P. gingivalis and the antigen I/II polypeptide of S. gordonii. To inhibit the
adherence of P. gingivalis to early colonizing oral bacterial species, 50 1,2,3-triazole
derivatives were synthesized in three to five standard synthetic steps involving
esterification, cyclization, and click reactions in overall yields of 33-100%. Out of the 50
derivatives, 26 contained 2-(azidomethyl)-4,5-diaryloxazoles (1-11), while 24 contained
2-(azidophenyl)-4,5-diaryloxazoles (12-25) linked by a substituted 1,2,3-triazole. None of
the compounds in this study inhibited the growth of S. gordonii or P. gingivalis. For
example, compound 11 displayed percent growth inhibition of 73% at the high
concentration of 60 µM against P. gingivalis. Although these compounds did not inhibit
the growth of P. gingivalis, four of them, 4c, 15b, 20a, and 20d displayed strong activity
in terms of inhibition of P. gingivalis adherence to S. gordonii with IC50 values of 5.3, 7.7,
5.9, and 5.0 µM (2.80, 3.90, 3.06, and 3.08 µg/mL), respectively. The rest of the
compounds displayed moderate to no inhibition of activity. As there was no standard
antibacterial agent used for comparison in these assays, it is difficult to determine the
potential value of these compounds as inhibitors of P. gingivalis adherence for the
treatment of chronic periodontitis.
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Figure 1.6. Three new scaffolds as representative examples of compounds that contain triazoles in their
structures that were tested as potential antibacterial agents against oral bacterial species.

In a follow up study, five of the most potent inhibitors 4b, 4c, 14d, 15b, and 18a were
further examined with a focus on inhibition of three-species biofilms, inhibition of P.
gingivalis virulence, and low toxicity profile (Figure 1.6).91 The dual-species biofilm of S.
gordonii and P. gingivalis demonstrated the triazole derivatives’ ability to inhibit P.
gingivalis adherence to the early colonizing bacterial species in a two bacterial species
biofilm model. As the oral cavity contains a more complex multi-species biofilm, S.
gordonii and P. gingivalis normally adhere to the bridging oral bacterial species F.
nucleatum. When tested against three-species biofilms comprising S. gordonii, F.
nucleatum, and P. gingivalis, all triazole derivatives 4b, 4c, 14d, 15b, and 18a displayed
the ability to inhibit the incorporation of P. gingivalis into the biofilm with IC50 values of
10-20 µM (5.27-9.89 µg/mL). Additionally, 15b displayed an ability to disrupt preformed
three-species biofilms with 61% inhibition at 20 µM (10.1 µg/mL). Therefore, these
compounds could act as inhibitors of P. gingivalis colonization in the oral cavity. Four out
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of the five compounds (excluding 4c) exhibited the ability to reduce P. gingivalis virulence
in vivo using a mouse model of periodontitis. These compounds reduced alveolar bone
resorption in P. gingivalis-infected mice. Triazole derivative 15b displayed good safety
profiles in cytotoxicity experiments with telomerase immortalized human gingival
keratinocytes (TIGK) and murine J774A.1 macrophage cell lines. Cytotoxicity assays
comprised determination of the release of lactate dehydrogenase, quantification of
adenosine triphosphate (ATP) levels, and apoptosis assays with TIGK and J774A.1 cells,
as well as hemolysis assays with sheep red blood cells (RBCs). Although compound 15b
displayed potent inhibition activity along with a good toxicity profile, there were no control
antibacterial agents used and a conclusion about the triazole derivatives potential for
clinical use as inhibitors remains to be determined.

In addition to the derivatization of 1,2,3-triazoles, 1,2,4-triazoles were also investigated for
their ability to inhibit the growth of P. gingivalis (Figure 1.6).92 A one-step synthesis
consisting of nucleophilic addition of the nitrogen at the N4-position on the 1,2,4-triazole
ring to the carbonyl carbon of 2,4-dinitrobenzaldehyde yielded two 1,2,4-triazole
derivatives 26 and 27. These triazole derivatives were tested against three strains of P.
gingivalis; one strain was fimbriated and more virulent, while the other two strains were
not fimbriated and less virulent. When tested against the three strains of P. gingivalis, the
MIC values were very similar, with the best MIC values being 0.062 mg/mL (62 µg/mL;
221 µM) for the most active compound 26. Through colony forming unit (CFU) assays, 26
was found to inhibit 99.99% of P. gingivalis growth with a minimum bactericidal
concentration (MBC) value of 0.25 mg/mL (250 µg/mL, 892 µM). Zone of inhibition
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assays revealed that the two triazole derivatives displayed inferior antibacterial activity
compared to the control antibiotics ERY, MTZ, and TET, with inhibition of P. gingivalis
growth at ≥1 µg/mL. No growth inhibition was observed with the control antibiotic
gentamicin. Slightly higher toxicity of 26 was seen compared to 27 when tested in human
cervical cancer (HeLa) cells. The lack of growth inhibition activity against P. gingivalis at
higher concentrations of 26 reveals that the derivatization of 1,2,4-triazoles should not be
further pursued for the treatment of P. gingivalis.

In brief, the azoles display little to no activity in terms of inhibiting growth of P. gingivalis.
However, some should be further investigated in mature biofilm studies with other early
colonizing Streptococcus spp., as the 1,2,3-triazoles showed the ability to inhibit P.
gingivalis incorporation into biofilms.

1.4.1.2. Heterocyclic derivatives
As the five-membered heterocyclic triazole ring has been used to develop novel
antibacterial agents to combat oral bacterial species, the five-membered heterocyclic
pyrrolidine ring has also been derivatized in an attempt to combat these pathogenic
bacterial species. A preliminary study explored the use of a commercially available
pyrrolidine derivative, pyrrolidine dithiocarbamate (PDTC, 28, Figure 1.7), which is an
antioxidant, as a potential treatment option to combat P. gingivalis.93 PDTC displayed low
MIC values of 1 µM (0.147 µg/mL) when tested against P. gingivalis compared to the
control antioxidant curcumin that had an MIC value of ~40 µM. Other control antioxidants
such as parthenolide, quercetin, epigallocatechin gallate (EGCG), and resveratrol were
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studied, but they did not inhibit 100% of the growth of P. gingivalis at any of the
concentrations tested. Slightly reduced activity was seen when 28 was tested against three
other bacterial species, A. actinomycetemcomitans, Staphylococcus aureus, and
Escherichia coli (MIC = 30, 30, and 400 µM, respectively). Preliminary studies into the
mechanism of action of 28 revealed that this known metal chelator with zinc ionophore
activity requires zinc to enhance antibacterial activity. With its potent activity against P.
gingivalis and promising preliminary mechanism of action data, further investigation into
the safety profile, resistance, and anti-biofilm studies of the antioxidant 28 should be
performed.

Figure 1.7. A representative example of compounds that contain heterocycles in their structures that were
tested as potential antibacterial agents and found active against P. gingivalis.

1.4.1.3. Bicyclic derivatives
Bicyclic compounds containing quinolines were also investigated for their antimicrobial
activity (Figure 1.8).94 A series of 39 lactone 1,4-dihydroquinoline derivatives were
synthesized in a one-step microwave-assisted high-yielding reaction between tetronic acid,
substituted anilines (e.g., methoxy and methylenedioxy), and substituted aromatic
aldehydes (e.g., methoxy-, methylenedioxy-, halogen-, nitro-, benzyl-, trifluoromethyl-,
hydroxy-, and methylthio-containing substituents). Three of the 29 derivatives, 36c, 37b,
and 42b, displayed some activity against P. gingivalis with MIC values of 12.5-25 µg/mL,
which are worse than that of the control chlorhexidine (MIC = 0.922 µg/mL). None of the
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compounds displayed activity when tested against other oral bacterial species, such as P.
nigrescens, S. mitis, and S. sanguinis, as well as Mycobacterium species, such as M.
tuberculosis, M. avium, and M. kansasii. With promising activity against P. gingivalis,
further lead optimization with the three most active compounds could be performed using
bioisosteric replacement of the substituents on the dihydroquinoline and benzylic rings, in
addition to cytotoxicity and mechanism of action studies.

Figure 1.8. Three new scaffolds as representative examples of compounds that contain bicyclic moieties in
their structures that were tested as potential antibacterial agents against oral bacterial species.

Additionally, a series of 4,6-dimethylisoxazolo[3,4-b]pyridine-3(1H)-one (43, Figure 1.8)
derivatives were synthesized through alkylation, acetylation, and sulfonylation reactions to
yield eight derivatives (43-51, Figure 1.8) that were tested as antibacterial agents.95 The
isoxazolone derivatives were tested against 68 strains of aerobic and anaerobic bacterial
species, including one strain of P. gingivalis, 12 reference bacterial strains, and clinically
isolated bacteria from the oral cavity, intestinal tract, and respiratory system. Derivatives
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44-51 displayed no activity against P. gingivalis (MIC = 100 to >200 µg/mL) when
compared to the parent compound 43 (lowest MIC value = 50 µg/mL), which itself was
way less active than the control MTZ (MIC <0.4 µg/mL). Thus, these isoxazolone
derivatives appear not to be promising as antibacterial agents for the control of P.
gingivalis.

A preliminary investigation led to the development of small molecule cationic steroid
antimicrobial (CSA) derivatives active against P. gingivalis and S. mutans (Figure 1.8).
These CSA derivatives mimic cationic antibacterial peptides, but are more cost effective
to synthetize, as they are small molecules synthesized in ten-steps including mesylation
and reduction to yield a final compound in moderate yield.96, 97 The most active compound
52 displayed good activity when tested against 23 strains of S. mutans and 24 strains of
Porphyromonas spp. with MIC values of 1-8 µg/mL and 1-16 µg/mL, respectively.98 As
they display increased antibacterial activity, future cytotoxicity studies with human oral
epithelial cells and biofilm studies with P. gingivalis and S. mutans should be pursued,
particularly with compound 52.

Overall, bicyclic derivatives containing quinolines and cationic steroid scaffolds show
potential as anti-P. gingivalis agents and should undergo cytotoxicity and anti-biofilm
studies.

1.4.1.4. Sulfonamide derivatives
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The sulfonamide antibiotics are commonly used to treat bacterial infections. Sulfonamidebased quinazoline derivatives, such as 53-61, were investigated as potential inhibitors of
carbonic anhydrases (γ-CAs), which are crucial for the survival of bacterial species,
including P. gingivalis (Figure 1.9).99 P. gingivalis γ-CAs are enzymes that catalyze the
physiologically important reaction of CO2 hydration to bicarbonate and protons.
Additionally, P. gingivalis γ-CAs are involved in biosynthetic reactions by supplying CO2
and bicarbonate, along with transportation of CO2 and bicarbonate, and regulation of pH.
A three to four-step synthesis yielded 13 sulfonamide derivatives.99 Out of the 13
sulfonamide derivatives, compound 55a, displayed strong inhibitory activity with an
inhibition constant (Ki) value of 3.5 nM (0.0035 µM, 0.0017 µg/mL) that was superior to
that of the control acetazolamide (Ki = 324 nM), a sulfonamide antibiotic FDA-approved
in 1953 to prevent and reduce the symptoms of altitude sickness.100 The strong inhibitory
activity of 55a against P. gingivalis γ-CAs suggested that MIC testing against P. gingivalis,
cytotoxicity studies, as well as anti-biofilm studies should be performed to determine its
potential as an anti-P. gingivalis agent.
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Figure 1.9. Four new scaffolds as representative examples of compounds that contain sulfonamide moieties
in their structures that were tested as potential antibacterial agents and found active against P. gingivalis.

In an in silico study, a virtual screening of more than 9 million small molecules from the
ZINC database of commercially available chemicals was used to explore the potential of
these compounds as inhibitors of the enzyme meso-2,6-diaminopimelate dehydrogenase
from P. gingivalis.101 The enzyme diaminopimelate dehydrogenase catalyzes a key step in
lysine biosynthesis, which is essential for P. gingivalis survival as the pathway is involved
in peptidoglycan biosynthesis. This study suggested a new target for the treatment of P.
gingivalis. Unfortunately, when 11 compounds were tested in vitro against that target (62,
Figure 1.9), no inhibition activity was observed (lowest IC50 value = 157 ± 26 µM for
compound 62). When tested against P. gingivalis and S. sanguinis, no activity was seen
(lowest MIC value = 167 µM against P. gingivalis by compound 62). There was also no
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control antibiotic used for comparison. These compounds should not be further pursued as
inhibitors or antibacterial agents due to their lack of activity.

A successful strategy employed by researchers to find new antibacterials is to reposition
drugs that were FDA-approved for the treatment of a different disease. Screening of a drug
repositioning library led to the identification of ZAF, which was FDA-approved in 1996
for the treatment of asthma, as an active drug against P. gingivalis.102 In a preliminary
investigation into derivatization of the parent compound ZAF, 11 first generation ZAF
derivatives were synthesized using a two- to four-step linear synthesis (63-73, Figure
1.9).62 ZAF was modified by removal of the cyclopental carbamate group on the indole
ring by replacement with either a hydrogen or nitro group, removal of the N-methyl group
on the indole ring, change in substituents and substitution patterns on the benzoyl ring (e.g.,
indole, methoxy, and arylsulfonamide), and removal of the methyl group on the
arylsulfonamide ring. When tested against P. gingivalis, five compounds, 67 and 70-73,
displayed good activity with 90-100% growth inhibition at 10 µM, which was comparable
to or superior to the activity of the controls TET at 2.25 µM and ZAF at 25 µM and 50 µM.
The three most active compounds displayed selective activity against P. gingivalis with no
activity seen when tested against other oral bacterial species such as A. naeslundii, A.
actinomycetemcomitans, V. parvula, F. nucleatum, and S. sanguinis. Bactericidal activity
was observed in CFU assays with compound 72 at 10 µM along with 60% inhibition of P.
gingivalis growth at 1 µM. In cytotoxicity experiments, an increased safety profile was
observed with compounds 71-73 compared to the parent ZAF when tested against
immortalized human oral keratinocyte cells (OKF6) with 50-70% cell viability at 1 µM
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and 10 µM. The three most active compounds 71-73 containing 2-methoxy-5-indoyl
substituents on the benzoyl ring displayed increased activity against P. gingivalis compared
to the parent ZAF as well as the other derivatives synthesized with 3-methoxy-5-indoyl
substituents on the benzoyl ring. As these compounds displayed increased activity against
P. gingivalis when compared to ZAF, further investigation into structure optimization was
pursued.

In the following lead optimization study, the three most active first generation ZAF
derivatives 71-73 (Figure 1.9) were used as starting points for the generation, in three to
four linear steps, of 15 second generation ZAF derivatives active against P. gingivalis (7488, Figure 1.9).103 The 15 second generation ZAF derivatives were modified on the indole
ring at R1 and R2 positions (e.g., nitro and methyl groups), arrangement of the indole,
methoxy, and arylsulfonamide substituents on the benzoyl ring, and substitution at the R3
position of the arylsulfonamide (e.g., fluoro and nitro phenyl, and naphthyl groups). When
tested against P. gingivalis, six out of the 15 compounds, 78-80, 82, 84, and 87, displayed
similar or superior percent growth inhibition values against P. gingivalis at 1 µM, 10 µM,
and 100 µM compared to ZAF at 25 µM and 50 µM, its first generation derivatives, and
TET at 2.81 µM. Compounds 78-80, 82, 84, and 87 displayed selective inhibition of P.
gingivalis with little to no activity against other oral bacterial species such as A.
actinomycetemcomitans, A. naeslundii, V. parvula, and S. sanguinis. When tested against
OKF6 cells, compounds 78-80, 82, 84, and 87 displayed decreased cytotoxicity compared
to the parent ZAF. In CFU assays, compounds 78-80, 82, 84, and 87 displayed bactericidal
activity at 100 µM and two of the most active compounds, 84 and 87, displayed bactericidal
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activity at concentrations as low as 1 µM. Due to increased activity against P. gingivalis,
increased safety profile in human oral epithelial cells, and selectivity, these compounds
would need to be further optimized and tested in oral biofilms.

In general, the use of sulfonamide-containing scaffolds as potent inhibitors of enzymes
crucial to P. gingivalis survival as well as the targeted inhibition of P. gingivalis growth
show great promise for the development of anti-P. gingivalis agents as treatment of chronic
periodontitis. Future experiments determining mechanism(s) of action, lead structure
optimization, and anti-biofilm studies should be performed.

1.4.2. Drug repositioning
As demonstrated with ZAF in the previous section, repositioning of FDA-approved drugs
that are not used for the treatment of periodontal diseases as new antibacterial agents active
against P. gingivalis is a strategy used due to the high cost of novel drug development.
Screening of a drug repositioning library led to the discovery of two FDA-approved drugs,
ZAF (discussed above) and toremifene (89, Figure 1.10) active against P. gingivalis.104
Toremifene (89) was FDA-approved in 1997 for the treatment of breast cancer as a 60 mg
oral tablet. In a preliminary study, toremifene (89) displayed good antibacterial activity
against P. gingivalis and S. mutans with MIC and minimum biofilm-inhibitory
concentration (MBIC) values of 12.5 µM and 25 µM (5.1 µg/mL and 10.1 µg/mL),
respectively. Mechanism of action studies focused on DNA, RNA, and protein synthesis
were performed in P. gingivalis and S. mutans and showed that toremifene (89) did not
inhibit the synthesis of DNA, RNA, or protein. Instead toremifene (89) caused increased
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membrane permeabilization along with binding to LPS produced by P. gingivalis. The
ability of toremifene (89) to bind to LPSs is important because the progression of
periodontal diseases is promoted by virulence factors produced by P. gingivalis, such as
LPSs, that contribute to the development of periodontal diseases. When tested in human
oral gingival epithelial cells, toremifene (89) was toxic at 25 µM, while no hemolytic
activity was observed when tested against horse RBCs at concentrations up to 100 µM.
Toremifene (89) is currently used in the clinic at a much higher dose than the MIC values
against P. gingivalis presented and is an ideal candidate as an antibacterial agent for use as
a mouthwash due to its toxicity of oral epithelial cells.

Figure 1.10. Four FDA-approved scaffolds and their derivatives as representative examples of compounds
that could be used as potential antibacterial agents.

With the preliminary success of five-membered heterocyclic triazole derivatives (discussed
in section 1.4.1.1) leading to strong inhibitors of P. gingivalis adherence to other oral
bacterial species within biofilms, it is no surprise that other heterocyclic-based inhibitors
have been investigated as potential therapeutic options. Proteases produced by P. gingivalis
are important virulence factors that contribute to tissue destruction, adhesion, and
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degradation of the ECM. Inhibition of the P. gingivalis protease dipeptidyl peptidase 4
(DPP4), which is involved in collagen degradation through interactions with ECM proteins
fibronectin and collagen, was investigated in a preliminary study that led to the screening
of 450 potential inhibitors (90, Figure 1.10).105 This preliminary investigation looked into
the similarity in structure and function of the human DPP4 and P. gingivalis DPP4. Some
of the library compounds were known inhibitors of the human DPP4 that are currently used
as antidiabetic drugs and others were DPP4 inhibitors that have previously been developed
and characterized as a part of a collection of mammalian DPP family inhibitors. The human
and P. gingivalis DPP4 were found to have similar overall structures along with similar
substrate specificity. Although inhibitors were active against the human DPP4, little to no
activity was seen when tested against P. gingivalis DPP4. Out of the 450 inhibitors
screened, 81 inhibitors displayed more than 50% growth inhibition at 100 µM and 33
displayed more than 50% growth inhibition of P. gingivalis at 10 µM. Out of the 81
compounds that exhibited 50% growth inhibition of P. gingivalis at 100 µM, only 16
displayed good IC50 values of 0.079-8 µM. With none of the compounds completely
inhibiting the growth of P. gingivalis along with a low affinity towards P. gingivalis DPP4,
these compounds show very limited promise as potential antibacterial agents.

Novel compounds tested as potential antibacterial agents active against P. gingivalis should
display properties of inhibiting the growth of P. gingivalis and/or inhibiting the virulence
factors produced by P. gingivalis that play key roles in the progression of periodontal
diseases. The most important and widely studied virulence factors produced by P.
gingivalis that contribute to its pathogenicity include gingipains, fimbriae, and LPSs.106 In
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a preliminary investigation, previously synthesized symmetrical aromatic compounds
(synthesized by J. Stürzebecher from the Institute of Vascular Biology and Medicine,
University Hospital of Jena) that contained benzamidines in their structures were found to
be potent inhibitors of arginine-specific cysteine proteinases, such as gingipains (Arggingipains, Rgp) (91, Figure 1.10). When tested against Rgp, benzamidine displayed no
activity with a Ki of 277 µM, while its derivatives 91 and pentamidine (as a control)
displayed better activity with Ki values of 0.51 and 40.3 µM, respectively.107 The
benzamidine derivative pentamidine was FDA approved in 1989 for the treatment of
Pneumocystic jiroveci pneumonia and has previously been shown to inhibit the growth of
P. gingivalis with an MIC value of 1 ng/mL (0.001 µg/mL).108 In a follow up study,106 91
displayed poor activity against P. gingivalis (20% growth inhibition) at the tested
concentration of 20 µM (7.17 µg/mL) in CFU assays, benzamidine displayed no activity at
20 µM (2.40 µg/mL), while pentamidine displayed the best activity with 90% growth
inhibition at 20 µM (6.81 µg/mL). No known antibacterial agent was used as a control in
these experiments. The benzamidine derivatives were also tested as inhibitors of the protein
GroEL, a virulence factor produced by P. gingivalis belonging to the heat shock protein 60
family. GroEL contributes to the progression of periodontal diseases and increases
inflammation due to its role in stimulating the production of inflammatory cytokines. The
virulence of P. gingivalis was reduced by 91 and pentamidine through binding of GroEL
and inhibition of the ability of P. gingivalis to kill Fertile White Leghorn eggs. Based on
these promising results, 91 should be further derivatized to increase its activity against P.
gingivalis growth inhibition and pentamidine could be further developed as a potent
inhibitor of P. gingivalis virulence. To conclude, the repositioning and/or derivatization of
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FDA-approved drugs, such as ZAF, toremifene, benzamidine, and pentamidine, could lead
to novel therapeutics for P. gingivalis infections.

1.4.3. Natural products
An alternative to synthetizing novel compounds and drug repositioning is utilizing Nature’s
treasure trove of naturally produced antibacterial agents. Natural products are a source of
many drugs and drug leads for different ailments. Therefore, it is no surprise that natural
products have been explored for P. gingivalis treatment. Although many natural products
have been tested, researchers are still in the early stages of developing/optimizing natural
products for the treatment of P. gingivalis. The following sections will cover: (i) natural
products from various organisms and their derivatives, (ii) plant essential oils and their
derivatives, and (iii) inactive natural products.

1.4.3.1. Natural products and their derivatives
Similar to the drug repositioning and derivatization of ZAF discussed in section 1.4.1.4,
scientists have also attempted to isolate natural products and test their crude extracts and
purified compounds against P. gingivalis as well as other oral bacterial species.
Modification of natural products occurs through a wide variety of methods such as
isolation, derivatization, semi-synthesis, synthesis, and biotransformation.

1.4.3.1.1. Compounds isolated from extracts from various organisms
In an early stage investigation, a total of eight compounds were isolated from the
methanolic extract of the bark of Haematoxylon brasiletto Karst.109 Starting with 1 kg of
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bark, 100 g was extracted by maceration with methanol along with 35.7 g of crude ethyl
acetate (EtOAc)-soluble extract, which displayed the most antibacterial activity. Eight pure
known compounds were isolated from EtOAc, all of which were phenolic compounds (92,
Figure 1.11). When tested against three strains of S. aureus, three strains of E. coli, one
strain of Enterococcus faecium, Bacillus subtilis, Klebsiella pneumoniae, Pseudomonas
aeruginosa, S. mutans, P. gingivalis, and Candida albicans, the methanolic extract along
with all of the pure compounds were inactive, with the exception of brazilin (92) against
P. gingivalis (MIC value of 8.7 µg/mL that was worse than that of the control chlorhexidine
gluconate (MIC = 0.6 µg/mL)). With its selective activity of against P. gingivalis, brazilin
(92) would be a good candidate for future investigations focused on mechanism of action
studies to aid structure optimization, along with cytotoxicity and combination studies with
known antibiotics to determine the potential of next generation phenolic compounds as
anti-P. gingivalis agents.
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Figure 1.11. Ten scaffolds as representative examples of compounds that were isolated from extracts from
various organisms that were tested as potential antibacterial agents against oral bacterial species.

In another preliminary study also focused on phenolic molecules, five polyphenolic
ketones known as gingerols were isolated and purified by silica-gel column
chromatography and preparative high-performance liquid chromatography (HPLC) from
ginger, Zingiber officinale Roscoe from the family Zingiberaceae (93 and 94, Figure
1.11).110 Dry rhizomes of Z. officinale (100 g) were purchased and 250 mg of active
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fractions were isolated. Ethanol and n-hexane extracts as well as isolated pure compounds
were tested against P. gingivalis, P. endodontalis, and P. intermedia, and were found to be
inactive with the exception of [10]-gingerol (93) and [12]-gingerol (94). The most active
compound, [10]-gingerol (93), displayed moderate antibacterial activity against P.
gingivalis, P. endodontalis, and P. intermedia with MIC/MBC values of 6/6 µg/mL, 8/4
µg/mL, and 14/14 µg/mL, respectively. Future studies to determine mechanism of action
as well as anti-biofilm experiments with P. gingivalis should be pursued with [10]-gingerol
(93).

In a different preliminary study in which no pure small molecules were isolated, five
extracts from the Mediterranean plants of Olea europaea (olive leaf extract and table olives
extract), mastic gum, and Inula viscosa were tested for their antimicrobial activity.111 One
of the main problems of using an extract as a treatment option is the many active and
inactive compounds within the extract could have synergistic or antagonistic activity with
one another. Therefore, the true potency of any one compound within the extract is not
known until it is isolated and individually tested. The extracts were tested against a wide
range of oral bacterial species comprising S. mutans, Streptococcus sobrinus, S. oralis,
Enterococcus faecalis, P. gingivalis, P. intermedia, F. nucleatum, and P. micra. To
determine the extracts specificity toward oral bacterial species they were tested against one
strain of S. aureus and E. coli, normally found on the skin and intestinal flora, and one
fungal strain of C. albicans, which can cause oral thrush, also known as oral candidiasis.
All extracts were found to be inactive against all tested bacterial and fungal strains, with
the exception of moderate activity seen with the mastic gum extract with an MIC value of
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20 µg/mL against P. gingivalis. However, the MBC values with the mastic gum extract
were high (MBC = 70 µg/mL). The active natural products in the mastic gum extract should
be isolated and tested alone with P. gingivalis to determine the most active compounds that
could be further investigated.

In addition to the extracts described above, pure isolated compounds from the
Mediterranean plant extracts of Olea europaea (olive) and Pistacia lentiscus (mastic gum)
were tested for their antimicrobial activity (95-97, Figure 1.11).112 Five known natural
products were isolated from O. europaea (oleuropein, hydroxytyrosol, oleocanthal,
oleacein, and maslinic acid (95)) and three were isolated from P. lentiscus (oleanonic
aldehyde, 24Z-isomasticadienolic acid (97), and oleanolic acid (96)). The two pentacyclic
triterpenoids maslinic acid (95) and oleanolic acid (96) along with the tetracyclic
triterpenoid 24Z-isomasticadienolic acid (97) displayed good to moderate antimicrobial
activity when tested against P. gingivalis with MIC/MBC values of 4.9/9.8 µg/mL, 9.8/9.8
µg/mL, and 2.4/9.8 µg/mL, respectively. Additionally, maslinic acid (95) and 24Zisomasticadienolic acid (97) displayed good activity against P. micra (MIC/MBC =
9.8/9.8 µg/mL and 2.4/9.8 µg/mL, respectively). Unfortunately, all compounds were found
to be inactive against the other eight bacterial species tested comprising S. mutans, S.
sobrinus, S. oralis, E. faecalis, E. coli, S. aureus, P. intermedia, F. nucleatum, and one C.
albicans fungal strain. It could be beneficial to perform anti-biofilm and cytotoxicity
studies with the three most active compounds.
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In another preliminary investigation now focused on plants from Mexico, one novel
compound along with six known compounds were extracted in a methanol soluble extract
and isolated from the tree bark of the Mexican plant Amphipterygium adstringens Standl
(98, Figure 1.11).113 The compounds consisted of four anacardic acids and three triterpenes.
When tested against P. gingivalis and S. mutans, the methanol extract was inactive with
MIC values of 82 µg/mL and 69 µg/mL, respectively. The only compound to display good
to moderate activity was 6-[16'Z-nonadecenyl]-salicylic acid (98), which displayed
respective MIC values of 12 µg/mL and 7 µg/mL against P. gingivalis and S. mutans
(worse than those of the control chlorhexidine gluconate (MIC = 1.4 µg/mL and 3.2 µg/mL,
respectively)). Lead optimization studies of 6-[16'Z-nonadecenyl]-salicylic acid (98) could
focus on treatment of dental caries as this compound displayed increased activity with S.
mutans.

In another study, 20 known isoflavonoids and coumarins were isolated along with one new
pterocarpan from Chinese licorice Glycyrrhiza uralensis and were tested as potential
antibacterial agents (99 and 100, Figure 1.11).114 Only seven of the compounds could be
tested as the remaining compounds could not be isolated in sufficient amount for the assays.
The licorice extract was shown to be inactive against all bacterial strains tested, while the
two major components isolated, licoricidin (99) and licorisoflavan A (100), displayed the
best activity against multiple bacterial strains.115 When tested against P. gingivalis,
licoricidin (99) and licorisoflavan A (100) displayed moderate activity with 80% growth
inhibition at 5 µg/mL, worse than that of the control penicillin G (90% growth inhibition
at 0.025 µg/mL). Additionally, 90% growth inhibition at 5 µg/mL of licoricidin (99) and
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2.5 µg/mL of licorisoflavan A (100) was exhibited when tested against P. intermedia. All
compounds displayed little to no activity against F. nucleatum, S. mutans, and S. sobrinus.
The good antibacterial activity displayed by licoricidin (99) and licorisoflavan A (100)
warrants further investigation into their mechanism(s) of action and safety profiles.

Four boswellic acids that are composed of triterpenic acids were isolated from the oleo
gum resin of the plant Boswellia serrata.116 These compounds were previously extracted,
isolated, and quantified from 1 kg of B. serrata and yielded an extract of 490 g that was
further purified to isolate the acidic mixture of boswellic acids as 280 g.117 When tested
against P. gingivalis, S. mutans, E. faecalis, E. faecium, Actinomyces viscosus, S. sanguinis,
F. nucleatum, and P. intermedia, the most active pentacyclic terpenoid acetyl-11-keto-βboswellic acid (AKBA, 101) displayed good activity with MIC values of 2-4 µg/mL, with
the exception of F. nucleatum (MIC >128 µg/mL). These values were similar to the control
triclosan that is commonly found in body washes, toothpastes, and soaps as an antibacterial
agent with MIC values of 1-4 µg/mL against all bacterial strains tested. Time-kill assays
with AKBA (101) in S. mutans revealed bacteriostatic activity at 32 µg/mL. At 8× MIC,
AKBA (101) suppressed the emergence of mutants in S. mutans and A. viscosus.
Additionally, AKBA (101) displayed good postantibiotic effect at 2× MIC at 5.7 h. In
biofilm studies with AKBA (101), preformed biofilms of S. mutans and A. viscosus were
eradicated and biofilm growth was inhibited with a MBIC50 value of 16 µg/mL. With low
MIC values, biofilm studies with P. gingivalis and cytotoxicity studies should be
performed.
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An investigation into inhibitors of gingipain virulence factors secreted by P. gingivalis
such as arginine-specific (Rgp) and lysine-specific (Lys-gingipains, Kgp) cysteine
proteinases led to the isolation of 17 prenylated flavonoids from the plant species
Epimedium (102, Figure 1.11).118 The compounds consisted of known and novel flavonoids
isolated from 3 kg of Epimedium and extracted to yield a residue of 485 g. Four compounds
completely inhibited P. gingivalis growth at 12.5 µM. Two of these compounds slightly
inhibited P. gingivalis biofilm formation at 1.25 µM. Of these two compounds,
epimedokoreanin B (102) displayed the most potent inhibition activity with Ki values of
1.67 ± 0.07 µM and 2.71 ± 0.22 µM for Rgp and Kgp, respectively. Mechanism of action
studies revealed that epimedokoreanin B (102) is a non-competitive inhibitor of cysteine
proteases, gingipains Rgp and Kgp. An important structural feature of the potent inhibitors
is a hydrophobic prenyl functional group on the aromatic rings of the flavonoids, as the
compounds with prenyl functional groups (e.g., epimedokoreanin B (102)) displayed better
inhibition activity compared to known unprenylated flavonoids such as quercetin and
luteolin. With its known mechanism of action, potent activity as an inhibitor, as well as
moderate activity against P. gingivalis, epimedokoreanin B (102) is an ideal starting point
for SAR studies to further optimize its activity.

Common prenyl functional groups attached to aromatic rings via a C-C or a C-O linkage
for natural products include geranyl (C10) and farnesyl (C15) chains. In a preliminary
investigation, the synthesis of two known phytochemical oxyprenylated secondary
metabolites, 2',6'-dihydroxy-4'-geranyloxyacetophenone (103) and 2',6'-dihydroxy-4'farnesyloxy-acetophenone (104), was performed in a single step using the prenylation of
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2,4,6-trihydroxyacetophenone at the 4'-position to obtain 103 and 104 with geranyl or
farnesyl chains in 55% and 62% yields (Figure 1.11).119 These compounds were
synthesized as they are normally produced/isolated in low amounts from the fruits and
aerial parts of plants belonging to the Rutaceae family. When tested against S. sobrinus, S.
mutans, A. actinomycetemcomitans, P. intermedia, and C. albicans, both compounds
displayed little to no activity with MIC values of 25 to >100 µg/mL, much worse than those
of the controls penicillin G (MIC = 0.049-3.125 µg/mL) and nystatin (MIC = 0.78-6.25
µg/mL). When tested against P. gingivalis, both compounds displayed moderate activity
with MIC of 12.5 µg/mL, much worse than that of the control penicillin G (MIC = 0.098
µg/mL). With an enticing one-step synthesis, compounds 103 and 104 are highly amenable
to SAR studies to increase their selective inhibition of P. gingivalis.

For the treatment of periodontal diseases, isolated extracts would not be a viable option as
the majority of extracts tested were inactive against oral bacterial species, while isolated
compounds displayed activity. Amongst the compounds isolated from extracts, the
triterpenic acids were the best followed by the triterpenoid scaffolds, then the phenolic
compounds, anacardic acids, prenylated flavonoids, isoflavonoids, coumarins, and
pterocarpans. Out of the four triterpenic acids isolated, one pentacyclic terpenoid, AKBA
(101), displayed the best activity and should be further investigated as an antibacterial
agent for the treatment of dental caries and periodontitis.

1.4.3.1.2. Purchased compounds that were identified from extracts
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In a comprehensive study, the two known major components (105 and 106, Figure 1.12)
of Psoraleae, a traditional Chinese medicine, were investigated for their antibacterial and
anti-inflammatory properties against P. gingivalis.120 These commercially available
coumarin-based compounds vary in the position of the fused furan ring. When tested
against planktonic P. gingivalis, psoralen (105) and angelicin (106) displayed good MIC
values of 6.25 µg/mL and 3.125 µg/mL, respectively. The cell viability and thickness of P.
gingivalis biofilms was also decreased at these concentrations with each compound. The
compounds displayed poor MBC values at 50 µg/mL against planktonic P. gingivalis. The
low MIC values against planktonic P. gingivalis prompted the exploration into their effects
on preformed biofilm growth as well as inhibition of biofilm formation of P. gingivalis.
Moderate inhibition of P. gingivalis biofilm formation (MBIC50 values of 15.8 µg/mL and
7.5 µg/mL for psoralen (105) and angelicin (106), respectively) was observed. Preformed
biofilms of P. gingivalis were eliminated by psoralen (105) and angelicin (106) with
respective minimum biofilm reduction concentration (MBRC50) values of 24.5 µg/mL and
23.7 µg/mL. The viability of P. gingivalis cells in preformed biofilms with the bacterial
cells attached to a surface, also known as sessile cells, was reduced with sessile MIC50
(SMIC50) values of 5.8 µg/mL and 6.5 µg/mL. When psoralen (105) and angelicin (106)
were tested in human periodontal ligament cells, an osteogenesis-potentiating effect was
observed in addition to no cytotoxic effect in this cell line or the monocyte-like THP-1
cells. With angelicin (106), alveolar bone loss and inflammation induced by LPS was
reduced in in vivo experiments using wild-type male C57BL/6 mice. With the ability to
disrupt preformed biofilms and inhibit biofilm formation of P. gingivalis along with anti-
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inflammatory properties, angelicin (106) should be further developed as an antibacterial
agent.

Figure 1.12. Five scaffolds as representative examples of purchased compounds that were identified from
extracts and tested as potential antibacterial agents against oral bacterial species.

A cranberry polyphenol, A-type cranberry proanthocyanidins (107), isolated from the
cranberry fruit Vaccinium macroacarpon, and a commercially available chalcone,
licochalcone A (108), a flavonoid originally isolated in the licorice Glycyrrhiza inflata,
were tested as antibacterial agents (Figure 1.12).121 Licochalcone A (108) displayed good
activity against P. gingivalis while compound 107 was inactive. When tested against
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planktonic P. gingivalis cells and preformed biofilms, licochalcone A (108) displayed good
MIC values of 10 µg/mL. Both compounds displayed synergy in combination with one
another against planktonic and preformed biofilms of P. gingivalis. In combinations, these
compounds also inhibited the adherence of P. gingivalis to the immortalized human oral
epithelial cell line GMSM-K. When tested against tissue destructive enzymes of P.
gingivalis, collagenase and human recombinant matrix metallopeptidase 9 (MMP-9),
licochalcone A (108) displayed slight inhibition of activity against collagenase with 35%
inhibition at 5 µg/mL, but was not really active against MMP-9 (15% inhibition of MMP9 at 5 µg/mL). In a macrophage model, the compounds displayed synergistic interactions
in combination with one another to reduce the LPS-induced secretion of IL-1β, TNF-α,
and IL-8, which are pro-inflammatory mediators. For future investigations, combination
studies with licochalcone A (108) and known antibiotics could potentially provide novel
treatment options.

With the promising anti-P. gingivalis activity seen with oxyprenylated compounds 103 and
104 and the coumarin-based compounds 105 and 106 discussed above, compounds
containing both groups would seem to be an interesting approach to target P. gingivalis. In
an early phase investigation, two known coumarin-based compounds were tested against
P. gingivalis (109 and 110, Figure 1.12).122 One of these was commercially available with
a geranyloxy group at the C-7 position, auraptene (109), and the other was synthesized
through condensation, alkylation, and methylation reactions123 to yield lacinartin (110)
with an isopentenyloxy moiety at the C-7 position. Unfortunately, these compounds were
found to be inactive, with auraptene (109) inhibiting P. gingivalis growth by 42% at 100
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µg/mL and lacinartin (110) inhibiting about 90% of P. gingivalis growth at 50 µg/mL.
Lacinartin (110) displayed poor activity through inhibition of P. gingivalis biofilm
formation by 75% at 50 µg/mL and 100 µg/mL. Although these compounds needed to be
given at high concentrations to inhibit P. gingivalis growth, they displayed promise as
potential anti-inflammatory agents. Both compounds inhibited the adherence of P.
gingivalis to the immortalized human oral epithelial cell line GMSM-K. Additionally, they
inhibited MMP-9 activity and decreased the secretion of cytokines TNF-α and IL-8. SAR
studies will be needed to improve P. gingivalis growth inhibition for these compounds to
be used as anti-inflammatory agents for the treatment of periodontal diseases.

All in all, coumarin-based and polyphenolic scaffolds yielded compounds with good
activity against P. gingivalis, increased ability to inhibit P. gingivalis biofilm formation,
decreased virulence of P. gingivalis, and/or displayed anti-inflammatory properties. These
scaffolds should be tested in multi-species biofilms to show their true potential as anti-P.
gingivalis agents.

1.4.3.1.3. Natural product derivatives
Nature provides an extensive selection of natural products that can be used as starting
points for investigation into their activity against P. gingivalis. The natural products
presented in this subsection include autoinducers secreted by bacteria, secondary
metabolites from marine sponges, and compounds originating from fungi and plants (fruits,
roots, aerial parts, and seeds) from California, Brazil, India, and Sri Lanka. These starting
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materials provide different structural scaffolds for derivatization through synthetic, semisynthetic, and biotransformation pathways.

Although there are a wide variety of natural products, the same natural products can be
isolated from various plants from different regions.112 Oleanolic acid (96, Figures 1.11 and
1.13) was isolated in a previous study from Mediterranean plant extracts of P. lentiscus. In
the current study, oleanolic acid (96) and nine other known compounds were isolated from
the California fruits of the Thompson seedless raisins (Vitis vinifera).124 A total of 5 kg of
raisins were used to yield 68.4 g of an hexane-soluble extract along with 86.2 g of an
EtOAc-soluble extract. From the hexane-soluble extract, 340 mg of the triterpenoid
oleanolic acid (96) was isolated. Oleanolic acid (96) was semi-synthetically derivatized in
previous studies125-128 through one chemical step consisting of acylation or esterification
reactions to yield six derivatives (111-116, Figure 1.13). None of the known compounds,
including oleanolic acid (96), displayed activity against P. gingivalis and S. mutans. Of the
six semi-synthetic derivatives, the oleanolic acid sodium salt 116 displayed the best activity
with MIC values of 3.9 µg/mL and 7.8 µg/mL against P. gingivalis and S. mutans,
respectively (worse than the control chlorhexidine gluconate with MIC values of 0.3
µg/mL and 1.2 µg/mL). Future investigations focused on structure optimization of
compound 116 should include derivatives with more polar functionality to enhance anti-P.
gingivalis activity.
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Figure 1.13. Seven scaffolds as representative examples of natural products and their derivatives that were
tested as potential antibacterial agents against oral bacterial species.

A study focused on the treatment of oral bacterial species for root canal infections led to
the isolation of six pimarane-type diterpenes from the Brazilian plant species Viguiera
arenaria Baker as well as two semi-synthetic derivatives (117-124, Figure 1.13).129 The
59

six natural products, 117-121 and 124, were isolated from the roots of V. arenaria (8 g) to
yield 2 g from n-hexane and 1 g of dichloromethane fractions.130 Two derivatives, 122131
and 123,132 were semi-synthetically made in one step from the respective starting materials
ent-8(14),15-pimaradien-3β-ol (119) and ent-pimara-8(14),15-dien-19-oic acid (118). All
compounds (with the exception of 117) displayed excellent to moderate activity against at
least one of the 14 oral bacterial species tested, including clinical isolates. Compounds 118124 displayed good activity when tested against a clinical isolate of Prevotella buccae with
a range of MIC values from 1.5-4.0 µg/mL (slightly worse than that of the control
chlorhexidine (MIC = 0.92 µg/mL)). When tested against a broad panel of oral bacterial
species comprising two strains of P. gingivalis and one strain of P. nigrescens, P.
intermedia, Bacteroides fragilis, A. naeslundii, P. micros, and A. actinomycetemcomitans,
compounds 118, 119, and 123 displayed excellent to moderate activity with a range of MIC
values from 0.5-10 µg/mL (similar to those of chlorhexidine (MIC = 0.92-7.38 µg/mL)).
None of the compounds displayed activity against F. nucleatum, E. faecalis, and clinical
isolates of A. naeslundii, A. viscosus, and E. faecalis. The three most active compounds,
118, 119, and 123, displayed MBC values that were 1-8× their MIC values. Due to the
broad spectrum of activity against Gram-negative bacteria, the most active compounds,
118, 119, and 123, should undergo further structure optimization, mechanism of action,
and anti-P. gingivalis biofilm studies.

In another study, extracts, known isolated compounds (including oleanolic acid (96)), and
semi-synthetic derivatives of ursolic acid (125) were tested for antibacterial activity (125131,133 Figure 1.13). The extracts and pure known compounds were isolated from the aerial
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parts of the Brazilian plant Tibouchina candolleana. 1 kg of T. candolleana yielded crude
extracts of n-hexane (10.0 g), dichloromethane (15.5 g), and ethanol (44.3 g). The four
known isolated compounds comprised the triterpenes ursolic acid (125) and oleanolic acid
(96), and the flavonoids luteolin and genistein. Four semi-synthetic derivatives (126-129)
of ursolic acid (125) were prepared in one synthetic step consisting of acetylation or
esterification. When tested against B. fragilis, A. naeslundii, P. gingivalis, P. nigrescens,
F. nucleatum, Bacteroides thetaiotaomicron, Peptostreptococcus anaerobius, all extracts,
isolated compounds, and ursolic acid derivatives were inactive with the exception of ursolic
acid (125) that displayed moderate activity against P. gingivalis and A. naeslundii with
MIC values of 20 µg/mL (worse than those of the control chlorhexidine (MIC = 3.7 and
7.4 µg/mL)). Due to their inactivity, these compounds should not be further investigated
for anti-P. gingivalis activity.

In addition to semi-synthesis, biotransformation of natural products is a method used for
structure modification. The fungus Mucor rouxii was used for derivatization of the
pentacyclic triterpene oleanolic acid (96) through biotransformation (132-136, Figure
1.13).134 Oleanolic acid (96) was purchased and five derivatives were made through
biotransformation using a two-step protocol. Out of the five derivatives prepared, three
were novel (132, 135, and 136), one was known, 21β-hydroxy-3-oxo-olean-12-en-28-oic
acid (133), and the last one was the sodium salt derivative of 133 (134). When tested against
P. gingivalis, compound 134 displayed good activity with MIC and MBC values both of
6.6 µM (3.25 µg/mL), although inferior to those of the control chlorhexidine
dihydrochloride (MIC and MBC = 1.5 µM). Additionally, the parent compound oleanolic
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acid (96) displayed excellent activity against A. naeslundii with MIC and MBC values of
2.1 µM (0.96 µg/mL), which were better than those of chlorhexidine dihydrochloride (MIC
and MBC = 3.18 µM). All compounds displayed little to no activity when tested against A.
actinomycetemcomitans, E. faecalis, and P. nigrescens. SAR studies focused on
derivatives with more polar functionality similar to compound 134 could be developed to
improve activity against P. gingivalis.

As isolated natural products generally do not display as potent activity as semi-synthetic
derivatives, (S)-bakuchiol (137), the major constituent isolated from the seeds of Psoralea
corylifolia Leguminosae, was derivatized in one to two steps using methylation,
acetylation, epoxidation, and/or C-C bond formation via Heck and oxidative Heck coupling
to yield 16 compounds (138-153, Figure 1.14) with excellent activity against P.
gingivalis.135 The meroterpene, (S)-bakuchiol (137), offered an ideal structure for SAR
studies with three major sites of modification: (i) the hydroxyl group at the meta or para
position of the aryl ring was modified (e.g., acetyl, methyl ether, nitro, and amino groups),
(ii) the isopropylidene group was modified at C-8 with an aldehyde or C-6 to C-7 with an
epoxide or to a single bond, and (iii) the ethylene group was modified from a double bond
to a single bond or addition of an aryl group. All compounds were inactive when tested
against F. nucleatum, with the exception of compound 146, which displayed good activity
with an MIC value of 8 µg/mL, worse than that of the control triclosan that is added in
consumer products as an antibacterial agent, but it is not FDA approved (MIC = 2 µg/mL).
Among the 16 semi-synthetic derivatives, nine displayed excellent to good activity when
tested against S. mutans, A. viscosus, S. sanguinis, P. intermedia, and P. gingivalis with
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MIC and MBC values in the range of 0.25-8 µg/mL, similar to those of the control triclosan
(MIC and MBC = 1-8 µg/mL). In single-species biofilm studies with S. mutans along with
multi-species biofilms (containing S. mutans, A. viscosus, F. nucleatum, and P. gingivalis),
the three most active compounds, 146-148, displayed good MBIC50 values of 1-2 µg/mL
against single-species biofilms and 4-16 µg/mL against multi-species biofilms. Mechanism
of action studies revealed that compounds 146-148 permeabilized the membrane of S.
mutans. Overall, modification of the ethylene group on the parent compound, (S)-bakuchiol
(137), with the addition of an aryl group containing para-hydroxy or para-methoxy groups
was a successful strategy for developing promising anti-P. gingivalis agents.
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Figure 1.14. Ten scaffolds as representative examples of natural products and their derivatives that were
tested as potential antibacterial agents against oral bacterial species.

In a comprehensive study, curcumin (154; normally found as the major component in
rhizomes of the plant Curcuma longa from the family Zingiberaceae) was purchased and
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semi-synthetically derivatized to yield quantum curcumin (155), which was tested against
oral bacterial species (Figure 1.14).136 Quantum curcumin (155) was synthesized in a twostep top-down method to yield a compound with a C=C double bond at the C-4 position
along with a hydroxyl group at the C-5 position rather than the carbonyl group seen in
curcumin (154). When tested against P. gingivalis, A. viscosus, and S. mutans, quantum
curcumin (155) displayed excellent activity with MIC values of 1.114 µM (0.42 µg/mL),
2.228 µM (0.82 µg/mL), and 8.913 µM (3.28 µg/mL), respectively. These MIC values
were much better than those of the control MTZ with respective MIC values of 1.46 mM,
2.921 mM, and 11.68 mM. In anti-biofilm studies, quantum curcumin (155) also displayed
low MBIC50 and MBIC90 values in the range of 0.557 to >17.826 µM. A total of 11 clinical
isolates of P. gingivalis were treated with quantum curcumin (155) and excellent MIC
values were observed in the range of 0.557-8.913 µM. Mechanism of action studies
revealed that quantum curcumin (155) inhibits Arg- and Lys-specific proteinases produced
by P. gingivalis at 17.826 µM with 99% and 89% inhibition, respectively. Inhibition of
gingipains is important as these are virulence factors that contribute to the progression of
periodontal diseases. In cytotoxicity studies, quantum curcumin (155) was found to be nontoxic as no hemolysis against human RBCs was observed at concentrations up to 100 µM
and no cell leakage was observed in cell viability assays using Vero (kidney) cells. With
their excellent activity against P. gingivalis, mechanism of action revealed, and low
toxicity, these highly promising compounds should be further studied in animal models.

Small signaling molecules called autoinducers mediate the cell-to-cell communication
known as quorum sensing (discussed in section 1.2.2). The macroalga Delisea pulchra
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produces brominated furanones such as 3-(dibromomethylene)isobenzofuran-1(3H)-one
(156a), which was derivatized in one to five steps using a Ramirez olefination reaction137
to yield 14 compounds that were tested for antibacterial activity. These compounds were
also tested for inhibition of F. nucleatum, P. gingivalis, and T. forsythia biofilm formation
by inhibiting autoinducer-2 (AI-2), which is secreted by F. nucleatum (156-168, Figure
1.14).138 Replacement of the fused aromatic ring of the bicyclic structure with fused
cyclohexyl or cyclopentyl groups along with substitution of the fused benzene ring with
methyl and alkoxy groups with varying chain lengths afforded the three most active
compounds, 167 (fused cyclopentyl group in place of the fused aromatic ring), 157a
(methyl group at the 5-position), and 162a (methyl group at the 7-position). Unfortunately,
none of the compounds inhibited the growth of planktonic F. nucleatum, P. gingivalis, or
T. forsythia. However, compounds 157a, 162a, and 167 inhibited a little over 40% of F.
nucleatum biofilm formation at 2 µM. Once pathogenic oral bacterial species colonize the
biofilm, they secrete small signaling molecules that enable them to communicate with other
bacterial species to increase biofilm production. By inhibiting these signaling molecules
the bacteria can no longer communicate with one another and the biofilm formation is
reduced. The mechanism of action of 157a, 162a, and 167 was determined to be inhibition
of AI-2 activity, as the compounds inhibited ~20-50% of activity at 2 µM (0.59-0.64
µg/mL). The compounds also inhibited biofilm formation induced by F. nucleatum AI-2
in biofilms of F. nucleatum, P. gingivalis, and T. forsythia at 2 µM. In cytotoxicity studies,
compounds 157a, 162a, and 167 displayed no cytotoxicity in human monocytic cell line
THP-1, human gingival fibroblasts, and human oral keratinocyte cell line HOK-16B at 2
µM. Additionally, these three compounds did not induce an inflammatory response in
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THP-1 cells or human gingival fibroblasts. Compounds 157a, 162a, and 167 should be
further investigated for their potential ability to control biofilm formation in animal models.

Gram-negative bacteria produce autoinducers, such as the AI-2 produced by F. nucleatum
as well as the N-acyl homoserine lactone (HSL) produced by P. gingivalis, that contribute
to the progression of periodontitis through the production of virulence factors and biofilm
formation. The previously synthesized derivative of N-acyl HSL,139 compound 169, was
used in combination with cefuroxime, ofloxacin, and MIN to study the effect on P.
gingivalis biofilm disruption (Figure 1.14).140 Alone, compound 169 was not active against
P. gingivalis even at a concentration of 100 µM (20.4 µg/mL). However, when compound
169 was used in combination with the known antibiotics cefuroxime, MIN, and ofloxacin,
there was a synergistic effect that allowed for a much better biofilm disruption, as
established by an ATP bioluminescence assay. The best combination that reduced the
viability P. gingivalis cells in biofilms was compound 169 with cefuroxime, followed by
MIN, and then by ofloxacin.

Inhibition of P. gingivalis biofilm formation was also investigated in a study where three
active compounds, 170-172, were selected from screening 506 derivatives of oroidin
(Figure 1.14).141 Oroidin, which belongs to a class of marine alkaloids, is a secondary
metabolite from the marine sponge Agelas conifera. The most active compounds 170-172
contained 2-aminoimidazole in their structures. Compounds 170-172 reduced the levels of
P. gingivalis without affecting S. gordonii. In multi-species biofilms comprising P.
gingivalis and S. gordonii, the most active compound, 170, displayed excellent IC50 values
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of 3.41 ± 0.92 µM against P. gingivalis biofilms. The biovolume of P. gingivalis was
reduced by 90% at 20 µM and 40% at 2.5 µM with the important aspect of not affecting
the commensal beneficial species S. gordonii. As the compounds did not inhibit the growth
of P. gingivalis, the mechanism of action was investigated to determine if the compounds
affected community mediators involved in the formation of multi-species biofilms.
Compounds 170-172 reduced the mRNA levels of fimA and mfa1, which reduce the
fimbrial adhesins Mfa1 and FimA to inhibit the ability of P. gingivalis to attach to the early
colonizer S. gordonii. As the most active compound 170 showed exciting data as an
inhibitor of the initial adherence of P. gingivalis to S. gordonii, it should be further tested
in mature biofilm models to determine if it can still be as effective in a more complex
system.

In sum, derivatives of natural products were generally more active against P. gingivalis
than the parent compound from which they were derived. Not all derivatives inhibited the
growth of P. gingivalis. The scaffolds containing brominated furones, HSL, and alkaloids
with 2-aminoimidazoles inhibited P. gingivalis biofilm formation. When tested against oral
bacterial species including P. gingivalis, the most active compounds were meroterpene
derivatives, followed by curcumin, pimarane-type diterpenes, pentacyclic triterpenes,
triterpenes, and flavonoids. Out of the 16 semi-synthetic meroterpene derivatives, nine
displayed the best activity and should be further investigated in cytotoxicity studies.

1.4.3.2. Essential oils and their derivatives
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Essential oils are extracts that contain many natural products that alone may not inhibit the
growth of P. gingivalis or other oral bacterial species, but together in a mixture they may
display synergistic activity against the targeted pathogen. Essential oils are traditional
herbal medicine that display antibacterial activity against oral bacterial species and could
be used to isolate active compounds within the extracts to determine the biologically active
compounds that could be used to treat periodontitis. Essential oils and their derivatives will
be presented in the two following subsections: (i) extracts and/or isolated compounds from
various plants and (ii) purchased extracts and/or individual compounds tested against oral
bacterial species. Compounds shown in these sections are representative structures of some
of the many compounds isolated and purchased.

1.4.3.2.1. Extracts and/or isolated compounds from various plants
Cinnamon bark essential oil (CBEO) originally extracted from the inner bark of trees from
the Sri Lankan cinnamon, Cinnamomum zeylanicum, contains 51 components that could
be tested against P. gingivalis.142 In a thorough study, the major known constituents
cinnamaldehyde (173), eugenol (174), and β-caryophyllene (175), as well as a minor
component, β-pinene (176), were tested for anti-P. gingivalis activity (Figure 1.15). When
tested against P. gingivalis, cinnamaldehyde (173) displayed excellent activity with an
MIC value of 2.5 µM (0.33 µg/mL), which was better than those of CBEO (MIC = 6.25
µg/mL) and the control tinidazole, a synthetic nitroimidazole antiprotozoal agent (MIC =
7.8 µM). In mechanism of action studies, CBEO and cinnamaldehyde (173) caused
membrane permeabilization of P. gingivalis cells and caused the loss of DNA, RNA, and
protein from cells resulting in cell death. P. gingivalis biofilm formation was inhibited with
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CBEO at 4.17 µg/mL by 74.5% and with cinnamaldehyde (173) at 1.67 µg/mL by 67.3%.
Only slight inhibition of preformed P. gingivalis biofilm growth was displayed with
CBEO, and cinnamaldehyde (173) displayed no inhibition. The major component of
CBEO, cinnamaldehyde (173), shows great promise with low MIC values, but it should be
tested in combination with an antibiotic that can disrupt preformed biofilms of P. gingivalis
as it is not a viable option to kill P. gingivalis in mature biofilms on its own.

Figure 1.15. Eight scaffolds as representative examples of compounds isolated from various plants that were
tested as potential antibacterial agents against oral bacterial species.

In a preliminary investigation, compounds were isolated from the oleoresin of the tropical
rainforest tree Copaifera langsdorfii and tested against P. gingivalis (Figure 1.15).143 A
total of 12 g of oleoresin was used to isolate four known diterpenes, (-)-copalic acid (177),
(-)-acetoxycopalic acid (178), (-)-hydroxycopalic acid (179), and (-)-agathic acid (180), as
well as two purchased diterpenes, sclareol (181) and manool (182). When tested against A.
naeslundii, P. gingivalis, and P. anaerobius, (-)-copalic acid (177) displayed the best
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activity with MIC values of 6.2 µg/mL, 3.1 µg/mL, and 3.1 µg/mL, respectively, which
were similar or worse than those of the control chlorhexidine dihydrochloride (MIC = 1.8,
0.9, and 7.4 µg/mL, respectively). All compounds displayed little to no activity against
Bacteroides fragilis, Bacteroides thetaiotaomicron, F. nucleatum, and P. nigrescens. In
time-kill assays, 177 displayed bactericidal activity at 3.1 µg/mL, which was 1× MBC
against P. gingivalis. In cytotoxicity studies, 177 displayed no toxicity in a human
fibroblast cell line up to 62.5 µM. With its low MIC values and good bactericidal activity,
(-)-copalic acid (177) warrants further investigation in P. gingivalis biofilm studies.

Just as CBEO was extracted from tree bark, essential oils isolated from the roots of trees
were tested against P. gingivalis. In a study that unfortunately yielded inactive compounds
against P. gingivalis, Miswak essential oil was extracted from chewing sticks called
Miswak from Salvadora persica, which was nicknamed “the toothbrush tree” as the
chewing sticks can be used as a natural toothbrush.144 When used as a toothbrush, the
chewing sticks releases the major component benzyl isothiocyanate (183) and minor
components benzyl cyanide (184) and benzaldehyde (185, Figure 1.15). When tested
against Haemophilus influenzae, A. actinomycetemcomitans, and P. gingivalis, low activity
was seen with a dose dependent response of Miswak essential oil and benzyl isothiocyanate
(183) inhibiting 100% of bacterial growth with CFU at 1170 µg/mL, worse than what was
observed with the control chlorhexidine (100% inhibition at 500 µg/mL). Benzyl cyanide
(184) and benzaldehyde (185) were found to be inactive. Due to their inactivity, these
compounds should not be further investigated for anti-P. gingivalis activity.
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Overall, the isolated compounds comprising cinnamaldehyde and the diterpenes showed
great promise as anti-P. gingivalis agents. These compounds should, respectively, be
further investigated in combination studies with known antibacterial agents and antibiofilm studies.

1.4.3.2.2. Purchased extracts and/or individual compounds
Natural product essential oils extracted from plants are commonly used today and they are
readily available for purchase along with their major constituents. Essential oils are
extracted from various parts of plants such as the leaves and peel of the Thai lime Citrus
hystrix de Candolle. In a study, the leaf and peel oil of Citrus hystrix as well as the terpenes
citronellal (186), linalool (187), and pinene (188) were purchased and tested for their
antibacterial activity (Figure 1.16).145 Unfortunately, the leaf oil, peel oil, and major
components were found to be inactive when tested against P. gingivalis, S. sanguinis, and
S. mutans. When tested against P. gingivalis biofilm formation, leaf oil displayed 99%
inhibition at 4.25 mg/mL (4250 µg/mL). Due to their inactivity against oral bacterial
species, these compounds should not be further pursued.
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Figure 1.16. Seven scaffolds as representative examples of purchased compounds that were tested as
potential antibacterial agents against oral bacterial species.

In another study, clove essential oil, originally extracted from the flower buds of Eugenia
caryophyllata L., was purchased along with its major components, eugenol (174) and βcaryophyllene (175), and these were tested for antibacterial activity (Figures 1.15 and
1.16).146 When tested against 11 oral bacterial species comprising S. mutans, S. sanguinis,
S. sorbinus, Streptococcus ratti, Streptococcus criceti, Streptococcus anginosus, S.
gordonii, A. actinomycetemcomitans, F. nucleatum, P. intermedia, and P. gingivalis, clove
essential oil, eugenol (174), and β-caryophyllene (175) were all found to be inactive with
the lowest MIC value observed being 100 µg/mL. In combination studies using
checkerboard and time-kill assays, there was a slight improvement with activity of clove
oil and eugenol (174) in combination with ampicillin and gentamicin with ≥4-fold
reduction. These compounds could potentially be used in combination with known
antibiotics to improve their activity against P. gingivalis as they are inactive when tested
alone.

The major components of essential oils can come from many different sources, as seen
with eugenol (174) and β-caryophyllene (175) from CBEO and clove oil. In a study that
yielded inactive compounds, the essential oils of Orthosiphon stamineus Benth and Ficus
deltoidea Jack and their components eugenol (174), β-caryophyllene (175), α-humulene
(189), and germacrene D (190) were tested alone and in combination with AMX (Figure
1.16).147 When tested against E. faecalis, S. mutans, S. mitis, S. salivarius, A.
actinomycetemcomitans, P. gingivalis, and F. nucleatum, the essential oils and their
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components were found to be inactive with the lowest MIC value observed being 630
µg/mL. These values were much worse than that of the control AMX (MIC = 50 µg/mL).
In combination studies, O. stamineus and F. deltoidea essential oils displayed an additive
effect with AMX with a 2-fold reduction in MIC values in all bacterial species tested. In
general, due to their inactivity, the purchased extracts and compounds described in this
section should not be further pursued.

1.4.3.3. Inactive natural products
Investigations into natural product scaffolds that are inactive as antibacterial agents are
rarely published in the scientific literature. However, these studies provide valuable
information as to which scaffolds should be avoided leading to more productive research
by focusing on those that show promise. In the studies described in this section, there were
many natural products tested that were inactive, therefore, the scaffolds below are
representative scaffolds. This section provides 13 representative natural products that were
synthetized, isolated, or purchased that were found to be inactive against oral bacterial
species such as P. gingivalis (Figure 1.17).

The peel of the lemon citrus fruit contains four natural products that were isolated and
tested against S. mutans, P. intermedia, and P. gingivalis. These compounds were inactive
against the bacterial species with 5-geranyloxypsolaren (191, Figure 1.17) that displayed
the best MIC value of 0.15 mM (51 µg/mL) against S. mutans and P. gingivalis.148 The
effects of resveratrol (192, Figure 1.17), which is a natural product originally found in
grape skin used as a dietary supplement, was purchased and thoroughly evaluated in an
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investigation with planktonic P. gingivalis, inhibition of biofilm formation studies,
cytotoxicity assays, and membrane permeabilization assays.149 When tested against P.
gingivalis, resveratrol (192) displayed no activity with an MIC value of 250 µg/mL and an
MBC value of 500 µg/mL. The evaluation of the crude extract and four fractions
(chloroform, hexane, ethanol, and butanol) isolated from the aerial parts (leaves and soft
stem) of the herb Phytolacca americana displayed no activity against P. gingivalis, S.
mutans, and E. coli.150 The crude extract of P. americana displayed 100% growth inhibition
of P. gingivalis at 1800 µg/mL. The major constituents of P. americana were purchased
and found to be inactive with the exception of kaempferol (193, Figure 1.17) that displayed
84% growth inhibition of P. gingivalis at 8 µg/mL. The tea catechin EGCG (194, Figure
1.17) was purchased and evaluated against planktonic P. gingivalis, preformed biofilms,
and established biofilms of P. gingivalis.151 EGCG (194) was found to be inactive with an
MIC value of 500 µg/mL against planktonic P. gingivalis. Similar results were displayed
in a separate study where green tea extracts and EGCG (194) were tested against three
strains of P. gingivalis and were found to be inactive.152
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Figure 1.17. Thirteen scaffolds as representative examples of compounds that were tested as potential
antibacterial agents and found to be inactive against oral bacterial species.
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The synthesis and evaluation of 10 known alcohol derivatives and 10 known ester
derivatives of 3-(4'-geranyloxy-3'-methoxyphenyl)-2-trans propenoic acid (195, Figure
1.17), which was originally isolated from the bark of Acronychia baueri Schott, against
biofilm formation of P. gingivalis and S. mutans produced inactive compounds.153 The
parent compound 195 displayed 80% inhibition of P. gingivalis biofilm formation at 31.3
µg/mL (78.1 µM). In another study, the pentacyclic triterpenoids oleanolic acid (96) and
ursolic acid (125) were tested against a wide variety of bacterial strains (Figure 1.17).154
Although oleanolic acid (96) was inactive against P. gingivalis with an MIC value of 625
µg/mL, both oleanolic acid (96) and ursolic acid (125) displayed excellent activity against
M. tuberculosis (MIC = 2.5 µg/mL). A black tea extract and two major components,
including theaflavin (196, Figure 1.17), were found to be completely inactive against P.
gingivalis, P. intermedia, F. nucleatum, and A. actinomycetemcomitans (MIC values in the
range of 125-2000 µg/mL).155 A separate in-depth study focused on the inactive theaflavin
(196) investigated its activity against planktonic P. gingivalis, biofilm formation, biofilm
reduction, biofilm viability, cytotoxicity in human gingival fibroblasts, and inhibition of
virulence factors produced by P. gingivalis such as gingipains and collagenases.156 It is of
no surprise that theaflavin (196) in this later study displayed no antibacterial activity with
an MIC value of 125 µg/mL against planktonic P. gingivalis. Originally isolated from the
root of Scutellaria baicalensis Georgi, the flavonoid baicalein (197, Figure 1.17) was tested
against 15 oral bacterial species, including P. gingivalis, and was found to be in active with
MIC values in the range of 80-320 µg/mL.157 Isolated from the mushroom Antrodia
camphorate, the ethanol, EtOAc, chloroform, and water extracts as well as its three major
components, 4,7-dimethoxy-5-methyl-1,3-benzodioxole (198), dehydrosulphurenic acid
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(199), and dehydroeburicoic acid (200), were tested for antibacterial activity (Figure
1.17).158 When tested against P. gingivalis and S. mutans, compounds 198-200 were found
to be inactive while the chloroform, EtOAc, and 95% ethanol extracts displayed good
antibacterial activity with MIC values in the range of 4-16 µg/mL. In another study that
evaluated the polyphenol myricetin (201, Figure 1.17) against four P. gingivalis strains, it
was found that myricetin (201) was inactive with MIC values in the range of 62.5-125
µg/mL.159

1.4.4. Overall summary of all molecules discussed in this review
Below, a table (Table 1.3) summarizing all the data that were discussed in this review is
presented to provide readers with a quick reference summary that can be used to identify
promising compounds they might be interested in pursuing or learning more about.

Table 1.3: Summary of activity of representative compounds presented in this review that
were tested against P. gingivalis.
Section 1.4.1. Novel compounds
Family
Cpd # Inhibition
of
P.
gingivalis
growth
1.4.1.1.
1-25
×
Triazoles

1.4.1.2.
Heterocyclic

26-27

×

28



1.4.1.3. Bicyclic 29-42
43-51
52
1.4.1.4.
Sulfonamides

53-61
62


×

N/A
×

Inhibition of P. gingivalis Antibiofilm activity
virulence factors

Cytotoxicity Appropriate controls

YES: Binds Mfa of P. Disrupt
preformed
gingivalis
biofilms and inhibited P.
gingivalis incorporation
into S. gordonii and F.
nucleatum biofilms
NO: Not active against N/A
fimbriated strain
N/A
N/A

NT: TIGK, NC
J774A.1, and
sheep RBCs

N/A
N/A
YES: Binds LPSs from P.
gingivalis
YES: Inhibits P. gingivalis
γ-CAs
NO: Not active against
meso-2,6-diaminopimelate

N/A
N/A
N/A

N/A
N/A
N/A

YES (ERY, MTZ, TET,
and gentamicin)
NO
(curcumin,
parthenolide, quercetin,
EGCG, and resveratrol)
YES (chlorhexidine)
YES (MTZ)
NC

N/A

N/A

NO (acetazolamide)

N/A

N/A

NC
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T: HeLa
N/A

Table 1.3 continued
dehydrogenase
gingivalis
N/A
N/A

from

P.


63-73

74-88
Section 1.4.2. Drug repositioning
Family
Cpd # Inhibition Inhibition of P. gingivalis
of
P. virulence factors
gingivalis
growth

89
YES: Binds LPSs from P.
gingivalis

90

×

91

×

Section 1.4.3. Natural products
Family
Cpd # Inhibition
of
P.
gingivalis
growth

1.4.3.1. Natural 92
products
and
their derivatives 93-94


95-97

98
99-100
101




102



103104
105106



107108



109110

×

111116





N/A
N/A

NT: OKF6
NT: OKF6

Antibiofilm activity

Cytotoxicity Appropriate controls

Inhibited P. gingivalis and T:
Human
S. mutans biofilms
oral gingival
epithelial
cells
NT:
horse
RBCs
NO: Low affinity towards N/A
N/A
P. gingivalis DPP4
YES: Binds GroEL from P. N/A
N/A
gingivalis

YES (TET and ZAF)
YES (TET and ZAF)

YES
(TET,
chlorhexidine, rifampin,
triclosan, ciprofloxacin,
and melittin)
NC
NO (pentamidine and
benzamidine)

Inhibition of P. gingivalis Antibiofilm activity
virulence factors

Cytotoxicity Appropriate controls

N/A

N/A

N/A

N/A
N/A
N/A

N/A
N/A
N/A

N/A
N/A
N/A

N/A
N/A

N/A
Inhibited biofilm growth
and disrupted preformed
biofilms of S. mutans and
A. viscosus
YES: Inhibited gingipains Slight inhibition of P.
Rgp and Kgp from P. gingivalis
biofilm
gingivalis
formation
N/A
N/A
YES: Reduced alveolar Inhibited biofilm growth
bone loss and inflammation and disrupted preformed
induced by LPSs from P. biofilms of P. gingivalis
gingivalis

N/A
N/A

YES
(chlorhexidine
gluconate)
NC
NC
YES
(chlorhexidine
gluconate)
YES (penicillin G)
NO (triclosan)

N/A

NC

N/A

YES (penicillin G)

NT: Human NC
periodontal
ligament cells
or monocytelike THP-1
cells
YES: Inhibited adherence Disrupted
preformed N/A
NC
of P. gingivalis to GMSM- biofilms of P. gingivalis
K cells, inhibited activity
against collagenase, and
reduced
LPS-induced
secretion of IL-1β, TNF-α,
and IL-8
NO: Not as active against
MMP-9
YES: Inhibited adherence No inhibition of P. N/A
NC
of P. gingivalis to GMSM- gingivalis
biofilm
K cells, inhibited MMP-9 formation
activity,
and
reduced
secretion of TNF-α and IL8
NO: No inhibition of P.
gingivalis
collagenase
activity
N/A
N/A
N/A
YES
(chlorhexidine
gluconate)
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Table 1.3 continued
117124
125131
132136
137153



N/A

N/A

N/A

YES (chlorhexidine)



N/A

N/A

N/A

YES (chlorhexidine)



N/A

N/A

N/A



N/A

YES
(chlorhexidine
dihydrochloride)
NO (triclosan)

154155



Inhibited
growth
of
single-species biofilms of
S. mutans along with
multi-species
biofilms
(containing S. mutans, A.
viscosus, F. nucleatum,
and P. gingivalis)
YES: Inhibited P. gingivalis Inhibited
biofilm
gingipains
formation of P. gingivalis
and A. viscosus
YES:
Inhibited
AI-2 Inhibited
biofilm
activity
formation of F. nucleatum

N/A

NT: Human YES (MTZ)
RBCs
and
Vero cells
156NT: THP-1, NO
((Z)-4-bromo-5×
168
human
(bromomethylene)furangingival
2(5H)-one)
fibroblasts,
and
HOK16B
169
N/A
Disrupted P. gingivalis N/A
YES
(cefuroxime,
×
biofilms in combination
ofloxacin, and MIN)
with
other
known
antibiotics
170YES: Reduced mRNA Inhibited the ability of P. N/A
NC
×
172
levels of fimA and mfa1
gingivalis to attach to S.
gordonii

1.4.3.2. Essential 173N/A
Inhibited
biofilm N/A
NO
(CBEO
and
oils and their 176
formation of P. gingivalis
tinidazole)
derivatives
and slightly inhibited
preformed biofilm growth

177N/A
N/A
NT: Human YES
(chlorhexidine
181
fibroblast
dihydrochloride)
cells
183N/A
N/A
T: Gingival YES (chlorhexidine)
×
185
fibroblasts
NT:
Oral
keratinocytes
186N/A
Not active against P. N/A
YES (chlorhexidine)
×
188
gingivalis biofilms
189N/A
Not active against P. N/A
YES (AMX)
×
190
gingivalis biofilms

Indicates active below 49 µg/mL for the best representative compounds in the series as determined by either MIC,
CFUs, or % growth inhibition.
×
Indicates not active (>50 µg/mL) for the best representative compounds in the series as determined by either MIC,
CFUs, or % growth inhibition.
N/A
Indicates not available for the best representative compounds in the series.
NT
Indicates not toxic for the best representative compounds in the series.
T
Indicates toxic for the best representative compounds in the series.
NC
Indicates no control used for comparison.
YES
Indicates that an appropriate antibacterial/antiseptic agent FDA-approved for periodontal therapy was used for
comparison.
NO
Indicates that either an antibacterial agent approved for indications other than periodontal therapy or not approved
by the FDA for any indications was used for comparison.
Indicates compounds that displayed good anti-P. gingivalis activity as identified by growth inhibition, virulence
factors inhibition, and/or antibiofilm activity.
Indicates compounds that displayed moderate anti-P. gingivalis activity as identified by growth inhibition, virulence
factors inhibition, and/or antibiofilm activity.
Indicates compounds that displayed poor anti-P. gingivalis activity as identified by growth inhibition, virulence
factors inhibition, and/or antibiofilm activity.

1.5. OVERALL CONCLUSION AND PERSPECTIVE
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Periodontal diseases can be treated with noninvasive techniques using antibacterial agents
as adjunctive therapy to mechanical debridement. The discovery and use of penicillin first
introduced into the market in 1942, revolutionized modern medicine and drug
development. Nevertheless, it is imperative for researchers to develop novel antibacterial
agents as many of the ones currently used for the treatment of periodontal diseases are
broad-spectrum and bacterial species are continuously developing increased resistance to
them.50 We encourage our colleagues to pursue novel targeted periodontal therapy as
broad-spectrum antibiotics can lead to the disruption of the oral bacterial homeostasis
leading to dysbiosis and chronic inflammatory disease.160 Targeted antibacterial therapy
will be able to prevent disruption of the normal abundance of commensal bacterial
communities, while eradicating specifically periodontopathogens such as P. gingivalis.

As targeting specific oral pathogenic bacterial species within biofilm structures is more
difficult, the development of novel compounds active against P. gingivalis are in early
stages of investigation. The early stages of development for these compounds generally
focus on the inhibition of bacterial growth with MIC testing, percent growth inhibition
assays, and CFU assays against planktonic oral bacterial species. Several of the small
molecules either novel or known discussed in this review show great promise as anti-P.
gingivalis agents. However, it is crucial to develop future studies using not only single- but
multi-species biofilms, testing for drug resistance in planktonic bacteria and biofilms,
cytotoxicity in oral epithelial cells, and testing new compounds in animal models of
periodontal diseases. Researchers should also investigate the mechanism of action of these
compounds as they may not inhibit growth of the bacteria, but they may be very active as
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inhibitors of bacterial virulence factors. This could be used as novel therapy as it could stop
the progression of periodontal diseases if the virulence of pathogenic bacteria could be
blocked. As many of these investigations are in their preliminary stages, it is difficult to
conclusively say what type(s) of scaffold should be used in the clinic in place of the
currently used antibacterial agents for the treatment of periodontal diseases. Nevertheless,
we hope this review will help guide researchers in a logical direction for in-depth studies
based on the summary of the types of scaffolds that have so far demonstrated great targeted
activity against P. gingivalis. Of note, many of the investigations are limited due to the use
of inappropriate controls. At least one antibacterial agent currently used in the clinic for
periodontal therapy should always be used as a control in the experiments to determine the
novel compounds true potential as an antibacterial agent. Importantly, the use of future
anti-P. gingivalis agents should consider their potential for topical use in addition to their
systemic use to ensure that there is a high concentration of the treatment at the site of the
infection.
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Chapter 2
Second generation of zafirlukast derivatives with improved activity against the oral
pathogen Porphyromonas gingivalis

2.1. ABSTRACT
Porphyromonas gingivalis is a Gram-negative anaerobic pathogen that can trigger oral
dysbiosis as an early event in the pathogenesis of periodontal disease. The FDA-approved
drug zafirlukast (ZAF) was recently shown to display antibacterial activity against P.
gingivalis. Here, 15 novel ZAF derivatives were synthesized and evaluated for their
antibacterial activity against P. gingivalis and for their cytotoxic effects. Most derivatives
displayed superior antibacterial activity against P. gingivalis compared to ZAF and its 1st
generation derivatives along with little to no growth inhibition of other oral bacterial
species. The most active compounds displayed bactericidal activity against P. gingivalis
and less cytotoxicity than ZAF. The superior and selective antibacterial activity of ZAF
derivatives against P. gingivalis along with an increased safety profile compared to ZAF
suggest these new compounds, especially 14b and 14e, show promise as antibacterials for
future studies aimed to test their potential for preventing/treating P. gingivalis-induced
periodontal disease.

2.2. INTRODUCTION
Periodontal diseases are bacterial infections characterized by unresolved inflammation that
leads to the destruction of the gum and bone that support the teeth.161 In the United States,
>47% of adults 30 years and older suffer from periodontal diseases.4 An early event in the
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pathogenesis of periodontal diseases is oral dysbiosis, a phenomenon that describes
changes in the abundance of specific bacterial species that are normally found in oral
health. Among the triggers of oral dysbiosis, “key stone” pathogens such as
Porphyromonas gingivalis have been identified. In addition to periodontal disease, P.
gingivalis has been correlated to diseases such as cardiovascular diseases, diabetes,
rheumatoid arthritis, and Alzheimer’s disease.12,

162-164

Therefore, P. gingivalis is a

plausible bacterial target for preventing/treating periodontal diseases with antibacterials.
The lack of clear guidelines for selecting the antibiotic regimen for treating generalized
aggressive forms of periodontal diseases has led to poor efficacy and development of drugresistant bacteria.61, 62, 165 One of the current treatment options for chronic periodontitis
includes scaling and root planning with antibiotic adjunctive therapy using doxycycline or
a combination of amoxicillin and metronidazole.166-169 Although there are antibiotics
currently used to treat chronic periodontitis, it is not feasible to use these antibiotics for a
prolonged period of time.170-172 Therefore, there is a growing need for novel and specific
antibacterials active against periodontopathogens such as P. gingivalis to prevent/treat
chronic periodontitis.

An appealing option to uncover new antibacterials with a fast and affordable strategy is the
repositioning of FDA-approved drugs for new applications to treat periodontitis.173, 174
Drug repositioning is simply using existing drugs approved for the treatment of one disease
to treat a different disease. Screening of a drug repositioning library has recently led to the
discovery that the FDA-approved drug zafirlukast (ZAF) displayed specific antibacterial
activity against P. gingivalis (Figure 2.1).62, 104, 175 This is significant given the need for

85

developing new antimicrobials with specificity for oral pathogens associated with
periodontal diseases without compromising the normal “good” oral bacteria associated
with periodontal health. Additionally, ZAF has been shown to be a potential treatment
option for Mycobacterium tuberculosis and West Nile virus infections.176, 177 Inspired by
these findings, we have been developing ZAF derivatives as novel drug candidates for
targeting P. gingivalis. We previously identified three ZAF derivatives with promising
anti-P. gingivalis activity.62 Herein, these 1st generation ZAF derivatives were used as
starting points for further structure optimization on the ZAF acylsulfonamide ring (e.g.,
addition of fluoro and nitro groups along with replacement of phenyl by a naphthyl moiety)
with the goal of increasing inhibition of P. gingivalis growth and reduce cytotoxicity. The
short 3-4 linear step synthesis of 15 ZAF derivatives is reported. The antibacterial activity
against P. gingivalis and other oral bacterial species as well as the cytotoxic activity against
human oral epithelial cells of these compounds is also presented.

Figure 2.1. Chemical structure of ZAF and overview of fifteen 2nd generation derivatives synthesized herein.
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2.3. DESIGN AND SYNTHESIS OF 2ND GENERATION ZAF DERIVATIVES
In our 1st generation of ZAF derivatives,62 the primary focus was to optimize the positions
of the substituents on the ZAF benzoyl ring. It was found that a compound with a 2methoxy-5-indoyl organization displayed increased P. gingivalis growth inhibition
compared to those with the 3-methoxy-4-indoyl from the parent ZAF (Figure 2.1), and this
new substitution pattern was therefore kept constant on the benzoyl ring of the 2nd
generation of compounds presented herein. With the limited preliminary structure-activity
relationship (SAR) that was performed in our previous study, it appeared that a methyl
group on the indole nitrogen might be beneficial for P. gingivalis growth inhibition and
that having a hydrogen versus a nitro group at the R1 position on the indole ring might not
have any effect on activity. To corroborate these very preliminary observations and to,
more importantly, investigate the potential of having different acylsulfonamides, which
was not investigated previously, we synthesized compounds 12a, 12c, 12f, 13a-13f, and
14a-14f.

The preparation of compounds 12a, 12c, 12f, 13a-13f, and 14a-14f was performed by a
linear 3-4 step synthesis to modify the following parts of the ZAF scaffold: its indole (at
the R1 and R2 positions), benzoyl (arrangement of the three different substituents “indole,
methoxy, and acylsulfonamide”), and acylsulfonamide (R3 position) rings (Scheme 2.1A).
Briefly, the synthesis proceeded as follows. Commercially available 5-nitroindole
underwent methylation to form compound 3 in 66% yield. The condensation reaction
between the commercially available (indicated by a $ sign in Scheme 2.1) indole (1) or 1methylindole (2), or the synthesized 1-methyl-5-nitroindole (3) with methyl-5-formyl-2-
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methoxybenzoate (4) first generated compounds 5, 6, and 7 in 10-93% yields. This
condensation proceeds via a unique mechanism, which involves resonance stabilized
carbocation formation in the presence of trifluoroacetic acid (TFA), followed by C-C bond
formation, reduction, protonation of hydroxyl group, and reduction with hydride from
triethylsilane (Et3SiH) to yield the methylene compounds 5, 6, and 7 (Scheme 2.1A and
Figure 2.2). Hydrolysis of the ester group of 5, 6, and 7 to a carboxylic acid then afforded
compounds 8, 9, and 10 in 85-96% yields. Finally, amide coupling of the carboxylic acids
with various commercially available acylsulfonamides (11a-11f) yielded 15 novel ZAF
derivatives 12a, 12c, 12f, 13a-13f, and 14a-14f in 16%-quantitative yields. Two of the
three 1st generation lead ZAF derivatives, 13g and 14h (previously published as 22b and
23a),62 were also re-synthesized in 38% and 24% yields (Scheme 2.1B) for comparison
study with the new 2nd generation ZAF derivatives 12a, 12c, 12f, 13a-13f, and 14a-14f. It
is important to note that as 13g and 14h had been found to display superior growth
inhibition of P. gingivalis compared to the parent ZAF from which they were derived, in
this study, the 2nd generation of compounds were mostly compared to 13g and 14h.
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Scheme 2.1. Synthetic scheme for the preparation of A. 2nd generation ZAF derivatives 12a, 12c, 12f, 13a13f, and 14a-14f and B. 1st generation ZAF derivatives 13g and 14h.62 Reaction conditions: (a) Et3SiH, TFA,
CH2Cl2, 0 °C to rt, 10-93%; (b) MeOH:THF:H2O/5:1:1, KOH, 65 °C, 85-96%; (c) acylsulfonamide,
EDC•HCl, DMAP, CH2Cl2, rt, 16%-quantitative yields.

With these 2nd generation ZAF derivatives aimed at increasing P. gingivalis growth
inhibition and decreasing cytotoxicity, the goal was to answer the following four a priori
questions in terms of SAR. The series/compound numbers used to answer these questions
are provided into parenthesis following the questions. The four questions are: (i) is a methyl
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R2 group on the indole nitrogen truly enhancing bacterial growth inhibition? (compounds
12a vs 13a, 12c vs 13c, and 12f vs 13f); (ii) what is the effect of adding an R3 electronwithdrawing group or bulkiness to the acylsulfonamide ring when R1 = H and R2 = Me?
(compounds 13a vs 13b vs 13c vs 13d vs 13e vs 13f); (iii) does an electron-withdrawing
group (e.g., R1 = NO2) on the indole ring affect the trend established for the
acylsulfonamide substituent patterns (trend for compounds 14a vs 14b vs 14c vs 14d vs
14e vs 14f compared to that of series 13)?; and (iv) is an electron-withdrawing group (e.g.,
R1 = NO2) on the indole ring beneficial for bacterial growth inhibition? (pairwise
comparison of series 13 vs 14).
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Figure 2.2. A representative synthetic mechanism for the condensation reaction, which is the first step in the
synthesis of the 2nd generation of ZAF derivatives as well as the two re-synthesized 1st generation ZAF
derivatives 13g and 14h.

2.4. ANTIBACTERIAL ACTIVITY
To answer the four a priori questions posed and to determine the potential of the 2nd
generation ZAF derivatives 12a, 12c, 12f, 13a-13f, and 14a-14f as antibacterials compared
to the 1st generation and the parent ZAF, they were first tested against P. gingivalis 381. A
colorimetric water-soluble tetrazolium-1 (WST-1) assay was used to determine the
antimicrobial effect of the 15 synthesized ZAF derivatives at 1, 10, and 100 µM. Their
activity was compared to commercially available positive controls tetracycline (Tet) (T, at
2.81 µM, which displayed 51% P. gingivalis growth inhibition) and ZAF (Z, at 25 and 50
µM, which displayed 70% and 68% P. gingivalis growth inhibition, respectively) (Figure
2.3, different blue bars), as well as to the 1st generation ZAF derivatives 13g and 14h (at 1,
10, and 100 µM). It is to be noted that, as expected, the DMSO control did not display any
bacterial growth inhibition. Additionally, it is important to note that the 2nd generation ZAF
derivatives were used as a preliminary screening of antibacterial activity in order to identify
lead compounds for further structure optimization along with future studies outside the
scope of this preliminary investigation. The concentrations of the ZAF control, 25 and 50
µM, were based on a previous publication, which showed that these concentrations were
the minimum concentration that inhibited the growth of P. gingivalis.104 In order to test the
ability of the ZAF derivatives to inhibit P. gingivalis growth, a wide range of
concentrations, 1-100 µM, was used to determine their level of potency.
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Figure 2.3. Percent growth inhibition of P. gingivalis 381 by ZAF derivatives 12a, 12c, 12f, 13a-13f, and
14a-14f, as determined by a colorimetric WST-1 assay after 24 h. Negative control = DMSO. Positive
controls = 2.81 µM of tetracycline (T) or 25 and 50 µM of ZAF (Z), and 1st generation ZAF derivatives 13g
and 14h. For each ZAF derivative, the data represent the average from six independent replicates per
condition of the growth inhibitory effect versus bacterial cultures grown in medium only. For the controls,
the data represent the average from 36 independent replicates. *The 1st generation ZAF derivatives 13g and
14h were previously published as 22b and 23a.62

At a quick glance, when compared to the 1st generation compounds 13g and 14h, it was
found that all 2nd generation compounds in series 14 were generally better at inhibiting the
growth of P. gingivalis at 1 µM. Overall, at 100 µM, 10 out of the 15 compounds (13b13d, 13f, and 14a-14f) displayed 58-75% growth inhibition comparable or superior to the
parent drug ZAF with 68% growth inhibition at 50 µM. In addition to these compounds,
one more compound (13a) also displayed superior activity with 55% inhibition of P.
gingivalis growth when compared to the effect of Tet with 51% growth inhibition. At 10
µM, six out of the 10 compounds (13c and 14a-14e) still exhibited 59-67% growth
inhibition similar to that of the parent ZAF with 68-70% growth inhibition. Additionally,
three more compounds (13b, 13d, and 14f) displayed 57%, 50%, 57% growth inhibition,
which were comparable or better than the antibiotic Tet with 51% growth inhibition. At 1
µM, four of these compounds (14a, 14b, 14d, and 14e) displayed 53-62% growth
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inhibition, which was comparable or superior to the parent compound ZAF (68% at 50
µM), its derivatives 13g and 14h (16% and 0%, respectively, at 1µM), and Tet (51% at
2.81 µM).

To establish the importance of an N-methyl R2 group on bacterial growth inhibition
(question i), three pairs of ZAF derivatives (12a and 13a, 12c and 13c, as well as 12f and
13f with 2-F-Ph, 4-F-Ph, and 2-naphthylsulfonamides, respectively) were generated
(Scheme 2.1) and tested for growth inhibition of P. gingivalis (Figure 2.3). As previously
observed, it was found that the compounds lacking the methyl group on the indole nitrogen
(series 12) were much less efficient at inhibiting bacterial growth at all three concentrations
tested when compared to those with a methyl at the R2 position (series 13). Having
confirmed the importance of the N-methyl R2 group, series 12 was not further
expanded/pursued.

To investigate the effect of adding an R3 electron-withdrawing group or bulkiness to the
acylsulfonamide ring when R1 = H and R2 = Me (question ii), three additional compounds
were prepared in series 13: 13b with R3 = 3-F-Ph, 13d with R3 = 3-NO2-Ph, and 13e with
a R3 = 4-NO2-Ph. The series 13 derivatives (13a-13f) was rationally designed to investigate
the effect of replacing the R3 = 2-Me on the acylsulfonamide of 1st generation 13g with a
weak electron-withdrawing group, the bioisostere fluorine, at the ortho (13a), meta (13b),
and para (13c) positions. It was postulated that due to the weak electron-withdrawing effect
fluorine has on the phenyl ring, a preferred conformational change in 13a-13c could lead
to increased antibacterial activity compared to the counterpart 1st generation 13g, which
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was indeed the case with compound 13c (with R3 = 4-F-Ph) at all concentrations tested.
Compound 13b (with R3 = 3-F-Ph) was also found to display 14%, 57%, and 73% growth
inhibition at 1, 10, and 100 µM, respectively, which were similar or superior to that of 13g
(16%, 56%, and 74%) at all concentrations tested. As addition of a weak electronwithdrawing group at the meta and para positions of the acylsulfonamide proved to be
beneficial for P. gingivalis growth inhibition, the effect of a strong electron-withdrawing
group, nitro, at these positions was also investigated. It was found that the R3 = 3-NO2-Ph
of 13d yielded 18-75% growth inhibition, which was better than the R3 = 4-NO2-Ph of 13e
with 0-27% growth inhibition. Finally, the phenyl ring of the acylsulfonamide was replaced
by its larger naphthyl bioisostere to yield compound 13f, which displayed intermediate
activity compared to the other series 13 compounds. Overall, at all concentrations tested,
it was found that compound 13c (R3 = 4-F-Ph) displayed better P. gingivalis growth
inhibition than (>) 13d (R3 = 3-NO2-Ph), which was better than (>) 13b (R3 = 3-F-Ph) >
13f (R3 = 2-naphthyl) > 13a (R3 = 2-F-Ph) > 13e (R3 = 4-NO2-Ph).

Having established the trend for the acylsulfonamide substituent patterns in series 13 in
terms of bacterial growth inhibition activity (question ii), the effect of an additional
electron-withdrawing group (e.g., R1 = NO2) on the indole ring on that trend was
investigated by generating the counterpart series 14a-14f (question iii). When comparing
the compounds of series 14, it was found that 14e (R3 = 4-NO2-Ph) displayed better P.
gingivalis growth inhibition than (>) 14b (R3 = 3-F-Ph), which was similar to (≈) 14a (R3
= 2-F-Ph), which was better than (>) 14d (R3 = 3-NO2-Ph) > 14c (R3 = 4-F-Ph) > 14f (R3
= 2-naphthyl). Interestingly, when compared to the trend observed with series 13, the trend
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with series 14 was completely opposite with the exception of compounds with R3 = 2naphthyl (13f and 14f), which were randomly placed in these series in term of their activity.
A summary of the SAR activity discussed above is presented in Figure 2.4.

Figure 2.4. Summary of SAR activity for the 2nd generation of ZAF derivatives for series 12, 13, and 14.

Finally, to establish if an electron-withdrawing group (e.g., R1 = NO2) on the indole ring is
beneficial for bacterial growth inhibition (question iv), a pairwise comparison of series 13
vs 14 was done. It was found that at 1 and 10 µM, the presence of the nitro group on the
indole ring was generally beneficial for P. gingivalis growth inhibition, with all compounds
in series 14 (with the exception of 14c) displaying comparable or superior activity to those
in series 13. At 100 µM, this was also mostly true, but compounds 13b, 13d, and 13f
displayed a weak improvement in activity over that of their series 14 counterparts. These
novel results indicate the importance of an electron-withdrawing group on the indole, while
in the 1st generation, because of the very limited SAR that was done, this conclusion could
not be made.
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These results indicated that the six most active 2nd generation ZAF derivatives against P.
gingivalis were 13b, 13c, 13d, 13f, 14b, and 14e. These compounds were then further
tested against other selected oral Gram-positive and Gram-negative bacterial species to
determine their antibacterial specificity profile (Figure 2.5). The oral bacterial species
chosen were representative of those more abundant in health (Actinomyces naeslundii,
Streptococcus sanguinis, and Veillonella parvula) and in periodontal diseases
(Aggregatibacter actinomycetemcomitans). Overall, the compounds displayed little to no
antibacterial activity against these other oral bacterial species, with the exception of 20%
growth inhibition with S. sanguinis and A. naeslundii. These data suggest that the six most
active 2nd generation ZAF derivatives seem to display specificity against P. gingivalis.
Future studies using an expanded number of oral bacterial species or whole subgingival
plaque samples from healthy and periodontitis patients will be useful to further validate the
specificity of these new ZAF compounds, but not necessary at this time.

96

Figure 2.5. Percent growth inhibition of oral bacterial species by ZAF derivatives 13b, 13c, 13d, 13f, 14b,
and 14e, as determined by a colorimetric WST-1 assay after 24 h. Negative control = DMSO. Positive
controls = 25 and 50 µM of ZAF (Z) or penicillin/streptomycin -1X (P/S) (100 U/mL of penicillin and 100
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µg/mL of streptomycin). These data show the average from six independent replicates per condition of the
growth inhibitory effect versus bacterial cultures grown in medium only.

Further investigation into the activity of the six most active ZAF derivatives (13b, 13c,
13d, 13f, 14b, and 14e) was performed to determine if they displayed bactericidal activity
by colony forming unit (CFU) assays (Figure 2.6). P. gingivalis 381 was incubated with
the antibiotic Tet (T, 2.81 µM) and ZAF (Z, 25 and 50 µM) as positive controls and bacteria
only with DMSO as a negative control. P. gingivalis was exposed to ZAF derivatives 13b,
13c, 13d, 13f, 14b, and 14e (1, 10, and 100 µM) for 24 h in media followed by bacterial
growth in blood agar plates for 5 days under anaerobic conditions and CFUs determination.
All six compounds exhibited bactericidal activity at 100 µM with 100% growth inhibition.
Compounds 14b and 14e were also bactericidal at 10 µM and 1 µM; however, at 10 µM,
compounds 13b, 13c, 13d, 13f were not. Even at 1 µM, compound 13d revealed moderate
antibacterial activity with 30% growth inhibition. At all three concentrations tested, the 2nd
generation compounds 14b and 14e proved to display a higher percent growth inhibition
by CFU assays than their 1st generation counterpart 14h. At 100 µM, compounds 13b, 13c,
13d, 13f displayed higher percent growth inhibition by CFU assays than their 1st generation
counterpart 13g, and most of them showed better antimicrobial activity than 13g at 10 µM.
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Figure 2.6. Bactericidal effect of ZAF derivatives 13b, 13c, 13d, 13f, 14b, and 14e determined by colony
forming unit (CFU) assays. Negative control = DMSO. Positive controls = tetracycline (T, 2.81 µM) or ZAF
(Z, 25 and 50 µM). The data shows the calculated percentage of inhibitory effect from six independent
replicates per condition by comparison of the treated bacteria groups (CFUs/mL) versus bacteria grown in
medium only (CFUs/mL) using the formula 100 × [CFUs/mL of (control) - CFUs/mL (experimental) /
CFUs/mL (control)]. For the controls, the data represent the average from 12 independent replicates per
condition.

2.5. CYTOTOXIC EFFECT OF ZAF DERIVATIVES IN ORAL EPITHELIAL
CELLS
The first line of defense against periodontopathogens are oral epithelial cells. To determine
the value of drugs as potential antibacterials their selectivity towards pathogenic bacterial
species with little to no cytotoxicity towards host cells has to be determined. The cytotoxic
effect of the six most active 2nd generation ZAF derivatives 13b, 13c, 13d, 13f, 14b, and
14e was therefore evaluated against immortalized oral keratinocyte (OKF6) cells. To
examine the effect of various treatments on OKF6 cell morphology and density, the cells
were visualized by microscopy (Figure 2.7). There was a higher density of OKF6 cells in
the control and DMSO wells, in contrast to the lower density in the ZAF and staurosporine
(STS, a pro-apoptotic chemical) wells. Wells containing compounds 13b and 13d had the
highest density of cells, followed closely by compound 13c. A decrease in cell density was
seen in the presence of compounds 13f, 14b, and 14e, indicating a slight increase in
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cytotoxicity against OKF6 cells, nowhere near that of the ZAF and STS positive controls.
Untreated OKF6 cells along with cells treated with DMSO displayed epithelial-like
morphology, i.e., elongated and flat.178 OKF6 cells treated with compounds 13b, 13c, 13d,
and 13f, resembled the large and flattened cells seen in the untreated OKF6 cells, which
are also all in close proximity to one another. This is in direct contrast to the OKF6 cells
treated with controls STS and ZAF as well as with compounds 14b and 14e that seem to
be smaller in size, more round in shape, and at an increased distance from one another.

Figure 2.7. Images representative of the whole well used to evaluate the effect of ZAF derivatives 13b, 13c,
13d, 13f, 14b, and 14e on cell morphology of oral epithelial cells (OKF6). Cells treated with medium only
or DMSO were used as negative controls, while cells treated with 8 µM of staurosporine (STS) or 25 µM of
ZAF were used as positive controls. Cells were treated with 10 µM of ZAF derivatives 13b, 13c, 13d, 13f,
14b, and 14e for 24 h.

Cytotoxicity determined by flow cytometry revealed 76-93% cell viability with ZAF
derivatives 13b, 13c, 13d, 13f, 14b, and 14e at the concentration of 1 µM, and 49-92% cell
viability at 10 µM (Figure 2.8). Of note, all ZAF derivatives displayed less cytotoxicity
than the parent drug ZAF. Overall, at 1 µM, it was found that compound 13b (R3 = 3-FPh) displayed less cytotoxicity than (<) 13c (R3 = 4-F-Ph), which was less toxic than (<)
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13d (R3 = 3-NO2-Ph) < 13f (R3 = 2-naphthyl) < 14e (R3 = 4-NO2-Ph) < 14b (R3 = 3-F-Ph).
At 10 µM, a similar trend was observed. As desired, these 2nd generation of ZAF
derivatives achieved the overall goal of increasing P. gingivalis growth inhibition and
decreasing cytotoxicity compared to the 1st generation compounds and ZAF parent drug.
Briefly, at all concentrations tested, compounds in series 13 all displayed less cytotoxicity
when compared to their 1st generation counterpart 13g. Compounds in series 14 also
displayed similar or decreased cytotoxicity when compared to their 1st generation
counterpart 14h (Note: the viability for 13g and 14h used for comparison is not shown in
this manuscript).

Figure 2.8. Cell viability assay used to evaluate the effect of ZAF derivatives 13b, 13c, 13d, 13f, 14b, and
14e on apoptosis and necrosis of oral epithelial cells (OKF6) after 24 h. Negative control = DMSO. Positive
controls = 8 µM of staurosporine (STS) or 25 µM of ZAF (Z). Two independent experiments analyzing at
least 10,000 events per condition in duplicate were used to generate the FACS data.

2.6. CONCLUSION
In summary, 15 novel ZAF derivatives (12a, 12c, 12f, 13a-13f, and 14a-14f) were
synthesized. Six of these (13b, 13c, 13d, 13f, 14b, and 14e) displayed increased
antibacterial activity against P. gingivalis and decreased cytotoxicity against OKF6 cells
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when compared to the parent ZAF and its 1st generation derivatives 13g and 14h. It was
found that the most promising compounds all contained a methyl group on the nitrogen of
the indole ring. It was also discovered that, at low concentrations (1 and 10 µM), the
presence of an electron-withdrawing group (e.g., R1 = NO2) on the indole ring, as in series
14, was beneficial for bacterial growth inhibition and seemed to determine which
acylsulfonamides imparted the best antibacterial activity (with complete opposite trends
observed with series 13 (R3 = 4-F-Ph > 3-NO2-Ph > 3-F-Ph > 2-F-Ph > 4-NO2-Ph) and 14
(R3 = 4-NO2-Ph > 2-F-Ph ≈ 3-F-Ph > 3-NO2-Ph > 4-F-Ph) when comparing which
sulfonamides results in better growth inhibition). These promising results pave the way for
future investigations, outside the scope of this study, seeking to identify the mechanism of
action as well as further optimization of these compounds for in vivo studies using animal
models of P. gingivalis-induced periodontal disease. These lengthy studies are currently
underway in our laboratory and will be reported in due course.

2.7. MATERIALS AND METHODS
2.7.1. Materials and instrumentation
We re-synthesized compounds 3 and 5-10 as previously reported62 and the yields that we
obtained for all of these reactions that we redid during the current study are reported in
Figure 2.1. We also re-synthesized compounds 13g and 14h (previously 22b and 23a,
respectively, this numbering is from previously published manuscript on our 1st generation
of zafirlukast (ZAF) derivatives)62 for new biological studies. All chemicals used in this
study (including compounds 1, 2, 4, and 11a-11f) to synthesize our ZAF derivatives and
their intermediates were purchased from Accela (San Ramon, CA), Combi-Blocks (San

102

Diego, CA), TCI America (Portland, OR), Chem-Impex (Wood Dale, IL), Oakwood
Chemical (San Diego, CA), Alfa Aesar (Ward Hill, MA), Matrix Scientific (Columbia,
SC), Acros Organics (Geel, Belgium), Sigma Aldrich (St. Louis, MO), Beantown
Chemical (Hudson, NH), and used without further purification. The chemical reactions
were monitored by thin layer chromatography (TLC) using glass plates coated with Merk
silica gel 60 F254. Chromotographic bands on the TLC plates were visualized using UV
light. Compounds were purified using silica gel column chromatography with SiliaFlash®
F60 (40-63 µM, SiliCycle, Québec, Canada). 1H NMR spectra were recorded at 500 or 400
MHz on a Varian 500 (VNMRS500) or 400 (MR400) MHz spectrometer, respectively. 13C
NMR spectra were recorded at 100 MHz on a Varian 400 MHz spectrometer. All NMR
spectra chemical shifts (δ) given in parts per million (ppm). All coupling constants (J)
given in Hertz (Hz), and the abbreviations used for signal shape are singlet (s), doublet (d),
triplet (t), multiplet (m), doublet of doublets (dd), doublet of triplets (dt), triplet of doublets
(td), and doublet of doublet of doublets (ddd). All mass spectra data were recorded using
an Agilent 1200 series Quaternary LC system (Agilent Technologies, Santa Clara, CA)
equipped with a diode array detector, Eclipse XDB-C18 column (150 mm × 4.6 mm, 5
µm), and an Agilent 6120 Quadrupole MSD mass spectrometer (located in Dr. Steven Van
Lanen laboratory at the University of Kentucky). For all compounds synthesized the LCMS
[M+H]+ signals were consistent with the calculated molecular weights. In order to establish
the C vs CH vs CH2 vs CH3 for the 13C NMR analysis of our compounds, we performed
distortionless enhancement by polarization transfer (DEPT) analysis of compounds 13c,
13e, and 13f. Further confirmation of purity for all final molecules was done on an Agilent
Technologies 1260 Infinity HPLC system (Santa Clara, CA, USA). The following HPLC
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method was used for confirmation of purity of compounds 12a, 12c, 12f, 13a, 13b, 13c,
13d, 13f, 14a, 14c, 14d, and 14e - method A: Flow rate = 0.5 mL/min; λ = 254 nm; column
= Vydac Denali C18 column, 250 × 4.6 mm, 120 Å, 5 µm; Eluents: A = H2O + 0.1%
trifluoroacetic acid, B = MeCN; gradient profile: starting from 5% B, increasing from 5%
B to 100% C over 10 min, hold at 100% B for 10 min, decreasing from 100% B to 5% B
in 3 min. Prior to each injection, the HPLC column was equilibrated for 10 min with 5%
B. The following method was used for 13e and 14b - method B: Flow rate = 0.5 mL/min;
λ = 254 nm; column = Vydac Denali C18 column, 250 × 4.6 mm, 120 Å, 5 µm, Eluents:
A = H2O + 0.1% trifluoroacetic acid, B = MeCN; gradient profile: starting from 5% B,
increasing from 5% B to 100% B over 10 min, hold at 100% B for 15 min, decreasing from
100% B to 5% B in 5 min. Prior to each injection, the HPLC column was equilibrated for
5 min with 5% B. The following method was used for 14f - method C: Flow rate = 0.5
mL/min; λ = 254 nm; column = Vydac Denali C18 column, 250 × 4.6 mm, 120 Å, 5 µm,
Eluents: A = H2O + 0.1% formic acid, B = MeCN + 0.1% formic acid; gradient profile:
starting from 5% B, increasing from 5% B to 100% B over 11 min, hold at 100% B for 6
min, decreasing from 100% B to 5% B in 3 min. Prior to each injection, the HPLC column
was equilibrated for 3 min with 5% B. All compounds were ≥91% pure.

2.7.2. Synthesis and characterization of compounds 12a, 12c, 12f, 13a-13f, and 14a14f
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Synthesis of compound 12a (SGT1735). A mixture of compound
8 (50 mg, 0.18 mmol), 2-fluorobenzenesulfonamide (11a) (34 mg,
0.20 mmol), EDC•HCl (44 mg, 0.23 mmol), and DMAP (33 mg,
0.27 mmol) in anhydrous CH2Cl2 (10 mL) was stirred at room
temperature overnight. The crude product obtained was purified by column
chromatography (SiO2 gel, CH2Cl2:MeOH/49:1, Rf 0.35 in CH2Cl2:MeOH/49:1) to afford
compound 12a (77 mg, 98%) as an off-white solid: 1H NMR (400 MHz, (CD3)2SO, Figure
A1) δ 12.20 (s, 1H, NHSO2), 10.80 (s, 1H, NH), 7.92 (t, J = 7.8 Hz, 1H, aromatic), 7.777.72 (m, 1H, aromatic), 7.46-7.33 (m, 4H, aromatic), 7.28 (d, J = 8.1 Hz, 1H, aromatic),
7.25 (s, 1H, aromatic), 7.11 (s, 1H, aromatic), 7.02-6.97 (m, 2H, aromatic), 6.87 (app. t, J
= 7.5 Hz, 1H, aromatic), 3.93 (s, 2H, CH2Ar), 3.74 (s, 3H, OCH3); 13C NMR (100 MHz,
(CD3)2SO, Figure A2) δ 165.6 (C=O), 160.0 (C), 157.4 (C), 155.6 (C), 137.0 (C), 136.8
(C), 134.3 (CH), 133.6 (CH), 131.7 (CH), 129.5 (CH), 127.2 (CH), 125.2 (C), 123.6 (CH),
121.4 (CH), 118.9 (CH), 118.7 (C), 117.8 (CH), 117.5 (CH), 114.0 (CH), 112.5 (C), 111.8
(CH), 56.4 (CH3), 30.2 (CH2); m/z calcd for C23H19FN2O4S 438.1; found 439.0 [M+H]+;
Purity of the compound was further confirmed by RP-HPLC method A: Rt = 18.45 min
(94% pure, Figure A3).

Synthesis of compound 12c (SGT1734). A mixture of
compound 8 (50 mg, 0.18 mmol), 4-fluorobenzenesulfonamide
(11c) (34 mg, 0.20 mmol), EDC•HCl (44 mg, 0.23 mmol), and
DMAP (33 mg, 0.27 mmol) in anhydrous CH2Cl2 (10 mL) was
stirred at room temperature overnight. The crude product obtained was purified by column
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chromatography (SiO2 gel, CH2Cl2:MeOH/49:1, Rf 0.50 in CH2Cl2:MeOH/49:1) to afford
compound 12c (82 mg, quant.) as an off-white solid: 1H NMR (400 MHz, (CD3)2SO,
Figure A4) δ 11.81 (s, 1H, NHSO2), 10.79 (s, 1H, NH), 8.00-7.97 (m, 2H, aromatic), 7.44
(app. t, J = 8.5 Hz, 2H, aromatic), 7.37 (d, J = 8.0 Hz, 1H, aromatic), 7.32 (d, J = 7.9 Hz,
1H, aromatic), 7.28 (d, J = 9.8 Hz, 1H, aromatic), 7.26 (s, 1H, aromatic), 7.10 (s, 1H,
aromatic), 7.01-6.97 (m, 2H, aromatic), 6.86 (app. t, J = 7.4 Hz, 1H, aromatic), 3.92 (s, 2H,
CH2Ar), 3.74 (s, 3H, OCH3); 13C NMR (100 MHz, (CD3)2SO, Figure A5) δ 166.5 (C=O),
165.3 (C), 164.0 (C), 155.7 (C), 136.8 (C), 134.4 (C), 133.8 (CH), 131.4 (CH), 131.3 (CH),
129.7 (CH), 127.2 (C), 123.6 (CH), 121.9 (CH), 121.4 (CH), 118.8 (C), 118.7 (CH), 116.8
(CH), 116.6 (CH), 114.0 (CH), 112.5 (C), 111.8 (CH), 56.4 (CH3), 30.1 (CH2); m/z calcd
for C23H19FN2O4S 438.1; found 439.1 [M+H]+; Purity of the compound was further
confirmed by RP-HPLC method A: Rt = 18.66 min (99% pure, Figure A6).

Synthesis of compound 12f (SGT1739). A mixture of
compound

8

(50

mg,

0.18

mmol),

2-

naphthalenebenzenesulfonamide (11f) (41 mg, 0.20 mmol),
EDC•HCl (44 mg, 0.23 mmol), and DMAP (33 mg, 0.27 mmol)
in anhydrous CH2Cl2 (10 mL) was stirred at room temperature overnight. The crude
product obtained was purified by column chromatography (SiO2 gel, CH2Cl2:MeOH/49:1,
Rf 0.50 in CH2Cl2:MeOH/49:1) to afford compound 12f (61 mg, 73%) as a white solid: 1H
NMR (400 MHz, (CD3)2SO, Figure A7) δ 11.86 (s, 1H, NHSO2), 10.76 (s, 1H, NH), 8.60
(s, 1H, aromatic), 8.19 (d, J = 8.2 Hz, 1H, aromatic), 8.11 (d, J = 8.8 Hz, 1H, aromatic),
8.03 (d, J = 8.2 Hz, 1H, aromatic), 7.89 (d, J = 8.7 Hz, 1H, aromatic), 7.72 (t, J = 7.8 Hz,
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1H, aromatic), 7.66 (t, J = 7.7 Hz, 1H, aromatic), 7.35 (d, J = 8.6 Hz, 1H, aromatic), 7.31
(d, J = 7.9 Hz, 1H, aromatic), 7.26 (d, J = 8.3 Hz, 1H, aromatic), 7.24 (s, 1H, aromatic),
7.08 (s, 1H, aromatic), 7.00-6.96 (m, 2H, aromatic), 6.84 (t, J = 7.6 Hz, 1H, aromatic), 3.90
(s, 2H, CH2Ar), 3.74 (s, 3H, OCH3); 13C NMR (100 MHz, (CD3)2SO, Figure A8) δ 165.3
(C=O), 155.6 (C), 136.8 (C), 135.1 (C), 134.4 (C), 133.7 (C), 131.8 (C), 129.9 (CH), 129.8
(CH), 129.73 (CH), 129.71 (CH), 129.6 (CH), 128.3 (CH), 128.2 (CH), 127.2 (C), 123.6
(CH), 123.0 (CH), 122.1 (CH), 121.4 (CH), 118.9 (C), 118.7 (CH), 114.0 (CH), 112.5 (C),
111.8 (CH), 56.4 (CH3), 30.1 (CH2); m/z calcd for C27H22N2O4S 470.1; found 471.1
[M+H]+; Purity of the compound was further confirmed by RP-HPLC method A: Rt = 19.26
min (99% pure, Figure A9).

Synthesis of compound 13a (SGT1617). A mixture of compound
9 (50 mg, 0.17 mmol), 2-fluorobenzenesulfonamide (11a) (35 mg,
0.20 mmol), EDC•HCl (52 mg, 0.27 mmol), and DMAP (37 mg,
0.30 mmol) in anhydrous CH2Cl2 (5 mL) was stirred at room
temperature overnight. Upon completion, the reaction mixture was diluted with H2O and
extracted with CH2Cl2 (3×). The combined organic layers were washed with brine, dried
over MgSO4, filtered, and concentrated. The crude product obtained was purified by
column chromatography (SiO2 gel, CH2Cl2:MeOH/49:1, Rf 0.86 in CH2Cl2:MeOH/49:1)
to afford compound 13a (32 mg, 42%) as a white solid: 1H NMR (400 MHz, CDCl3, Figure
A10) δ 10.60 (s, 1H, NH), 8.16 (td, J1 = 7.6 Hz, J2 = 1.8 Hz, 1H, aromatic), 7.95 (d, J =
2.4 Hz, 1H, aromatic), 7.63-7.56 (m, 1H, aromatic), 7.41 (dd, J1 = 8.6 Hz, J2 = 2.5 Hz, 1H,
aromatic), 7.37 (app. d, J = 7.8 Hz, 1H, aromatic), 7.32 (app. t, J = 7.7 Hz, 1H, aromatic),
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7.26-7.23 (m, 1H, aromatic), 7.19-7.13 (m, 2H, aromatic), 7.03-6.98 (m, 1H, aromatic),
6.90 (d, J = 8.6 Hz, 1H, aromatic), 6.73 (s, 1H, aromatic), 4.02 (s, 3H, NCH3), 3.99 (s, 2H,
CH2Ar), 3.70 (s, 3H, OCH3); 13C NMR (100 MHz, CDCl3, Figure A11) δ 162.6 (C=O),
160.3-157.7 (d, 1JC-F = 255.8 Hz, C, 1 carbon), 156.2 (C), 137.14 (C), 136.08 (C), 136.0135.2 (d, 2JC-F = 76.1 Hz, C, 1 carbon), 135.4 (CH), 132.4 (CH), 132.1 (CH), 127.4 (C),
127.1 (CH), 124.43 (CH), 124.40 (CH), 121.6 (CH), 118.9 (CH), 118.8 (CH), 118.2 (C),
117.0-116.8 (d, 2JC-F = 20.7 Hz, CH, 1 carbon), 113.3 (C), 111.9 (CH), 109.2 (CH), 56.6
(CH3), 32.6 (CH3), 30.4 (CH2); m/z calcd for C24H21FN2O4S 452.1; found 453.1 [M+H]+;
Purity of the compound was further confirmed by RP-HPLC method A: Rt = 19.30 min
(96% pure, Figure A12).

Synthesis of compound 13b (SGT1618). A mixture of compound
9 (50 mg, 0.17 mmol), 3-fluorobenzenesulfonamide (11b) (35 mg,
0.20 mmol), EDC•HCl (52 mg, 0.27 mmol), and DMAP (37 mg,
0.30 mmol) in anhydrous CH2Cl2 (5 mL) was stirred at room
temperature overnight. Upon completion, the reaction mixture was diluted with H2O and
extracted with CH2Cl2 (3×). The combined organic layers were washed with brine, dried
over MgSO4, filtered, and concentrated. The crude product obtained was purified by
column chromatography (SiO2 gel, CH2Cl2:MeOH/49:1, Rf 0.76 in CH2Cl2:MeOH/49:1)
to afford compound 13b (20 mg, 25%) as a yellow solid: 1H NMR (400 MHz, CDCl3,
Figure A13) δ 10.43 (s, 1H, NH), 8.00 (d, J = 2.4 Hz, 1H, aromatic), 7.94 (ddd, J1 = 7.9
Hz, J2 = 1.8 Hz, J3 = 1.0 Hz, 1H, aromatic), 7.84 (ddd, J1 = 8.2 Hz, J2 = 2.6 Hz, J3 = 2.0
Hz, 1H, aromatic), 7.51 (td, J1 = 8.3 Hz, J2 = 8.0 Hz, 1H, aromatic), 7.41 (dd, J1 = 8.6 Hz,
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J2 = 2.5 Hz, 1H, aromatic), 7.37 (dt, J1 = 8.1 Hz, J2 = 1.0 Hz, 1H, aromatic), 7.33-7.28 (m,
1H, aromatic), 7.25-7.23 (m, 1H, aromatic), 7.19-7.15 (m, 1H, aromatic), 7.03-6.98 (m,
1H, aromatic), 6.88 (d, J = 8.6 Hz, 1H, aromatic), 6.74 (s, 1H, aromatic), 4.004 (s, 2H,
CH2Ar), 3.998 (s, 3H, ArOCH3), 3.70 (s, 3H, NCH3); 13C NMR (100 MHz, CDCl3, Figure
A14) δ 163.3-160.8 (d, 1JC-F = 249.9 Hz, C, 1 carbon) 162.4 (C=O), 156.1 (C), 140.9-140.8
(d, 3JC-F = 7.2 Hz, C, 1 carbon), 137.2 (C), 135.5 (CH), 135.3 (2C), 132.5 (CH), 130.6130.5 (d, 3JC-F = 7.6 Hz, CH, 1 carbon), 127.4 (C), 127.1 (CH), 124.44-124.41 (d, 4JC-F =
3.4 Hz, CH, 1 carbon), 121.6 (CH), 121.1-120.9 (d, 2JC-F = 21.2 Hz, CH, 1 carbon), 118.9
(CH), 118.8 (CH), 118.1 (C), 116.1-115.8 (d, 2JC-F = 24.7 Hz, CH, 1 carbon), 113.4 (C),
111.8 (CH), 109.2 (CH), 56.5 (CH3), 32.6 (CH3), 30.4 (CH2); m/z calcd for C24H21FN2O4S
452.1; found 453.1 [M+H]+; Purity of the compound was further confirmed by RP-HPLC
method A: Rt = 19.51 min (94% pure, Figure A15).

Synthesis of compound 13c (SGT1619). A mixture of
compound 9 (30 mg, 0.10 mmol), 4-fluorobenzenesulfonamide
(11c) (21 mg, 0.12 mmol), EDC•HCl (31 mg, 0.16 mmol), and
DMAP (22 mg, 0.18 mmol) in anhydrous CH2Cl2 (5 mL) was
stirred at room temperature overnight. Upon completion, the reaction mixture was diluted
with H2O and extracted with CH2Cl2 (3×). The combined organic layers were washed with
brine, dried over MgSO4, filtered, and concentrated. The crude product obtained was
purified by column chromatography (SiO2 gel, CH2Cl2:MeOH/49:1, Rf 0.85 in
CH2Cl2:MeOH/49:1) to afford compound 13c (29 mg, 64%) as an off-white solid: 1H NMR
(400 MHz, CDCl3, Figure A16) δ 10.41 (s, 1H, NH), 8.19-8.14 (m, 2H, aromatic), 8.00 (d,
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J = 2.5 Hz, 1H, aromatic), 7.40 (dd, J1 = 8.5 Hz, J2 = 2.4 Hz, 1H, aromatic), 7.37 (dd, J1 =
8.0 Hz, J2 = 0.6 Hz, 1H, aromatic), 7.25-7.24 (m, 1H, aromatic), 7.22-7.15 (m, 3H,
aromatic), 7.03-6.98 (m, 1H, aromatic), 6.88 (d, J = 8.6 Hz, 1H, aromatic), 6.73 (s, 1H,
aromatic), 4.00 (s, 2H, CH2Ar), 3.99 (s, 3H, ArOCH3), 3.70 (s, 3H, NCH3); 13C NMR (100
MHz, CDCl3, Figure A17) δ 167.0-164.5 (d, 1JC-F = 255.0 Hz, C, 1 carbon), 162.5 (C=O),
156.1 (C), 137.2 (C), 135.4 (CH), 135.3 (C), 134.93-134.90 (d, 4JC-F = 3.1 Hz, C, 1 carbon),
132.4 (CH), 131.7-131.6 (d, 3JC-F = 9.7 Hz, CH, 2 carbons), 127.4 (C), 127.1 (CH), 121.6
(CH), 118.9 (CH), 118.8 (CH),118.1 (C), 116.2-116.0 (d, 2JC-F = 22.7 Hz, CH, 2 carbons),
113.4 (C), 111.8 (CH), 109.2 (CH), 56.5 (CH3), 32.6 (CH3), 30.4 (CH2); m/z calcd for
C24H21FN2O4S 452.1; found 453.0 [M+H]+. We used DEPT (Figure A18) to determine the
C vs CH vs CH2 vs CH3 for

13

C NMR analysis; Purity of the compound was further

confirmed by RP-HPLC method A: Rt = 19.48 min (92% pure, Figure A19).

Synthesis of compound 13d (SGT1620). A mixture of
compound 9 (30 mg, 0.10 mmol), 3-nitrobenzenesulfonamide
(11d) (24 mg, 0.12 mmol), EDC•HCl (31 mg, 0.16 mmol), and
DMAP (22 mg, 0.18 mmol) in anhydrous CH2Cl2 (5 mL) was
stirred at room temperature overnight. Upon completion, the reaction mixture was diluted
with H2O and extracted with CH2Cl2 (3×). The combined organic layers were washed with
brine, dried over MgSO4, filtered, and concentrated. The crude product obtained was
purified by column chromatography (SiO2 gel, CH2Cl2:MeOH/49:1, Rf 0.61 in
CH2Cl2:MeOH/49:1) to afford compound 13d (13 mg, 26%) as a yellow solid: 1H NMR
(400 MHz, CDCl3, Figure A20) δ 10.53 (s, 1H, NH), 8.93 (t, J = 2.0 Hz, 1H, aromatic),
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8.53 (ddd, J1 = 7.9 Hz, J2 = 1.8 Hz, J3 = 1.1 Hz, 1H, aromatic), 8.46 (ddd, J1 = 8.2 Hz, J2
= 2.2 Hz, J3 = 1.1 Hz, 1H, aromatic), 7.97 (d, J = 2.4 Hz, 1H, aromatic), 7.75 (app. t, J =
8.2 Hz, 1H, aromatic), 7.42 (dd, J1 = 8.6 Hz, J2 = 2.4 Hz, 1H, aromatic), 7.35 (dt, J1 = 8.0
Hz, J2 = 1.1 Hz, 1H, aromatic), 7.25-7.23 (m, 1H, aromatic), 7.19-7.15 (m, 1H, aromatic),
7.02-6.97 (m, 1H, aromatic), 6.90 (d, J = 8.6 Hz, 1H, aromatic), 6.74 (s, 1H, aromatic),
4.02 (s, 3H, ArOCH3), 4.00 (s, 2H, CH2Ar), 3.70 (s, 3H, NCH3);

13

C NMR (100 MHz,

CDCl3, Figure A21) δ 158.6 (C=O), 152.2 (C), 137.0 (C), 133.2 (C), 131.8 (CH), 131.4
(C), 130.8 (CH), 128.5 (CH), 126.2 (CH), 124.2 (CH), 123.4 (C), 123.1 (CH), 119.9 (CH),
117.7 (CH), 114.93 (CH), 114.89 (CH), 113.8 (C), 109.3 (C), 107.8 (CH), 105.3 (CH), 52.7
(CH3), 28.7 (CH3), 26.5 (CH2); m/z calcd for C24H21N3O6S 479.1; found 480.1 [M+H]+;
Purity of the compound was further confirmed by RP-HPLC method A: Rt = 19.32 min
(99% pure, Figure A22).

Synthesis of compound 13e (SGT1621). A mixture of
compound 9 (30 mg, 0.10 mmol), 4-nitrobenzenesulfonamide
(11e) (24 mg, 0.12 mmol), EDC•HCl (31 mg, 0.16 mmol), and
DMAP (22 mg, 0.18 mmol) in anhydrous CH2Cl2 (5 mL) was
stirred at room temperature overnight. Upon completion, the reaction mixture was diluted
with H2O and extracted with CH2Cl2 (3×). The combined organic layers were washed with
brine, dried over MgSO4, filtered, and concentrated. The crude product obtained was
purified by column chromatography (SiO2 gel, CH2Cl2:MeOH/49:1, Rf 0.61 in
CH2Cl2:MeOH/49:1) to afford compound 13e (34 mg, 70%) as a white solid: 1H NMR
(400 MHz, CDCl3, Figure A23) δ 10.51 (s, 1H, NH), 8.36 (d, J = 9.2 Hz, 2H, aromatic),
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8.33 (d, J = 9.2 Hz, 2H, aromatic), 7.96 (d, J = 2.4 Hz, 1H, aromatic), 7.43 (dd, J1 = 8.5
Hz, J2 = 2.5 Hz, 1H, aromatic), 7.35 (dt, J1 = 8.0 Hz, J2 = 1.0 Hz, 1H, aromatic), 7.25-7.24
(m, 1H, aromatic), 7.19-7.15 (m, 1H, aromatic), 7.02-6.97 (m, 1H, aromatic), 6.89 (d, J =
8.5 Hz, 1H, aromatic), 6.74 (s, 1H, aromatic), 4.01 (s, 3H, ArOCH3), 4.00 (s, 2H, CH2Ar),
3.70 (s, 3H, NCH3); 13C NMR (100 MHz, CDCl3, Figure A24) δ 162.5 (C=O), 156.2 (C),
150.6 (C), 144.4 (C), 137.2 (CH), 135.7 (CH), 135.5 (C), 132.4 (CH), 130.1 (2CH), 127.4
(CH), 127.1 (CH), 124.0 (CH), 121.7 (CH), 118.9 (C), 118.8 (2CH), 117.7 (C), 113.2 (C),
111.8 (CH), 109.2 (CH), 56.6 (CH3), 32.6 (CH3), 30.4 (CH2); m/z calcd for C24H21N3O6S
479.1; found 480.0 [M+H]+. We used DEPT (Figure A25) to determine the C vs CH vs
CH2 vs CH3 for 13C NMR analysis; Purity of the compound was further confirmed by RPHPLC method B: Rt = 20.20 min (97% pure, Figure A26).

Synthesis of compound 13f (SGT1622). A mixture of
compound

9

(30

mg,

0.10

mmol),

2-

naphthalenebenzenesulfonamide (11f) (25 mg, 0.12 mmol),
EDC•HCl (31 mg, 0.16 mmol), and DMAP (22 mg, 0.18 mmol)
in anhydrous CH2Cl2 (5 mL) was stirred at room temperature overnight. Upon completion,
the reaction mixture was diluted with H2O and extracted with CH2Cl2 (3×). The combined
organic layers were washed with brine, dried over MgSO4, filtered, and concentrated. The
crude product obtained was purified by column chromatography (SiO2 gel,
CH2Cl2:MeOH/49:1, Rf 0.74 in CH2Cl2:MeOH/49:1) to afford compound 13f (31 mg,
62%) as an orange solid: 1H NMR (400 MHz, CDCl3, Figure A27) δ 10.47 (s, 1H, NH),
8.73 (d, J = 2.0 Hz, 1H, aromatic), 8.07 (dd, J1 = 8.8 Hz, J2 = 2.0 Hz, 1H, aromatic), 8.01
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(d, J = 8.0 Hz, 1H, aromatic), 7.98 (d, J = 2.44 Hz, 1H, aromatic), 7.95 (d, J = 8.7 Hz, 1H,
aromatic), 7.88 (d, J = 7.9 Hz, 1H, aromatic), 7.65-7.56 (m, 2H, aromatic), 7.39-7.34 (m,
2H, aromatic), 7.25-7.24 (m, 1H, aromatic), 7.17-7.13 (m, 1H, aromatic), 7.01-6.96 (m,
1H, aromatic), 6.87 (d, J = 8.6 Hz, 1H, aromatic), 6.70 (s, 1H, aromatic), 4.01 (s, 3H,
ArOCH3), 3.97 (s, 2H, CH2Ar), 3.68 (s, 3H, NCH3); 13C NMR (100 MHz, CDCl3, Figure
A28) δ 162.4 (C=O), 156.1 (C), 137.1 (C), 135.8 (C), 135.4 (C), 135.23 (CH), 135.17 (2C),
132.5 (CH), 131.9 (C), 130.7 (CH), 129.6 (CH), 129.2 (CH), 129.0 (CH), 127.8 (CH),
127.4 (CH), 127.0 (CH), 123.1 (CH), 121.6 (CH), 118.9 (CH), 118.8 (CH), 118.3 (C),
113.4 (C), 111.7 (CH), 109.2 (CH), 56.5 (CH3), 32.6 (CH3), 30.4 (CH2); m/z calcd for
C28H24N2O4S 484.2; found 485.2 [M+H]+. We used DEPT (Figure A29) to determine the
C vs CH vs CH2 vs CH3 for

13

C NMR analysis; Purity of the compound was further

confirmed by RP-HPLC method A: Rt = 19.32 min (93% pure, Figure A30).

Synthesis of compound 14a (SGT1623). A mixture of
compound

10

(50

mg,

0.15

mmol),

2-

fluorobenzenesulfonamide (11a) (30 mg, 0.17 mmol),
EDC•HCl (45 mg, 0.24 mmol), and DMAP (32 mg, 0.26 mmol)
in anhydrous CH2Cl2 (3 mL) was stirred at room temperature overnight. Upon completion,
the reaction mixture was diluted with H2O and extracted with CH2Cl2 (3×). The combined
organic layers were washed with brine, dried over MgSO4, filtered, and concentrated. The
crude product obtained was purified by column chromatography (SiO2 gel, pure Hexanes
to Hexanes:EtOAc/1:1, Rf 0.13 in Hexanes:EtOAc/1:1) followed by preparative thin layer
chromatography to afford compound 14a (23 mg, 31%) as an orange solid: 1H NMR (500

113

MHz, CDCl3, Figure A31) δ 10.60 (s, 1H, NH), 8.21 (d, J = 2.2 Hz, 1H, aromatic), 8.11
(dd, J1 = 9.1 Hz, J2 = 2.3 Hz, 2H, aromatic), 7.92 (d, J = 2.5 Hz, 1H, aromatic), 7.63-7.59
(m, 1H, aromatic), 7.57 (dd, J1 = 8.5 Hz, J2 = 2.5 Hz, 1H, aromatic), 7.31 (d, J = 9.1 Hz,
2H, aromatic), 7.21-7.16 (m, 1H, aromatic), 7.04 (d, J = 8.6 Hz, 1H, aromatic), 6.57 (s, 1H,
aromatic), 4.10 (s, 3H, ArOCH3), 3.73 (s, 5H, CH2Ar and NCH3); 13C NMR (100 MHz,
(CD3)2SO, Figure A32) δ 160.0 (C=O), 157.5 (C), 155.7 (C), 140.7 (C), 140.2 (2C), 132.2
(2CH), 131.1 (C), 129.1 (CH), 126.3 (C, CH), 124.3 (CH), 120.6 (C), 117.0 (2CH), 116.8
(2CH), 112.5 (C), 110.9 (2CH), 56.1 (CH3), 37.3 (CH3), 33.3 (CH2); m/z calcd for
C24H20FN3O6S 497.1; found 498.9 [M+H]+; Purity of the compound was further confirmed
by RP-HPLC method A: Rt = 19.11 min (99% pure, Figure A33).

Synthesis of compound 14b (SGT1624). A mixture of
compound

10

(50

mg,

0.15

mmol),

3-

fluorobenzenesulfonamide (11b) (30 mg, 0.17 mmol),
EDC•HCl (45 mg, 0.24 mmol), and DMAP (32 mg, 0.26 mmol)
in anhydrous CH2Cl2 (3 mL) was stirred at room temperature overnight. Upon completion,
the reaction mixture was diluted with H2O and extracted with CH2Cl2 (3×). The combined
organic layers were washed with brine, dried over MgSO4, filtered, and concentrated. The
crude product obtained was purified by column chromatography (SiO2 gel, pure Hexanes
to Hexanes:EtOAc/1:1, Rf 0.24 in Hexanes:EtOAc/3:4) to afford compound 14b (91 mg,
quant.) as a yellow solid: 1H NMR (500 MHz, CDCl3, Figure A34) δ 10.44 (s, 1H, NH),
8.21 (d, J = 2.5 Hz, 1H, aromatic), 8.12 (dd, J1 = 9.1 Hz, J2 = 2.2 Hz, 1H, aromatic), 7.98
(d, J = 2.5 Hz, 1H, aromatic), 7.92 (ddd, J1 = 7.9 Hz, J2 = 1.8 Hz, J3 = 1.0 Hz, 1H, aromatic),
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7.83 (ddd, J1 = 8.1 Hz, J2 = 2.6 Hz, J3 = 1.9 Hz, 1H, aromatic), 7.56 (dd, J1 = 8.7 Hz, J2 =
2.5 Hz, 1H, aromatic), 7.51 (td, J1 = 8.2 Hz, J2 = 5.3 Hz, 1H, aromatic), 7.32 (d, J = 9.2
Hz, 2H, aromatic), 7.16 (d, J = 8.7 Hz, 1H, aromatic), 6.59 (s, 1H, aromatic), 4.08 (s, 3H,
ArOCH3), 3.74 (s, 5H, CH2Ar, NCH3);

13

C NMR (100 MHz, (CD3)2SO, Figure A35) δ

165.3 (C=O), 156.2 (C), 140.7 (C), 140.2 (C), 136.4 (C), 133.6 (C), 132.2 (C), 132.0 (CH),
129.6 (CH), 126.2 (CH), 124.3 (CH), 122.0 (C), 121.5 (CH), 121.2 (C), 120.2 (CH), 117.1
(CH), 116.7 (CH), 115.2 (CH), 114.9 (CH), 112.8 (C), 110.9 (CH), 56.5 (CH3), 37.0 (CH3),
33.4 (CH2); m/z calcd for C24H20FN3O6S 497.1; found 498.3 [M+H]+; Purity of the
compound was further confirmed by RP-HPLC method B: Rt = 19.22 min (95% pure,
Figure A36).

Synthesis of compound 14c (SGT1625). A mixture of
compound

10

(50

mg,

0.15

mmol),

4-

fluorobenzenesulfonamide (11c) (30 mg, 0.17 mmol),
EDC•HCl (45 mg, 0.24 mmol), and DMAP (32 mg, 0.26
mmol) in anhydrous CH2Cl2 (3 mL) was stirred at room temperature overnight. Upon
completion, the reaction mixture was diluted with H2O and extracted with CH2Cl2 (3×).
The combined organic layers were washed with brine, dried over MgSO4, filtered, and
concentrated. The crude product obtained was purified by column chromatography (SiO2
gel, pure Hexanes to Hexanes:EtOAc/1:1, Rf 0.28 in Hexanes:EtOAc/3:4) to afford
compound 14c (24 mg, 32%) as a yellow solid: 1H NMR (500 MHz, CDCl3, Figure A37)
δ 10.42 (s, 1H, NH), 8.20 (d, J = 2.2 Hz, 1H, aromatic), 8.16-8.13 (m, 1H, aromatic), 8.12
(dd, J1 = 9.4 Hz, J2 = 2.5 Hz, 2H, aromatic), 7.98 (d, J = 2.4 Hz, 1H, aromatic), 7.55 (dd,
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J1 = 8.6 Hz, J2 = 2.5 Hz, 1H, aromatic), 7.32 (d, J = 9.2 Hz, 1H, aromatic), 7.19 (t, J = 8.6
Hz, 2H, aromatic), 7.02 (d, J = 8.5 Hz, 1H, aromatic), 6.59 (s, 1H, aromatic), 4.07 (s, 3H,
ArOCH3), 3.74 (s, 5H, CH2Ar, NCH3);

13

C NMR (100 MHz, (CD3)2SO, Figure A38) δ

166.5-165.1 (d, 1JC-F = 141.8 Hz, C, 1 carbon), 164.0 (C=O), 156.1 (C), 140.7 (C), 140.2
(C), 136.4 (C), 136.0 (C), 133.5 (CH), 132.2 (CH), 131.4-131.3 (d, 3JC-F = 9.7 Hz, CH, 2
carbons), 129.6 (C), 126.2 (CH), 120.2 (C), 117.1 (CH), 116.8 (CH), 116.7-116.6 (d, 2JC-F
= 12.7 Hz, CH, 2 carbons), 112.8 (C), 110.9 (2CH), 56.5 (CH3), 37.0 (CH3), 33.4 (CH2);
m/z calcd for C24H20FN3O6S 497.1; found 498.6 [M+H]+; Purity of the compound was
further confirmed by RP-HPLC method A: Rt = 17.65 min (91% pure, Figure A39).

Synthesis of compound 14d (SGT1626). A mixture of
compound

10

(50

mg,

0.15

mmol),

3-

nitrobenzenesulfonamide (11d) (35 mg, 0.17 mmol),
EDC•HCl (45 mg, 0.24 mmol), and DMAP (32 mg, 0.26
mmol) in anhydrous CH2Cl2 (3 mL) was stirred at room temperature overnight. Upon
completion, the reaction mixture was diluted with H2O and extracted with CH2Cl2 (3×).
The combined organic layers were washed with brine, dried over MgSO4, filtered, and
concentrated. The crude product obtained was purified by column chromatography (SiO2
gel, pure Hexanes to Hexanes:EtOAc/1:1, Rf 0.15 in Hexanes:EtOAc/1:1) to afford
compound 14d (16 mg, 20%) as a yellow solid: 1H NMR (500 MHz, CDCl3, Figure A40)
δ 10.52 (s, 1H, NH), 8.93 (t, J = 2.5 Hz, 1H, aromatic), 8.49-8.43 (m, 2H, aromatic), 8.18
(d, J = 2.8 Hz, 1H, aromatic), 8.10 (dd, J1 = 11.4 Hz, J2 = 2.8 Hz, 1H, aromatic), 7.95 (d, J
= 3.1 Hz, 1H, aromatic), 7.73 (app. t, J = 10.2 Hz, 1H, aromatic), 7.54 (dd, J1 = 10.8 Hz,
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J2 = 3.1 Hz, 1H, aromatic), 7.30 (d, J = 11.5 Hz, 1H, aromatic), 7.01 (d, J = 10.8 Hz, 1H,
aromatic), 6.58 (s, 1H, aromatic), 4.08 (s, 3H, ArOCH3), 3.72 (s, 5H, CH2Ar and NCH3);
13

C NMR (100 MHz, (CD3)2SO, Figure A41) δ 165.4 (C=O), 156.2 (C), 148.0 (C), 141.1

(C), 140.7 (C), 140.2 (C), 136.5 (C), 134.1 (CH), 133.8 (CH), 132.2 (CH), 131.7 (CH),
129.7 (C), 128.8 (CH), 126.2 (C), 122.9 (CH), 121.7 (CH), 120.2 (CH), 117.1 (CH), 116.7
(CH), 112.8 (C), 110.9 (CH), 56.5 (CH3), 37.0 (CH3), 33.3 (CH2); m/z calcd for
C24H20N4O8S 524.1; found 525.6 [M+H]+; Purity of the compound was further confirmed
by RP-HPLC method A: Rt = 19.09 min (98% pure, Figure A42).

Synthesis of compound 14e (SGT1627). A mixture of
compound

10

(50

mg,

0.15

mmol),

4-

nitrobenzenesulfonamide (11e) (35 mg, 0.17 mmol),
EDC•HCl (45 mg, 0.24 mmol), and DMAP (32 mg, 0.26
mmol) in anhydrous CH2Cl2 (3 mL) was stirred at room temperature overnight. Upon
completion, the reaction mixture was diluted with H2O and extracted with CH2Cl2 (3×).
The combined organic layers were washed with brine, dried over MgSO4, filtered, and
concentrated. The crude product obtained was purified by column chromatography (SiO2
gel, pure Hexanes to Hexanes:EtOAc/1:1, Rf 0.25 in Hexanes:EtOAc/3:4) to afford
compound 14e (28 mg, 36%) as a yellow solid: 1H NMR (500 MHz, CDCl3, Figure A43)
δ 10.52 (s, 1H, NH), 8.36 (d, J = 9.1 Hz, 2H, aromatic), 8.32 (d, J = 9.1 Hz, 2H, aromatic),
8.19 (d, J = 2.2 Hz, 1H, aromatic), 8.12 (dd, J1 = 9.1 Hz, J2 = 2.2 Hz, 1H, aromatic), 7.95
(d, J = 2.5 Hz, 1H, aromatic), 7.57 (dd, J1 = 8.8 Hz, J2 = 2.5 Hz, 1H, aromatic), 7.32 (d, J
= 9.1 Hz, 1H, aromatic), 7.03 (d, J = 8.7 Hz, 1H, aromatic), 6.60 (s, 1H, aromatic), 4.09 (s,

117

3H, ArOCH3), 3.74 (s, 5H, CH2Ar, NCH3); 13C NMR (100 MHz, (CD3)2SO, Figure A44)
δ 156.1 (C=O), 143.2 (C), 140.7 (2C), 140.2 (C), 137.6 (C), 136.2 (C), 132.2 (CH), 129.6
(2CH), 129.5 (CH), 126.2 (C), 124.6 (CH), 123.6 (C), 120.3 (CH), 117.1 (2CH), 116.7
(CH), 112.7 (CH), 110.9 (C), 110.0 (CH), 56.4 (CH3), 37.1 (CH3), 33.3 (CH2); m/z calcd
for C24H20N4O8S 524.1; found 525.1 [M+H]+; Purity of the compound was further
confirmed by RP-HPLC method A: Rt = 19.07 min (91% pure, Figure A45).

Synthesis of compound 14f (SGT1628). A mixture of
compound

10

(50

mg,

0.15

mmol),

2-

naphthalenesulfonamide (11f) (36 mg, 0.17 mmol),
EDC•HCl (45 mg, 0.24 mmol), and DMAP (32 mg, 0.26
mmol) in anhydrous CH2Cl2 (3 mL) was stirred at room temperature overnight. Upon
completion, the reaction mixture was diluted with H2O and extracted with CH2Cl2 (3×).
The combined organic layers were washed with brine, dried over MgSO4, filtered, and
concentrated. The crude product obtained was purified by column chromatography (SiO2
gel, pure Hexanes to Hexanes:EtOAc/1:1, Rf 0.49 in Hexanes:EtOAc/3:4) followed by
preparative thin layer chromatography to afford compound 14f (13 mg, 16%) as a yellow
solid: 1H NMR (500 MHz, CDCl3, Figure A46) δ 10.49 (s, 1H, NH), 8.19 (d, J = 2.2 Hz,
1H, aromatic), 8.10 (dd, J1 = 9.1 Hz, J2 = 2.2 Hz, 1H, aromatic), 8.06 (dd, J1 = 8.8 Hz, J2
= 2.0 Hz, 1H, aromatic), 8.00 (d, J = 8.1 Hz, 1H, aromatic), 7.96-7.94 (m, 2H, aromatic),
7.89 (d, J = 8.1 Hz, 1H, aromatic), 7.66-7.62 (m, 1H, aromatic), 7.61-7.58 (m, 1H,
aromatic), 7.55 (dd, J1 = 8.6 Hz, J2 = 2.5 Hz, 1H, aromatic), 7.29 (d, J = 9.2 Hz, 2H,
aromatic), 7.02 (d, J = 8.6 Hz, 1H, aromatic), 6.56 (s, 1H, aromatic), 4.09 (s, 3H, ArOCH3),
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3.71 (s, 5H, CH2Ar and NCH3);

13

C NMR (100 MHz, (CD3)2SO, Figure A47) δ 157.3

(C=O), 155.4 (C), 140.6 (C), 140.2 (C), 135.1 (C), 133.8 (C), 132.2 (2C), 132.1 (C), 129.1
(CH), 128.9 (CH), 127.9 (CH), 127.7 (CH), 127.6 (CH), 127.0 (CH), 126.7 (2CH), 126.3
(CH), 124.4 (CH), 120.8 (C), 117.0 (CH), 116.9 (CH), 112.3 (CH), 110.9 (C), 110.0 (CH),
56.0 (CH3), 37.5 (CH3), 33.3 (CH2); m/z calcd for C28H23N3O6S 529.1; found 529.7
[M+H]+ Purity of the compound was further confirmed by RP-HPLC method C: Rt = 15.17
min (97% pure, Figure A48).

2.8. BIOLOGICAL EXPERIMENTS
2.8.1. Bacterial strains and growth conditions
The following bacterial strains were used in this study: Porphyromonas gingivalis 381,
Actinomyces naeslundii ATCC 49340, Aggregatibacter actinomycetemcomitans JP2,
Streptococcus sanguinis ATCC 10556, and Veillonella parvula ATCC 10790. All bacterial
strains were initially grown on blood agar plates (BBL, Becton Dickinson, Sparks, MD)
from a frozen stock and incubated in appropriate aerobic (for S. sanguinis) or anaerobic
(for P. gingivalis, A. naeslundii, A. actinomycetemcomitans, and V. parvula) conditions at
37 °C for 24 h or 3 days, respectively, as previously reported.62 A liquid culture was then
started for each strain in 3 mL of Brain Hearth Infusion (BHI) broth supplemented with 5
µg/mL of hemin and 1 µg/mL of menadione for P. gingivalis, A. naeslundii, A.
actinomycetemcomitans, and S. sanguinis, or Reinforced Clostridial medium with 60%
sodium lactate pH 7 for V. parvula. Overnight cultures were inoculated in corresponding
fresh broth and allowed to reach logarithmic growth for 3-4 h, the time at which
antimicrobial activity of different treatments was evaluated.
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2.8.2. Effect of zafirlukast (ZAF) derivatives on the viability of different bacterial
strains
A colorimetric water-soluble tetrazolium-1 (WST-1) assay was used to establish the
antimicrobial effect of ZAF derivatives 12a, 12c, 12f, 13a-13f, and 14a-14f as previously
reported.62,
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WST-1 acts as a surrogate marker for cell viability and proliferation.

Bacterial strains (108/well) were logarithmically grown in appropriate broth (90 µL) using
96-wells plates and were exposed to different treatments for 24 h. 10 µL of WST-1 reagent
(Roche, Mannheim, Germany) was then added to each well. The plates were incubated for
2 h under appropriate culture conditions and the absorbance at 405 nm was measured, with
a reference wavelength of 600 nm, by using a SpectraMax M2 plate reader (Molecular
Devices, Sunnyvale, CA). The percentage of inhibitory effect (i.e., % growth inhibition)
was calculated by using the optical densities (ODs) of bacterial metabolic activity, under
different experimental conditions by utilizing the following formula: 100 × [OD (control)
- OD (experimental) / OD (control)]. For P. gingivalis, bacteria exposed to only medium
(sterility control) or DMSO were used as negative controls, and bacteria exposed to 2.81
µM of Tet (equivalent to 1.25 µg/mL, a standard concentration usually used for this
control) and ZAF at 25 and 50 µM diluted in DMSO (concentrations that previously
showed antimicrobial effect against P. gingivalis) were used as positive controls. The 1st
generation ZAF derivatives 13g and 14h (previously 22b and 23a)62 (at 1, 10, and 100 µM)
were also used as positive controls for comparison studies. These data are presented in
Figure 2.3. For testing against A. naeslundii, A. actinomycetemcomitans, S. sanguinis, and
V. parvula, control cultures were treated with medium only (sterility control), exposed to

120

DMSO (vehicle for ZAF and its derivatives, negative control), or treated with
penicillin/streptomycin -1X (100 U/mL of penicillin and 100 µg/mL of streptomycin) or
ZAF at 25 and 50 µM diluted in DMSO as positive controls. These data are presented in
Figure 2.5.

2.8.3. Bactericidal effect of ZAF derivatives on P. gingivalis
The bactericidal effect of ZAF derivatives 13b, 13c, 13d, 13f, 14b, and 14e (as these
compounds exhibited the best antimicrobial potential at lower concentrations as
determined by the WST-1 assay) was investigated by measuring colony forming units per
milliliter (CFUs/mL) after different treatments. In 96-well plates, P. gingivalis (108/well),
which was grown in the appropriate medium and anaerobic conditions was treated with
ZAF derivatives (1, 10, and 100 µM) dissolved in DMSO. After 24 h, the treated bacteria
were diluted (1:400) and 50 µL of the diluted samples 13f, 14b, and 14e or 100 µL of the
diluted samples 13b, 13c, and 13d were plated and spread onto blood agar plates. After 5
days of incubation on the blood agar plate in an anaerobic chamber, the numbers of CFUs
were counted. The following controls were used: P. gingivalis growing only in medium
(sterility control) or DMSO (negative control), or with 2.81 µM of Tet (positive control),
or ZAF at 25 and 50 µM diluted in DMSO (positive control). These data are presented in
Figure 2.6.

2.8.4. Cytotoxic effect of ZAF derivatives on oral epithelial cells
To evaluate the cytotoxic effect of ZAF derivatives 13b, 13c, 13d, 13f, 14b, and 14e, the
immortalized oral keratinocyte cell line OKF6/hTERT (OKF6) was used in viability
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assays.178 The OKF6 cells were cultured in keratinocyte-serum free medium (SFM)
supplemented with bovine pituitary extract (25 µg/mL) and recombinant epidermal growth
factor (0.2 ng/mL) (Ker-SFM). The cells were maintained at 37 °C in a humidified
incubator with 5% CO2. For these experiments, medium only (sterility control) or DMSO
were used as negative controls, while 8 µM of staurosporine (STS) or 25 µM of ZAF were
used as positive controls. To establish the volume needed to be added to each well of 24well plates to provide 105 cells/well, equal volumes of cell suspension and trypan blue were
mixed and 10 µL were counted in an automated cell counter (Countess II FL, Life
Technologies, Singapore) to determine the percentage of alive and dead cells. To perform
the viability assays, cells (105 cells/well) were seeded in 24-well plates overnight in KerSFM medium and the cells were further exposed to ZAF derivatives (1 and 10 µM)
dissolved in DMSO or appropriate negative and positive controls for 24 h. The morphology
and density of the treated cells were documented by using a light inverted microscope
Nikon Eclipse Ti-Series (Nikon Instruments Inc., Melville, NY). One well from each
control treatment was visualized along with one well from each 10 µM concentration of
the ZAF derivatives, 13b, 13c, 13d, 13f, 14b, and 14e. These data are presented in Figure
2.7. The cytotoxic effects of ZAF derivatives were also established by flow cytometry
analysis (FACS). After different treatments, OKF6 cells were harvested by trypsinization,
washed with phosphate buffered saline (PBS), pelleted at 1100 rpm for 5 min, and were
further labeled with 5 µL of FITC-Annexin V and 5 µL of propidium iodide (BD
Pharmingen, San Jose, CA) for 15 min at room temperature. The FACS analyses were done
for at least 10,000 acquired events in a flow cytometer FACSCalibur (Becton Dickinson,
San Jose, CA). These data are presented in Figure 2.8 as well as in Table 2.1.
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Table 2.1: The percentage of viable, apoptosis, and necrosis of OKF6 cells treated with
controls (STS and ZAF) and ZAF derivatives 13b, 13c, 13d, 13f, 14b, and 14e.a
Cpd and concentration used
Viable
Apoptosis (%)
DMSO
87.8 ± 4.6
1.60 ± 0.73
34.6 ± 17.3
52.4 ± 26.2
STS (8 µM)
5.90 ± 1.18
10.6 ± 2.5
ZAF (25 µM)
93.1 ± 0.7
0.51 ± 0.18
13b (1 µM)
92.9 ± 0.5
1.24 ± 0.81
13b (10 µM)
89.2 ± 1.1
1.83 ± 0.54
13c (1 µM)
90.3 ± 2.2
1.60 ± 0.81
13c (10 µM)
88.4 ± 3.1
1.52 ± 0.31
13d (1 µM)
92.5 ± 1.6
1.18 ± 0.73
13d (10 µM)
87.2 ± 0.7
1.71 ± 0.01
13f (1 µM)
78.0 ± 7.1
1.85 ± 0.21
13f (10 µM)
76.6 ± 1.8
1.70 ± 0.18
14b (1 µM)
52.2 ± 5.0
10.1 ± 0.5
14b (10 µM)
79.5 ± 5.9
1.03 ± 0.40
14e (1 µM)
49.5 ± 0.4
15.0 ± 0.3
14e (10 µM)
a
Figure 2.8 was generated using the percentage values presented in this Table.

Necrosis (%)
10.6 ± 3.4
13.0 ± 6.5
83.5 ± 2.9
6.43 ± 0.48
5.84 ± 0.32
8.97 ± 1.63
8.12 ± 1.38
10.1 ± 2.7
6.33 ± 0.87
11.1 ± 0.7
20.1 ± 6.9
21.7 ± 1.6
37.7 ± 4.4
19.5 ± 5.5
35.6 ± 0.6
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Chapter 3
Selective inhibition of the periodontal pathogen Porphyromonas gingivalis by third
generation zafirlukast derivatives

3.1. ABSTRACT
Periodontal diseases, such as periodontitis, are inflammatory diseases triggered by
pathogenic oral bacterial species that can lead to damage of the soft tissue and bone
supporting the teeth. The Gram-negative anaerobic keystone pathogen Porphyromonas
gingivalis enhances oral dysbiosis that induces chronic inflammation. The FDA-approved
drug zafirlukast (ZAF), used for the treatment of asthma, has displayed antibacterial
activity against P. gingivalis. Herein, we report the design, synthesis, and selective
antibacterial activity of 14 novel 3rd generation ZAF derivatives. Two 2nd generation ZAF
derivatives were also tested as they were not previously tested against P. gingivalis ATCC
33277. Most 3rd generation derivatives displayed superior antibacterial activity against P.
gingivalis compared to ZAF and its 2nd generation derivatives along with little to no growth
inhibition of other oral bacterial species. The most promising compounds displayed
bactericidal activity against P. gingivalis, inhibited P. gingivalis biofilm growth, and
displayed less cytotoxicity against mammalian cells than ZAF. The compounds displayed
little to no hemolytic activity. The superior and selective antibacterial activity of 2nd and
3rd generation ZAF derivatives against P. gingivalis, increased safety profile compared to
ZAF, and inhibition of biofilm growth compared to ZAF indicate that these new
compounds, especially 21a, 21b, and 24g, show promise as antibacterial agents for future
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studies to test their potential for preventing and treating P. gingivalis-induced periodontal
diseases.

3.2 INTRODUCTION
In 2018, the economic burden due to periodontal diseases caused an estimated loss of $154
B in the United States and €149 B in Europe due to direct (e.g., overall expenses of
periodontal care) and indirect (e.g., loss of productivity) costs.180, 181 Periodontal diseases
are chronic inflammatory diseases of the gum and bone that support the tooth.182-184 The
preventable but more severe and irreversible form of periodontal disease, periodontitis, is
associated with dysbiotic dental plaque, known as oral biofilms, that are the major cause
of the destruction of periodontal tissue and alveolar bone that support the tooth. The Gramnegative periodontopathogenic bacterium Porphyromonas gingivalis is a major keystone
anaerobic pathogen found below the gum line in plaque.185 P. gingivalis is associated with
the initiation and progression of periodontitis, causes tissue damage, increases the
pathogenicity of the biofilm community, and is able to invade the weakened epithelial cell
layers leading to the development of systemic diseases such as rheumatoid arthritis,
Alzheimer’s disease, diabetes, and cancer.8, 12, 24, 186-189 Therefore, P. gingivalis is an ideal
target for antibacterial agents for the treatment and prevention of periodontal diseases.
Current treatment options for periodontal diseases include scaling and root planning, and
surgery to remove the infected tissue with antibiotic adjunctive therapy using doxycycline
or a combination of amoxicillin and metronidazole.190 Lack of specificity of the broadspectrum antibiotics and lack of clear guidelines for choosing an antibiotic that specifically
targets pathogenic oral bacterial species such as P. gingivalis can lead to the development
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of antibiotic resistance by some bacterial species.191 Therefore, it is of interest to develop
highly specific antibacterial agents that target pathogenic bacteria without harming
commensal bacteria that are critical for oral health and homeostasis.

For the discovery of novel antibacterial agents, an appealing option is to use drug
repositioning as a starting point to develop medications in a fast and an affordable way.
Drug repositioning is where a medication that is FDA-approved for the treatment of one
disease is used to treat a different disease.174 Previously, we discovered that derivatives of
the FDA-approved anti-asthma oral medication zafirlukast (ZAF) led to compounds that
are highly specific for P. gingivalis only, while displaying less toxicity to oral epithelial
cells, which are the first line of defense against invading pathogens.62, 103, 175, 192 In the
current study, the two most active 2nd generation ZAF derivatives103 were further tested for
their anti-P. gingivalis biofilm activity and were used as starting points for further structure
optimization on the ZAF indole ring (e.g., alkyl groups and bulky aryl groups) and
arylfulfonamide ring (e.g., halogens) with the goal of increasing inhibition of P. gingivalis
growth, retaining specificity, and having the ability to inhibit P. gingivalis biofilm growth
(Figure 3.1). Herein, the short 4-step linear synthesis of 14 3rd generation ZAF derivatives
is reported. Additionally, we present their antibacterial activity against P. gingivalis ATCC
33277 and other oral bacterial species, their cytotoxic activity against human oral epithelial
cells and mammalian cells, as well as their inhibition of biofilm formation and disruption
of pre-formed P. gingivalis biofilm growth.
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Figure 3.1. Chemical structure of zafirlukast (ZAF) and overview of the R1 and R2 substituents present in
the two previously published 2nd generation as well as 14 novel 3rd generation ZAF derivatives synthesized
herein.

3.3 RESULTS AND DISCUSSION
3.3.1. Design and synthesis of 3rd generation ZAF derivatives
In our previous structure-activity relationship (SAR) studies with 1st and 2nd generation
ZAF derivatives, the primary focus was the modification of the substituents’ positions on
the ZAF benzoyl ring along with bioisosteric replacement of substituents on the indole and
arylsulfonamide ring.62, 103 Through these studies we discovered that: (i) modification of
the 3-methoxy-4-indoyl organization of ZAF to a 2-methoxy-5-indoyl arrangement
increased activity of the ZAF derivatives; (ii) the presence of the cyclopentyl carbamate
group at the C5 position of the indole ring of ZAF is not needed for activity, but its
complete removal (i.e., having a hydrogen at that position) decreased activity, while its
replacement by an electron-withdrawing group (e.g., NO2) at C5 increased activity of the
derivatives when compared to the parent ZAF; (iii) removal of the methyl group on the
nitrogen of the indole of ZAF decreased activity of the derivatives, and (iv) modification
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of the substitution pattern on the arylsulfonamide ring of ZAF by removal of the methyl
group at C2 decreased activity of the ZAF derivatives, while addition of electronwithdrawing groups (e.g., F at C2 and NO2 at C4) increased antibacterial activity when
compared to ZAF. Based on these observations, for the design of the 3rd generation ZAF
derivatives, we used two 2nd generation ZAF derivatives (21a and 21g previously 14a and
14e; Scheme 3.1)103 as starting points. We kept the C5 NO2 group of the indole and
positions of the substituents (i.e., substituents at positions C1, C2, and C5) on the benzoyl
ring constant. Herein, we synthesized 14 novel 3rd generation ZAF derivatives (21b-f, 22a,
22g, 23a, 23g, 24a, 24g, 25a, 25g, and 26g) to (i) examine the effect of various electronwithdrawing groups on the arylsulfonamide ring while keeping the N-methyl group on the
indole ring constant, and (ii) investigate the importance of the methyl group on the nitrogen
of the indole of ZAF by its replacement with longer alkyl chains or bulky aryl groups.

We used a linear 4-step synthesis for the preparation of these 14 novel 3rd generation ZAF
derivatives (Scheme 3.1). The commercially available 5-nitroindole was alkylated to form
compounds 1-6 (1-methyl-5-nitroindole (1), 1-ethyl-5-nitroindole (2), 1-propyl-5nitroindole (3), 1-n-butyl-5-nitroindole (4), 1-isobutyl-5-nitroindole (5), and 1-benzyl-5nitroindole (6)) in 28-72% yields. A condensation reaction “a” between the synthesized 1alkyl-5-nitroindoles 1-6 with the commercially available (indicated by a $ sign in Scheme
3.1) methyl-5-formyl-2-methoxybenzoate (7) generated compounds 8-13 in 8-63% yields.
The condensation reaction used triethylsilane (Et3SiH), which is a source of hydride,
trifluoroacetic acid (TFA), and dichloromethane (CH2Cl2). Hydrolysis of the methyl ester
group of 8-13 to a carboxylic acid “b” using methanol (MeOH), tetrahydrofuran (THF),
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and water in potassium hydroxide (KOH), then afforded compounds 14-19 in 31-96%
yields. Finally, amide coupling “c” of the carboxylic acids 14-19 with various
commercially available arylsulfonamides (20a-20g) using N-(3-dimethylaminopropyl)-N′
-ethylcarbodiimide hydrochloride (EDC•HCl), 4-dimethylaminopyridine (DMAP), and
CH2Cl2 yielded 14 novel 3rd generation ZAF derivatives 21b-f, 22a, 22g, 23a, 23g, 24a,
24g, 25a, 25g, and 26g in 12%-quantitative yields. Additionally, two of the lead 2nd
generation ZAF derivatives 21a and 21g (previously 14a and 14e),103 were also resynthesized in quantitative and 82% yields, respectively (Scheme 3.1), for novel testing
against a different strain of P. gingivalis and testing against mono-species biofilms along
with the new 3rd generation ZAF derivatives 21b-f, 22a, 22g, 23a, 23g, 24a, 24g, 25a, 25g,
and 26g synthesized herein.
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Scheme 3.1. Synthetic scheme for the preparation of 2nd generation ZAF derivatives 21a and 21g and 3rd
generation ZAF derivatives 21b-21f, 22a, 22g, 23a, 23g, 24a, 24g, 25a, 25g, and 26g. Reaction conditions:
(a) Et3SiH, TFA, CH2Cl2, 0 °C to room temperature, 8-63%; (b) MeOH:THF:H2O/5:1:1, KOH, 65 °C, 3196%; (c) arylsulfonamide, EDC•HCl, DMAP, CH2Cl2, room temperature, 12%-quantitative yields.

3.3.2. Anti-P. gingivalis activity and structure-activity relationship (SAR)
With the aim of increasing P. gingivalis ATCC 33277 growth inhibition in planktonic and
mono-species biofilms with these novel 3rd generation ZAF derivatives, we set to answer
four questions in terms of SAR (Note: The compound number for the ZAF derivatives used
to answer the questions are provided into parentheses following the questions). (i) What is
the effect of varying the R2 electron-withdrawing group(s) on the arylsulfonamide ring
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when R1 = Me? (comparing R2 = 2-F (21a), 4-NO2 (21g), 2-Cl (21b), 2-Br (21c), 2,6-diF
(21d), 2,4-diF (21e), 3,4-diF (21f)). (ii) Are compounds with R2 = 4-NO2 always more
active than those with R2 = 2-F when the R1 substituent is varied? (comparing g (R2 = 4NO2) vs a (R2 = 2-F) counterparts). (iii) What is the effect of adding a longer linear or
larger branched R1 group or a bulkier benzyl group to the nitrogen of the indole ring when
R2 = 4-NO2? (comparing R1 = methyl (21g), ethyl (22g), propyl (23g), n-butyl (24g),
isobutyl (25g), and benzyl (26g)). (iv) Does changing the substitution pattern on the
arylsulfonamide from R2 = 4-NO2 to R2 = 2-F affect the activity trend established in
question iii for the various R1 substituents when R2 = 4-NO2? (comparing R1 = methyl
(21a), ethyl (22a), propyl (23a), n-butyl (24a), isobutyl (25a) to their counterparts 21g25g).

To answer the four questions posed and to determine the potential of the 3rd generation
ZAF derivatives 21b-f, 22a, 22g, 23a, 23g, 24a, 24g, 25a, 25g, and 26g as antibacterial
agents compared to the parent ZAF, we first tested them against P. gingivalis ATCC 33277
(Figures 3.2 and B87 as bar graph representations of the data and Figure B88 as heat map
representation of the data). We also tested the two most active 2nd generation ZAF
derivatives (21a and 21g) against P. gingivalis ATCC 33277 (Figures 3.2, B87, and B88),
as this strain is more virulent than P. gingivalis 381 that we used in our previous study. To
determine the antimicrobial effect of the 16 synthesized ZAF derivatives (including the
two 2nd generation compounds), we used a colorimetric water-soluble tetrazolium-1 (WST1) assay to test the compounds at 1, 10, and 100 µM. Positive controls for this assay were
the commercially available tetracycline (Tet, at 2.81 µM, which displayed 33% P.
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gingivalis growth inhibition) and ZAF (at 25 and 50 µM, which displayed 74% and 88%
P. gingivalis growth inhibition, respectively; pale blue, grey, and orange bars, respectively
in Figures 3.2 and B87). We opted to test ZAF at 25 and 50 µM, based on a previous
publication using P. gingivalis ATCC 33277, which showed that these concentrations were
the minimum concentration that inhibited bacterial growth on titanium discs.192
Additionally, we used Tet as a positive control as it is a common antibiotic used for the
treatment of periodontitis and it has been shown to be active against many P. gingivalis
species within the range of 2.81 µM.193 It is also important to note that the 2nd and 3rd
generation ZAF derivatives were tested in preliminary percent growth inhibition assays
with a wide range of concentrations in order to determine their initial activity to be used in
future studies and further investigation for lead optimization outside the scope of this
preliminary investigation. As these compounds were not previously tested against this
specific strain of P. gingivalis, in order to test the ability of the ZAF derivatives to inhibit
P. gingivalis growth a wide range, 1-100 µM, of concentrations was used to determine their
level of potency against planktonic oral bacterial species. As expected, we did not observe
bacterial growth inhibition with dimethyl sulfoxide (DMSO), which we used as a negative
control along with bacteria grown in medium only.
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Figure 3.2. Percent growth inhibition effect of 2nd generation ZAF derivatives 21a and 21g and 3rd generation
ZAF derivatives 21b-21f, 22a, 22g, 23a, 23g, 24a, 24g, 25a, 25g, and 26g on P. gingivalis ATCC 33277
determined by a colorimetric WST-1 assay. In supplemented brain heart infusion (BHI), planktonic P.
gingivalis (108 cells/well) was exponentially grown and incubated under anaerobic conditions and was
incubated with different treatments of ZAF derivatives 21a-21g, 22a, 22g, 23a, 23g, 24a, 24g, 25a, 25g, and
26g (1, 10, and 100 µM) for 24 h. The cultures were treated with medium only (sterility control) and the
experimental cultures were treated with DMSO (vehicle for ZAF and its derivatives, negative control) and
2.81 µM of tetracycline (Tet) or 25 and 50 µM of ZAF. The data represent the average from 42 independent
replicates for the controls. For each ZAF derivative, the data represent the average from six independent
replicates per condition of the growth inhibitory effect vs bacterial cultures grown in medium only. These
data represent the percent growth inhibition 2.5 h after the addition of the WST-1 reagent. Note: The data for
30 min after the addition of the WST-1 reagent are presented in Figure B87. Additionally, the data 2.5 h after
the addition of the WST-1 reagent is presented in a visual form as a heat map in Figure B88.

When looking broadly at the data collected 2.5 h after the addition of the WST-1 reagent
(Figure 3.2), we observed that when tested against P. gingivalis ATCC 33277 compared to
P. gingivalis 381, the 2nd generation ZAF derivative 21g displayed more activity than 21a
against this more virulent strain. When comparing the 16 synthesized ZAF derivatives to
the Tet control, we found that, at 100, 10, and 1 µM, nine (21a, 21g, 21b, 21c, 21d, 22g,
23g, 24g, and 25g), four (21g, 22g, 23g, and 24g), and two (23g and 24g) out of the 16
compounds displayed comparable or superior activity when compared to Tet (33% growth
inhibition), respectively. When comparing these ZAF derivatives to the parent ZAF, we
observed that, at 10 µM, three out of the 16 compounds (22g, 23g, and 24g) displayed
comparable/superior activity (77-90% growth inhibition) to ZAF (74% growth inhibition
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at 25 µM and 88% at 50 µM). At 1 µM, compounds 23g and 24g also displayed
comparable/superior activity (60% and 69% growth inhibition, respectively) when
compared to ZAF. It is important to note that an increased antibacterial activity of
compounds 21a, 21b, 21c, 21d, and 25g was observed 30 min after the addition of WST1 (Figure B87) at 100 µM with activity between 61-73% growth inhibition. Therefore,
these compounds were additionally selected for further biological tests along with the
active compounds of 21g, 22g, 23g, and 24g.

Next, by taking a deeper look into the data, we aimed to answer the four questions posed
above. Question i: What is the effect of varying the R2 electron-withdrawing group(s) on
the arylsulfonamide ring when R1 = Me? To answer this question, we compared
compounds 21a-g at 100 µM concentration and 2.5 h after the addition of the WST-1
reagent. Overall, it was found that compound 21g (R2 = 4-NO2) displayed better P.
gingivalis growth inhibition than (>) 21a (R2 = 2-F), which was similar to (≈) 21b (R2 = 2Cl) (≈) 21d (R2 = 2,6-diF), which was better than (>) 21c (R2 = 2-Br) (>) 21f (R2 = 3,4diF) and (>) 21e (R2 = 2,4-diF).

Having confirmed the importance of the R2 2-F and 4-NO2 groups, the next set of
derivatives prepared kept these two R2 groups constant while varying R1. To verify if ZAF
derivatives with R2 = 4-NO2 are always more active than those with R2 = 2-F, we performed
a pairwise comparison of 21a-25a vs 21g-25g (question ii). We found that at 10 and 100
µM, R2 = 4-NO2 always yielded more active compounds than R2 = 2-F. At 1 µM, this was
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also true for compounds 23g and 24g that displayed significant activity, while their 2fluorinated counterparts 23a and 24a displayed little to no activity at that concentration.

To investigate the importance of the R1 group attached to the nitrogen of the indole when
R2 = 4-NO2 (question iii), we compared compounds 22g with R1 = ethyl, 23g with R1 =
propyl, 24g with R1 = n-butyl, 25g with R1 = isobutyl, and 26g with R1 = benzyl to
compound 21g with R1 = methyl. We observed that replacing the R1 methyl group of 21g
by a bulky aromatic benzyl moiety (26g) resulted in an almost complete loss of activity.
Thus, the benzylated counterpart 26a with R2 = 2-F was not synthesized to answer question
iv. In general, we discovered that substitution of the R1 methyl group on the nitrogen of the
indole of 21g with longer/larger alkyl chains (22g-24g) yielded a significant increase in
activity when tested at 1, 10, and 100 µM. A decrease in activity was seen with compound
25g (R1 = isobutyl), which indicated the limit of the size of the group that can be attached
to the nitrogen of the indole ring. More specifically, compound 22g (R1 = ethyl) was found
to display 6, 77, and 81% P. gingivalis growth inhibition at 1, 10, and 100 µM, respectively,
which were superior to that of 21g (0, 63, and 56%) at all concentrations tested. As the
increase in chain length proved to be beneficial for P. gingivalis growth inhibition, the
effect of longer chain lengths was also investigated. At all concentrations tested, compound
23g (R1= propyl) yielded 60-90% growth inhibition, which was similar to the activity
observed with 24g (R1 = n-butyl) (with 69-90% growth inhibition). Overall, at 100 µM, it
was found that compound 23g (R1 = propyl) displayed better P. gingivalis growth
inhibition than (>) 22g (R1 = ethyl) (>) 24g (R1 = n-butyl) (>) 21g (R1 = methyl) (>) 25g
(R1 = isobutyl) and (>) 26g (R1 = benzyl).
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With the trend established for the substitution patterns of the arylsulfonamides with R2 =
4-NO2 (series g) and various alkyl chains for R1 (question iii), the effect of the
arylsulfonamide with R2= 2-F (series a) with these same N-alkyl groups on the indole ring
was investigated by generating the counterpart series 22a-25a (question iv). When
comparing the N-alkylated compounds 21a-25a with R2 = 2-F within that specific series a,
it was found that compound 21a (R1 = methyl) displayed better P. gingivalis growth
inhibition than (>) 23a (R1 = propyl) (>) 22a (R1 = ethyl), which was similar to (≈) 24a (R1
= n-butyl) (≈) 25a (R1 = isobutyl). Interestingly, when compared to the trend observed for
compounds 21g-25g with R2 = 4-NO2, the trend remained the same with the exception of
the methyl groups. The overall SAR for all compounds evaluated summarized based on
their activity at 100 µM is presented in Figure 3.3. Although 100 µM is a high therapeutic
concentration, all comparisons were made at the 100 µM concentration (even though some
compounds displayed excellent activity at 1 and 10 µM) due to most compounds not being
active at the lower concentrations. In the preliminary study, we wanted to make
comparisons of each group modified in the structure in order to get a clear picture of which
groups were better or worse for inhibiting planktonic P. gingivalis growth. Additionally,
there are many ways to test the activity of the ZAF derivatives against oral bacterial species
such as minimum inhibitory concentration (MIC) or IC50 assays. In the literature it is
common to see both MIC testing and percent growth inhibition assays performed for testing
with oral bacterial species.105, 106, 108, 115, 194 As this was an initial screening of activity for
percent growth inhibition to determine if the compounds were active against P. gingivalis
a wide range of concentrations were chosen to determine if the compounds displayed
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activity, and future studies, outside the scope of this investigation, will be performed to
determine the exact dose response of the most active compounds against P. gingivalis. To
perform other assays, such as determination of IC50 values, the compounds would have to
be tested at a much larger range of 2-fold dilutions, which is impractical while we are
currently optimizing the structure of the ZAF derivatives based on the data observed in the
additional assays performed in this study. For the most active compounds a much higher
range of concentrations would need to be used that are over 200 µM. Whereas for the least
active compounds a range of concentrations much less than 1 µM would need to be used
in order to determine exact IC50 values for these compounds. For these reasons, we opted
to analyze the activity of the compounds in the initial screening by the percent growth
inhibition assays.

Figure 3.3. Summary of the SAR for the 2nd (21a and 21g) and 3rd generation (21b-21f, 22a, 22g, 23a, 23g,
24a, 24g, 25a, 25g, and 26g) ZAF derivatives when tested against P. gingivalis ATCC 33277 at 100 µM.

3.3.3. Antibacterial activity against non-P. gingivalis oral bacterial species
Based on the results of the percent growth inhibition assay presented in Figures 3.2 and
B87, the seven most active 3rd generation ZAF derivatives were established to be 21b, 21c,
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21d, 22g, 23g, 24g, and 25g. These compounds, along with two 2nd generation ZAF
derivatives (21a and 21g), were then further tested against other Gram-positive and Gramnegative oral bacterial species to determine their antibacterial specificity profile (Figure
3.4 as a bar graph representation of the data and Figure B89 as a visual heat map
representation of the data). The oral bacterial species chosen were a variety of early and
late colonizers found in oral biofilms, also known as dental plaque. The early colonizers
abundant in periodontal health include Streptococcus sanguinis ATCC 10556 (Grampositive aerobic), Actinomyces naeslundii ATCC 49340 (Gram-positive anaerobic), and
Veillonella parvula ATCC 10790 (Gram-negative anaerobic), while the late colonizers
abundant in periodontal disease include Aggregatibacter actinomycetemcomitans JP2
(Gram-negative anaerobic) and Fusobacterium nucleatum ATCC 25586 (Gram-negative
anaerobic). In Figures 3.4 and B89, the percent growth inhibition data for F. nucleatum are
presented 30 min after the addition of the WST-1 reagent because this was the time when
the standard positive controls of Tet and ZAF reached the percent growth inhibition values
consistent with the literature and consistent within the experiments performed in the
laboratory. All other oral bacterial species data are presented 2.5 h after the addition of the
WST-1 reagent for the same reason. The compounds displayed little to no activity against
V. parvula, A. naeslundii, S. sanguinis, and A. actinomycetemcomitans, with the exception
of about 40% growth inhibition at 100 µM by 21d against A. naeslundii and S. sanguinis.
Compound 21d also displayed 76% growth inhibition against F. nucleatum at 100 µM, but
there was no activity seen at 1 or 10 µM. This bacterium is considered a bridge colonizer,
where it can attach to both early colonizing bacterial species abundant in periodontal health
and late-stage colonizing pathogenic bacterial species. Therefore, if some of the
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compounds display activity against F. nucleatum, that will only aid in the ability of these
ZAF derivatives to act as a treatment for periodontal diseases. Overall, these data suggest
that the 3rd generation ZAF derivatives display specificity against P. gingivalis.
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Figure 3.4. Percent growth inhibition effect of ZAF derivatives 21a, 21g, 21b, 21c, 21d, 22g, 23g, 24g, and
25g on A. naeslundii ATCC 49340 (anaerobic), A. actinomycetemcomitans JP2 (anaerobic), F. nucleatum
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ATCC 25586 (anaerobic), S. sanguinis ATCC 10556 (aerobic), and V. parvula ATCC 10790 (anaerobic)
determined by a colorimetric WST-1 assay. Grown supplemented BHI for P. gingivalis, A. naeslundii, A.
actinomycetemcomitans, F. nucleatum, and S. sanguinis, or Reinforced Clostridial medium for V. parvula
(108 cells/well) was exponentially grown and incubated under aerobic or anaerobic conditions and was treated
with ZAF derivatives 21a, 21g, 21b, 21c, 21d, 22g, 23g, 24g, and 25g (1, 10, and 100 µM) for 24 h. The
cultures were treated with medium only (sterility control) and the experimental cultures were treated with
DMSO (vehicle for ZAF and its derivatives, negative control), 2.81 µM of Tet (for F. nucleatum), the
antibiotics penicillin/streptomycin (P/S) 1X (100 U/mL of penicillin and 100 µg/mL of streptomycin for all
other oral bacterial species), and 25 and 50 µM of ZAF. The data represent the average from 30 independent
replicates for the controls. For each ZAF derivative, the data represent the average from six independent
replicates per condition of the growth inhibitory effect vs bacterial cultures grown in medium only. These
data represent the percent growth inhibition 30 min (for F. nucleatum as this was the time when the controls
reached the standard percent growth inhibition values consistent with the literature) or 2.5 h for the other oral
bacterial species after the addition of the WST-1 reagent. Note: A visual representation of the data in the form
of a heat map is presented in Figure B89.

3.3.4. Colony forming unit (CFU) assays
To determine if the nine most active ZAF derivatives (21a, 21g, 21b, 21c, 21d, 22g, 23g,
24g, and 25g) displayed bactericidal activity, colony forming unit (CFU) assays were
performed with P. gingivalis ATCC 33277 (Figure 3.5). P. gingivalis was exposed to all
controls and treatments for 24 h in medium followed by bacterial growth in blood agar
plates for 5 days under anaerobic conditions and CFUs determination. For positive
controls, P. gingivalis was incubated with the antibiotic Tet (2.81 µM) and ZAF (25 and
50 µM). For a negative control bacteria grown with only DMSO were used. P. gingivalis
was exposed to ZAF derivatives 21a, 21g, 21b, 21c, 21d, 22g, 23g, 24g, and 25g at 10 and
100 µM. At 100 µM, all nine compounds exhibited bactericidal activity with 100% growth
inhibition. At 10 µM, compounds 21g, 21b, and 21c were also bactericidal, compound 21a
displayed 96% growth inhibition, and 24g displayed 71% growth inhibition. Compounds
21d, 22g, 23g, and 25g were not bactericidal at 10 µM. At both concentrations tested, the
2nd generation compounds 21a and 21g, along with 3rd generation compounds 21b, 21c,
and 24g displayed similar or higher percent growth inhibition than the controls Tet and
ZAF (25 and 50 µM). At 100 µM, compound 22g displayed higher percent growth
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inhibition by CFU assays than the controls and displayed 19% growth inhibition at 10 µM.
Based on these results, we decided to continue with further investigation of 21a, 21b, 21c,
21g, 22g, and 24g.

Figure 3.5. Bactericidal effect of ZAF derivatives 21a-21d, 21g, 22g, 23g, 24g, and 25g on P. gingivalis
ATCC 33277 determined by colony forming unit (CFU) assays. In supplemented BHI, P. gingivalis (108
cells/well) was exponentially grown and incubated under anaerobic conditions and was treated with ZAF
derivatives 21a-21d, 21g, 22g, 23g, 24g, and 25g (1 (data not shown), 10, and 100 µM) for 24 h. The bacteria
exposed to treatment were diluted (1:400) and spread onto blood agar plates. After 5 days of incubation under
anaerobic conditions CFUs were counted. Negative controls were bacteria exposed to only medium or
DMSO. Bacteria exposed to antibiotic Tet (2.81 µM) or ZAF (25 and 50 µM) were used as positive controls.
For each control and ZAF derivative, the data represent the average from three independent replicates per
condition. The data shows the calculated percentage of inhibitory effect by comparison of the treated bacteria
groups (CFUs/mL) vs bacteria grown in medium only (CFUs/mL) using the formula 100 × [CFUs/mL of
(control) - CFUs/mL (experimental) / CFUs/mL (control)].

3.3.5. Disruption of pre-formed biofilms and prevention of P. gingivalis biofilm
formation by ZAF derivatives
Two of the most active 2nd generation ZAF derivatives (21a and 21g) and four of the most
active 3rd generation ZAF derivatives (21b, 21c, 22g, and 24g) were first tested to
determine their ability to disrupt mono-species biofilms of P. gingivalis ATCC 33277
(Figure 3.6). P. gingivalis was grown in medium for 48 h with gentle shaking under
appropriate anaerobic conditions to form the biofilm. Then the bacteria were exposed to all

143

controls and treatments for 24 h in medium followed by staining with safranin to determine
the percentage of biofilm growth. For positive controls, P. gingivalis was incubated with
the antibiotic Tet (2.81 µM) and ZAF (50 µM). Bacteria grown with only DMSO were
used as a negative control. P. gingivalis was exposed to ZAF derivatives 21a-21c, 21g,
22g, and 24g at 50 and 100 µM. All compounds were compared to the DMSO control to
calculate the percentage of biofilm growth where 100% biofilm growth was observed.
Unfortunately, at 100 µM, none of the six compounds tested appear to be able to disrupt
pre-formed P. gingivalis biofilms.

Figure 3.6. Effect of ZAF derivatives 21a-c, 21g, 22g, and 24g on their ability to disrupt pre-formed biofilms
of P. gingivalis ATCC 33277 determined by a safranin staining assay of mono-species P. gingivalis cultures.
In supplemented BHI, P. gingivalis (108 cells/well) was exponentially grown and incubated under anaerobic
conditions for 48 h with gentle shaking in 96-well plates (100 µL). After biofilm formation, the old medium
was removed, cells were washed with phosphate buffered saline (PBS), and 100 µL of BHI was added to
each well. The bacteria were treated with 100 µL of ZAF derivatives 21a-c, 21g, 22g, and 24g (10 and 100
µM) for 24 h. The negative control was bacteria grown in the presence of DMSO. Bacteria exposed to Tet
(2.81 µM) or ZAF (50 µM) were used as positive controls. The cells were stained with 0.1% safranin (100
µL) and absorbance was measured at 492 nm. The data show the calculated percentage of biofilm growth by
comparison of the treated bacteria groups vs bacteria grown in DMSO only using the formula 100 × [OD
(experimental) / OD (DMSO control)].

We next investigated the ability of these six selected ZAF derivatives to inhibit monospecies biofilm growth of P. gingivalis ATCC 33277 (Figure 3.7). Although these
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compounds cannot disrupt pre-formed biofilms, they can however be tested for their ability
to prevent oral biofilm from forming, which is known as dental plaque that is home to many
oral bacterial species.1, 2, 17, 25, 195 As these compounds show specificity with bactericidal
activity against planktonic P. gingivalis, this would mean that it would kill P. gingivalis
before it can even form a biofilm and it would help slow down biofilm formation. This
could have many downstream effects for the pathogenicity of the biofilm and could help
inhibit the growth of other pathogenic oral bacterial species for which the growth is
enhanced by P. gingivalis.3, 17, 24, 27, 185 P. gingivalis was grown in medium and exposed to
different treatments for 48 h with gentle shaking under anaerobic conditions, followed by
staining with safranin to determine the percentage of biofilm growth. P. gingivalis was
incubated with Tet (2.81 µM) and ZAF (50 µM) as positive controls. Bacteria grown with
DMSO only were utilized as a negative control. P. gingivalis was exposed to ZAF
derivatives 21a-21c, 21g, 22g, and 24g at 10, 25, 50, and 100 µM. All compounds were
compared to the DMSO control to calculate the percentage of biofilm growth where 100%
biofilm growth was observed. All compounds tested displayed the ability to inhibit growth
of P. gingivalis biofilm with at least two of the concentrations tested. Overall, compound
21g displayed the least activity at inhibiting biofilm growth with at least 86% of biofilm
growth at all concentrations tested. At 100 µM, compound 24g displayed the same activity
of 57% biofilm growth as the controls Tet and ZAF with 57% and 58%, respectively. At
50 µM, compounds 21a, 21b, and 24g displayed similar activity to the controls with 61%,
58%, and 63% biofilm growth. Compounds 21a (52%) and 21b (55%) displayed increased
activity compared to the controls at 25 µM. Additionally, the most active compound 21b
displayed better activity than the parent drug ZAF with 53% biofilm growth at
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concentrations as low as 10 µM. With the ability to inhibit P. gingivalis biofilm growth, it
is next important to determine if these active compounds have any toxic effect to oral
epithelial cells and mammalian cells as activity is not the only determining factor when
developing an antibacterial agent.

Figure 3.7. Effect of ZAF derivatives 21a-c, 21g, 22g, and 24g on their ability to inhibit growth of P.
gingivalis ATCC 33277 biofilm determined by a safranin staining assay of mono-species cultures. In
supplemented BHI (100 µL), P. gingivalis (108 cells/well) was exponentially grown and incubated under
anaerobic conditions and exposed to different treatments (100 µL) for 48 h with gentle shaking in 96-well
plates. The bacteria were treated with ZAF derivatives 21a-c, 21g, 22g, and 24g (10, 25, 50, and 100 µM).
Negative controls were bacteria grown with DMSO only. Bacteria exposed to Tet (2.81 µM) or ZAF (50 µM)
were used as positive controls. The cells were stained with 0.1% safranin (100 µL) and absorbance was
measured at 492 nm. The data show the calculated percentage of biofilm growth by comparison of the treated
bacteria groups vs bacteria grown in DMSO only using the formula 100 × [OD (experimental) / OD (DMSO
control)].

3.3.6. Cytotoxic effect of ZAF derivatives on oral epithelial cells
Oral epithelial cells are the body’s first line of defense against invading
periodontopathogenic bacterial species. For a compound to be a promising lead candidate
it needs to have selective activity against the targeted pathogen to not disrupt the host cells
defense mechanisms along with not disturbing the commensal bacterial species found in
periodontal health. Therefore, the three most active 3rd generation ZAF derivatives 21b,
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21c, and 24g were evaluated at 10 and 100 µM for their cytotoxic effect against
immortalized oral keratinocyte (OKF6) cells by using flow cytometry and visualization by
microscopy (Figure 3.8). When tested at 10 µM, compounds 21b and 21c displayed
bactericidal activity in CFU assays against P. gingivalis and compound 24g displayed 71%
growth inhibition at this concentration along with bactericidal activity at 100 µM.
Therefore, the compounds were tested against OKF6 cells at concentrations from 1- to 10fold higher than their P. gingivalis percent growth inhibition activity. Microscopy was used
to visualize the OKF6 cell morphology and density to examine the effect of the various
treatments on the cells. In the cytotoxicity assay, the no treatment control and DMSO
control wells had a higher density of OKF6 cells, which were spatially close together and
had an elongated and flat epithelial-like morphology.178 Wells with cells treated with
staurosporine (8 µM, STS, a pro-apoptotic chemical) and ZAF (25 µM) had a lower density
of cells. Wells treated with positive controls were in direct contrast to the negative controls
as the OKF6 cells were smaller in size, more round in shape, and farther apart from one
another. Wells containing compounds 21c and 24g had the highest density of cells,
followed by compound 21b. At 10 µM, compounds 21c and 24g had a higher cell density
than the positive controls STS and ZAF, which indicated low toxicity to OKF6 cells. Cell
morphology of the wells containing compound 24g at 10 µM resembled the elongated and
flat OKF6 cells of the negative controls indicating little to no cytotoxicity, with only a
slight decrease in cell density at 100 µM. Although the wells containing compounds 21b
and 21c at 100 µM indicate a slight increase in cytotoxicity with round OKF6 cells spread
farther apart from one another, this concentration is 10-fold higher than their bactericidal
activity and display less cytotoxicity compared to the commercially available STS that was
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tested at a much lower concentration of 8 µM. The concentrations that we tested ZAF
derivatives 21b, 21c, and 24g at are much higher than what is needed to inhibit 100% P.
gingivalis growth. Thus these compounds should be safe at the dose that would be needed
for treatment.

Figure 3.8. Effect of ZAF derivatives 21b, 21c, and 24g on cell morphology of oral epithelial cells (OKF6)
visualized under a microscope (Note: the images represent the entire well). OKF6 cells treated with medium
only or 1% DMSO were used as negative controls, while cells treated with 8 µM of staurosporine (STS) or
25 µM of ZAF were used as positive controls. Cells were treated with 10 and 100 µM of ZAF derivatives
21b, 21c, and 24g for 24 h.

In these cytotoxicity studies on ZAF derivatives 21b, 21c, and 24g, 9-63% cell viability at
the concentration of 10 µM, and 5-23% cell viability at 100 µM were observed (yellow
bars in Figure 3.9, Table 3.1). All compounds tested displayed less cytotoxicity than the
control STS. At 10 µM, compounds 21c and 24g displayed less cytotoxicity than the parent
drug ZAF (41% cell viability). Overall, at 10 µM, it was found that compound 24g (R1 =
n-butyl and R2 = 4-NO2) displayed less cytotoxicity than (<) 21c (R1 = methyl and R2 = 2Br), which was less toxic than (<) 21b (R1 = methyl and R2 = 2-Cl). At 100 µM, a similar
trend was observed. Overall, with compounds 21c and 24g, the desired effect of these 3rd
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generation ZAF derivatives achieved the goal of increasing P. gingivalis growth inhibition
with decreased cytotoxicity at their bactericidal concentration of 10 µM, compared to the
most active 2nd generation ZAF derivatives and ZAF parent drug.

Figure 3.9. Effect of ZAF derivatives 21b, 21c, and 24g on apoptosis and necrosis of oral epithelial cells
(OKF6) evaluated in a cell viability assay. OKF6 cells treated with medium only or 1% DMSO were used as
negative controls, while cells were treated with 8 µM of staurosporine (STS) or 25 µM of ZAF were used as
positive controls. Cells were treated with 10 and 100 µM of ZAF derivatives 21b, 21c, and 24g for 24 h and
the cytotoxic effect was established by flow cytometry analysis (FACS) using an FITC-Annexin V apoptosis
detection kit (BD, Pharmingen). Two independent experiments analyzing at least 10,000 events per condition
in duplicate were used to generate the FACS data.

3.3.7. Cytotoxic effect of ZAF derivatives on mammalian cell lines
Although there was a decrease in the cytotoxic effect of 21c compared to the most active
2nd generation ZAF derivatives and the parent compound ZAF with OKF6 cells, there was
a slight increase in cytotoxicity with compound 21b. Therefore, another crucial parameter
to consider when developing antibacterial drugs is to ensure they are not toxic to
mammalian cells. The most active halogenated compounds 21a (R2 = 2-F), 21b (R2 = 2Cl), and 21c (R2 = 2-Br) were tested against three different mammalian cell lines: human
embryonic kidney (HEK-293), human bronchus normal (BEAS-2B), and liver
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hepatocellular carcinoma (HepG2) cells along with ZAF as a control (Figures B90 and
B91). In instances where >100% cell survival was observed, the data displayed in Figure
3.10 were normalized to 100% cell survival (Note: the non-normalized data are presented
in Figure B90). When tested against P. gingivalis ATCC 33277 in CFU assays compounds
21a-c displayed 96% growth inhibition (for 21a) or displayed a bactericidal effect with
100% growth inhibition (for 21b and 21c) at 10 µM. Each compound was tested against
the mammalian cell lines in a concentration range of 0-62.6 µg/mL (i.e., concentrations at
least up to 10-fold higher than those displaying complete growth inhibition). Against HEK293 and HepG2, compounds 21a, 21b, and 21c exhibited no toxicity up to 62.6 µg/mL (11to 13-fold of their bactericidal concentrations). Against BEAS-2B, no toxicity was
observed with compounds 21a, 21b, and 21c up to 62.6 µg/mL (11- to 13-fold of their
bactericidal concentrations), 31.3 µg/mL (6-fold of their bactericidal concentrations), and
31.3 µg/mL (6-fold of their bactericidal concentrations), respectively. ZAF displayed no
toxicity up to 31.3 µg/mL, 62.6 µg/mL, and 62.6 µg/mL for HEK-293, BEAS-2B, and
HepG2, respectively. With little to no toxicity (>76% cell survival) at all concentrations
tested against mammalian cells, these data are very encouraging.
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Figure 3.10. Evaluation of cytotoxicity for compounds 21a (dark green bars), 21b (dark yellow bars), 21c
(dark purple bars), and ZAF (grey bars) against (A) HEK-293, (B) BEAS-2B, and (C) HepG2. Controls
included treatment with Triton™ X-100 (TX, 1% v/v, positive control) and 1% DMSO (negative control).
ZAF and its derivatives were tested at concentrations from 0 to 62.6 µg/mL. In instances where >100% cell
survival was observed, the data was displayed as 100% cell survival (normalized data). Experiments were
performed in quadruplicate. The corresponding non-normalized data are presented in Figure B90.

3.3.8. Hemolytic effect of N-alkyl ZAF derivatives
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Due to the promising antibacterial activity of the N-alkylated 3rd generation ZAF
derivatives, we wanted to confirm that they would display no or reasonable (<50%)
hemolytic activity against murine red blood cells (mRBCs). We tested compounds 23a,
23g, 24a, and 24g at concentrations ranging from 3.13 to 100 µM (Figure 3.11, Table 3.2).
The negative control was phosphate buffered saline (PBS) only and the positive control
was Triton™ X-100 (1% v/v, 2 µL). Additionally, amphotericin B (data not shown) was
tested and displayed no hemolytic activity (0%) at concentrations up to 27 µg/mL.
Compounds 23a (R1 = propyl) and 24a (R1 = n-butyl) displayed ≤25% hemolysis of
mRBCs at concentrations up to 100 µM. Compounds 23g (R1 = propyl) and 24g (R1 = nbutyl) displayed ≤15% hemolysis at concentrations up to 100 µM. We found that the parent
compound ZAF displayed high hemolytic activity with 72% lysis of mRBCs at 100 µM.
Therefore, with little to no hemolytic activity, the most active 3rd generation ZAF
derivatives are highly promising for further development as anti-P. gingivalis.

Figure 3.11. Bar graph depicting the dose-dependent hemolytic activity of compounds 23a (dark green bars),
23g (dark yellow bars), 24a (pink bars), 24g (dark purple bars), and ZAF (grey bars) against murine red blood
cells (mRBCs). mRBCs were treated and incubated for 1 h at 37 °C with the compounds at concentrations
ranging from 3.13 to 100 µM. Triton™ X-100 (1% v/v) was used as a positive control (100% hemolysis, not
shown).
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3.4 CONCLUSION
In summary, 14 novel 3rd generation ZAF derivatives (21b-f, 22a, 22g, 23a, 23g, 24a, 24g,
25a, 25g, and 26g) were synthesized. Seven of these compounds (21b-d, 22-25g), in
addition to the two most active 2nd generation ZAF derivatives (21a and 21g) displayed
increased and selective antibacterial activity against P. gingivalis ATCC 33277.
Modifications to the ZAF structure included testing the effects of various electronwithdrawing groups on the arylsulfonamide on the C2 and C4 positions of the benzene ring
(e.g., halogens, difluoro, and nitro groups). Substitution of the N-methyl of the indole ring
with various alkyl or bulky aryl groups were also performed. Increased antibacterial
activity against P. gingivalis in percent growth inhibition assays, was observed with
compounds containing either halogens (e.g., F and Cl) at the C2 position or electronwithdrawing groups (e.g., NO2) at the C4 position on the arylsulfonamide ring.
Additionally, longer alkyl chains on the nitrogen of the indole ring of compounds with R2
= 4-NO2 increased antibacterial activity, while branched chains and bulky substituents
negatively affected activity. Superior activity was observed with R2 = 4-NO2 and various
linear N-alkyl chains compared to the decreased activity with derivatives containing R2 =
2-F and various N-alkyl chains. While branched chains and bulky substituents on the
nitrogen of the indole ring negatively affected activity. The most active compounds 21a,
21b, and 21c displayed bactericidal activity at concentrations as low as 10 µM, along with
increased antibacterial activity of compounds 21a and 24g compared to the parent ZAF
and control Tet when tested against P. gingivalis. Interestingly, compounds 21a, 21b, and
24g displayed increased antibacterial activity compared to the controls with inhibition of
P. gingivalis biofilm growth at 25, 10, and 50 µM, respectively. When tested against OKF6
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cells, compounds 21c and 24g achieved the overall goal of increasing activity against P.
gingivalis while decreasing cytotoxicity compared to the most active 2nd generation ZAF
derivatives and the ZAF and Tet controls. Additionally, little to no cytotoxicity against
HEK-293, BEAS-2B, and HepG2 was observed with 21a, 21b, and 21c. In addition, little
to no hemolytic activity was observed with N-alkylated compounds 23a, 23g, 24a, and 24g.
In the future, outside the scope of this study, as there are over 700 bacterial species found
in the oral cavity, with only a small number of those bacterial species being pathogenic that
lead to inflammation and bone destruction, it would be interesting to evaluate these
compounds in multi-species biofilm studies. Important multi-species biofilms to test will
be the dual species of F. nucleatum and P. gingivalis as well as the tri-species biofilms of
S. sanguinis, P. gingivalis, and A. actinomycetemcomitans. These bacterial species have
important synergistic (F. nucleatum enhances the growth of P. gingivalis by providing a
carbon dioxide rich microenvironment) and antagonistic interactions (S. sanguinis
produced hydrogen peroxide to inhibit the growth of P. gingivalis and A.
actinomycetemcomitans) that are vital to the progression or the regression of periodontal
diseases. The development of the multi-species biofilms tests is currently underway in our
laboratory and will be presented in future studies. Additionally, it will be interesting to see
how these promising molecules will fare in in vivo studies using animal models of P.
gingivalis-induced periodontal disease.

3.5. EXPERIMENTAL SECTION
3.5.1. Chemistry
3.5.1.1. Materials and instrumentation
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The intermediates of the zafirlukast (ZAF) derivatives with 1-methyl-5-nitroindole
(compounds 1, 8, and 14) were resynthesized as previously reported62, 103 and the yields
that we obtained from these reactions in the current study are reported in Scheme 3.1.
Compounds 21a and 21g (previously 14a and 14e, respectively, in our previously
published manuscript with our 2nd generation ZAF derivatives)103 were also re-synthesized
for new biological biofilms studies and for testing against a different strain of P. gingivalis.
For this study, all chemicals that were used for the synthesis of the intermediates (including
7 and 20a-20g), ZAF derivatives, and for biological evaluation were purchased from
Oakwood Chemical (San Diego, CA), Combi-Blocks (San Diego, CA), TCI America
(Portland, OR), Sigma Aldrich (St. Louis, MO), Synthonix (Wake Forest, NC), Matrix
Scientific (Columbia, SC), Ricca Chemical Company (Arlington, TX), Acros Organics
(Geel, Belgium), Beantown Chemical (Hudson, NH), Chem-Impex (Wood Dale, IL), Alfa
Aesar (Ward Hill, MA), and used without further purification. All chemical reactions were
monitored by thin layer chromatography (TLC) using glass plates coated with Merk silica
gel 60 F254. UV light was used to visualize the chromatographic bands on the TLC plates.
Silica gel column chromatography with SiliaFlash® F60 (40-63 µM, SiliCycle, Québec,
Canada) was used to purify compounds. Varian 500 (VNMRS500) or 400 (MR400) MHz
spectrometers were used to record 1H NMR spectra at 500 or 400 MHz, respectively. A
Varian 400 MHz spectrometer was used to record all 13C NMR spectra at 100 MHz. All
NMR spectra chemical shifts (δ) are given in parts per million (ppm). All coupling
constants (J) are given in Hertz (Hz), and the abbreviations used for signal shape are singlet
(s), doublet (d), triplet (t), multiplet (m), doublet of doublets (dd), doublet of triplets (dt),
and triplet of doublets (td). High-resolution mass spectrometry (HRMS) was performed on

155

an AB SCIEX TripleTOFTM5600 mass spectrometer to record mass spectra data for all
final compounds (21b-f, 22a, 22g, 23a, 23g, 24a, 24g, 25a, 25g, and 26g). The HRMS
[M+H]+ signals for all compounds synthesized were consistent with the calculated
molecular weights. To further confirm purity of all final compounds 21b-f, 22a, 22g, 23a,
23g, 24a, 24g, 25a, 25g, and 26g, an Agilent Technologies 1260 Infinity HPLC system
(Santa Clara, CA, USA) was used. Purity of the compounds was confirmed using the
following HPLC method - method A: Flow rate = 0.5 mL/min; λ = 254 nm; column =
Vydac Denali C18 column, 250 × 4.6 mm, 120 Å, 5 µm; Eluents: A = H2O + 0.1%
trifluoroacetic acid, B = MeCN; gradient profile: starting from 5% B, increasing from 5%
B to 100% C over 10 min, hold at 100% B for 10 min, decreasing from 100% B to 5% B
in 3 min. Prior to each injection, the HPLC column was equilibrated for 10 min with 5%
B. All compounds were ≥95% pure.

3.5.1.2. Synthesis and characterization of compounds 21b-21f, 22a, 22g, 23a, 23g, 24a,
24g, 25a, 25g, and 26g
Synthesis of compound 2 (SGT1629). A solution of 5-nitroindole (3.0 g,
18.5 mmol) in anhydrous DMF (15 mL) was cooled to 0 °C and treated with
NaH (60% in mineral oil, 1.48 g, 37.0 mmol). The reaction mixture was allowed to stir at
room temperature for 1 h. The mixture was cooled to 0 °C, iodoethane (2.98 mL, 37.0
mmol) was then slowly added, and the resulting mixture was stirred at room temperature
for 1 h. The reaction was quenched by pouring onto ice and extracted with CH2Cl2 (3×).
The combined organic layers were washed with NaHCO3, H2O, and brine, dried over
MgSO4, filtered, and concentrated. The crude product obtained was purified by column
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chromatography (SiO2 gel, Hexanes:EtOAc/3:1, Rf 0.46) to yield compound 2 (1.70 g,
48%) as a yellow solid: 1H NMR (500 MHz, CDCl3, Figure B1) δ 8.58 (dd, J1 = 2.2 Hz, J2
= 0.5 Hz, 1H, aromatic), 8.10 (dd, J1 = 9.1 Hz, J2 = 2.3 Hz, 1H, aromatic), 7.34 (dt, J1 =
9.1 Hz, J2 = 0.7 Hz, 1H, aromatic), 7.25 (d, J = 3.3 Hz, 1H, aromatic), 6.66 (dd, J1 = 3.3
Hz, J2 = 0.9 Hz, 1H, aromatic), 4.21 (q, J = 7.4 Hz, 2H, NCH2CH3), 1.49 (t, J = 7.4 Hz,
3H, NCH2CH3);

13

C NMR (100 MHz, CDCl3, Figure B2) δ 138.7, 131.9, 130.4, 128.0,

118.5, 117.3, 109.3, 104.2, 41.7, 15.6.

Synthesis of compound 3 (SGT1630). A solution of 5-nitroindole (3.0 g,
18.5 mmol) in anhydrous DMF (15 mL) was cooled to 0 °C and treated with
NaH (60% in mineral oil, 1.48 g, 37.0 mmol). The reaction mixture was allowed to stir at
room temperature for 1 h. The mixture was cooled to 0 °C, 1-iodopropane (3.59 mL, 37.0
mmol) was then slowly added, and the resulting mixture was stirred at room temperature
for 1 h. The reaction was quenched by pouring onto ice and extracted with CH2Cl2 (3×).
The combined organic layers were washed with NaHCO3, H2O, and brine, dried over
MgSO4, filtered, and concentrated. The crude product obtained was purified by column
chromatography (SiO2 gel, Hexanes:EtOAc/1:1, Rf 0.81) to yield compound 3 (2.71 g,
72%) as a brown liquid: 1H NMR (500 MHz, CDCl3, Figure B3) δ 8.57 (d, J = 2.3Hz, 1H,
aromatic), 8.09 (dd, J1 = 9.1 Hz, J2 = 2.3 Hz, 1H, aromatic), 7.33 (dd, J1 = 9.1 Hz, J2 = 0.7
Hz, 1H, aromatic), 7.23 (d, J = 3.2 Hz, 1H, aromatic), 6.66 (dt, J1 = 3.3 Hz, J2 = 0.8 Hz,
1H, aromatic), 4.12 (t, J = 7.1 Hz, 2H, NCH2CH2CH3), 1.88 (sextet, J = 7.4 Hz, 2H,
NCH2CH2CH3), 0.93 (t, J = 7.4 Hz, 3H, NCH2CH2CH3);

13

C NMR (100 MHz, CDCl3,

Figure B4) δ 141.6, 139.0, 131.2, 127.8, 118.4, 117.2, 109.4, 104.0, 48.7, 23.7, 11.6.
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Synthesis of compound 4 (SGT1631). A solution of 5-nitroindole (3.0 g,
18.5 mmol) in anhydrous DMF (15 mL) was cooled to 0 °C and treated with
NaH (60% in mineral oil, 1.48 g, 37.0 mmol). The reaction mixture was
allowed to stir at room temperature for 1 h. The mixture was cooled to 0 °C, 1-iodobutane
(4.20 mL, 37.0 mmol) was then slowly added, and the resulting mixture was stirred at room
temperature for 1 h. The reaction was quenched by pouring onto ice and extracted with
CH2Cl2 (3×). The combined organic layers were washed with NaHCO3, H2O, and brine,
dried over MgSO4, filtered, and concentrated. The crude product obtained was purified by
column chromatography (SiO2 gel, Hexanes:EtOAc/3:1, Rf 0.53) to yield compound 4
(1.54 g, 38%) as a brown liquid: 1H NMR (500 MHz, CDCl3, Figure B5) δ 8.57 (d, J = 2.2
Hz, 1H, aromatic), 8.09 (dd, J1 = 9.1 Hz, J2 = 2.3 Hz, 1H, aromatic), 7.33 (d, J = 9.1 Hz,
1H, aromatic), 7.23 (d, J = 3.3 Hz, 1H, aromatic), 6.65 (dd, J1 = 3.3 Hz, J2 = 0.8 Hz, 1H,
aromatic), 4.15 (t, J = 7.2 Hz, 2H, NCH2CH2CH2CH3), 1.82 (p, J = 7.7 Hz, 2H,
NCH2CH2CH2CH3), 1.33 (sextet, J = 7.7 Hz, 2H, NCH2CH2CH2CH3), 0.93 (t, J = 7.4 Hz,
3H, NCH2CH2CH2CH3); 13C NMR (100 MHz, CDCl3, Figure B6) δ 141.7, 139.0, 131.2,
127.9, 118.5, 117.3, 109.4, 104.0, 46.8, 32.5, 20.3, 13.8.

Synthesis of compound 5 (SGT1633). A solution of 5-nitroindole (3.0 g,
18.5 mmol) in anhydrous DMF (15 mL) was cooled to 0 °C and treated with
NaH (60% in mineral oil, 1.48 g, 37.0 mmol). The reaction mixture was allowed to stir at
room temperature for 1 h. The mixture was cooled to 0 °C, 1-iodo-2-methylpropane (4.25
mL, 37.0 mmol) was then slowly added, and the resulting mixture was stirred at room
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temperature for 1 h. The reaction was quenched by pouring onto ice and extracted with
CH2Cl2 (3×). The combined organic layers were washed with NaHCO3, H2O, and brine,
dried over MgSO4, filtered, and concentrated. The crude product obtained was purified by
column chromatography (SiO2 gel, Hexanes:EtOAc/1:1, Rf 0.89) to yield compound 5
(1.12 g, 28%) as a yellow solid: 1H NMR (500 MHz, CDCl3, Figure B7) δ 8.57 (d, J = 2.3
Hz, 1H, aromatic), 8.09 (dd, J1 = 9.1 Hz, J2 = 2.3 Hz, 1H, aromatic), 7.32 (dt, J1 = 9.1 Hz,
J2 = 0.7 Hz, 1H, aromatic), 7.20 (d, J = 3.3 Hz, 1H, aromatic), 6.66 (dd, J1 = 3.2 Hz, J2 =
0.8 Hz, 1H, aromatic), 3.94 (d, J = 7.4 Hz, 2H, NCH2), 2.18 (septet, J = 7.3 Hz, 1H,
CH(CH3)2), 0.92 (d, J = 6.7 Hz, 6H, CH(CH3)2); 13C NMR (100 MHz, CDCl3, Figure B8)
δ 141.6, 139.3, 131.7, 127.8, 118.4, 117.3, 109.6, 103.9, 54.7, 29.9, 20.4 (2CH3).

Synthesis of compound 6 (SGT1632). A solution of 5-nitroindole (3.0 g,
18.5 mmol) in anhydrous DMF (15 mL) was cooled to 0 °C and treated with
NaH (60% in mineral oil, 1.11 g, 27.8 mmol). The reaction mixture was
allowed to stir at room temperature for 1 h. The mixture was cooled to 0 °C, benzyl bromide
(3.30 mL, 27.8 mmol) was then slowly added, and the resulting mixture was stirred at room
temperature for 1 h. The reaction was quenched by pouring onto ice and extracted with
CH2Cl2 (3×). The combined organic layers were washed with NaHCO3, H2O, and brine,
dried over MgSO4, filtered, and concentrated. The crude product obtained was purified by
column chromatography (SiO2 gel, Hexanes:EtOAc/3:1, Rf 0.58) to yield compound 6
(3.10 g, 66%) as a tan solid: 1H NMR (500 MHz, CDCl3, Figure B9) δ 8.59 (dd, J1 = 2.3
Hz, J2 = 0.6 Hz, 1H, aromatic ), 8.06 (dd, J1 = 9.1 Hz, J2 = 2.3 Hz, 1H, aromatic), 7.337.27 (m, 4H, aromatic), 7.26 (d, J = 3.3 Hz, 1H, aromatic), 7.09-7.18 (m, 2H, aromatic),
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6.72 (dd, J1 = 3.3 Hz, J2 = 0.9 Hz, 1H, aromatic), 5.35 (s, 2H, NCH2); 13C NMR (100 MHz,
CDCl3, Figure B10) δ 142.0, 139.2, 136.4, 131.7, 129.2 (2CH), 128.3, 128.1, 127.0 (2CH),
118.4, 117.6, 109.8, 104.6, 50.8.

Synthesis of compound 9 (SGT1639). A solution of compound 2
(0.20 g, 1.05 mmol) and methyl-5-formyl-2-methoxybenzoate
(0.20 g, 1.05 mmol) in anhydrous CH2Cl2 (5 mL) was cooled to 0
°C in an ice-H2O bath. Then Et3SiH (0.5 mL, 2.94 mmol) was added, followed by TFA
(0.2 mL, 2.10 mmol). The mixture was stirred at 0 °C for 10 min and was allowed to warm
to room temperature overnight. The reaction was quenched with H2O and extracted with
CH2Cl2 (3×). The combined organic layers were washed with NaHCO3, H2O, and brine,
dried over MgSO4, filtered, and concentrated. The crude product obtained was purified by
column chromatography (SiO2 gel, Hexanes:EtOAc/1:1, Rf 0.60) to yield compound 9
(0.24 g, 63%) as a yellow solid: 1H NMR (500 MHz, CDCl3, Figure B11) δ 8.46 (dd, J1 =
2.2 Hz, J2 = 0.6 Hz, 1H, aromatic), 8.09 (dd, J1 = 9.1 Hz, J2 = 2.3 Hz, 1H, aromatic), 7.69
(d, J = 2.5 Hz, 1H, aromatic), 7.35 (dd, J1 = 8.6 Hz, J2 = 2.4 Hz, 1H, aromatic), 7.30 (dd,
J1 = 9.2 Hz, J2 = 0.7 Hz, 1H, aromatic), 6.91 (d, J = 8.7 Hz, 1H, aromatic), 6.90 (s, 1H,
aromatic), 4.14 (q, J = 7.4 Hz, 2H, NCH2CH3), 4.06 (s, 2H, CH2Ar), 3.87 (s, 3H, ArOCH3),
3.85 (s, 3H, ArCO2CH3), 1.44 (t, J = 7.4 Hz, 3H, NCH2CH3); 13C NMR (100 MHz, CDCl3,
Figure B12) δ 167.0, 157.9, 141.4, 139.2, 133.8, 132.1, 131.9, 128.6, 127.3, 120.3, 117.7,
117.6, 116.8, 112.5, 109.3, 56.4, 52.3, 41.6, 30.4, 15.6.
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Synthesis of compound 10 (SGT1640). A solution of compound
3 (0.20 g, 0.98 mmol) and methyl-5-formyl-2-methoxybenzoate
(0.19 g, 0.98 mmol) in anhydrous CH2Cl2 (5 mL) was cooled to 0
°C in an ice-H2O bath. Then Et3SiH (0.4 mL, 2.74 mmol) was
added, followed by TFA (0.1 mL, 1.96 mmol). The mixture was stirred at 0 °C for 10 min
and was allowed to warm to room temperature overnight. The reaction was quenched with
H2O and extracted with CH2Cl2 (3×). The combined organic layers were washed with
NaHCO3, H2O, and brine, dried over MgSO4, filtered, and concentrated. The crude product
obtained was purified by column chromatography (SiO2 gel, Hexanes:EtOAc/1:1, Rf 0.73)
to yield compound 10 (0.24 g, 63%) as a dark yellow solid: 1H NMR (500 MHz, CDCl3,
Figure B13) δ 8.46 (dd, J1 = 2.3 Hz, J2 = 0.5 Hz, 1H, aromatic), 8.08 (dd, J1 = 9.1 Hz, J2 =
2.2 Hz, 1H, aromatic), 7.68 (d, J = 2.5 Hz, 1H, aromatic), 7.34 (dd, J1 = 8.6 Hz, J2 = 2.5
Hz, 1H, aromatic), 7.29 (d, J = 9.1 Hz, 1H, aromatic), 6.91 (d, J = 8.6 Hz, 1H, aromatic),
6.88 (app. t, J = 1.1 Hz, 1H, aromatic), 4.06 (s, 2H, CH2Ar), 4.04 (t, J = 7.2 Hz, 2H,
NCH2CH2CH3), 3.87 (s, 3H, ArOCH3), 3.85 (s, 3H, ArCO2CH3), 1.83 (sextet, J = 7.4 Hz,
3H, NCH2CH2CH3), 0.90 (t, J = 7.4 Hz, 3H, NCH2CH2CH3); 13C NMR (100 MHz, CDCl3,
Figure B14) δ 166.9, 157.9, 141.3, 139.6, 133.7, 132.1, 131.9, 129.4, 127.2, 120.2, 117.54,
117.46, 116.8, 112.5, 109.5, 56.3, 52.2, 48.5, 30.3, 23.8, 11.6.

Synthesis of compound 11 (SGT1641). A solution of compound
4 (0.70 g, 3.21 mmol) and methyl-5-formyl-2-methoxybenzoate
(0.62 g, 3.21 mmol) in anhydrous CH2Cl2 (5 mL) was cooled to 0
°C in an ice-H2O bath. Then Et3SiH (1.4 mL, 8.98 mmol) was
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added, followed by TFA (0.5 mL, 6.41 mmol). The mixture was stirred at 0 °C for 10 min
and was allowed to warm to room temperature overnight. The reaction was quenched with
H2O and extracted with CH2Cl2 (3×). The combined organic layers were washed with
NaHCO3, H2O, and brine, dried over MgSO4, filtered, and concentrated. The crude product
obtained was purified by column chromatography (SiO2 gel, Hexanes:EtOAc/1:1, Rf 0.60)
to yield compound 11 (0.10 g, 8%) as a yellow liquid (which contained some methyl-5formyl-2-methoxybenzoate that was removed in the next synthetic step): 1H NMR (500
MHz, CDCl3, Figure B15) δ 8.45 (dd, J1 = 2.3 Hz, J2 = 0.5 Hz, 1H, aromatic), 8.08 (dd, J1
= 9.1 Hz, J2 = 2.3 Hz, 1H, aromatic), 7.68 (d, J = 2.4 Hz, 1H, aromatic), 7.34 (dd, J1 = 8.6
Hz, J2 = 2.5 Hz, 1H, aromatic), 7.29 (d, J = 9.1 Hz, 1H, aromatic), 6.90 (d, J = 8.6 Hz, 1H,
aromatic), 6.88 (app. t, J = 1.1 Hz, 1H, aromatic), 4.07 (t, J = 7.3 Hz, 2H,
NCH2CH2CH2CH3), 4.05 (s, 2H, CH2Ar), 3.87 (s, 3H, ArOCH3), 3.85 (s, 3H, ArCO2CH3),
1.81-1.75 (m, 2H, NCH2CH2CH2CH3), 1.34-1.27 (m, 2H, NCH2CH2CH2CH3), 0.92 (t, J =
7.4 Hz, 3H, NCH2CH2CH2CH3);

13

C NMR (100 MHz, (CD3)2SO, Figure B16) δ 166.2,

156.5, 140.2, 134.8, 133.3, 132.5, 130.4, 126.4, 119.8, 116.54, 116.47, 116.0, 113.2, 112.7,
110.4, 55.8, 51.8, 31.9, 29.0, 19.4, 13.5.

Synthesis of compound 12 (SGT1660). A solution of compound
5 (0.20 g, 0.92 mmol) and methyl-5-formyl-2-methoxybenzoate
(0.18 g, 0.92 mmol) in anhydrous CH2Cl2 (5 mL) was cooled to 0
°C in an ice-H2O bath. Then Et3SiH (0.4 mL, 2.57 mmol) was
added, followed by TFA (0.1 mL, 1.83 mmol). The mixture was stirred at 0 °C for 10 min
and was allowed to warm to room temperature overnight. The reaction was quenched with
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H2O and extracted with CH2Cl2 (3×). The combined organic layers were washed with
NaHCO3, H2O, and brine, dried over MgSO4, filtered, and concentrated. The crude product
obtained was purified by column chromatography (SiO2 gel, Hexanes:EtOAc/1:1, Rf 0.72)
to yield compound 12 (0.11 g, 36%) as a yellow solid: 1H NMR (500 MHz, CDCl3, Figure
B17) δ 8.45 (d, J = 2.2 Hz, 1H, aromatic), 8.08 (dd, J1 = 9.1 Hz, J2 = 2.2 Hz, 1H, aromatic),
7.68 (d, J = 2.5 Hz, 1H, aromatic), 7.34 (dd, J1 = 8.6 Hz, J2 = 2.5 Hz, 1H, aromatic), 7.28
(d, J = 9.1 Hz, 1H, aromatic), 6.90 (d, J = 8.6 Hz, 1H, aromatic), 6.87 (app. t, J = 1.1 Hz,
1H, aromatic), 4.06 (s, 2H, CH2Ar), 3.87 (d, J = 7.4 Hz, 2H, NCH2), 3.87 (s, 3H,
ArOCH3),3.84 (s, 3H, ArCO2CH3), 2.14 (septet, J = 7.0 Hz, 1H, CH(CH3)2), 0.90 (t, J =
6.7 Hz, 6H, CH(CH3)2); 13C NMR (100 MHz, CDCl3, Figure B18) δ 166.9, 157.9, 141.3,
139.9, 133.7, 132.1, 131.9, 129.9, 127.1, 120.2, 117.6, 117.4, 116.8, 112.5, 109.7, 56.3,
54.5, 52.2, 30.3, 29.9, 20.4.

Synthesis of compound 13 (SGT1642). A solution of compound
6 (0.70 g, 2.77 mmol) and methyl-5-formyl-2-methoxybenzoate
(1.08 g, 2.77 mmol) in anhydrous CH2Cl2 (5 mL) was cooled to 0
°C in an ice-H2O bath. Then Et3SiH (1.2 mL, 7.77 mmol) was
added, followed by TFA (0.4 mL, 5.55 mmol). The mixture was stirred at 0 °C for 10 min
and was allowed to warm to room temperature overnight. The reaction was quenched with
H2O and extracted with CH2Cl2 (3×). The combined organic layers were washed with
NaHCO3, H2O, and brine, dried over MgSO4, filtered, and concentrated. The crude product
obtained was purified by column chromatography (SiO2 gel, Hexanes:EtOAc/1:1, Rf 0.59)
to yield compound 13 (0.23 g, 20%) as a yellow solid: 1H NMR (500 MHz, CDCl3, Figure
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B19) δ 8.47 (dd, J1 = 2.3 Hz, J2 = 0.5 Hz, 1H, aromatic), 8.05 (dd, J1 = 9.1 Hz, J2 = 2.2 Hz,
1H, aromatic), 7.68 (d, J = 2.4 Hz, 1H, aromatic), 7.35 (dd, J1 = 8.6 Hz, J2 = 2.5 Hz, 1H,
aromatic), 7.32-7.27 (m, 3H, aromatic), 7.08-7.05 (m, 2H, aromatic), 6.95 (app. t, J = 1.1
Hz, 1H, aromatic), 6.90 (d, J = 8.6 Hz, 1H, aromatic), 5.28 (s, 2H, NCH2Ar), 4.07 (s, 2H,
CH2Ar), 3.87 (s, 3H, ArOCH3), 3.85 (s, 3H, ArCO2CH3);

13

C NMR (100 MHz, CDCl3,

Figure B20) δ 166.9, 157.9, 141.6, 139.8, 136.5, 133.7, 131.93, 131.87, 129.8, 129.2,
128.3, 127.5, 126.9, 120.3, 118.0, 117.9, 116.8, 112.5, 109.9, 56.3, 52.2, 50.7, 30.4.

Synthesis of compound 15 (SGT1644). A solution of compound
9 (0.23 g, 0.62 mmol) in MeOH:THF:H2O/10:2:2 (14 mL total)
was stirred and treated with KOH pellets (0.25 g, 4.37 mmol). The
resulting mixture was refluxed at 65 °C for 2 h. The organic solvents were removed in
vacuo after the reaction was complete. The resulting mixture was acidified to pH 1 with 1
N aqueous HCl and extracted with CH2Cl2 (3×). The combined organic layers were washed
with brine, dried over MgSO4, filtered, and concentrated to yield compound 15 (0.17 g,
75%) as a yellow solid: 1H NMR (500 MHz, CDCl3, Figure B21) δ 8.38 (d, J = 2.2 Hz,
1H, aromatic), 8.09 (dd, J1 = 9.1 Hz, J2 = 2.3 Hz, 1H, aromatic), 8.06 (d, J = 2.5 Hz, 1H,
aromatic), 7.49 (dd, J1 = 8.5 Hz, J2 = 2.5 Hz, 1H, aromatic), 7.30 (d, J = 9.2 Hz, 1H,
aromatic), 7.00 (d, J = 8.2 Hz, 1H, aromatic), 6.99 (s, 1H, aromatic), 4.15 (q, J = 7.4 Hz,
2H, NCH2CH3), 4.10 (s, 2H, CH2Ar), 4.05 (s, 3H, ArOCH3), 1.46 (t, J = 7.3 Hz, 3H,
NCH2CH3); 13C NMR (100 MHz, CDCl3, Figure B22) δ 165.5, 156.8, 135.3, 134.7, 133.9,
128.7, 127.1, 117.8, 117.6, 116.9, 116.7, 112.1, 109.4, 57.0, 41.6, 30.5, 15.6.
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Synthesis of compound 16 (SGT1645). A solution of compound
10 (0.20 g, 0.52 mmol) in MeOH:THF:H2O/10:2:2 (14 mL total)
was stirred and treated with KOH pellets (0.21 g, 3.66 mmol). The
resulting mixture was refluxed at 65 °C for 2 h. The organic
solvents were removed in vacuo after the reaction was complete. The resulting mixture was
acidified to pH 1 with 1 N aqueous HCl and extracted with CH2Cl2 (3×). The combined
organic layers were washed with brine, dried over MgSO4, filtered, and concentrated to
yield compound 16 (0.17 g, 88%) as a yellow solid: 1H NMR (500 MHz, CDCl3, Figure
B23) δ 8.38 (d, J = 2.2 Hz, 1H, aromatic), 8.08 (dd, J1 = 9.1 Hz, J2 = 2.3 Hz, 1H, aromatic),
8.06 (d, J = 2.5 Hz, 1H, aromatic), 7.48 (dd, J1 = 8.5 Hz, J2 = 2.5 Hz, 1H, aromatic), 7.30
(d, J = 9.2 Hz, 1H, aromatic), 6.99 (d, J = 8.6 Hz, 1H, aromatic), 6.97 (app. t, J = 1.0 Hz,
1H, aromatic), 4.10 (s, 2H, CH2Ar), 4.06 (t, J = 7.2 Hz, 2H, NCH2CH2CH3), 4.05 (s, 3H,
ArOCH3), 1.85 (sextet, J = 7.4 Hz, 2H, NCH2CH2CH3), 0.92 (t, J = 7.4 Hz, 3H,
NCH2CH2CH3); 13C NMR (100 MHz, CDCl3, Figure B24) δ 165.5, 156.8, 141.3, 139.7,
135.2, 134.6, 133.8, 129.5, 127.0, 117.8, 117.6, 116.68, 116.66, 112.1, 109.6, 57.0, 48.6,
30.4, 23.8, 11.7.

Synthesis of compound 17 (SGT1646). A solution of compound
11 (90 mg, 0.23 mmol) in MeOH:THF:H2O/5:1:1 (7 mL total) was
stirred and treated with KOH pellets (89 mg, 1.59 mmol). The
resulting mixture was refluxed at 65 °C for 2 h. The organic
solvents were removed in vacuo after the reaction was complete. The resulting mixture was
acidified to pH 1 with 1 N aqueous HCl and extracted with CH2Cl2 (3×). The combined
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organic layers were washed with brine, dried over MgSO4, filtered, and concentrated to
yield compound 17 (71 mg, 82%) as a yellow solid: 1H NMR (500 MHz, CD3OD, Figure
B25) δ 8.30 (dd, J1 = 2.3 Hz, J2 = 0.6 Hz, 1H, aromatic), 7.97 (dd, J1 = 9.1 Hz, J2 = 2.3 Hz,
1H, aromatic), 7.66 (d, J = 2.4 Hz, 1H, aromatic), 7.42 (d, J = 9.1 Hz, 1H, aromatic), 7.39
(dd, J1 = 8.6 Hz, J2 = 2.5 Hz, 1H, aromatic), 7.17 (app. t, J = 1.0 Hz, 1H, aromatic), 6.99
(d, J = 8.6 Hz, 1H, aromatic), 4.13 (t, J = 7.1 Hz, 2H, NCH2CH2CH2CH3), 4.04 (s, 2H,
CH2Ar), 3.91 (s, 1H, OH), 3.81 (s, 3H, ArOCH3), 1.76-1.70 (m, 2H, NCH2CH2CH2CH3),
1.27-1.20 (m, 2H, NCH2CH2CH2CH3), 0.86 (t, J = 7.5 Hz, 3H, NCH2CH2CH2CH3); 13C
NMR (100 MHz, (CD3)2SO, Figure B26) δ 156.4, 140.2, 139.1, 132.8, 132.6, 132.5, 130.4,
126.4, 121.0, 116.6, 116.5, 116.0, 113.0, 112.5, 110.4, 55.8, 45.5, 31.9, 29.1, 19.4, 13.5.

Synthesis of compound 18 (SGT1648). A solution of compound
12 (0.10 g, 0.25 mmol) in MeOH:THF:H2O/10:2:2 (14 mL total)
was stirred and treated with KOH pellets (99 mg, 1.77 mmol). The
resulting mixture was refluxed at 65 °C for 2 h. The organic
solvents were removed in vacuo after the reaction was complete. The resulting mixture was
acidified to pH 1 with 1 N aqueous HCl and extracted with CH2Cl2 (3×). The combined
organic layers were washed with brine, dried over MgSO4, filtered, and concentrated to
yield compound 18 (81 mg, 84%) as a yellow solid (which contained some methyl-5formyl-2-methoxybenzoate that was removed in the next synthetic step): 1H NMR (500
MHz, (CD3)2SO, Figure B27) δ 8.41 (d, J = 2.3 Hz, 1H, aromatic), 8.00 (dd, J1 = 9.1 Hz,
J2 = 2.3 Hz, 1H, aromatic), 7.68 (d, J = 9.2 Hz, 1H, aromatic), 7.54 (d, J = 2.5 Hz, 1H,
aromatic), 7.47 (s, 1H, aromatic), 7.42 (dd, J1 = 8.6 Hz, J2 = 2.4 Hz, 1H, aromatic), 7.05
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(d, J = 8.6 Hz, 1H, aromatic), 4.10 (s, 2H, CH2Ar), 4.04 (d, J = 7.4 Hz, 2H, NCH2), 3.77
(s, 3H, ArOCH3), 2.10 (septet, J = 7.2 Hz, 1H, CH(CH3)2), 0.84 (d, J = 6.7 Hz, 6H,
CH(CH3)2);

13

C NMR (100 MHz, (CD3)2SO, Figure B28) δ 166.4, 162.6, 140.2, 134.3,

132.8, 132.54, 132.45, 130.9, 128.7, 121.8, 121.0, 116.5, 116.0, 113.0, 112.5, 110.7, 56.4,
55.8, 29.3, 19.7 (2CH3).

Synthesis of compound 19 (SGT1647). A solution of compound
13 (0.20 g, 0.46 mmol) in MeOH:THF:H2O/10:2:2 (14 mL total)
was stirred and treated with KOH pellets (0.18 g, 3.25 mmol). The
resulting mixture was refluxed at 65 °C for 2 h. The organic
solvents were removed in vacuo after the reaction was complete. The resulting mixture was
acidified to pH 1 with 1 N aqueous HCl and extracted with CH2Cl2 (3×). The combined
organic layers were washed with brine, dried over MgSO4, filtered, and concentrated to
yield compound 19 (60 mg, 31%) as a yellow solid: 1H NMR (500 MHz, CD3OD, Figure
B29) δ 8.33 (d, J = 2.1 Hz, 1H, aromatic), 7.94 (dd, J1 = 9.2 Hz, J2 = 2.3 Hz, 1H, aromatic),
7.64 (d, J = 2.5 Hz, 1H, aromatic), 7.39 (dd, J1 = 8.5 Hz, J2 = 2.6 Hz, 1H, aromatic), 7.37
(d, J = 9.1 Hz, 1H, aromatic), 7.24-7.20 (m, 3H, aromatic), 7.20-7.15 (m, 1H, aromatic),
7.09-7.07 (m, 2H, aromatic), 6.99 (d, J = 8.6 Hz, 1H, aromatic), 5.35 (s, 2H, NCH2Ar),
4.06 (s, 2H, CH2Ar), 3.90 (s, 1H, OH), 3.80 (s, 3H, ArOCH3); 13C NMR (100 MHz, CDCl3,
Figure B30) δ 165.5, 156.8, 141.6, 139.9, 136.4, 135.2, 134.5, 133.8, 130.0, 129.3, 128.3,
127.3, 126.9, 118.0, 117.8, 117.2, 116.7, 112.1, 110.0, 57.0, 50.7, 30.4.
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Synthesis of compound 21b (SGT1649). A solution of
compound 14 (synthesized as previously published)62 (30 mg,
0.09 mmol), 2-chlorobenzenesulfonamide (20b; 20 mg, 0.10
mmol), EDC•HCl (27 mg, 0.14 mmol), and DMAP (19 mg,
0.16 mmol) in anhydrous CH2Cl2 (3 mL) was stirred at room temperature overnight. The
reaction was quenched with H2O and extracted with CH2Cl2 (3×). The combined organic
layers were washed with brine, dried over MgSO4, filtered, and concentrated. The crude
product obtained was purified by column chromatography (SiO2 gel, Hexanes:EtOAc/1:1,
Rf 0.17) to yield compound 21b (18 mg, 40%) as an orange solid: 1H NMR (500 MHz,
CDCl3, Figure B31) δ 10.66 (s, 1H, NH), 8.29 (dd, J1 = 7.9 Hz, J2 = 1.7 Hz, 1H, aromatic),
8.20 (d, J = 2.2 Hz, 1H, aromatic), 8.09 (dd, J1 = 9.1 Hz, J2 = 2.2 Hz, 1H, aromatic), 7.89
(d, J = 2.5 Hz, 1H, aromatic), 7.56 (dd, J1 = 8.6 Hz, J2 = 2.5 Hz, 1H, aromatic), 7.53-7.42
(m, 3H, aromatic), 7.29 (d, J = 9.1 Hz, 1H, aromatic), 7.03 (d, J = 8.6 Hz, 1H, aromatic),
6.55 (s, 1H, aromatic), 4.08 (s, 3H, NCH3), 3.71 (s, 5H, CH2Ar, ArOCH3); 13C NMR (100
MHz, (CD3)2SO, Figure B32) δ 155.5, 140.3, 139.8, 135.9, 135.2, 133.1, 132.3, 131.8
(2CH), 131.7, 130.8, 128.9, 127.61, 127.59, 125.8 (2CH), 119.8, 116.7, 116.3, 112.3,
110.5, 56.0, 36.6, 32.9; m/z calcd for C24H20ClN3O6S 513.9490; found 515.4124 [M+H]+
and sodium adduct 537.3946 (Figure B33); Purity of the compound was further confirmed
by RP-HPLC method A: Rt = 13.03 min (98% pure, Figure B34).
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Synthesis of compound 21c (SGT1650). A solution of
compound 14 (synthesized as previously published)62 (30 mg,
0.09 mmol), 2-bromobenzenesulfonamide (20c; 25 mg, 0.10
mmol), EDC•HCl (27 mg, 0.14 mmol), and DMAP (19 mg,
0.16 mmol) in anhydrous CH2Cl2 (3 mL) was stirred at room temperature overnight. The
reaction was quenched with H2O and extracted with CH2Cl2 (3×). The combined organic
layers were washed with brine, dried over MgSO4, filtered, and concentrated. The crude
product obtained was purified by column chromatography (SiO2 gel, Hexanes:EtOAc/1:1,
Rf 0.25) to yield compound 21c (26 mg, 53%) as an orange solid: 1H NMR (500 MHz,
CDCl3, Figure B35) δ 10.72 (s, 1H, NH), 8.33 (dd, J1 = 7.9 Hz, J2 = 1.7 Hz, 1H, aromatic),
8.20 (d, J = 2.2 Hz, 1H, aromatic), 8.10 (dd, J1 = 9.1 Hz, J2 = 2.3 Hz, 1H, aromatic), 7.89
(d, J = 2.5 Hz, 1H, aromatic), 7.69 (dd, J1 = 7.9 Hz, J2 = 1.3 Hz, 1H, aromatic), 7.56 (dd,
J1 = 8.6 Hz, J2 = 2.6 Hz, 1H, aromatic), 7.49 (td, J1 = 7.7 Hz, J2 = 1.3 Hz, 1H, aromatic),
7.42 (qd, J1 = 8.5 Hz, J2 = 1.8 Hz, 1H, aromatic), 7.29 (d, J = 9.1 Hz, 1H, aromatic), 7.03
(d, J = 8.6 Hz, 1H, aromatic), 6.55 (s, 1H, aromatic), 4.08 (s, 3H, NCH3), 3.71 (s, 5H,
CH2Ar, ArOCH3);

13

C NMR (100 MHz, (CD3)2SO, Figure B36) δ 155.6, 140.3, 139.8,

136.0, 135.2, 132.6, 131.9 (2CH), 129.1, 128.1, 125.8 (2CH), 119.8, 119.2 (2C), 116.7,
116.3, 112.4, 110.5 (2CH), 109.6, 56.1, 36.6, 32.9; m/z calcd for C24H20BrN3O6S 558.4030;
found 559.1314 [M+H]+ (Figure B37); Purity of the compound was further confirmed by
RP-HPLC method A: Rt = 13.03 min (98% pure, Figure B38).
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Synthesis of compound 21d (SGT1662). A solution of
compound 14 (synthesized as previously published)62 (30 mg,
0.09 mmol), 2,6-difluorobenzenesulfonamide (20d; 20 mg,
0.10 mmol), EDC•HCl (27 mg, 0.14 mmol), and DMAP (19
mg, 0.16 mmol) in anhydrous CH2Cl2 (3 mL) was stirred at room temperature overnight.
The reaction was quenched with H2O and extracted with CH2Cl2 (3×). The combined
organic layers were washed with brine, dried over MgSO4, filtered, and concentrated. The
crude product obtained was purified by column chromatography (SiO2 gel,
Hexanes:EtOAc/1:1, Rf 0.29) to yield compound 21d (11 mg, 25%) as an yellow solid: 1H
NMR (500 MHz, CDCl3, Figure B39) δ 10.64 (s, 1H, NH), 8.33 (d, J = 2.8 Hz, 1H,
aromatic), 8.08 (dd, J1 = 9.3 Hz, J2 = 2.4 Hz, 1H, aromatic), 7.90 (d, J = 2.4 Hz, 1H,
aromatic), 7.56-7.51 (m, 1H, aromatic), 7.48 (dd, J1 = 8.6 Hz, J2 = 2.6 Hz, 1H, aromatic),
7.26 (d, J = 9.2 Hz, 1H, aromatic), 7.01 (t, J = 8.7 Hz, 2H, aromatic), 6.84 (d, J = 8.6 Hz,
1H, aromatic), 6.88 (s, 1H, aromatic), 4.05 (s, 3H, NCH3), 4.03 (s, 2H, CH2Ar), 3.76 (s,
3H, ArOCH3); 13C NMR (100 MHz, (CD3)2SO, Figure B40) δ 164.1, 157.9, 148.8 (2C),
140.2, 139.6, 131.4, 129.2, 129.13 (2CH), 129.10, 129.06, 126.3, 126.0, 117.5, 116.6,
116.5, 115.9 (2CH), 112.2, 110.4, 55.9, 43.5, 32.8; m/z calcd for C24H19F2N3O6S 515.4878;
found 516.1034 [M+H]+ and sodium adduct 538.0856 (Figure B41); Purity of the
compound was further confirmed by RP-HPLC method A: Rt = 13.03 min (99% pure,
Figure B42).
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Synthesis of compound 21e (SGT1663). A solution of
compound 14 (synthesized as previously published)62 (30
mg, 0.09 mmol), 2,4-difluorobenzenesulfonamide (20e; 20
mg, 0.10 mmol), EDC•HCl (27 mg, 0.14 mmol), and DMAP
(19 mg, 0.16 mmol) in anhydrous CH2Cl2 (3 mL) was stirred at room temperature
overnight. The reaction was quenched with H2O and extracted with CH2Cl2 (3×). The
combined organic layers were washed with brine, dried over MgSO4, filtered, and
concentrated. The crude product obtained was purified by column chromatography (SiO2
gel, Hexanes:EtOAc/1:1, Rf 0.41) to yield compound 21e (16 mg, 35%) as an yellow solid:
1

H NMR (500 MHz, CDCl3, Figure B43) δ 10.57 (s, 1H, NH), 8.33 (d, J = 2.2 Hz, 1H,

aromatic), 8.18-8.14 (m, 1H, aromatic), 8.08 (dd, J1 = 9.1 Hz, J2 = 2.4 Hz, 1H, aromatic),
7.87 (d, J = 2.5 Hz, 1H, aromatic), 7.47 (dd, J1 = 8.5 Hz, J2 = 2.1 Hz, 1H, aromatic), 7.26
(d, J = 9.1 Hz, 1H, aromatic), 7.05-7.01 (m, 1H, aromatic), 6.97 (d, J = 8.6 Hz, 1H,
aromatic), 6.92-6.88 (m, 1H, aromatic), 6.87 (s, 1H, aromatic), 4.05 (s, 3H, NCH3), 4.03
(s, 2H, CH2Ar), 3.76 (s, 3H, ArOCH3);

13

C NMR (100 MHz, (CD3)2SO, Figure B44) δ

155.3, 140.2, 139.6 (2C), 133.6, 133.5, 132.9, 131.4, 129.1, 126.3, 116.5, 116.4, 115.9,
112.3, 112.2, 110.4 (2CH), 106.2, 105.94, 105.91, 105.7, 55.9, 32.8, 28.9; m/z calcd for
C24H19F2N3O6S 515.4878; found 516.1027 [M+H]+ and sodium adduct 538.0848 (Figure
B45); Purity of the compound was further confirmed by RP-HPLC method A: Rt = 17.41
min (99% pure, Figure B46).
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Synthesis of compound 21f (SGT1651). A solution of
compound 14 (synthesized as previously published)62 (30
mg, 0.09 mmol), 3,4-difluorobenzenesulfonamide (20f; 20
mg, 0.10 mmol), EDC•HCl (27 mg, 0.14 mmol), and DMAP
(19 mg, 0.16 mmol) in anhydrous CH2Cl2 (3 mL) was stirred at room temperature
overnight. The reaction was quenched with H2O and extracted with CH2Cl2 (3×). The
combined organic layers were washed with brine, dried over MgSO4, filtered, and
concentrated. The crude product obtained was purified by column chromatography (SiO2
gel, Hexanes:EtOAc/1:1, Rf 0.18) to yield compound 21f (12 mg, 26%) as an amber solid:
1

H NMR (500 MHz, CDCl3, Figure B47) δ 10.43 (s, 1H, NH), 8.19 (d, J = 2.0 Hz, 1H,

aromatic), 8.10 (dd, J1 = 9.1 Hz, J2 = 2.2 Hz, 1H, aromatic), 7.99-7.94 (m, 2H, aromatic),
7.92-7.89 (m, 1H, aromatic), 7.54 (dd, J1 = 8.6 Hz, J2 = 2.5 Hz, 1H, aromatic), 7.31 (d, J =
9.1 Hz, 2H, aromatic), 7.00 (d, J = 8.7 Hz, 1H, aromatic), 6.58 (s, 1H, aromatic), 4.06 (s,
3H, NCH3), 3.73 (s, 5H, CH2Ar, ArOCH3); 13C NMR (100 MHz, (CD3)2SO, Figure B48)
δ 172.0, 164.1, 154.9 (2C), 140.2, 139.8, 134.6, 131.8, 131.7, 131.5, 128.3, 128.2, 125.9,
120.4 (2CH), 117.5, 116.8, 116.62, 116.58, 116.4, 110.5, 55.5, 37.1, 32.9; m/z calcd for
C24H19F2N3O6S 515.4878; found 516.1763 [M+H]+ and sodium adduct 536.1524 (Figure
B49); Purity of the compound was further confirmed by RP-HPLC method A: Rt = 13.03
min (97% pure, Figure B50).
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Synthesis of compound 22a (SGT1652). A solution of
compound

15

(30

mg,

0.08

mmol),

2-

fluorobenzenesulfonamide (20a; 18 mg, 0.10 mmol), EDC•HCl
(26 mg, 0.14 mmol), and DMAP (19 mg, 0.15 mmol) in
anhydrous CH2Cl2 (3 mL) was stirred at room temperature overnight. The reaction was
quenched with H2O and extracted with CH2Cl2 (3×). The combined organic layers were
washed with brine, dried over MgSO4, filtered, and concentrated. The crude product
obtained was purified by column chromatography (SiO2 gel, Hexanes:EtOAc/1:1, Rf 0.46)
to yield compound 22a (50 mg, quant.) as a yellow solid: 1H NMR (500 MHz, (CD3)2SO,
Figure B51) δ 12.25 (s, 1H, NH), 8.43 (dd, J1 = 2.4 Hz, J2 = 0.5 Hz, 1H, aromatic), 8.00
(dd, J1 = 9.1 Hz, J2 = 2.3 Hz, 1H, aromatic), 7.95 (t, J = 7.7 Hz, 1H, aromatic), 7.81-7.75
(m, 1H, aromatic), 7.65 (dd, J1 = 9.2 Hz, J2 = 0.5 Hz, 1H, aromatic), 7.49 (s, 1H, aromatic),
7.47-7.43 (m, 1H, aromatic), 7.30 (d, J = 2.3 Hz, 1H, aromatic), 7.06 (d, J = 8.6 Hz, 1H,
aromatic), 4.24 (q, J = 7.3 Hz, 2H, NCH2CH3), 4.07 (s, 2H, CH2Ar), 3.78 (s, 3H, ArOCH3),
1.35 (t, J = 7.3 Hz, 3H, NCH2CH3); 13C NMR (100 MHz, (CD3)2SO, Figure B52) δ 164.0,
157.0, 155.3, 140.2, 138.7, 132.9, 131.2, 129.8, 129.1, 126.4, 124.7, 117.5, 117.2, 117.0,
116.6, 116.4, 116.0, 112.2, 110.3, 109.6, 55.9, 40.7, 29.0, 15.4; m/z calcd for
C25H22FN3O6S 511.5244; found 512.1273 [M+H]+ and sodium adduct 534.1097 (Figure
B53); Purity of the compound was further confirmed by RP-HPLC method A: Rt = 13.03
min (97% pure, Figure B54).
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Synthesis of compound 22g (SGT1653). A solution of
compound

15

(30

mg,

0.08

mmol),

4-

nitrobenzenesulfonamide (20g; 20 mg, 0.10 mmol),
EDC•HCl (26 mg, 0.14 mmol), and DMAP (19 mg, 0.15
mmol) in anhydrous CH2Cl2 (3 mL) was stirred at room temperature overnight. The
reaction was quenched with H2O and extracted with CH2Cl2 (3×). The combined organic
layers were washed with brine, dried over MgSO4, filtered, and concentrated. The crude
product obtained was purified by column chromatography (SiO2 gel, Hexanes:EtOAc/1:1,
Rf 0.27) to yield compound 22g (37 mg, 82%) as an orange solid: 1H NMR (500 MHz,
(CD3)2SO, Figure B55) δ 12.19 (s, 1H, NH), 8.45 (d, J = 8.9 Hz, 2H, aromatic), 8.40 (d, J
= 2.3 Hz, 1H, aromatic), 8.20 (d, J = 9.0 Hz, 2H, aromatic), 7.99 (dd, J1 = 9.1 Hz, J2 = 2.3
Hz, 1H, aromatic), 7.64 (d, J = 9.1 Hz, 1H, aromatic), 7.48 (s, 1H, aromatic), 7.46 (dd, J1
= 8.6 Hz, J2 = 2.4 Hz, 1H, aromatic), 7.33 (d, J = 2.3 Hz, 1H, aromatic), 7.06 (d, J = 8.6
Hz, 1H, aromatic), 4.23 (q, J = 7.3 Hz, 2H, NCH2CH3), 4.06 (s, 2H, CH2Ar), 3.80 (s, 3H,
ArOCH3), 1.33 (t, J = 7.3 Hz, 3H, NCH2CH3);

13

C NMR (100 MHz, (CD3)2SO, Figure

B56) δ 165.1, 155.5, 150.3, 144.6, 140.2, 138.6, 133.5, 133.0, 129.8, 129.4, 129.3, 126.4,
124.4, 121.6, 116.5, 116.4, 115.9, 112.3, 110.3, 56.0, 40.7, 28.9, 15.3; m/z calcd for
C25H22N4O8S 538.5310; found 539.1226 [M+H]+ and sodium adduct 561.1050 (Figure
B57); Purity of the compound was further confirmed by RP-HPLC method A: Rt = 17.77
min (99% pure, Figure B58).
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Synthesis of compound 23a (SGT1654). A solution of
compound

16

(30

mg,

fluorobenzenesulfonamide

(20a;

0.08
17

mg,

mmol),
0.10

2-

mmol),

EDC•HCl (25 mg, 0.13 mmol), and DMAP (18 mg, 0.15 mmol)
in anhydrous CH2Cl2 (3 mL) was stirred at room temperature
overnight. The reaction was quenched with H2O and extracted with CH2Cl2 (3×). The
combined organic layers were washed with brine, dried over MgSO4, filtered, and
concentrated. The crude product obtained was purified by column chromatography (SiO2
gel, Hexanes:EtOAc/1:1, Rf 0.46) to yield compound 23a (39 mg, 91%) as a yellow solid:
1

H NMR (500 MHz, (CD3)2SO, Figure B59) δ 12.25 (s, 1H, NH), 8.42 (d, J = 2.3 Hz, 1H,

aromatic), 7.99 (dd, J1 = 9.2 Hz, J2 = 2.4 Hz, 1H, aromatic), 7.95 (t, J = 7.3 Hz, 1H,
aromatic), 7.81-7.74 (m, 1H, aromatic), 7.66 (d, J = 9.2 Hz, 1H, aromatic), 7.47 (s, 1H,
aromatic), 7.44 (m, 3H, aromatic), 7.29 (d, J = 2.3 Hz, 1H, aromatic), 7.05 (d, J = 8.6 Hz,
1H, aromatic), 4.17 (t, J = 7.0 Hz, 2H, NCH2CH2CH3), 4.07 (s, 2H, CH2Ar), 3.78 (s, 3H,
ArOCH3), 1.79 (sextet, J = 7.3 Hz, 2H, NCH2CH2CH3), 0.80 (t, J = 7.4 Hz, 3H,
NCH2CH2CH3); 13C NMR (100 MHz, (CD3)2SO, Figure B60) δ 159.5, 157.0, 155.3, 140.2,
139.1, 136.5, 133.1, 132.9, 131.2, 130.4, 129.1, 126.3, 124.8, 124.7, 117.2, 117.0, 116.44,
116.37, 115.9, 112.2, 110.4, 59.7, 55.9, 47.3, 28.9, 23.1, 11.0; m/z calcd for C26H24FN3O6S
525.5514; found 526.1448 [M+H]+ and sodium adduct 548.1272 (Figure B61); Purity of
the compound was further confirmed by RP-HPLC method A: Rt = 17.86 min (98% pure,
Figure B62).
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Synthesis of compound 23g (SGT1655). A solution of
compound

16

(30

mg,

0.08

mmol),

4-

nitrobenzenesulfonamide (20g; 19 mg, 0.10 mmol),
EDC•HCl (25 mg, 0.13 mmol), and DMAP (18 mg, 0.15
mmol) in anhydrous CH2Cl2 (3 mL) was stirred at room temperature overnight. The
reaction was quenched with H2O and extracted with CH2Cl2 (3×). The combined organic
layers were washed with brine, dried over MgSO4, filtered, and concentrated. The crude
product obtained was purified by column chromatography (SiO2 gel, Hexanes:EtOAc/1:1,
Rf 0.26) to yield compound 23g (22 mg, 49%) as an orange solid: 1H NMR (500 MHz,
CDCl3, Figure B63) δ 10.49 (s, 1H, NH), 8.35 (d, J = 9.1 Hz, 2H, aromatic), 8.32 (d, J =
8.8 Hz, 2H, aromatic), 8.30 (d, J = 2.3 Hz, 1H, aromatic), 8.06 (dd, J1 = 9.1 Hz, J2 = 2.2
Hz, 1H, aromatic), 7.90 (d, J = 2.4 Hz, 1H, aromatic), 7.45 (dd, J1 = 8.6 Hz, J2 = 2.5 Hz,
1H, aromatic), 7.28 (d, J = 9.1 Hz, 1H, aromatic), 6.95 (d, J = 8.6 Hz, 1H, aromatic), 6.93
(s, 1H, aromatic), 4.03 (t, J = 7.2 Hz, 2H, NCH2CH2CH3), 4.04 (s, 2H, CH2Ar), 4.02 (s,
3H, ArOCH3), 1.83 (sextet, J = 7.3 Hz, 2H, NCH2CH2CH3), 0.90 (t, J = 7.4 Hz, 3H,
NCH2CH2CH3); 13C NMR (100 MHz, CDCl3, Figure B64) δ 162.6, 156.7, 150.9, 144.6,
141.3, 139.6, 135.8, 134.4, 132.7, 130.3, 129.5, 127.0, 124.2, 118.3, 117.6, 116.6, 116.5,
112.3, 109.6, 56.9, 48.6, 30.3, 23.8, 11.7; m/z calcd for C26H24N4O8S 552.5580; found
553.1369 [M+H]+ and sodium adduct 575.1195 (Figure B65); Purity of the compound was
further confirmed by RP-HPLC method A: Rt = 17.82 min (95% pure, Figure B66).
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Synthesis of compound 24a (SGT1657). A solution of
compound

17

(30

mg,

0.08

mmol),

2-

fluorobenzenesulfonamide (20a; 16 mg, 0.09 mmol), EDC•HCl
(24 mg, 0.13 mmol), and DMAP (17 mg, 0.14 mmol) in
anhydrous CH2Cl2 (3 mL) was stirred at room temperature
overnight. The reaction was quenched with H2O and extracted with CH2Cl2 (3×). The
combined organic layers were washed with brine, dried over MgSO4, filtered, and
concentrated. The crude product obtained was purified by column chromatography (SiO2
gel, Hexanes:EtOAc/1:1, Rf 0.63) to yield compound 24a (24 mg, 56%) as a yellow solid:
1

H NMR (500 MHz, CDCl3, Figure B67) δ 10.57 (s, 1H, NH), 8.33 (d, J = 2.3 Hz, 1H,

aromatic), 8.14 (td, J1 = 7.6 Hz, J2 = 1.8 Hz, 1H, aromatic), 8.06 (dd, J1 = 9.1 Hz, J2 = 2.2
Hz, 1H, aromatic), 7.88 (d, J = 2.5 Hz, 1H, aromatic), 7.61-7.57 (m, 1H, aromatic), 7.44
(dd, J1 = 8.6 Hz, J2 = 2.6 Hz, 1H, aromatic), 7.33-7.30 (m, 1H, aromatic), 7.27 (d, J = 9.1
Hz, 1H, aromatic), 7.17-7.13 (m, 1H, aromatic), 6.96 (d, J = 8.6 Hz, 1H, aromatic), 6.89
(s, 1H, aromatic), 4.05 (t, J = 7.3 Hz, 2H, NCH2CH2CH2CH3), 4.05 (s, 3H, ArOCH3), 4.02
(s, 2H, CH2Ar), 1.76 (p, J = 7.6 Hz, 2H, NCH2CH2CH2CH3), 1.30 (sextet, J = 7.7 Hz, 2H,
NCH2CH2CH2CH3), 0.91 (t, J = 7.4 Hz, 3H, NCH2CH2CH2CH3);

13

C NMR (100 MHz,

CDCl3, Figure B68) δ 162.7, 156.7, 141.3, 139.6, 136.4, 136.3, 135.5, 134.2, 132.6, 132.3,
129.4, 127.0, 124.7, 124.6, 118.8, 117.6, 117.3, 117.1, 116.6, 112.3, 109.5, 56.9, 46.7, 32.5,
30.3, 20.3, 13.8; m/z calcd for C27H26FN3O6S 539.5784; found 540.1576 [M+H]+ and
sodium adduct 562.1398 (Figure B69); Purity of the compound was further confirmed by
RP-HPLC method A: Rt = 18.26 min (95% pure, Figure B70).
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Synthesis of compound 24g (SGT1656). A solution of
compound

17

(30

mg,

0.08

mmol),

4-

nitrobenzenesulfonamide (20g; 19 mg, 0.09 mmol),
EDC•HCl (24 mg, 0.13 mmol), and DMAP (17 mg, 0.14
mmol) in anhydrous CH2Cl2 (3 mL) was stirred at room
temperature overnight. The reaction was quenched with H2O and extracted with CH2Cl2
(3×). The combined organic layers were washed with brine, dried over MgSO4, filtered,
and concentrated. The crude product obtained was purified by column chromatography
(SiO2 gel, Hexanes:EtOAc/1:1, Rf 0.45) to yield compound 24g (28 mg, 62%) as a yellow
solid: 1H NMR (500 MHz, CDCl3, Figure B71) δ 10.49 (s, 1H, NH), 8.35 (d, J = 9.0 Hz,
2H, aromatic), 8.32 (d, J = 9.1 Hz, 2H, aromatic), 8.29 (d, J = 2.3 Hz, 1H, aromatic), 8.05
(dd, J1 = 9.1 Hz, J2 = 2.2 Hz, 1H, aromatic), 7.90 (d, J = 2.5 Hz, 1H, aromatic), 7.45 (dd,
J1 = 8.6 Hz, J2 = 2.5 Hz, 1H, aromatic), 7.28 (d, J = 9.1 Hz, 1H, aromatic), 6.95 (d, J = 8.6
Hz, 1H, aromatic), 6.92 (s, 1H, aromatic), 4.06 (t, J = 7.2 Hz, 1H, aromatic), 4.04 (s, 2H,
CH2Ar), 4.03 (s, 3H, ArOCH3), 1.77 (p, J = 7.5 Hz, 2H, NCH2CH2CH2CH3), 1.30 (sextet,
J = 7.6 Hz, 2H, NCH2CH2CH2CH3), 0.92 (t, J = 7.4 Hz, 3H, NCH2CH2CH2CH3); 13C NMR
(100 MHz, CDCl3, Figure B72) δ 162.6, 156.7, 150.9, 144.6, 141.3, 139.6, 135.8, 134.4,
132.6, 130.3, 129.4, 126.9, 124.2, 118.3, 117.6, 116.6, 116.5, 112.3, 109.6, 56.9, 46.7, 32.5,
30.3, 20.3, 13.8; m/z calcd for C27H26N4O8S 566.5850; found 567.1532 [M+H]+ and
sodium adduct 589.1355 (Figure B73); Purity of the compound was further confirmed by
RP-HPLC method A: Rt = 13.02 min (99% pure, Figure B74).
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Synthesis of compound 25a (SGT1659). A solution of
compound

18

(30

mg,

fluorobenzenesulfonamide

(20a;

0.08
16

mg,

mmol),
0.09

2-

mmol),

EDC•HCl (24 mg, 0.13 mmol), and DMAP (17 mg, 0.14 mmol)
in anhydrous CH2Cl2 (3 mL) was stirred at room temperature
overnight. The reaction was quenched with H2O and extracted with CH2Cl2 (3×). The
combined organic layers were washed with brine, dried over MgSO4, filtered, and
concentrated. The crude product obtained was purified by column chromatography (SiO2
gel, Hexanes:EtOAc/1:1, Rf 0.29) to yield compound 25a (22 mg, 52%) as a yellow solid:
1

H NMR (500 MHz, (CD3)2SO, Figure B75) δ 12.24 (s, 1H, NH), 8.41 (d, J = 7.7 Hz, 1H,

aromatic), 7.98 (dd, J1 = 9.1 Hz, J2 = 2.3 Hz, 1H, aromatic), 7.95 (t, J = 7.7 Hz, 1H,
aromatic), 7.82-7.75 (m, 1H, aromatic), 7.67 (d, J = 9.1 Hz, 1H, aromatic), 7.45 (s, 1H,
aromatic), 7.44 (m, 3H, aromatic), 7.28 (d, J = 2.3 Hz, 1H, aromatic), 7.06 (d, J = 8.6 Hz,
1H, aromatic), 4.07 (s, 2H, CH2Ar), 4.03 (d, J = 7.3 Hz, 2H, NCH2), 3.78 (s, 3H, ArOCH3),
2.09 (septet, J = 7.2 Hz, 1H, CH(CH3)2), 0.82 (d, J = 6.7 Hz, 6H, CH(CH3)2); 13C NMR
(100 MHz, (CD3)2SO, Figure B76) δ 164.2, 159.6, 155.3, 140.2, 139.4, 136.6, 133.0, 131.2,
130.9, 129.1, 126.3, 124.8, 117.4, 117.3, 117.1, 116.5, 116.3, 115.9, 115.3, 112.2, 110.7,
55.9, 52.9, 29.2, 28.9, 19.7; m/z calcd for C27H26FN3O6S 539.5784; found 540.1599
[M+H]+ and sodium adduct 562.1422 (Figure B77); Purity of the compound was further
confirmed by RP-HPLC method A: Rt = 13.03 min (98% pure, Figure B78).
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Synthesis of compound 25g (SGT1661). A solution of
compound

18

(30

mg,

0.08

mmol),

4-

nitrobenzenesulfonamide (20g; 19 mg, 0.09 mmol),
EDC•HCl (24 mg, 0.13 mmol), and DMAP (17 mg, 0.14
mmol) in anhydrous CH2Cl2 (3 mL) was stirred at room temperature overnight. The
reaction was quenched with H2O and extracted with CH2Cl2 (3×). The combined organic
layers were washed with brine, dried over MgSO4, filtered, and concentrated. The crude
product obtained was purified by column chromatography (SiO2 gel, Hexanes:EtOAc/1:1,
Rf 0.41) to yield compound 25g (5 mg, 12%) as a yellow solid: 1H NMR (500 MHz,
CD3OD, Figure B79) δ 8.40 (d, J = 8.9 Hz, 2H, aromatic), 8.31 (d, J = 2.2 Hz, 1H,
aromatic), 8.27 (d, J = 9.0 Hz, 2H, aromatic), 8.02 (dd, J1 = 9.1 Hz, J2 = 2.3 Hz, 1H,
aromatic), 7.49 (d, J = 9.2 Hz, 1H, aromatic), 7.48 (d, J = 2.2 Hz, 1H, aromatic), 7.45 (dd,
J1 = 8.7 Hz, J2 = 1.8 Hz, 1H, aromatic), 7.23 (s, 1H, aromatic), 7.06 (d, J = 8.5 Hz, 1H,
aromatic), 4.09 (s, 2H, CH2Ar), 3.99 (d, J = 7.4 Hz, 2H, NCH2), 3.91 (s, 3H, ArOCH3),
2.15 (septet, J = 7.3 Hz, 1H, CH(CH3)2), 0.89 (d, J = 6.7 Hz, 6H, CH(CH3)2); 13C NMR
(100 MHz, (CD3)2SO, Figure B80) δ 165.1, 155.5, 150.2, 144.6, 140.1, 139.4, 133.4, 133.0,
130.9, 129.32, 129.26, 126.2, 124.4, 121.6, 116.4, 116.2, 115.9, 112.2, 110.6, 56.0, 52.9,
29.2, 28.8, 19.7; m/z calcd for C27H26N4O8S 566.5850; found 567.1539 [M+H]+ and
sodium adduct 589.1361 (Figure B81); Purity of the compound was further confirmed by
RP-HPLC method A: Rt = 18.11 min (99% pure, Figure B82).
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Synthesis of compound 26g (SGT1658). A solution of
compound

19

(30

mg,

0.07

mmol),

4-

nitrobenzenesulfonamide (20g; 17 mg, 0.09 mmol),
EDC•HCl (22 mg, 0.12 mmol), and DMAP (16 mg, 0.13
mmol) in anhydrous CH2Cl2 (3 mL) was stirred at room
temperature overnight. The reaction was quenched with H2O and extracted with CH2Cl2
(3×). The combined organic layers were washed with brine, dried over MgSO4, filtered,
and concentrated. The crude product obtained was purified by column chromatography
(SiO2 gel, Hexanes:EtOAc/1:1, Rf 0.42) to yield compound 26g (29 mg, 66%) as a yellow
solid: 1H NMR (500 MHz, CDCl3, Figure B83) δ 10.49 (s, 1H, NH), 8.35 (d, J = 9.1 Hz,
2H, aromatic), 8.32 (d, J = 9.1 Hz, 2H, aromatic), 8.31 (d, J = 2.3 Hz, 1H, aromatic), 8.02
(dd, J1 = 9.1 Hz, J2 = 2.3 Hz, 1H, aromatic), 7.90 (d, J = 2.4 Hz, 1H, aromatic), 7.46 (dd,
J1 = 8.6 Hz, J2 = 2.5 Hz, 1H, aromatic), 7.32-7.27 (m, 3H, aromatic), 7.23 (d, J = 9.5 Hz,
1H, aromatic), 7.05 (dd, J1 = 7.9 Hz, J2 = 2.2 Hz, 2H, aromatic), 6.97 (s, 1H, aromatic),
6.96 (d, J = 8.7 Hz, 1H, aromatic), 5.27 (s, 2H, NCH2Ar), 4.05 (s, 2H, CH2Ar), 4.04 (s, 3H,
ArOCH3); 13C NMR (100 MHz, CDCl3, Figure B84) δ 162.6, 156.7, 150.8, 144.6, 141.6,
139.8, 136.3, 135.8, 134.2, 132.6, 130.3, 129.9, 129.2, 128.3, 127.2, 126.9, 124.2, 118.3,
117.9, 117.0, 116.6, 112.3, 110.0, 56.9, 50.7, 30.3; m/z calcd for C30H24N4O8S 600.6020;
found 601.1373 [M+H]+ and sodium adduct 623.1203 (Figure B85); Purity of the
compound was further confirmed by RP-HPLC method A: Rt = 17.81 min (97% pure,
Figure B86).
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3.5.2.1. Organisms and growth conditions
All oral bacterial strains were grown from a frozen stock on blood agar plates (BBL, Becton
Dickinson, Sparks, MD) and incubated in appropriate aerobic or anaerobic conditions at
37 °C for 24 h or 3 days, respectively, as previously reported.62, 103 In this study the
following bacterial strains were used: Porphyromonas gingivalis ATCC 33277
(anaerobic), Actinomyces naeslundii ATCC 49340 (anaerobic), Aggregatibacter
actinomycetemcomitans JP2 (anaerobic), Fusobacterium nucleatum ATCC 25586
(anaerobic), Streptococcus sanguinis ATCC 10556 (aerobic), and Veillonella parvula
ATCC 10790 (anaerobic). After 3 days of growth, a liquid culture was started for each
strain in 3 mL of Brain Heart Infusion (BHI) broth supplemented with 5 µg/mL of hemin
and 1 µg/mL of menadione for P. gingivalis, A. naeslundii, A. actinomycetemcomitans, F.
nucleatum, and S. sanguinis, or Reinforced Clostridial medium with 60% sodium lactate
pH 7 for V. parvula. After 24 h, the liquid cultures were inoculated with the corresponding
fresh growth medium and allowed to reach logarithmic growth for 3-4 h, the time at which
antimicrobial activity of different treatments was evaluated. All 96-well plates for
experiments using oral bacterial species used in this study were VWR Tissue Culture Plates
96-wells-F, sterile flat-bottom plates.

The human embryonic kidney cell line HEK-293 (ATCC CRL-1573), the human bronchus
normal cell line BEAS-2B (ATCC CRL-9609), and the liver hepatocellular carcinoma
HepG2 (ATCC HB-8065) were kind gifts from the laboratories of Dr. Matthew S. Gentry
(University of Kentucky, Lexington, KY, USA), Dr. David K. Orren (University of
Kentucky, Lexington, KY, USA), and Dr. Vincent Venditto (University of Kentucky,
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Lexington, KY, USA), respectively. Mammalian cells were grown in Dulbecco’s Modified
Eagle’s Medium (DMEM) (from ATCC) with 10% fetal bovine serum (FBS) (from ATCC)
and 1% Pen/Strep (from ATCC). Cell lines were incubated at 37 °C and 5% CO2 and
passaged by trypsinization with 0.05% trypsin:0.53 mM EDTA (from ATCC). Cell
confluency was determined by using a Nikon Eclipse TS100 microscope (Minato, Tokyo,
Japan).

3.5.2.2. Effect of zafirlukast (ZAF) derivatives on the viability of different bacterial strains
The antimicrobial effect of ZAF derivatives 21a-g, 22a, 22g, 23a, 23g, 24a, 24g, 25a, 25g,
and 26g was investigated using a colorimetric water-soluble tetrazolium-1 (WST-1) assay
as previously reported.62, 103, 196 The WST-1 cell proliferation reagent acts as a surrogate
marker for cell proliferation and viability. All bacterial strains were logarithmically grown
in appropriate broth (90 µL) using 96-well plates (108/well) and were incubated with
different treatments for 24 h. Then 10 µL of WST-1 reagent (Roche, Mannheim, Germany)
was added to each well. The treated plates were then incubated for 2.5 h under the
appropriate culture conditions and the absorbance was measured at 405 nm, with a
reference wavelength at 600 nm, by using a SpectraMax M2 plate reader (Molecular
Devices, Sunnyvale, CA). The data for percent growth inhibition assays with P. gingivalis
2.5 h after the addition of the WST-1 reagent are presented in Figures 3.2 and B88. Whereas
the data for 30 minutes after the addition of the WST-1 reagent are presented in Figure
B87. The optical densities (ODs) at 405 nm of bacterial metabolic activity were used to
calculate the percentage of inhibitory effect (i.e., % growth inhibition) under different
experimental conditions by utilizing the following formula: 100 × [OD (control) - OD
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(experimental) / OD (control)]. For F. nucleatum and P. gingivalis, negative controls were
bacteria exposed to only medium (sterility control) or DMSO, and positive controls were
bacteria exposed to 2.81 µM of tetracycline (Tet, equivalent to 1.25 µg/mL, a standard
concentration usually used for this control) and ZAF at 25 and 50 µM diluted in DMSO
(concentrations that previously showed antimicrobial effect against P. gingivalis). The 2nd
and 3rd generation ZAF derivatives were tested at 1, 10, and 100 µM. For testing against
the other oral bacterial species of A. naeslundii, A. actinomycetemcomitans, S. sanguinis,
and V. parvula, control cultures were treated with medium only (sterility control), exposed
to DMSO (vehicle for ZAF and its derivatives, negative control), or treated with
penicillin/streptomycin 1X (100 U/mL of penicillin and 100 µg/mL of streptomycin) or
ZAF at 25 and 50 µM diluted in DMSO as positive controls. These data are presented in
Figures 3.4 and B89.

Figure B87: The colorimetric WST-1 assay was used to determine the percent growth inhibition effect of
2nd generation ZAF derivatives 21a and 21g and 3rd generation ZAF derivatives 21b-21f, 22a, 22g, 23a, 23g,
24a, 24g, 25a, 25g, and 26g on P. gingivalis ATCC 33277. In supplemented brain heart infusion (BHI),
planktonic P. gingivalis (108 cells/well) was exponentially grown and incubated under anaerobic conditions
and was incubated with different treatments of ZAF derivatives 21a-21g, 22a, 22g, 23a, 23g, 24a, 24g, 25a,
25g, and 26g (1, 10, and 100 µM) for 24 h. The cultures were treated with medium only (sterility control)
and the experimental cultures were treated with DMSO (vehicle for ZAF and its derivatives, negative control)
and 2.81 µM of tetracycline (Tet) or 25 and 50 µM of ZAF. The data represent the average from 42
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independent replicates for the controls. For each ZAF derivative, the data represent the average from six
independent replicates per condition of the growth inhibitory effect vs bacterial cultures grown in medium
only. These data represent the percent growth inhibition 30 min after the addition of the WST-1 reagent.

Figure B88: Percent growth inhibition effect of 2nd generation ZAF derivatives 21a and 21g and 3rd
generation ZAF derivatives 21b-21f, 22a, 22g, 23a, 23g, 24a, 24g, 25a, 25g, and 26g on P. gingivalis ATCC
33277 determined by a colorimetric WST-1 assay. In supplemented brain heart infusion (BHI), P. gingivalis
(108 cells/well) was exponentially grown and incubated under anaerobic conditions and was treated with ZAF
derivatives 21a-21g, 22a, 22g, 23a, 23g, 24a, 24g, 25a, 25g, and 26g (1, 10, and 100 µM) for 24 h. The
cultures were treated with medium only (sterility control) and the experimental cultures were treated with
DMSO (vehicle for ZAF and its derivatives, negative control) and 2.81 µM of tetracycline (Tet) or 25 and
50 µM of ZAF. The data represent the average from 42 independent replicates for the controls. For each ZAF
derivative, the data represent the average from six independent replicates per condition of the growth
inhibitory effect vs bacterial cultures grown in medium only. These data represent the percent growth
inhibition 2.5 h after the addition of the WST-1 reagent. The percent growth inhibition values are displayed
as a heat map where blue are low percent growth inhibition values (indicating the compounds did not inhibit
P. gingivalis growth), yellow are middle percent growth inhibition values (indicating the compounds
inhibited around half of P. gingivalis growth), and orange are high percent growth inhibition values
(indicating the compounds inhibited almost all P. gingivalis growth).

Figure B89: Percent growth inhibition effect of ZAF derivatives 21a, 21g, 21b, 21c, 21d, 22g, 23g, 24g, and
25g on A. naeslundii ATCC 49340 (anaerobic), A. actinomycetemcomitans JP2 (anaerobic), F. nucleatum
ATCC 25586 (anaerobic), S. sanguinis ATCC 10556 (aerobic), and V. parvula ATCC 10790 (anaerobic)
determined by a colorimetric WST-1 assay. Grown supplemented BHI for P. gingivalis, A. naeslundii, A.
actinomycetemcomitans, F. nucleatum, and S. sanguinis, or Reinforced Clostridial medium for V. parvula
(108 cells/well) was exponentially grown and incubated under aerobic or anaerobic conditions and was treated
with ZAF derivatives 21a, 21g, 21b, 21c, 21d, 22g, 23g, 24g, and 25g (1, 10, and 100 µM) for 24 h. The
cultures were treated with medium only (sterility control) and the experimental cultures were treated with
DMSO (vehicle for ZAF and its derivatives, negative control), 2.81 µM of Tet (for F. nucleatum), the
antibiotics penicillin/streptomycin (P/S) 1X (100 U/mL of penicillin and 100 µg/mL of streptomycin for all
other oral bacterial species), and 25 and 50 µM of ZAF. The data represent the average from 30 independent
replicates for the controls. For each ZAF derivative, the data represent the average from six independent
replicates per condition of the growth inhibitory effect vs bacterial cultures grown in medium only. These
data represent the percent growth inhibition 30 min (for F. nucleatum as this was the time when the controls
reached the standard percent growth inhibition values consistent with the literature) or 2.5 h for the other oral
bacterial species after the addition of the WST-1 reagent. The percent growth inhibition values are displayed
as a heat map where blue are low percent growth inhibition values (indicating the compounds did not inhibit
bacterial growth), yellow are middle percent growth inhibition values (indicating the compounds inhibited
around half of the bacterial growth), and orange are high percent growth inhibition values (indicating the
compounds inhibited almost all bacterial growth).
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3.5.2.3. Colony forming unit (CFU) assays
The bactericidal effect of the most active ZAF derivatives (21a-d, 21g, 22g, 23g, 24g, and
25g), which exhibited the best antimicrobial potential at lower concentrations as
determined by the WST-1 assay, were further investigated by measuring colony forming
units per milliliter (CFUs/mL) after different treatments. P. gingivalis (108/well) was
grown under anaerobic conditions in the appropriate medium in 96-well plates. The
bacteria were exposed to only medium or DMSO as negative controls, and exposed to 2.81
µM of Tet and ZAF at 25 and 50 µM diluted in DMSO as positive controls. The bacteria
were also treated with ZAF derivatives (1, 10, and 100 µM) dissolved in DMSO. After 24
h, the treated bacteria were diluted (1:400) and 100 µL of the diluted samples 21a-d, 21g,
22g, 23g, 24g, and 25g were plated and spread onto blood agar plates. The number of CFUs
were counted after 5 days of incubation on the blood agar plate in an anaerobic chamber.
These data are presented in Figure 3.5.

3.5.2.4. Disruption of pre-formed biofilms of P. gingivalis
The most active ZAF derivatives (21a-c, 21g, 22g, and 24g), which exhibited the best
antimicrobial potential at lower concentrations as determined by the WST-1 assay, were
further investigated by determining their ability to disrupt pre-formed biofilms of P.
gingivalis ATCC 33277. Liquid cultures of P. gingivalis were grown as described above.
Then P. gingivalis (1×108 bacteria/well)1, 25, 197 was grown for 48 h with gentle shaking
under anaerobic conditions in supplemented BHI medium in flat-bottom VWR® multiwell cell culture 96-well plates (100 µL). The 96-well plates were gently shaken on a
Scilogex MX-M Microplate Mixer (Scilogex LLC, Rocky Hill, CT). After biofilm
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formation, the old medium was removed and the biofilm was washed three times with
phosphate buffered saline (PBS), and then 100 µL of BHI was added to each well. Then,
the bacteria were exposed to 100 µL of different treatments for 24 h. The bacteria were
exposed to only medium or DMSO as negative controls, and exposed to 2.81 µM of Tet
and 50 µM of ZAF diluted in DMSO as positive controls. The bacteria were also treated
with ZAF derivatives (50 and 100 µM) dissolved in DMSO. The old medium was removed,
the biofilm was washed three times with PBS, and 100 µL of 0.1% safranin was added to
each well. After 15 min, the excess safranin was removed by washing four times with PBS.
To quantify the amount of biofilm, 100 µL of 95% EtOH was added to each well and after
5 min (time to solubilize the safranin), the EtOH was transferred to a new 96-well plate
and the absorbance was measured at 492 nm, with a reference wavelength at 600 nm, by
using a SpectraMax M2 plate reader (Molecular Devices, Sunnyvale, CA). The percentage
of biofilm growth was determined by utilizing the following formula: 100 × [OD600
(experimental) / OD600 (DMSO control)]. These data are presented in Figure 3.6.

3.5.2.5. Inhibition of P. gingivalis biofilm growth
The most active ZAF derivatives (21a-c, 21g, 22g, and 24g) were further investigated by
determining their ability to inhibit biofilm growth of P. gingivalis ATCC 33277. Liquid
cultures of P. gingivalis were grown as described above. P. gingivalis was logarithmically
grown in supplemented BHI (100 µL) using flat-bottom VWR® multi-well cell culture 96well plates (1×108 bacteria/well)1, 25, 197 and was exposed to different treatments (100 µL)
for 48 h with gentle shaking under anaerobic conditions. The bacteria were exposed to only
medium or DMSO as negative controls, and exposed to 2.81 µM of Tet and 50 µM of ZAF
187

diluted in DMSO as positive controls. The bacteria were also treated with ZAF derivatives
(10, 25, 50, and 100 µM) dissolved in DMSO. The old medium was removed and the
biofilm was washed three times with PBS, and 100 µL of 0.1% safranin was added to each.
After 15 min, the excess safranin was removed by washing four times with PBS. To
quantify the amount of biofilm, 100 µL of 95% EtOH was added to each well and after 5
min (time to solubilize the safranin), the EtOH was transferred to a new 96-well plate and
the absorbance was measured at 492 nm, with a reference wavelength at 600 nm, by using
a SpectraMax M2 plate reader (Molecular Devices, Sunnyvale, CA). The percentage of
biofilm growth was determined by utilizing the following formula: 100 × [OD600
(experimental) / OD600 (DMSO control)]. These data are presented in Figure 3.7.

3.5.2.6. Cytotoxic effect of ZAF derivatives on oral epithelial cells
The immortalized oral keratinocyte cell line OKF6/hTERT (OKF6) were used in viability
assays178 to evaluate the cytotoxic effect of ZAF derivatives 21b, 21c, and 24g. The OKF6
cells were cultured in keratinocyte-serum free medium (SFM) supplemented with bovine
pituitary extract (25 µg/mL) and recombinant epidermal growth factor (0.2 ng/mL) (KerSFM). The cells were grown at 37 °C in a humidified incubator with 5% CO2. The cells
were treated with negative controls of medium only (sterility control) or DMSO and
positive controls were 8 µM of staurosporine (STS) or 25 µM of ZAF. Then a 1:1 ratio of
cell suspension and trypan blue were mixed and 10 µL were counted in an automated cell
counter (Countess II FL, Life Technologies, Singapore) to determine the percentage of
alive and dead cells. The counted cells were used to establish the volume needed to be
added to each well of 24-well plates to provide 105 cells/well. To perform the viability
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assays, cells were seeded in 24-well plates overnight in Ker-SFM medium and the cells
were further exposed to ZAF derivatives (10 and 100 µM) dissolved in DMSO or
appropriate negative and positive controls for 24 h. The morphology and density of the
treated cells were documented by using a light inverted microscope Nikon Eclipse TiSeries (Nikon Instruments Inc., Melville, NY). One well from each control treatment was
visualized along with one well from each 10 µM concentration of the ZAF derivatives,
21b, 21c, and 24g. These data are presented in Figure 3.8. Flow cytometry analysis (FACS)
was used to establish the cytotoxic effects of ZAF derivatives. OKF6 cells were harvested
by trypsinization 24 h after exposure to treatments, washed with phosphate buffered saline
(PBS), pelleted at 1100 rpm for 5 min, and were further labeled with 5 µL of FITC-Annexin
V and 5 µL of propidium iodide (BD Pharmingen, San Jose, CA) for 15 min at room
temperature. The FACS analyses were done for at least 10,000 acquired events in a flow
cytometer FACSCalibur (Becton Dickinson, San Jose, CA). These data are presented in
Figure 3.9 as well as in Table 3.1.

Table 3.1: The percentage of viable, apoptosis, and necrosis of OKF6 cells treated with
controls (STS and ZAF) and ZAF derivatives 21b, 21c, and 24g with the error bars (± %
error).a
Cpd and concentration used
Viable
Apoptosis (%)
DMSO
90.3 ± 0.1
5.6 ± 1.4
2.9 ± 0.5
94.8 ± 0.8
STS (8 µM)
40.7 ± 4.1
22.8 ± 9.0
ZAF (25 µM)
9.3 ± 2.7
75.0 ± 0.3
21b (10 µM)
5.7 ± 0.4
10.8 ± 2.6
21b (100 µM)
56.7 ± 3.1
20.6 ± 2.4
21c (10 µM)
18.8 ± 3.1
46.4 ± 1.3
21c (100 µM)
63.6 ± 4.0
19.7 ± 0.1
24g (10 µM)
23.0 ± 11.0
50.4 ± 8.8
24g (100 µM)
a
Figure 3.9 was generated using the percentage values presented in this Table.
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Necrosis (%)
4.1 ± 1.3
2.2 ± 1.3
36.5 ± 4.9
15.8 ± 2.9
83.4 ± 2.1
22.7 ± 5.5
34.8 ± 1.8
16.7 ± 4.0
26.6 ± 2.2

3.5.2.7. Cytotoxic effect of ZAF derivatives on mammalian cell lines
Mammalian cytotoxicity assays were performed as previously described with minor
modifications.198 HEK-293, BEAS-2B, and HepG2 cells were cultured as described in the
section “organisms and growth conditions” above and were counted by a hemocytometer
when cells were about 80% confluent in flasks. The mammalian cells were plated in 96well microtiter plates at concentrations of 10,000 cells per well for HEK-293 and 3,000
cells per well for BEAS-2B and HepG2. The plates were then incubated at 37 °C and 5%
CO2 for 16 h to allow time for the cells to adhere to the wells. The medium was removed
and fresh medium with ZAF or compounds 21a-c at 0-62.6 µg/mL were added. The
compounds were previously prepared in stock solutions at 1000× of the intended tested
concentrations. The cells were treated with negative controls of medium only (sterility
control) or 0.1% DMSO, and the positive control contained 20% Triton™ X-100. The
percentage of cell survival was evaluated after 24 h of incubation via addition of resazurin
(10 µL of 10 mM solution) for 6 h. A SpectraMax M5 plate reader was used to detect live
cells by a color change from purple to pink depicting the conversion of the compound to
resorufin, which could be quantified at λ560 absorption and λ590 emission. The percent cell
survival rates were calculated by using the following equation: % cell survival =
[(fluorescence of sample) - (fluorescence of negative control with medium only)] × 100 /
[(fluorescence of DMSO negative control) - (fluorescence of negative control with medium
only)]. These experiments were performed in quadruplicate. The normalized data are
presented in Figure 3.10 (Note: For instances where >100% cell survival was observed, the
data was displayed as 100% cell survival). The corresponding non-normalized data are
presented in Figure B90.
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Figure B90: Non-normalized data of the evaluation of cytotoxicity for compounds 21a (dark green bars),
21b (dark yellow bars), 21c (dark purple bars), and ZAF (grey bars) against (A) HEK-293, (B) BEAS-2B,
and (C) HepG2. Controls included treatment with Triton™ X-100 (TX, 1% v/v, positive control) and 1%
DMSO (negative control). Experiments were performed in quadruplicate. The corresponding normalized data
are presented in Figure 3.10.

3.5.2.8. Hemolytic effect of N-alkyl ZAF derivatives
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The hemolytic activity of ZAF and its derivatives 21a-c was determined by using methods
previously described with minor modifications.199 In 4 mL of PBS, murine whole blood
was suspended and centrifuged at 1,000 rpm for 10 min at room temperature to obtain the
murine red blood cells (mRBCs). Then the mRBCs were washed 4× in PBS and
resuspended in the same buffer to a final concentration of 1×107 erythrocytes/mL. A twofold serial dilution of ZAF and compounds 21a, 21b, and 21c was prepared using 100 µL
of PBS buffer in Eppendorf tubes followed by the addition of 100 µL of mRBC suspension
that produced the final concentrations of compounds as 3.13-100 µM and 5×106
erythrocytes/mL, respectively. The tubes were incubated at 37 °C for 1 h. The negative
control was tubes with 200 µL of PBS and the positive control was Triton™ X-100 (1%
v/v, 2 µL). The percentage of hemolysis was calculated using the equation: % hemolysis =
[(absorbance of sample) - (absorbance of negative control)] × 100 / (absorbance of positive
control). These data are presented in Figure 3.11 as well as in Table 3.2.

Table 3.2: The % hemolysis caused by ZAF and its’ derivatives against mRBCs with the
error bars (± SDEV).a
Cpd concentration (µg/mL)
Cpd #
3.13
6.25
12.5
25
ZAF
0
0
0
0
23a
11.5 ± 0.6
24.1 ± 6.4
16.3 ± 1.0
16.8 ± 2.8
23g
0.2 ± 2.0
5.0 ± 1.4
0.2 ±1.3
12.3 ± 4.5
24a
0
25.1 ± 3.5
23.2 ± 1.6
20.0 ± 1.6
24g
5.8 ± 0.7
4.1 ± 0.8
4.4 ± 1.6
14.6 ± 3.5
a
Figure 3.11 was generated using the percentage values presented in this Table.

3.6. ASSOCIATED CONTENT
3.6.1. Supporting information
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50
0
21.7 ± 1.2
2.0 ± 1.1
24.8 ± 3.1
5.5 ± 1.0

100
71.6 ± 3.2
19.8 ± 3.7
6.6 ± 2.9
24.2 ± 2.7
7.9 ± 0.9

The supporting information in Appendix B contains all 1H and

13

C NMR spectra along

with HRMS and HPLC traces B1-B86 for the compounds tested in Chapter 3.
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Chapter 4
Novel fluconazole derivatives with promising antifungal activity

4.1. ABSTRACT
The fungistatic nature and toxicity concern associated with the azole drugs currently on the
market have resulted in an increased demand for new azole antifungal agents for which
these problematic characteristics do not exist. The extensive use of azoles has resulted in
fungal strains capable of resisting the action of these drugs. Herein, we report the synthesis
and antifungal activities of novel fluconazole (FLC) analogues with alkyl-, aryl-,
cycloalkyl-, and dialkyl-amino substituents. We evaluated their antifungal activity by MIC
determination and time-kill assay as well as their safety profile by hemolytic activity
against murine erythrocytes as well as cytotoxicity against mammalian cells. The best
compounds from our study exhibited broad-spectrum activity against most of the fungal
strains tested, with excellent MIC values against a number of clinical isolates. The most
promising compounds were found to be less hemolytic than the least hemolytic FDAapproved azole antifungal agent voriconazole (VRC previously published as VOR).
Finally, we demonstrated that the synthetic alkyl-amino FLC analogues displayed chaindependent fungal membrane disruption as well as inhibition of ergosterol biosynthesis as
possible mechanisms of action.

4.2. INTRODUCTION
The rise in the number of infections caused by fungi poses a serious threat to human health
and life.200 Fungal infections can be endogenous (e.g., Candida infections) or acquired
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from the environment (e.g., Cryptococcus and Aspergillus infections). Invasive fungal
infections have become a major problem for patients with immunodeficiency syndrome
(e.g., AIDS), organ transplant patients, and patients receiving chemotherapeutic agents for
cancer treatment.201-203 Clinically, candidiasis, aspergillosis, and cryptococcosis are the
major infections in immunocompromised patients.204, 205 Candida and Aspergillus species
are responsible for the majority of documented fungal infections. Recent studies indicated
an epidemiological shift towards infections caused by emerging non-albicans Candida and
Aspergillus species resistant to the current antifungal drugs.206-208 Non-albicans Candida
species such as C. glabrata, C. parapsilosis, C. tropicalis, and C. krusei are more
prominent now and they account for more incidence of invasive candidiasis such as
candidemia than C. albicans.209-212 The relative presence of these fungal strains is region
dependent. For example, C. glabrata is the second most common species after C. albicans
in North America.210 Fungal strains such as C. parapsilosis and C. tropicalis are relatively
more common in Europe, Australia, Latin America, and Asia.213-215 As resistance to the
currently available antifungal agents is emerging in many of these non-albicans Candida,
there is a need for developing novel antifungals.216

Most of the current drugs on the market are either highly toxic (e.g., amphotericin B
(AmB)) or becoming ineffective due to appearance of resistant fungal strains (e.g., azoles
such as fluconazole (FLC) and voriconazole (VRC)) (Figure 4.1).217 Azoles are the most
frequent class of antifungals used to treat fungal infections as they are inexpensive and are
available for oral administration.218 However, there is an extensive documentation of
intrinsic and developed resistance to azole drugs among C. albicans and non-albicans
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Candida species. As the frequency of occurrence of infections caused by non-albicans
Candida species is increasing in clinical settings, there is currently a need to improve on
the existing azole scaffolds to develop novel antifungals. Various studies were reported by
our and other groups, which illustrated the role of alkylation on different drug scaffolds
resulting in promising antifungal activity.198, 199, 219-223 There are examples of 2,4-difuoro2-(1H-1,2,4-triazo-1-yl)acetophenone analogues with linear C5-C8 alkyl chains221 and of
an n-alkylated ebsulfur derivative with a linear C5 alkyl chain, which displayed strong
antifungal activity.198 Similarly, examples of aminoglycosides (e.g., kanamycin B (KANB)
and tobramycin (TOB)) with linear alkyl chains with 12 and 14 carbons (C12 and C14)
displaying antifungal activity were also reported.199, 219

Figure 4.1. Structures of all antifungal agents used as controls in this study.

197

Based on the information provided above and the promise shown by these small molecules,
herein, we decided to generate novel FLC derivatives in which the triazole ring on the
carbon alpha to the dihalophenyl ring of FLC was displaced by various linear alkyl-, aryl, dialkyl-, and cycloalkyl-amino substituents. We report the synthesis of twelve novel FLC
derivatives (Figure 4.2) and their antifungal activity against a variety of C. albicans, nonalbicans Candida, Aspergillus, and Cryptococcus strains as established by in vitro MIC
determination as well as by time-kill studies. We explore the hemolytic activity as well as
cytotoxicity of these compounds against murine erythrocytes and mammalian cell lines,
respectively. Finally, we investigate the potential mechanism of action of selected
compounds by probing their ability to disrupt fungal membrane.
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Figure 4.2. Synthetic schemes for the preparation of A. amine derivative 3, and B. novel azole analogues 516.

4.3. Results and discussion
4.3.1. Design and synthesis of antifungal agents 5-16
We synthesized the alkyl-/aryl- and cycloalkyl-amino FLC derivatives 5-16 in two steps
by using the commercially available fluorinated compound 2,4-difuoro-2-(1H-1,2,4-triazo1-yl)acetophenone as a starting material (Figure 4.2B). We first converted the carbonyl
group of 2,4-difuoro-2-(1H-1,2,4-triazo-1-yl)acetophenone to an epoxide by using
trimethylsulfoxonium iodide in the presence of a strong base and a surfactant to yield the
oxirane intermediate 4, which we then reacted with various amines (all commercially
available, with the exception of amine 3 used in the synthesis of derivative 12) under mild
basic conditions to afford derivatives 5-16. The amine 3 used for the synthesis of derivative
12 was prepared in three steps (Figure 4.2A). The amino group of 6-aminohexanol was
protected with Boc to yield compound 1, which was then subjected to nucleophilic
substitution reaction with 1-iodopentane. The deprotection of the Boc group of
intermediate 2 yielded the desired amine 3.

4.3.2. Antifungal activity and structure-activity relationship (SAR) analysis
We first evaluated the antifungal activity of the newly prepared FLC derivatives 5-16
against a panel of seven C. albicans (ATCC 10231 (A), ATCC 64124(R) (B), ATCC
MYA-2876(S) (C), ATCC 90819(R) (D), ATCC MYA-2310(S) (E), ATCC MYA1237(R) (F), and ATCC MYA-1003(R) (G)), three non-albicans Candida (C. glabrata
ATCC 2001 (H), C. krusei ATCC 6258 (I), and C. parapsilosis ATCC 22019 (J)), and
three Aspergillus (A. flavus ATCC MYA-3631 (K), A. nidulans ATCC 38163 (L), and A.
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terreus ATCC MYA-3633 (M)) strains using a concentration range of 0.03-31.3 µg/mL
(Tables 4.1 and 4.4). We used the commercially available antifungal agents such as AmB,
caspofungin (CAS), FLC, and VRC as positive controls for comparison. For derivatives 516 as well as the reference drugs AmB and CAS, we reported MIC-0 values, which
correspond to no visible growth. We reported MIC-2 values (i.e., 50% growth inhibition)
for FLC and VRC against all fungal strains tested with the exception of strain A by VRC.
We defined antifungal activity as excellent (0.03-1.95 µg/mL), good (3.9 µg/mL),
moderate (7.8-15.6 µg/mL), or poor (≥31.3 µg/mL) based on MIC values. In this
manuscript, we performed all activity comparisons by using the MIC values reported in
µg/mL (Note: the corresponding MIC values are also provided in µM into parentheses in
Tables 4.1, 4.2, 4.4, and 4.5).

Table 4.1: MIC valuesa (in µg/mL) (the corresponding values in µM are provided in Table
4.4) determined for compounds 5-16 and for four control antifungal agents (AmB, CAS,
FLC, and VRC) against various yeast strains and filamentous fungi. Each experiment was
performed in triplicate.
Yeast strains
Filamentous fungi
Cpd # A
B
C
D
E
F
G
H
I
J
K
L
M
5
7.8
>31.3 15.6
31.3
31.3
>31.3 31.3
15.6
7.8
0.975
>31.3 >31.3 >31.3
6
0.975
>31.3 31.3
7.8
31.3
15.6
31.3
7.8
0.975
0.06
>31.3 1.95
15.6
7
0.48
15.6
3.9
3.9
7.8
7.8
7.8
0.975
0.48
0.03
7.8
0.975
3.9
8
0.975
15.6
3.9
1.95
15.6
7.8
15.6
0.975
0.975
0.48
7.8
1.95
3.9
9
1.95
>31.3 >31.3 7.8
31.3
>31.3 31.3
0.975
3.9
0.48
>31.3 3.9
7.8
10
>31.3 >31.3 31.3
31.3
3.9-31.3 >31.3 >31.3 0.975
3.9
0.48
>31.3 3.9
>31.3
11
>31.3 >31.3 31.3
31.3
>31.3
>31.3 >31.3 >31.3 >31.3 >31.3 >31.3 >31.3 >31.3
12
3.9
>31.3 31.3
3.9
15.6
3.9
7.8
15.6
1.95
0.24
>31.3 7.8
31.3
13
>31.3 >31.3 >31.3 >31.3 >31.3
>31.3 >31.3 >31.3 >31.3 31.3
>31.3 >31.3 >31.3
14
31.3
>31.3 31.3
31.3
>31.3
31.3
>31.3 31.3
31.3
0.975
>31.3 15.6
>31.3
15
31.3
31.3
>31.3 31.3
3.9-31.3 31.3
>31.3 31.3
31.3
3.9
31.3
>31.3 >31.3
16
>31.3 >31.3 >31.3 31.3
31.3
31.3
31.3
7.8
>31.3 7.8
31.3
7.8
15.6
AmB
3.9
3.9
1.95
0.975
1.95
3.9
3.9
1.95
3.9
1.95
15.6
3.9
3.9
CAS
0.975
0.24
0.06
0.12
0.12
0.24
0.48
0.06
0.48
1.95
>31.3 >31.3 >31.3
FLC
62.5
>125
15.6
>125
>125
62.5
62.5
>31.3 >31.3 1.95
62.5
62.5
62.5
VRC
0.24
3.9
1.95
1.95
0.975
7.8
1.95
0.06
0.12
<0.03 0.24
0.12
0.12
Yeast strains: A = Candida albicans ATCC 10231, B = C. albicans ATCC 64124, C = C. albicans ATCC MYA-2876(S), D = C.
albicans ATCC 90819(R), E = C. albicans ATCC MYA-2310(S), F = C. albicans ATCC MYA-1237(R), G = C. albicans ATCC
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Table 4.1 continued
MYA-1003(R), H = Candida glabrata ATCC 2001, I = Candida krusei ATCC 6258, J = Candida parapsilosis ATCC 22019. NOTE:
Here, the (S) and (R) indicate that ATCC reports these strains to be susceptible (S) and resistant (R) to ITC and FLC.
Filamentous fungi: K = Aspergillus flavus ATCC MYA-3631, L = Aspergillus nidulans ATCC 38163, M = Aspergillus terreus ATCC
MYA-3633.
Known antifungal agents: AmB = amphotericin B, CAS = caspofungin, FLC = fluconazole, VRC = voriconazole.
a
For yeast strains: MIC-0 values are reported for FLC analogues 5-16, AmB, and CAS, whereas MIC-2 values are reported for azoles.
For filamentous fungi, MIC-0 values are reported for all compounds.

By a survey of the data reported in Table 4.1, the following observations could rapidly be
made. The introduction of a side-chain comprising (i) a terminal hydroxyl group as in
compound 11, (ii) a dialkyl-amino moiety as in derivatives 13 and 14, (iii) a cycloalkylamino group as in compound 15, and (iv) an aryl-amino functionality as in compound 16,
resulted in all cases in molecules that were generally poor antifungals. A few exceptions
were noted: compounds 14 and 15 displayed excellent (0.975 µg/mL) and good (3.9
µg/mL) activity against the C. parapsilosis strain J. In contrary, we found that monoalkylation resulted in much better antifungals. For derivatives 5-10, we generally observed
better activity against non-albicans Candida and Aspergillus strains than against C.
albicans. More specifically, when exploring the data for strains H-M, we found that
compounds 7 and 8 displayed excellent (0.03-1.95 µg/mL) activity against the nonalbicans Candida strains H, I, and J, as well as against the Aspergillus strain L.
Additionally, both compounds 7 and 8 exhibited moderate (7.8 µg/mL) and good (3.9
µg/mL) activity against the Aspergillus strains K and M, respectively. Compounds 5, 6, 9,
and 10, displayed excellent activity (0.06-1.95 µg/mL) against strains J, (I, J and L), (H
and J), and (H and J), respectively. Compounds 5, 6, and 9 displayed moderate activity
(7.8-15.6 µg/mL) against strains (H and I), (H and M), and M, respectively. In addition,
derivatives 9 and 10 showed good (3.9 µg/mL) activity against strains I and L. When
assessing the data for the C. albicans strains A-G, we found that compounds 6-9 exhibited
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excellent activity (0.48-1.95 µg/mL) against strain A. We also observed that derivatives 7
and 8 generally displayed good to moderate (3.9-15.6 µg/mL) activity against strains B-G,
with the exception of compound 8 displaying excellent (1.95 µg/mL) activity against strain
D. In addition, compounds 7 and 8 displayed excellent to good antifungal activity against
most strains tested and derivative 9 displayed strong activity against non-albicans Candida
and Aspergillus strains. These data indicated that the optimal chain lengths for maximal
antifungal activity were C10 and C12, and the general trend for activity versus chain length
was C10 > C12 > C8 > C14 > C16 = C6. Finally, we observed that replacing one of the carbon
atom in the side-chain by an oxygen as in compound 12 was detrimental as its activity
against all strains was generally lower (higher MIC values) than that of its counterpart 8.

Having established that derivatives 5-16 displayed excellent antifungal activity against
non-albicans Candida strains, we further evaluated these compounds against three clinical
strains of C. glabrata (CG1, CG2, and CG3) and C. parapsilosis (CP1, CP2, and CP3),
as well as three Cryptococcus neoformans (CN1, CN2, and CN3) clinical isolates (Table
4.2). The trends observed in Table 4.2 correlated perfectly to those described for the data
presented in Table 4.1. Compounds 11 and 13 were inactive against all nine clinical isolates
tested, whereas compounds 14-16 exhibited excellent to good (0.975-3.9 µg/mL) activity
against C. parapsilosis CP1, CP2, and CP3. For derivatives 5-10, we generally observed
excellent activity against most C. glabrata, C. parapsilosis, and C. neoformans clinical
isolates. More precisely, we found that compound 8 displayed excellent (0.06-1.95 µg/mL)
activity against all clinical isolates tested. Compounds 7, 9, and 10 displayed excellent
(0.03-1.95 µg/mL) activity against all isolates, with the exception of C. glabrata CG3. In
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addition, compound 6 displayed excellent (0.12-1.95 µg/mL) activity against CG2, CP1,
CP2, CP3, and CN1, whereas compound 5 was found to display excellent (0.975 µg/mL)
activity against C. parapsilosis CP1, CP2, and CP3 isolates. Overall, compounds 6-10
displayed better activity against the clinical isolates presented in Table 4.2 than they did
against the commercially available strains for which the data are presented in Table 4.1. In
general, we found that the three most active compounds synthesized (based on the data
from Tables 4.1 and 4.2), 7-9, displayed better activity than FLC and similar or better
activity than AmB against most of the fungal strains tested, as well as better activity than
CAS against the three Aspergillus strains tested. When examining the data obtained with
clinical isolates of C. glabrata, C. parapsilosis, and C. neoformans (Table 4.2), we
observed that compounds 7-9 displayed similar or better activity than both CAS and FLC.
When comparing compounds 7-9 to VRC, we found them to display stronger activity
against some of the clinical strains tested.

Table 4.2: MIC valuesa (in µg/mL) (the corresponding values in µM are provided in Table
4.5) determined for compounds 5-16 and for two control antifungal agents (FLC and VRC)
against various non-albicans Candida and Cryptococcus neoformans clinical isolates. Each
experiment was performed in triplicate.
Cpd #
5
6
7
8
9
10
11
12
13
14
15
16

H
7.8
0.975
0.48
0.975
1.95
>31.3
>31.3
3.9
>31.3
31.3
31.3
>31.3

CG1
31.3
7.8
1.95
1.95
1.95
1.95
>31.3
15.6
>31.3
15.6
31.3
7.8

CG2
7.8
0.975
0.48
0.975
1.95
0.975
>31.3
1.95
>31.3
7.8
15.6
7.8

CG3
31.3
15.6
3.9
1.95
3.9
7.8
>31.3
31.3
>31.3
31.3
31.3
7.8

J
0.975
0.06
0.03
0.48
0.48
0.48
>31.3
0.24
31.3
0.975
3.9
7.8

Yeast strains
CP1
CP2
0.975
0.975
0.48
0.12
0.06
0.12
0.06
0.24
0.48
0.975
0.975
0.48
31.3
31.3
0.12
0.12
>31.3
>31.3
0.975
1.95
0.975
0.975
3.9
3.9
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CP3
0.975
0.24
0.24
0.12
0.48
0.975
31.3
0.12
>31.3
1.95
1.95
3.9

CN1
7.8
1.95
0.24
0.24
0.12
0.48
>31.3
0.48
>31.3
>31.3
7.8
7.8

CN2
>31.3
3.9
0.24
0.24
0.24
0.48
>31.3
1.95
>31.3
>31.3
>31.3
31.3

CN3
31.3
3.9
0.48
0.48
0.48
0.48
>31.3
1.95
15.6
>31.3
15.6
>31.3

Table 4.2 continued
CAS
0.06
1.95
0.24
0.975
1.95
0.48
0.48
0.48
15.6
31.3
15.6
FLC
62.5
>31.3
>31.3
>31.3
1.95
0.975
0.975
0.975
7.8
>31.3
>31.3
VRC
0.24
0.975
3.9
>31.3
<0.03
<0.03
<0.03
<0.03
0.24
0.975
0.12
Yeast strains: H = Candida glabrata ATCC 2001, CG1-CG3 = C. glabrata clinical isolates, J = Candida parapsilosis ATCC 22019,
CP1-CP3 = C. parapsilosis clinical isolates, CN1-CN3 = Cryptococcus neoformans clinical isolates.
Known antifungal agents: CAS = caspofungin, FLC = fluconazole, VRC = voriconazole.
a
For these yeast strains: MIC-0 values are reported for FLC analogues 5-16, whereas MIC-2 values are reported for azoles.

The antifungals currently on the market are known to bind to proteins and be less efficient
in intracellular matrices. For this reason, we tested the three best compounds, 7-9, against
three representative strains, the C. albicans A, the non-albicans Candida (C. parapsilosis)
J, and the Aspergillus L, in presence and absence of fetal bovine serum (FBS) (Table 4.3).
We found that the alkyl-amino azole analogue 7 retained its full antifungal activity (only 1
double dilution difference in some cases) against all three strains tested in the presence of
FBS. Compound 8 retained its full activity against strain J and experienced a 2- and 4-fold
decrease in activity in the presence of FBS against strains A and L, respectively.
Compound 9 displayed a 2- to 8-fold decrease in activity against the strains tested. Even
though there was a small loss in activity in some instances, analogues 7-9 still remained
good antifungal with the exception of compound 9 against strain L.

Table 4.3: MIC valuesa (in µg/mL) determined for compounds 7-9 and for two control
antifungal agents (AmB and VRC) against various yeast strains and filamentous fungi in
the absence or presence of FBS. Each experiment was performed in triplicate.
Cpd #

7
8
9
AmB
VRC

Candida
albicans ATCC
10231 (A) (no
FBS)
0.48
0.975
1.95
3.9
0.48

Yeast strains
Filamentous fungi
Candida
Candida
Candida
Aspergillus nidulans Aspergillus
nidulans
albicans ATCC parapsilosis
parapsilosis ATCC ATCC 38163 (L) (no ATCC 38163 (L) (+10%
10231
(A) ATCC 22019 (J) 22019 (J) (+10% FBS)
FBS)
(+10% FBS)
(no FBS)
FBS)
0.48
0.03
0.06
0.975
1.95
1.95
0.48
0.24
1.95
7.8
7.8
0.48
0.975
3.9
31.2
7.8
1.95
15.6
3.9
15.6
0.48
0.015
0.015
0.12
0.12
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4.3.3. Time-kill studies
The information regarding the rate and extend of fungicidal activity can be gathered by
time-kill assays. To determine the fungistatic or fungicidal nature of the compounds
generated, we performed time-kill assays over a 24-h period with one of the best FLC
derivatives, compound 7, and one of the good ones, compound 6. These compounds and
VRC (positive control) were tested against fungal strains C. albicans ATCC 10231 (A) and
C. parapsilosis ATCC 22019 (J) (Figure 4.3). At 4× their respective MIC values, when
tested against strain A, compounds 6 and 7 were found to be fungistatic and to be better
than the control drug VRC. When tested against strain J, both compounds also displayed
fungistatic activity at up to 4× their MIC values. However, against strain J, compound 6
displayed lower reduction in fungal growth than VRC, but compound 7 displayed activity
equal to VRC. Overall, the compounds 6 and 7 performed better in time-kill studies than
the control drug VRC.
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Figure 4.3. Representative time-kill curves for compounds 6 and 7 against C. albicans ATCC 10231 (strain
A; panels A and C, respectively) and C. parapsilosis ATCC 22019 (strain J; panels B and D, respectively).
Fungal strains were treated with no drug (black circles), 1× MIC (white circles), 2× MIC (inverted black
triangles), or 4× MIC (white triangles) of compounds 6 or 7, or with 4× MIC (black squares) of VRC
(previously published as VOR). The experiments were performed in duplicate.

4.3.4. Hemolysis assay
The promising antifungal activity shown by the synthetic analogues demanded further
safety analysis for these compounds. We tested compounds 6-10 for their hemolytic
activity against murine red blood cells (mRBCs) (Figure 4.4 and Table 4.6). Compounds 6
(C8) and 7 (C10) displayed <10% and <40% hemolysis at concentrations of 31.3 µg/mL (1to 512-fold of its overall MIC values) and 15.6 µg/mL (1- to 512-fold of its overall MIC
values), respectively. Similarly, compound 8 (C12) induced only 21% lysis at 7.8 µg/mL
(1- to 218-fold of its overall MIC values). In addition, compounds 9 (C14) and 10 (C16)
displayed <50% and <10% hemolysis at concentrations of 31.3 µg/mL (1- to 256-fold of
its overall MIC values) and 62.5 µg/mL (2- to 128-fold of its overall MIC values),
respectively. By comparing the hemolysis of compounds 6-10 with their corresponding
MIC values against the non-albicans Candida, A. nidulans, and C. neoformans strains
tested, we concluded that all of these compounds displayed minimal hemolytic activity.
Overall, compounds 6 and 10 displayed the lowest hemolytic activity. Importantly, some
of the newly synthesized compounds displayed less hemolytic effect than the FDAapproved control drug VRC.
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Figure 4.4. 3D bar graph depicting the dose-dependent hemolytic activity of azole derivatives 6-10 and VRC
(previously published as VOR) against mRBCs, which were treated and incubated for 1 h at 37 °C with each
compound tested at concentrations ranging from 0.48-62.5 µg/mL. Triton X-100® (1% v/v) was used as a
positive control (100% hemolysis, not shown).

4.3.5. In vitro cytotoxicity assay
Another crucial parameter to consider when developing antifungal drugs is their selectivity
for fungal over mammalian cells. We tested our active compounds 6-10 against three
different cell lines, HEK-293, BEAS-2B, and A549, along with the FDA-approved
antifungal agent VRC as a positive control (Figure 4.5). Against HEK-293, compounds 6,
7, and 10 exhibited no toxicity up to 31 µg/mL (1- to 512-fold of its overall MIC values),
7.8 µg/mL (1- to 256-fold of its overall MIC values), and 7.8 µg/mL (1- to 16-fold of its
overall MIC values), respectively. However, compounds 8 and 9 exhibited some toxicity
(>50% cell survival) at a concentration of 3.9 µg/mL (1- to 64-fold of its overall MIC
values) against HEK-293. Interestingly, compounds 8-10 were non-toxic to both BEAS2B and A549 at up to 7.8 µg/mL (1- to 128-fold of its overall MIC values). In the case of
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compound 6, no toxicity was observed against BEAS-2B (at 31 µg/mL) (1- to 512-fold of
its overall MIC values) and A549 (at 15.5 µg/mL) (1- to 256-fold of its overall MIC
values). With compound 10 we basically observed no toxicity against BEAS-2B and A549
at 7.8 µg/mL (1- to 16-fold of its overall MIC values). A general trend of greater toxicity
with respect to longer chain substitution was observed against the three cell lines.
Compounds 6 and 7 exhibited better overall safety profiles than compounds 8-10. When
considering the very low MIC values for these analogues against clinical isolates, these
cytotoxicity data provide us with a reasonable therapeutic window.
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Figure 4.5. Representative cytotoxicity assays of compounds 6-10 against three mammalian cell lines: A.
HEK-293, B. BEAS-2B, and C. A549. Cells were treated with various concentrations of compounds 6
(yellow), 7 (orange), 8 (turquoise), 9 (blue), 10 (pink), and VRC (previously published as VOR, purple). The
positive control consisted of cells treated with Triton X-100® (TX, 20% v/v, pink). The negative control
consisted of cells treated with DMSO (no drug, green). The experiments were performed in duplicate.

4.3.6. Membrane permeabilization assay
Some amphiphilic molecules have been shown to cause membrane disruption and fungal
cell death. Therefore, we decided to study the potential effect of compounds 8 and 9 with
C12 and C14 linear alkyl chains to determine the impact of chain length on membrane
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disruption (Figure 4.6). The control drug VRC and the KANB (C14) derivative with a 14carbon linear alkyl chain, were used as negative and positive controls, respectively. The
propidium iodide (PI) dye was used as a probe as it can only enter cells with compromised
membrane and bind to nucleic acid to emit fluorescence, which can be observed under a
fluorescence microscope. At 4× MIC, the positive control KANB (C14) significantly
increased PI dye uptake by C. albicans ATCC 10231 (strain A), whereas the negative
control VRC (at 4× MIC) did not allow for PI uptake by fungal cells. Compound 8 with a
C12 linear alkyl chain (at 4× MIC) induced cellular uptake of PI dye into C. albicans ATCC
10231 (strain A), whereas compound 9 (with a C14 linear alkyl chain) did not cause cell
membrane disruption. Interestingly, the chain length played a crucial role on membrane
disruption of C. albicans ATCC 10231 (strain A), surprisingly with C12 being more
membrane disrupting than C14. In order to completely understand the effect of chain length
on membrane disruption, we additionally performed membrane permeabilization with
compounds 5, 6, and 7 (C6 -C10 linear alkyl chains) at 4× MIC. None of these compounds
induced cellular uptake of the PI drug. From this study, we can conclude that one of the
possible mechanisms of action for compound 8 is membrane disruption. Interestingly, any
other linear chains beside the C12 displayed no membrane disruption.

210

Figure 4.6. Effect of the controls VRC (previously published as VOR, negative) and KANB (C14) (positive)
as well as compounds 5-9 on the cell membrane integrity of C. albicans ATCC 10231 (strain A). For the
three columns on the left from top to bottom: Propidium iodide (PI) dye uptake by yeast cells without drug,
with VRC (0.975 µg/mL), KANB (C14) (31.3 µg/mL), and compound 8 (1×, 2×, and 4× MIC). For the three
columns on the right from top to bottom: Propidium iodide (PI) dye uptake by yeast cells with compound 9
(1×, 2×, and 4× MIC), as well as compound 5, 6, and 7 at 4× MIC. The experiments were performed in
duplicate.

4.3.7. Sterol profile by GC-MS
Since out of our compounds displaying antifungal activity only compound 8 caused
membrane disruption of C. albicans ATCC 10231 (strain A) in the membrane
permeabilization assay (section 4.3.6), we decided to explore by using gas
chromatography-mass spectrometry (GC-MS) the effect of compounds 8 and 9 on sterol
composition during ergosterol biosynthesis (the mechanism of action of other conventional
azoles) (Figure 4.7). We evaluated the effect of the compounds 8 and 9 on sterol
composition in C. albicans ATCC 10231 (strain A) at sub-MIC levels of 0.48 µg/mL
(Figure 4.7D) and 0.975 µg/mL (Figure 4.7E), respectively. We also used VRC at 0.12
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µg/mL and no drug control for comparison (Figure 4.7B and 4.7A, respectively). In the
absence of drug, strain A accumulated 100% ergosterol (2), suggesting that the sterol
biosynthesis was fully functional in this fungal strain. When treating strain A with VRC,
we detected a lower amount of ergosterol (2, 50.80%), and an increased amount of
lanosterol (1, 15.21%) and eburicol (3, 1.73%). However, when strain A was treated with
compound 8, we observed a relatively low amount of ergosterol (2, 36.62%) compared to
VRC, but observed lower amounts of lanosterol (1, 10.03%), eburicol (3, 0.57%), and the
fungistatic metabolite 14α-methyl ergosta-8,24(28)-diene-3β,6α-diol (4, 4.69%) with
respect to VRC. Interestingly, when strain A was treated with compound 9, we observed
similar reduction in the amount of ergosterol (2, 36.43%) along with a related increase in
lanosterol (1, 15.56%), eburicol (3, 1.16%) and the fungistatic metabolite 14α-methyl
ergosta-8,24(28)-diene-3β,6α-diol (4, 15.56%). From these experiments, we can conclude
that our compounds inhibit ergosterol biosynthesis similarly to the azole drug control VRC.
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Figure 4.7. A. A simplified ergosterol biosynthetic pathway and products resulting from inhibition of
ERG11. B-E. GC-MS chromatograms of the sterols extracted from untreated and antifungal-treated C.
albicans ATCC 10231 (strain A). The fungal strain treated with DMSO (no drug control, panel B), VRC
(previously published as VOR) at 0.12 µg/mL (panel C), compound 8 at 0.48 µg/mL (panel D), and
compound 9 at 0.975 µg/mL (panel E). The peaks in these chromatograms are for lanosterol (1), ergosterol
(2), eburicol (3), 14α-methyl ergosta-8,24(28)-dien-3β,6α-diol (4). F. A table summarizing the percentage
of each sterol from panels B-E.

4.4. CONCLUSIONS
In summary, we have synthesized novel FLC derivatives in which the triazole ring on the
carbon alpha to the dihalophenyl ring of FLC was displaced by various linear alkyl-, aryl, dialkyl-, and cycloalkyl-amino substituents. We did not detect any antifungal activity with
the aryl- and cycloalkyl-amino substituted FLC analogues. We observed that the antifungal
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activity of the alkyl-amino FLC derivatives depends on the length of the alkyl chains.
Compounds 6-9 were identified as promising antifungal agents with low hemolytic activity
and low cytotoxicity. These analogues displayed great activity against some of the C.
albicans, non-albicans Candida, and Aspergillus strains, and, in addition they were
particularly excellent against the clinical strains of C. glabrata, C. parapsilosis, as well as
C. neoformans tested. These compounds also exhibited superior activity against the clinical
strains when compared to the control drugs CAS, FLC, and VRC. The possible mechanism
of action for these FLC analogues was identified as membrane disruption with compound
8 with a C12 alkyl chain being more membrane disrupting than compound 9 with a C14 alkyl
chain. Additionally, they were found to inhibit ergosterol biosynthesis. In the future,
outside of the scope of this work, it will be interesting to see how these promising
molecules will fair in the drug development process.

4.5. EXPERIMENTAL SECTION
4.5.1. Chemistry
4.5.1.1. Materials and instrumentation
All the chemicals used in this study (including compounds 1 and 9) were purchased from
Sigma-Aldrich (St. Louis, MO) or AK Scientific (Union City, CA) and used without any
further purification. DMF and THF were freshly distilled prior to use. Chemical reactions
were monitored by TLC (Merck, Silica gel 60 F254). Visualization was achieved using one
of the following methods: Iodine stain (I2 in SiO2 gel) or UV light. Compounds were
purified by SiO2 flash chromatography (Dynamic Adsorbents Inc., Flash SiO2 gel 32-63µ).
1

H and 13C NMR spectra were recorded on a Varian 400 MHz spectrometer. Mass spectra
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were recorded using an Agilent 1200 series Quaternary LC system equipped with a diode
array detector, and Eclipse XDB-C18 column (250 mm × 4.6 mm, 5 µm), and an Agilent
6120 Quadrupole MSD mass spectrometer. For compounds 1 and 2 [M-Boc+H]+ are
reported, which correspond to the mass of the molecules that have lost their Boc protecting
group during the mass spectrometry experiments. All reactions were carried out under
nitrogen atmosphere and all yields reported represent isolated yields. Known compounds
were characterized by 1H NMR and are in complete agreement with samples reported in
the literature.

4.5.1.2. Experimental protocols for the preparation of compounds 1-16
Synthesis of compound 1. To a solution of 6-amino-1-hexanol
(700 mg, 5.97 mmol) in CH2Cl2 (8 mL), di-tert-butyldicarbonate
(1.95 g, 8.96 mmol) and Et3N (1.2 mL, 8.96 mmol) were added. The reaction mixture was
stirred at room temperature for 12 h and progress of the reaction was monitored by TLC
(1:19/MeOH:CH2Cl2, Rf 0.45). The organic layer was removed under reduced pressure and
the residue was purified by column chromatography (SiO2, 1:19/MeOH:CH2Cl2) to afford
compound 1 (1.02 g, 79%) as a colorless liquid: 1H NMR (400 MHz, CD3OD, Figure C1)
δ 3.52 (t, J = 6.6 Hz, 2H), 3.00 (t, J = 7.0 Hz, 2H), 1.58-1.46 (m, 2H), 1.44-1.42 (m, 2H),
1.41 (s, 9H), 1.38-1.26 (m, 4H); 13C NMR (100 MHz, CD3OD, Figure C2) δ 157.1, 78.3,
61.4, 39.9, 32.1, 29.5, 27.4, 26.2, 25.2; LRMS m/z calcd for C11H23NO3: 217.2; found 117.2
[M-Boc+H]+.
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Synthesis of compound 2. A solution of compound 1 (500
mg, 2.30 mmol) in DMF (5 mL) was cooled to 0 °C
followed by the addition of sodium hydride (72 mg, 2.99 mmol) and 1-iodopentane (0.4
mL, 2.99 mmol). The reaction mixture was stirred at room temperature for 24 h and
progress of the reaction was monitored by TLC (1:19/EtOAc:Hexanes, Rf 0.65). The
reaction mixture was quenched with H2O (20 mL) and extracted with EtOAc (60 mL). The
organic layer was washed with H2O (60 mL) and brine (20 mL), and dried over MgSO4.
The organic layer was removed under reduced pressure and the residue was purified by
column chromatography (SiO2, 1:19/EtOAc:Hexanes) to afford compound 2 (241 mg,
36%) as a colorless liquid: 1H NMR (400 MHz, CD3OD, Figure C3) δ 3.39 (td, J1 = 6.6
Hz, J2= 1.8 Hz, 4H), 3.00 (t, J = 7.0 Hz, 2H), 1.56-1.50 (m, 4H), 1.46-1.42 (m, 2H), 1.41
(s, 9H), 1.38-1.26 (m, 8H), 0.90 (m, 3H);

13

C NMR (100 MHz, CD3OD, Figure C4) δ

157.1, 78.3, 70.5, 70.4, 39.9, 29.5, 29.3, 29.0, 28.1, 27.4, 26.3, 25.5, 22.1, 13.0; LRMS m/z
calcd for C16H33NO3: 287.3; found 187.2 [M-Boc+H]+.

Synthesis of compound 3. To a solution of compound 2 (200
mg, 0.69 mmol) in CH2Cl2 (2 mL), trifluoroacetic acid (1.5 mL) was added. The reaction
mixture was stirred at room temperature for 2 h and progress of the reaction was monitored
by TLC (1:19/MeOH:CH2Cl2, Rf 0.25). The organic layer was removed under reduced
pressure to afford compound 3 (118 mg, 90%) as a colorless liquid: 1H NMR (400 MHz,
CD3OD, Figure C5) δ 3.40 (q, J = 6.4 Hz, 4H), 2.89 (t, J = 7.7 Hz, 2H), 1.65-1.61 (m, 2H),
1.59-1.50 (m, 4H), 1.40 (p, J = 3.7 Hz, 4H), 1.31 (p, J = 3.7 Hz, 4H), 0.90 (m, 3H); 13C
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NMR (100 MHz, CD3OD, Figure C6) δ 70.5, 70.2, 39.2, 29.0 (2C), 28.1, 27.1, 25.8, 25.3,
22.1, 12.9; LRMS m/z calcd for C11H25NO: 187.2; found 188.2 [M+H]+.

Synthesis of compound 4. To a solution of 2,4-difuoro-2-(1H-1,2,4triazo-1-yl)acetophenone (1 g, 4.48 mmol) in toluene (10 mL),
trimethylsulfoxonium iodide (1.08 g, 4.93 mmol), hexadecyltrimethylammonium bromide
(163 mg, 0.45 mmol) and 1.5 mL 20% (v/v) sodium hydroxide was added. The reaction
mixture was stirred at 60 °C for 1 h and progress of the reaction was monitored by TLC
(3:2/EtOAc:Hexanes, Rf 0.35). The reaction mixture was diluted with EtOAc (20 mL) and
washed with H2O (20 mL). The organic layer was removed under reduced pressure and the
residue was purified by flash column chromatography (SiO2, 3:2/EtOAc:Hexanes) to
afford compound (720 mg, 68%) as a yellow gummy liquid: 1H NMR (400 MHz, CDCl3,
Figure C7) δ 8.08 (s, 1H), 7.86 (s, 1H), 7.20-7.11 (m, 1H), 6.86-6.75 (m, 2H), 4.82 (d, J =
14.8 Hz, 1H), 4.49 (d, J = 14.8 Hz, 1H), 2.93 (d, J = 4.6 Hz, 1H), 2.87 (d, J = 4.6 Hz, 1H);
13

C NMR (100 MHz, CDCl3, Figure C8) δ 164.4, 164.3, 161.9, 161.8, 161.7, 159.4, 159.2,

151.8, 144.1, 129.64, 129.59, 129.55, 129.49, 111.90, 111.87, 111.69, 111.65, 104.3,
104.1, 103.8, 56.3, 53.59, 53.55, 52.2; LRMS m/z calcd for C11H9F2N3O: 237.1; found
238.1 [M+H]+.

Synthesis of compound 5. To a solution of compound 4 (50 mg, 0.21
mmol) in EtOH (3 mL), hexylamine (0.07 mL, 0.32 mmol) and Et3N
(0.04 mL, 0.32 mmol) were added. The reaction mixture was stirred at
80 °C for 12 h and progress of the reaction was monitored by TLC (3:2/EtOAc:Hexanes,
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Rf 0.09). The organic layer was removed under reduced pressure and the residue was
purified by column chromatography (SiO2, 3:2/EtOAc:Hexanes) to afford compound 5 (11
mg, 14%) as a colorless liquid: 1H NMR (400 MHz, CDCl3, Figure C9) δ 8.10 (s, 1H), 7.81
(s, 1H), 7.60-7.46 (m, 1H), 6.85-6.75 (m, 2H), 4.65 (d, J = 14.2 Hz, 1H), 4.52 (d, J = 14.2
Hz, 1H), 3.20 (d, J = 12.6 Hz, 1H), 3.00 (d, J = 12.6 Hz, 1H), 2.56 (t, J = 7.2 Hz, 2H), 1.421.38 (p, J = 7.6 Hz, 2H), 1.28-1.16 (m, 6H), 0.85 (t, J = 6.8 Hz, 3H); 13C NMR (100 MHz,
CDCl3, Figure C10) δ 166.5, 164.1, 153.2, 153.1, 151.8, 151.4, 144.5, 124.93, 124.92,
124.0, 123.9, 110.0, 104.1, 103.8, 95.6, 95.4, 78.1, 63.4, 56.0, 49.8, 47.9, 31.5, 31.4, 29.7,
26.8, 26.7, 26.5, 22.6, 22.5, 14.1, 14.0, 13.9; LRMS m/z calcd for C17H24F2N4O: 338.2;
found 338.3 [M+H]+.

Synthesis of compound 6. To a solution of compound 4 (80 mg, 0.33
mmol) in EtOH (3 mL), n-octylamine (0.12 mL, 0.51 mmol) and Et3N
(0.07 mL, 0.51 mmol) were added. The reaction mixture was stirred at
80 °C for 12 h and progress of the reaction was monitored by TLC (3:2/EtOAc:Hexanes,
Rf 0.20). The organic layer was removed under reduced pressure and the residue was
purified by flash column chromatography (SiO2, 3:2/EtOAc:Hexanes) to afford compound
6 (85 mg, 70%) as a colorless liquid: 1H NMR (400 MHz, CDCl3, Figure C11) δ 8.10 (s,
1H), 7.81 (s, 1H), 7.60-7.49 (m, 1H), 6.85-6.75 (m, 2H), 4.63 (d, J = 14.3 Hz, 1H), 4.51
(d, J = 14.3 Hz, 1H), 3.18 (d, J = 12.6 Hz, 1H), 2.95 (d, J = 12.6 Hz, 1H), 2.52 (t, J = 7.2
Hz, 2H), 1.42-1.36 (m, 2H), 1.29-1.18 (m, 10H), 0.85 (t, J = 6.6 Hz, 3H); 13C NMR (100
MHz, CDCl3, Figure C12) δ 164.0, 163.9, 161.6, 161.4, 160.2, 160.1, 157.8, 157.7, 151.3,
144.7, 129.9, 129.83, 129.79, 129.7, 124.99, 124.86, 111.7, 111.6, 111.44, 111.41, 104.5,
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104.22, 104.20, 104.0, 73.0, 72.9, 56.1, 56.0, 54.13, 54.09, 50.0, 31.7, 29.5, 29.3, 29.1,
26.9, 22.6, 14.1; LRMS m/z calcd for C19H28F2N4O: 366.2; found 367.2 [M+H]+.

Synthesis of compound 7. To a solution of compound 4 (50 mg, 0.21
mmol) in EtOH (3 mL), n-decylamine (0.06 mL, 0.32 mmol) and Et3N
(0.04 mL, 0.32 mmol) were added. The reaction mixture was stirred at
80 °C for 12 h and progress of the reaction was monitored by TLC (3:2/EtOAc:Hexanes,
Rf 0.20). The organic layer was removed under reduced pressure and the residue was
purified by column chromatography (SiO2, 3:2/EtOAc:Hexanes) to afford compound 7 (75
mg, 91%) as a yellow liquid: 1H NMR (400 MHz, CD3OD, Figure C13) δ 8.32 (s, 1H),
7.76 (s, 1H), 7.48-7.42 (m, 1H), 6.96-6.82 (m, 2H), 4.69 (d, J = 14.3 Hz, 1H), 4.61 (d, J =
14.3 Hz, 1H), 3.15 (dd, J1 = 12.6 Hz, J2 = 1.4 Hz 1H), 2.98 (dd, J1 = 12.6 Hz, J2 = 1.4 Hz
1H), 2.56-2.44 (m, 2H), 1.42 (p, J = 7.2 Hz, 2H), 1.34-1.25 (m, 14H), 0.90 (t, J = 6.6 Hz,
3H); 13C NMR (100 MHz, CD3OD, Figure C14) δ 164.0, 163.9, 161.6, 161.5, 160.6, 160.5,
158.2, 158.1, 149.8, 144.6, 129.8, 129.73, 129.69, 129.6, 125.02, 124.98, 124.8, 110.71,
110.68, 110.50, 110.47, 103.8, 103.6, 103.5, 103.3, 73.83, 73.78, 55.92, 55.87, 54.92,
54.87, 49.8, 31.6, 29.30, 29.26, 29.25, 29.1, 29.0, 26.8, 22.3, 13.0; LRMS m/z calcd for
C21H32F2N4O: 394.3; found 395.2 [M+H]+.

Synthesis of compound 8. To a solution of compound 4 (50 mg, 0.21
mmol) in EtOH (3 mL), dodecylamine (0.07mL, 0.32 mmol) and Et3N
(0.04 mL, 0.32 mmol) were added. The reaction mixture was stirred at
80 °C for 2 h and progress of the reaction was monitored by TLC (1:10/MeOH:CH2Cl2, Rf
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0.19). The organic layer was removed under reduced pressure and the residue was purified
by column chromatography (SiO2, 1:10/MeOH:CH2Cl2) to afford compound 8 (49 mg,
59%) as a yellow solid: 1H NMR (400 MHz, CDCl3, Figure C15) δ 8.09 (s, 1H), 7.82 (s,
1H), 7.59-7.53 (m, 1H), 6.85-6.76 (m, 2H), 4.67 (d, J = 14.2 Hz, 1H), 4.54 (d, J = 14.2 Hz,
1H), 3.23 (d, J = 12.6 Hz, 1H), 3.08 (d, J = 12.6 Hz, 1H), 2.60 (t, J = 7.4 Hz, 2H), 1.491.43 (m, 2H), 1.29-1.21 (m, 18H), 0.86 (t, J = 6.4 Hz, 3H); 13C NMR (100 MHz, CDCl3,
Figure C16) δ 164.0, 161.5, 161.4, 160.2, 160.1, 157.8, 157.7, 151.2, 144.7, 129.9, 129.84,
129.80, 129.7, 125.04, 125.00, 124.9, 111.62, 111.58, 111.41, 111.38, 104.5, 104.20,
104.19, 103.9, 73.0, 72.9, 56.1, 56.0, 54.2, 54.2, 54.1, 50.0, 31.9, 29.7, 29.60, 29.59, 29.54,
29.5, 29.4, 29.34, 29.30, 26.9, 22.7, 14.1; LRMS m/z calcd for C23H36F2N4O: 422.3; found
423.2 [M+H]+.

Synthesis of compound 9. To a solution of compound 4 (50 mg, 0.21
mmol) in EtOH (3 mL), tetradecylamine (68 mg, 0.32 mmol) and Et3N
(0.04 mL, 0.32 mmol) were added. The reaction mixture was stirred at
room temperature for 3 h and progress of the reaction was monitored by TLC
(1:10/MeOH:CH2Cl2, Rf 0.31). The organic layer was removed under reduced pressure and
the residue was purified by column chromatography (SiO2, 1:10/MeOH:CH2Cl2) to afford
compound 9 (90 mg, 94%) as a yellow liquid: 1H NMR (400 MHz, CD3OD, Figure C17)
δ 8.29 (s, 1H), 7.74 (s, 1H), 7.46-7.40 (m, 1H), 6.93-6.80 (m, 2H), 4.67 (d, J = 14.3 Hz,
1H), 4.59 (d, J = 14.3 Hz, 1H), 3.13 (dd, J1 = 12.6 Hz, J2 = 1.3 Hz, 1H), 2.96 (dd, J1 = 12.6
Hz, J2 = 1.3 Hz, 1H), 2.54-2.42 (m, 2H), 1.42-1.36 (p, J = 7.1 Hz, 2H), 1.32-1.23 (m, 22H),
0.88 (t, J = 6.6 Hz, 3H); 13C NMR (100 MHz, CD3OD, Figure C18) δ 164.0, 163.9, 161.6,
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160.6, 160.5, 158.2, 158.1, 149.7, 144.6, 129.8, 129.72, 129.69, 129.6, 125.0, 124.8,
110.71, 110.68, 110.50, 110.47, 103.8, 103.6, 103.5, 103.3, 73.82, 73.76, 55.9, 55.85,
54.91, 54.86, 49.8, 31.7, 29.37, 29.35, 29.34, 29.28, 29.27, 29.14, 29.10, 29.06, 26.8, 22.3,
13.0; LRMS m/z calcd for C25H40F2N4O: 450.3; found 451.3 [M+H]+.

Synthesis of compound 10. To a solution of compound 4 (50 mg, 0.21
mmol) in EtOH (3 mL), hexadecylamine (76 mg, 0.32 mmol) and Et3N
(0.04 mL, 0.32 mmol) were added. The reaction mixture was stirred at
room temperature for 2 h and progress of the reaction was monitored by TLC
(1:10/MeOH:CH2Cl2, Rf 0.29). The organic layer was removed under reduced pressure and
the residue was purified by column chromatography (SiO2, 1:10/MeOH:CH2Cl2) to afford
compound 10 (92 mg, 91%) as a yellow liquid: 1H NMR (400 MHz, CD3OD, Figure C19)
δ 8.29 (s, 1H), 7.74 (s, 1H), 7.47-7.40 (m, 1H), 6.93-6.80 (m, 2H), 4.67 (d, J = 14.3 Hz,
1H), 4.59 (d, J = 14.3 Hz, 1H), 3.13 (dd, J1 = 12.6 Hz, J2 = 1.3 Hz, 1H), 2.96 (dd, J1 = 12.6
Hz, J2 = 1.3 Hz, 1H), 2.54-2.41 (m, 2H), 1.40 (p, J = 7.1 Hz, 2H), 1.32-1.23 (m, 26H), 0.88
(t, J = 6.7 Hz, 3H); 13C NMR (100 MHz, CD3OD, Figure C20) δ 164.0, 163.9, 161.6, 161.4,
160.6, 160.5, 158.2, 158.1, 150.6, 149.7, 144.6, 129.8, 129.72, 129.69, 129.63, 125.02,
124.98, 124.89, 124.85, 110.71, 110.68, 110.50, 110.47, 103.8, 103.6, 103.5, 103.3, 73.83,
73.78, 55.91, 55.86, 54.94, 54.90, 49.8, 31.7, 29.39, 29.37, 29.35, 29.30, 29.28, 29.2, 29.1,
26.8, 22.3, 13.0; LRMS m/z calcd for C27H44F2N4O: 478.4; found 479.3 [M+H]+.

Synthesis of compound 11. To a solution of compound 4 (50 mg, 0.21
mmol) in EtOH (3 mL), 6-amino-1-hexanol (37 mg, 0.32 mmol) and
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Et3N (0.04 mL, 0.32 mmol) were added. The reaction mixture was stirred at room
temperature for 12 h and progress of the reaction was monitored by TLC
(1:20/MeOH:CH2Cl2, Rf 0.66). The organic layer was removed under reduced pressure and
the residue was purified by column chromatography (SiO2, 1:20/MeOH:CH2Cl2) to afford
compound 11 (35 mg, 51%) as a colorless liquid: 1H NMR (400 MHz, CD3OD, Figure
C21) δ 8.31 (s, 1H), 7.80 (s, 1H), 7.52-7.45 (m, 1H), 7.00-6.95 (m, 1H), 6.93-6.87 (m, 1H),
4.71 (d, J = 14.5 Hz, 1H), 4.66 (d, J = 14.5 Hz, 1H), 3.51 (t, J = 6.5 Hz, 2H), 3.40 (d, J =
12.8 Hz, 1H), 3.20 (d, J = 12.8 Hz, 1H), 2.77-2.65 (m, 2H), 1.56-1.45 (m, 4H), 1.38-1.25
(m, 4H); 13C NMR (100 MHz, CD3OD, Figure C22) δ 164.5, 164.4, 162.0, 161.9, 160.7,
160.6, 158.3, 158.2, 150.2, 144.8, 129.92, 129.86, 129.82, 129.76, 123.2, 111.14, 111.11,
110.93, 110.90, 104.2, 103.9, 103.6, 73.1, 73.0, 61.3, 55.52, 55.47, 53.8, 53.7, 49.1, 32.0,
27.1, 26.3, 25.2; LRMS m/z calcd for C17H24F2N4O2: 354.2; found 355.1 [M+H]+.

Synthesis of compound 12. To a solution of compound 4 (50 mg, 0.21
mmol) in EtOH (3 mL), compound 3 (60 mg, 0.32 mmol) and Et3N (0.04
mL, 0.32 mmol) were added. The reaction mixture was stirred at 80 °C
for 12 h and progress of the reaction was monitored by TLC (3:2/EtOAc:Hexanes, Rf 0.30).
The organic layer was removed under reduced pressure and the residue was purified by
column chromatography (SiO2, 3:2/EtOAc:Hexanes) to afford compound 12 (34 mg, 39%)
as a yellow liquid: 1H NMR (400 MHz, CD3OD, Figure C23) δ 8.29 (s, 1H), 7.75 (s, 1H),
7.47-7.40 (m, 1H), 6.95-6.80 (m, 2H), 4.67 (d, J = 14.3 Hz, 1H), 4.60 (d, J = 14.3 Hz, 1H),
3.39 (t, J = 6.6 Hz, 2H), 3.38 (t, J = 6.6 Hz, 2H), 3.16 (d, J = 12.6 Hz, 1H), 2.99 (d, J =
12.6 Hz, 1H), 2.59-2.43 (m, 2H), 1.58-1.46 (m, 4H), 1.43 (p, J = 6.9 Hz, 2H), 1.36-1.22
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(m, 8H), 0.89 (t, J = 6.2 Hz, 3H);

13

C NMR (100 MHz, CD3OD, Figure C24) δ 164.1,

161.6, 158.2, 149.8, 144.6, 129.8, 129.7, 129.6, 124.8, 110.7, 110.6, 103.9, 103.6, 103.3,
73.73, 73.67, 70.5, 70.3, 55.9, 55.8, 54.8, 54.7, 49.7, 29.2, 29.0, 28.8, 28.1, 26.6, 25.6, 22.1,
13.0; LRMS m/z calcd for C22H34F2N4O2: 424.3; found 425.2 [M+H]+.

Synthesis of compound 13. To a solution of compound 4 (80 mg, 0.33
mmol) in EtOH (3 mL), di-n-hexylamine (0.12 mL, 0.51 mmol) and
Et3N (0.07 mL, 0.51 mmol) were added. The reaction mixture was stirred
at 80 °C for 12 h and progress of the reaction was monitored by TLC (3:2/EtOAc:Hexanes,
Rf 0.82). The organic layer was removed under reduced pressure and the residue was
purified by flash column chromatography (SiO2, 1:4/EtOAc:Hexanes) to afford compound
13 (82 mg, 57%) as a colorless liquid: 1H NMR (400 MHz, CDCl3, Figure C25) δ 8.17 (s,
1H), 7.77 (s, 1H), 7.55 (m, 1H), 6.85-6.74 (m, 2H), 5.66 (br s, 1H), 4.50 (d, J = 14.1 Hz,
1H), 4.41 (d, J = 14.1 Hz, 1H), 3.05 (d, J = 13.7 Hz, 1H), 2.69 (d, J = 13.7 Hz, 1H), 2.262.04 (m, 4H), 1.25-0.98 (m, 16H), 0.83 (t, J = 7.2 Hz, 6H); 13C NMR (100 MHz, CDCl3,
Figure C26) δ 160.2, 160.1, 157.7, 157.6, 150.8. 144.8, 129.5, 127.1, 111.4, 111.2, 104.4,
104.1, 103.9, 71.0, 58.9, 56.52, 56.47, 55.0, 31.5, 26.8, 26.7, 22.5, 13.9; LRMS m/z calcd
for C23H36F2N4O: 422.3; found 423.2 [M+H]+.

Synthesis of compound 14. To a solution of compound 4 (50 mg, 0.21
mmol) in EtOH (3 mL), di-n-octylamine (0.09 mL, 0.32 mmol) and Et3N
(0.04 mL, 0.32 mmol) were added. The reaction mixture was stirred at
80 °C for 12 h and progress of the reaction was monitored by TLC (3:2/EtOAc:Hexanes,
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Rf 0.60). The organic layer was removed under reduced pressure and the residue was
purified by flash column chromatography (SiO2, 1:4/EtOAc:Hexanes) to afford compound
14 (65 mg, 65%) as a yellow liquid: 1H NMR (400 MHz, CD3OD, Figure C27) δ 8.39 (s,
1H), 7.79 (s, 1H), 7.60-7.54 (m, 1H), 6.98-6.85 (m, 2H), 4.59 (d, J = 14.3 Hz, 1H), 4.55
(d, J = 14.3 Hz, 1H), 3.09 (dd, J1 = 13.9 Hz, J2 = 1.8 Hz, 1H), 2.81 (d, J = 13.9 Hz, 1H),
2.34-2.20 (m, 4H), 1.34-1.05 (m, 24H), 0.90 (t, J = 6.7 Hz, 6H);

13

C NMR (100 MHz,

CD3OD, Figure C28) δ 164.1, 163.9, 161.6, 161.5, 160.5, 160.4, 158.0, 157.9, 149.6, 144.9,
129.61, 129.55, 129.52, 129.46, 126.95, 126.91, 126.82, 126.78, 110.8, 110.7, 110.6,
110.5, 103.8, 103.57, 103.56, 103.3, 71.7, 71.6, 59.23, 59.19, 56.1, 56.0, 54.9, 31.5, 29.0,
28.9, 26.8, 26.6, 22.3, 13.0; LRMS m/z calcd for C27H44F2N4O: 478.4; found 479.3
[M+H]+.

Synthesis of compound 15. To a solution of compound 4 (50 mg, 0.21
mmol) in EtOH (3 mL), cyclooctylamine (0.04 mL, 0.32 mmol) and
Et3N (0.04 mL, 0.32 mmol) were added. The reaction mixture was
stirred at 80 °C for 2 h and progress of the reaction was monitored by TLC
(1:20/MeOH:CH2Cl2, Rf 0.52). The organic layer was removed under reduced pressure and
the residue was purified by column chromatography (SiO2, 1:20/MeOH:CH2Cl2) to afford
compound 15 (43 mg, 57%) as a colorless liquid: 1H NMR (400 MHz, CDCl3, Figure C29)
δ 8.11 (s, 1H), 7.81 (s, 1H), 7.59-7.53 (m, 1H), 6.85-6.75 (m, 2H), 4.62 (d, J = 14.2 Hz,
1H), 4.48 (d, J = 14.2 Hz, 1H), 3.14 (d, J = 12.6 Hz, 1H), 2.96 (d, J = 12.6 Hz, 1H), 2.53
(br s, 1H), 2.02-1.22 (m, 15H); 13C NMR (100 MHz, CDCl3, Figure C30) δ 164.0, 163.9,
161.5, 161.4, 160.3, 160.2, 157.8, 157.7, 151.2, 144.8, 129.9, 129.82, 129.78, 129.7, 125.3,
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125.2, 111.6, 111.5, 111.4, 111.3, 104.4, 104.2, 103.9, 72.63, 72.58, 58.0, 56.24, 56.19,
51.73, 51.69, 32.6, 32.1, 27.1, 27.0, 25.6, 23.8, 23.6; LRMS m/z calcd for C19H26F2N4O:
364.2; found 365.1 [M+H]+.

Synthesis of compound 16. To a solution of compound 4 (50 mg,
0.21 mmol) in EtOH (3 mL), 4-isopropylaniline (0.04mL, 0.32 mmol)
and Et3N (0.04 mL, 0.32 mmol) were added. The reaction mixture
was stirred at 80 °C for 2 h and progress of the reaction was monitored by TLC
(1:10/MeOH:CH2Cl2, Rf 0.88). The organic layer was removed under reduced pressure and
the residue was purified by column chromatography (SiO2, 1:20/MeOH:CH2Cl2) to afford
compound 16 (45 mg, 57%) as a yellow solid: 1H NMR (400 MHz, CDCl3, Figure C31) δ
7.96 (s, 1H), 7.83 (s, 1H), 7.53-7.47 (m, 1H), 7.03 (d, J = 8.4 Hz, 1H), 6.81-6.73 (m, 2H),
6.63 (d, J = 8.4 Hz, 2H), 4.76 (d, J = 14.2 Hz, 1H), 4.70 (d, J = 14.2 Hz, 1H), 3.64 (dd, J1
= 13.1 Hz, J2 = 1.3 Hz, 1H), 3.51 (dd, J1 = 13.1 Hz, J2 = 1.3 Hz, 1H), 2.79 (septet, J = 6.9
Hz, 1H), 1.17 (d, J = 6.9 Hz, 6H); 13C NMR (100 MHz, CDCl3, Figure C32) δ 164.1, 164.0,
161.6, 161.5, 159.9, 159.8, 157.5, 157.4, 151.9, 145.4, 144.4, 139.6, 130.1, 130.04, 130.00,
129.9, 127.2, 124.04, 124.00, 123.91, 123.87, 114.0, 111.91, 111.88, 111.71, 111.68,
104.5, 104.27, 104.26, 104.0, 75.7, 75.6, 55.2, 55.1, 51.24, 51.20, 33.2, 24.2; LRMS m/z
calcd for C20H22F2N4O: 372.2; found 373.1 [M+H]+.

4.5.2. Biological experiments
4.5.2.1. Antifungal agents
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Azole derivatives 5-16 were chemically synthesized as described in section 4.5.2 above. A
5 mg/mL stock solution of compounds 5-16 was prepared in DMSO and stored at -20 °C.
The antifungal agents amphotericin B (AmB), fluconazole (FLC), and voriconazole (VRC)
were obtained from AK Scientific Inc. (Mountain View, CA). The antifungal agent
caspofungin (CAS) was purchased from Sigma-Aldrich (St. Louis, MO). AmB, FLC,
VRC, and CAS were dissolved in DMSO at a final concentration of 5 mg/mL and were
stored at -20 °C.

4.5.2.2. Organisms and culture conditions
Candida albicans ATCC 10231 (A), C. albicans ATCC 64124 (B), and C. albicans ATCC
MYA2876 (C) were kindly provided by Dr. Jon Y. Takemoto (Utah State University,
Logan, UT, USA). C. albicans ATCC MYA90819 (D), C. albicans ATCC MYA2310
(E), C. albicans ATCC MYA1237 (F), C. albicans ATCC MYA1003 (G), Candida
glabrata ATCC 2001 (H), Candida krusei ATCC 6258 (I), Candida parapsilosis ATCC
22019 (J), Aspergillus flavus ATCC MYA-3631 (K), and Aspergillus terreus ATCC
MYA-3633 (M) were obtained from the American Type Culture Collection (ATCC;
Manassas, VA, USA). Aspergillus nidulans ATCC 38163 (L) was received from Dr. Jon
S. Thorson (University of Kentucky, Lexington, KY, USA). All clinical fungal isolates, C.
glabrata (CG1, CG2, and CG3), C. parapsilosis (CP1, CP2, CP3), and Cryptococcus
neoformans (CN1, CN2, and CN3) were obtained from Dr. Nathan P. Wiederhold,
University of Texas Health Science Center, San Antonio, USA). Filamentous fungi and
yeasts were cultivated at 35 °C in RPMI 1640 medium (with L-glutamine, without sodium
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bicarbonate, Sigma-Aldrich, St. Louis, MO, USA) buffered to a pH of 7.0 with 0.165 M
morpholinepropanesulfonic acid (MOPS) buffer (Sigma-Aldrich).

The human embryonic kidney cell line HEK-293 (ATCC CRL-1573), the human bronchus
normal cell line BEAS-2B (ATCC CRL-9609), and the human lung carcinoma cell line
A549 (ATCC CRL-185) were kind gifts from the laboratories of Dr. Matthew S. Gentry
(University of Kentucky, Lexington, KY, USA) and Dr. David K. Orren (University of
Kentucky, Lexington, KY, USA). Mammalian cells were grown in Dulbecco’s Modified
Eagle’s Medium (DMEM) (from ATCC) with 10% fetal bovine serum (FBS) (from ATCC)
and 1% Pen/Strep (from ATCC). Cell lines were incubated at 37 °C and 5% CO2 and
passaged by trypsinization with 0.05% trypsin:0.53 mM EDTA (from ATCC). Cell
confluency was determined by using a Nikon Eclipse TS100 microscope (Minato, Tokyo,
Japan).

4.5.2.3. Antifungal susceptibility testing
The MIC values of compounds 5-16 against yeasts (strains A-J (Table 4.1), and CG1-3,
CP1-3, and CN1-3 (Table 4.2)) were evaluated in 96-well microtiter plates as described in
the CLSI document M27-A3224 with minor modifications. The final concentrations of
antifungal agents studied ranged from 0.03-31.3 µg/mL for compounds 5-16, 0.48-31.3
µg/mL for AmB (only presented in Table 4.1), 0.03-31.3 µg/mL for CAS, 0.975-62.5
µg/mL for FLC, and 0.03-31.3 µg/mL for VRC. Briefly, overnight yeast cultures were
grown in yeast peptone dextrose (YPD) broth and the cell density was adjusted to an OD600
of 0.12 (~1×106 CFU/mL) by using a spectrophotometer. Yeast cell suspensions were
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further diluted to achieve 1-5×103 CFU/mL in RPMI 1640 medium, and 100 µL of these
yeast cells was added to 96-well microtiter plates containing RPMI 1640 medium and
titrated compounds. Each test was performed in triplicate. The plates were incubated at 35
°C for 48 h. The MIC values for compounds 5-16, AmB, and CAS were defined as the
lowest drug concentration that prevented visible growth (also known as MIC-0) when
compared to the growth control. For FLC and VRC, the minimum drug concentration that
yielded at least 50% growth inhibition (MIC-2) when compared with the growth control
well was reported. One exception for the reporting of the MIC of the azoles was that of
VRC against C. albicans ATCC 10231 (strain A), where the MIC-0 (indicating optically
clear well) was reported. These data are presented in Tables 4.1 (MIC values in µg/mL)
and 4.4 (MIC values in µM) (for strains A-J) and 4.2 (MIC values in µg/mL) and 4.5 (MIC
values in µM) (for strains CG1-3, CP1-3, and CN1-3).

Similarly, the MIC values of compounds 5-16, as well as that of all control drugs against
filamentous fungi (strains K-M) were determined as previously described in CLSI
document M38-A2.224 Spores were harvested from sporulating cultures growing on potato
dextrose agar (PDA) by ﬁltration through sterile glass wool and enumerated by using a
hemocytometer (Hausser Scientific, PA, USA) to obtain the desired inoculum size. Twofold serial dilutions of compounds 5-16, as well as VRC and CAS were made in sterile 96well microtiter plates in the range of 0.03-31.3 µg/mL in RPMI 1640 medium. The
concentration range for FLC and AmB were 0.975-62.5 µg/mL and 0.48-31.3 µg/mL,
respectively. Spore suspensions were added to the wells to afford a ﬁnal concentration of
5×105 spores/mL. The plates were incubated at 35 °C for 48 h. The MIC values of all
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compounds, including compounds 5-16, azoles, AmB, and CAS against filamentous fungi
were based on complete inhibition of growth (optically clear well) when compared to the
growth control (MIC-0). Each test was performed in triplicate. These data are also
presented in Table 4.1 (strains K-M).

Table 4.4: MIC valuesa (in µM) (the corresponding values in µg/mL are presented in Table
4.1) determined for compounds 5-16 and for four control antifungal agents (AmB, CAS,
FLC, and VRC) against various yeast strains and filamentous fungi.
Yeast strains
Filamentous fungi
Cpd # A
B
C
D
E
F
G
H
I
J
K
L
M
5
23.0
>92.3
46.1
92.3
92.3
>92.3 92.3
46.1
23.0
2.9
>92.3 >92.3 >92.3
6
2.7
>85.4
85.4
21.3
85.4
42.6
85.4
21.3
2.7
0.16
>85.4 5.3
42.6
7
1.2
39.5
9.9
9.9
19.8
19.8
19.8
2.5
1.2
0.08
19.8
2.5
9.9
8
2.3
76.0
9.2
4.6
76.0
18.5
76.0
2.3
2.3
1.1
18.5
4.6
9.2
9
4.3
>69.5
>69.5 17.3
69.5
>69.5 69.5
2.2
8.7
1.1
>69.5 8.7
17.3
10
>65.4 >65.4
65.4
65.4
8.1-65.4 >65.4 >65.4 2.0
8.1
1.0
>65.4 8.1
>65.4
11
>88.3 >88.3
88.3
88.3
>88.3
>88.3 >88.3 >88.3
>88.3
>88.3 >88.3 >88.3 >88.3
12
9.2
>73.7
73.7
9.2
36.7
9.2
18.4
36.7
4.6
0.57
>73.7 18.4
73.7
13
>74.1 >74.1
>74.1 >74.1
>74.1
>74.1 >74.1 >74.1
>74.1
74.1
>74.1 >74.1 >74.1
14
65.4
>65.4
65.4
65.4
>65.4
65.4
>65.4 65.4
65.4
2.0
>65.4 32.7
>65.4
15
85.8
85.8
>85.8 85.8
10.7-85.8 85.8
>85.8 85.8
85.8
10.7
85.8
>85.8 >85.8
16
>84.0 >84.0
>84.0 84.0
84.0
84.0
84.0
20.9
>84.0
20.9
84.0
20.9
41.9
AmB 4.2
4.2
2.1
1.1
2.1
4.2
4.2
2.1
4.2
2.1
15.6
4.2
4.2
CAS
0.8
0.2
0.05
0.1
0.1
0.2
0.4
0.05
0.4
1.6
>25.8 >25.8 >25.8
FLC
204.1 >408.1 50.9
>408.1 >408.1
204.1 204.1 >102.2 >102.2 6.4
204.1 204.1 204.1
VRC 0.69
11.2
5.6
5.6
2.8)
22.3
5.6
0.17
0.34
<0.06 0.69
0.34
0.34
Yeast strains: A = Candida albicans ATCC 10231, B = C. albicans ATCC 64124, C = C. albicans ATCC MYA-2876(S), D = C.
albicans ATCC 90819(R), E = C. albicans ATCC MYA-2310(S), F = C. albicans ATCC MYA-1237(R), G = C. albicans ATCC
MYA-1003(R), H = Candida glabrata ATCC 2001, I = Candida krusei ATCC 6258, J = Candida parapsilosis ATCC 22019. NOTE:
Here, the (S) and (R) indicate that ATCC reports these strains to be susceptible (S) and resistant (R) to ITC and FLC.
Filamentous fungi: K = Aspergillus flavus ATCC MYA-3631, L = Aspergillus nidulans ATCC 38163, M = Aspergillus terreus ATCC
MYA-3633.
Known antifungal agents: AmB = amphotericin B, CAS = caspofungin, FLC = fluconazole, VRC = voriconazole.
a
For yeast strains: MIC-0 values are reported for FLC analogues 5-16, AmB, and CAS, whereas MIC-2 values are reported for azoles.
For filamentous fungi, MIC-0 values are reported for all compounds.

Table 4.5: MIC valuesa (in µM) (the corresponding values in µg/mL are presented in Table
4.2) determined for compounds 5-16 and for three control antifungal agents (CAS, FLC,
and VRC) against various non-albicans Candida and Cryptococcus neoformans clinical
isolates.
Cpd #

Yeast strains
H
CG1

CG2

CG3

J

CP1
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CP2

CP3

CN1

CN2

CN3

Table 4.5 continued
5
23.0
92.3
23.0
92.3
2.9
2.9
2.9
2.9
23.0
>92.3
92.3
6
2.7
21.3
2.7
42.6
0.16
1.3
0.33
0.65
5.3
10.6
10.6
7
1.2
4.9
1.2
9.9
0.08
0.15
0.30
0.61
0.61
0.61
1.2
8
2.3
4.6
2.3
4.6
1.1
0.14
0.57
0.28
0.57
0.57
1.1
9
4.3
4.3
4.3
8.7
1.1
1.1
2.2
1.1
0.27
0.53
1.1
10
>65.4
4.1
2.0
16.3
1.0
2.0
1.0
2.0
1.0
1.0
1.0
11
>88.3
>88.3
>88.3
>88.3
>88.3
88.3
88.3
88.3
>88.3
>88.3
>88.3
12
9.2
36.7
4.6
73.7
0.57
0.28
0.28
0.28
1.1
4.6
4.6
13
>74.1
>74.1
>74.1
>74.1
74.1
>74.1
>74.1
>74.1
>74.1
>74.1
37.1
14
65.4
32.6
16.3
>65.4
2.0
2.0
4.1
4.1
>65.4
>65.4
>65.4
15
85.8
85.8
42.8
85.8
10.7
2.7
2.7
5.4
21.4
>85.8
42.8
16
>84.0
20.9
20.9
20.9
20.9
10.5
10.5
10.5
20.9
84.0
>84.0
CAS
0.05
0.16
0.2
0.8
1.6
0.4
0.4
0.4
12.9
25.8
12.9
FLC
204.1
>102.1
>102.1
>102.1
6.4
3.2
3.2
3.2
25.6
>102.1
>102.1
VRC
0.69
2.76
11.2
>89.9
<0.06
<0.06
<0.06
<0.06
0.69
2.76
0.35
Yeast strains: H = Candida glabrata ATCC 2001, CG1-CG3 = C. glabrata clinical isolates, J = Candida parapsilosis ATCC 22019,
CP1-CP3 = C. parapsilosis clinical isolates, CN1-CN3 = Cryptococcus neoformans clinical isolates.
Known antifungal agents: CAS = caspofungin, FLC = fluconazole, VRC = voriconazole.
a
For these yeast strains: MIC-0 values are reported for FLC analogues 5-16, whereas MIC-2 values are reported for azoles.

4.5.2.4. Time-kill studies
The time-kill curve analyses were done using a previously published protocol.199 Fungal
cells (C. albicans ATCC 10231 (strain A) and C. parapsilosis ATCC 22019 (strain J))
were cultured in YPD medium (3 mL) overnight. Cells (~10-15 µL) were then added to
Eppendorf tubes and diluted (to 1 mL) with RPMI 1640 medium to achieve the proper
concentration of working stocks with OD600 of 0.12-0.13. Prior to performing the time-kill
studies, cells (300 µL) were aliquoted into 15 mL conical tubes along with 3.7 mL of RPMI
1640 medium (total of 4 mL) to establish that 300 µL from working stock of OD600 of 0.120.13 would be sufficient to achieve the initial inoculum (time 0 h) of 1-4×105 CFU/mL on
PDA plates after at least 24 h incubation. Once established, 300 µL of cells and appropriate
volumes of RPMI 1640 medium and compounds (6, 7, and VRC) were then added to make
up solutions of cells and drugs with concentrations of 1×, 4×, and 8× the respective MIC
values of each compound. The final volume for each tube was 4 mL. The tubes were then
incubated at 35 °C and agitated at 200 rpm for 24 h. At 0, 3, 6, 9, 12, and 24 h time points,
100 µL of cells from each tube was serially diluted with RPMI 1640 medium to the
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appropriate dilutions (102-107 times) depending on turbidity. Afterwards, the cells were
plated on PDA plates. Please note that proper dilution comes with experience and the
dilutions were done to make sure that each plate contains 30-300 colonies, which is
considered statistically significant. The plates were then incubated for 24-48 h and the
number of colonies were counted. The experiments were performed in duplicate. These
data are presented in Figure 4.3.

4.5.2.5. Hemolytic activity assay
The hemolytic activity of compounds 6-10 was determined by using previously described
methods with minor modifications.219 Murine whole blood was suspended in 4 mL of PBS
and centrifuged at 1,000 rpm for 10 min at room temperature to obtain the mRBCs. The
mRBCs were washed four times in PBS and resuspended in the same buffer to a final
concentration of 107 erythrocytes/mL. Two-fold serial dilutions of compounds 6-10 were
prepared using 100 µL of PBS buffer in Eppendorf tubes followed by the addition of 100
µL of mRBC suspension that made the final concentration of compounds and mRBCs to
be 0.48-62.5 µg/mL and 5×106 erythrocytes/mL, respectively. The tubes were incubated at
37 °C for 1 h. Tubes with PBS buffer (200 µL) and Triton™ X-100 (1% v/v, 2 µL) served
as negative (blank) and positive controls, respectively. The percentage of hemolysis was
calculated using the following equation: % hemolysis = [(absorbance of sample) –
(absorbance of blank)] × 100/(absorbance of positive control). These data are presented in
Table 4.6 and Figure 4.4.
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Table 4.6: The % hemolysis caused by azole derivatives and VRC against mRBCs with the
error bars (± SDEV).
Cpd #
6
7
8
9
10
VRC

Concentration (µg/mL)
0.48
0.975
2.0 ± 0.3
2.0 ± 1.0
0
0
2.0 ± 0.9
2.0 ± 0.8
2.0 ± 0.9
6.0 ± 3.0
4.0 ± 0.2
5.0 ± 4.2
9.0 ± 5.0
10.0 ± 2.0

1.95
0
2.0 ± 0.1
2.0 ± 1.4
3.0 ± 2.0
6.0 ± 4.0
6.0 ± 2.0

3.9
2.0 ± 0.8
3.0 ± 3.0
8.0 ± 4.0
10.0 ± 2.0
3.0 ± 2.0
7.0 ± 0.5

7.8
0
8.0 ± 2.0
21.0 ± 5.0
17.0 ± 2.0
4.0 ± 0.2
11.0 ± 11.0

15.6
3.0 ± 0.3
33.0 ± 7.0
86.0 ± 11.0
29.0 ± 0.3
4.0 ± 1.0
3.0 ± 1.2

31.3
9.0 ± 0.3
92.0 ± 7.0
100.0 ± 5.0
57.0 ± 6.0
4.0 ± 0.5
83.0 ± 5.0

62.5
78.0 ± 1.0
100.0 ± 3.0
98.0 ± 2.0
77.0 ± 8.0
8.0 ± 3.0
100.0 ± 2.3

4.5.2.6. In vitro cytotoxicity assay
Mammalian cytotoxicity assays were performed as previously described with minor
modifications.198 HEK-293, BEAS-2B, and A549 were cultured as described in section
4.6.2 and were counted by a hemocytometer when cells were about 80% confluent in flasks.
Cells were plated in 96-well microtiter plates at concentrations of 10,000 cells per well for
HEK-293 and 3,000 cells per well for BEAS-2B and A549. The 96-well microtiter plates
were incubated at 37 °C and 5% CO2 for 16 h to allow time for adherence. The medium
was then removed and fresh medium with compounds 6-10 or VRC at 0.13-31 µg/mL and
0.1% DMSO vehicle were added. The stock solutions of compounds 6-10 were previously
prepared at 1000× the intended tested concentrations. The positive control contained 20%
Triton™ X-100. The negative control contained 0.1% DMSO and no drugs. A blank
control was also prepared to have only medium and no cells. After 24 h of incubation, cell
survival was assessed via addition of resazurin (10 µL of 10 mM solution) for 6-10 h. Live
cells were detected by a color change from purple to pink via conversion of the compound
to resorufin, which could be quantified at λ560 absorption and λ590 emission by a
SpectraMax M5 plate reader. The percentage survival rates were calculated by using the
following formula: % cell survival = [(fluorescence of sample) – (fluorescence of blank)]
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× 100/[(fluorescence of negative control)-(fluorescence of blank)]. The experiments were
performed in duplicate. These data are presented in Figure 4.5.

4.5.2.7. Membrane permeabilization assay
2 mL of YPD broth was first inoculated using a fresh colony of C. albicans ATCC 10231
(strain A) in a sterile culture tube and was grown overnight at 35 °C at 200 rpm. 50 µL of
an overnight culture was transferred to RPMI 1640 medium (0.5 mL) containing no drug
(negative control) or compound 8 at 1× MIC (1.95 µg/mL), 2× MIC (3.9 µg/mL), and 4×
MIC (7.8 µg/mL) or compound 9 at 1× MIC (3.9 µg/mL), 2× MIC (7.8 µg/mL), and 4×
MIC (15.6 µg/mL). VRC at 4× MIC (0.975 µg/mL), and KANB (C14)219 at 4× MIC (15.6
µg/mL) were also used as negative and positive controls, respectively. After establishing
that using 4× MIC was required to display membrane permeabilization, compounds 5, 6,
and 7 were also tested at their respective 4× MIC (31.2, 3.9, and 1.95 µg/mL, respectively).
The cell suspensions were then treated for 1 h at 35 °C with continuous agitation (200 rpm).
The cells were then centrifuged and resuspended in 500 µL of PBS buffer (pH 7.2).
Subsequently, cells were treated with propidium iodide (9 µM, final concentration) and
incubated for 20 min at room temperature in the dark. Glass slides prepared with 10 µL of
each mixture were observed in bright field and fluorescence modes (using Texas red filter
set, excitation and emission wavelengths of 535 and 617 nm, respectively) using a Zeiss
Axiovert 200M fluorescence microscope. A magnification lens of 63X was used. Data
were obtained from at least two independent experiments. The images were also postprocessed utilizing automatic contrast and brightness setting in Microsoft PowerPoint 2013
to eliminate background noise. These images are presented in Figure 4.6.
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4.5.2.8. Sterol profile by GC-MS
A single colony of C. albicans ATCC 10231 (strain A) was picked from a fresh culture
plate to inoculate 3 mL of yeast peptone dextrose broth (YPDB) and was incubated at 35
°C for ~18 h with continuous agitation (180 rpm). The overnight yeast culture was used to
inoculate RPMI 1640 medium (15 mL) and the final inoculum concentration was adjusted
to 1×106 CFU/mL (~OD600 = 0.12) by using spectrophotometric method. Afterwards, the
yeast cells were treated with compounds 8 (0.48 µg/mL), compound 9 (0.975 µg/mL), or
VRC (0.12 µg/mL) at their sub-MIC values. An equivalent amount of DMSO without drug
(untreated control) was also prepared. Cells were harvested by centrifugation (5,000 rpm)
for 10 min at room temperature, and cell pellets were saponified at 80 °C for 2 h with 3 mL
of MeOH, 2 mL of pyrogallol dissolved in MeOH (0.5%, wt/v) (CAS # 87-66-1, SigmaAldrich, St. Louis, MO), and 2 mL of KOH (60%, wt/v). The non-saponifiable sterols were
then extracted with 3×5 mL of heptane. The extracts were evaporated under a stream of
nitrogen to dryness and resuspended in 500 µL of heptane. The sterol suspension was then
transferred to a GC-MS vial and derivatized with 250 µL of N-methyl-N-(trimethylsilyl)
trifluoroacetamide (MSTFA, CAS # 24589-78-4, Sigma-Aldrich, St. Louis, MO) at 70 °C
for 20 min. GC-MS analyses were performed on an Agilent 7890A gas chromatograph
with splitless injection, coupled to an Agilent 5970C inert XL mass spectrometer with a
triple-axis detector and an Agilent 19091S-433 capillary column (30 m x 250 µm). The
oven temperature was programmed to hold at 70 °C for 2 min and then ramped to 270 °C
at a rate of 20 °C/min. Helium (10 psi) was used as the carrier gas, the electron ionization
energy was 70 eV, and the inlet temperature 250 °C. Identification of sterols was achieved
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using the NIST (the National Institute of Standards and Technology) reference database.
These data are presented in Figure 4.7.

4.6. ASSOCIATED CONTENT
4.6.1. Supporting information
The supporting information in Appendix C contains all 1H and

13

C NMR spectra along

with HPLC traces C1-C32 for the compounds tested in Chapter 4.
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Chapter 5
Alkylated piperazines and piperazine-azole hybrids as antifungal agents

5.1 ABSTRACT
The extensive use of fluconazole (FLC) and other azole drugs has caused the rise and
emergence of azole-resistant fungi. The fungistatic nature of FLC in combination with
toxicity concerns have resulted in an increased demand for new azole antifungal agents.
Herein, we report the synthesis and antifungal activity of novel alkylated piperazines and
alkylated piperazine-azole hybrids, their time-kill studies, their hemolytic activity against
murine erythrocytes, as well as their cytotoxicity against mammalian cells. Many of these
molecules exhibited broad-spectrum activity against all tested fungal strains, with excellent
minimum inhibitory concentration (MIC) values against non-albicans Candida and
Aspergillus strains. The most promising compounds were found to be less hemolytic than
the FDA-approved antifungal agent voriconazole (VRC previously published as VOR).
Finally, we demonstrate that the synthetic alkylated piperazine-azole hybrids do not
function by fungal membrane disruption, but instead by disruption of the ergosterol
biosynthetic pathway via inhibition of the 14α-demethylase enzyme present in fungal cells.

5.2 INTRODUCTION
For the last decade, reported cases of diseases caused by fungi are on the rise, which
presents a great threat to human health.225 Fungal infections are especially problematic for
patients with immune systems compromised either by HIV infections, the administration
of immunosuppressive drugs, or organ transplantations.201-203, 226-229 The overreliance on
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conventional antifungal agents such as azoles (e.g., fluconazole (FLC), voriconazole
(VRC), itraconazole (ITC), and posaconazole (POS)), polyenes (e.g., amphotericin B
(AmB)), echinocandins (e.g., caspofungin (CAS) and micafungin), and allylamines (e.g.,
terbinafine and naftifine) has caused the development of drug-resistant fungal strains.230235

Therefore, the identification and development of novel antifungal agents capable of

eliminating these drug-resistant fungi are a priority.142, 228, 236 Fungal infections vary in
pathogenicity; some are merely superficial and benign, whereas others are associated with
significant morbidity and mortality. Serious fungal infections are caused by Candida
albicans, Cryptococcus neoformans, and Aspergillus fumigatus.200, 237, 238 Azole antifungal
agents have emerged as front-line drugs for the treatment of fungal infections because of
their favorable pharmacokinetics and better safety profiles than AmB, albeit still toxic at
high concentrations.239 Azoles disrupt the formation of ergosterol in fungi by inhibiting
sterol 14α-demethylase, the enzyme that converts lanosterol into ergosterol in the
ergosterol biosynthetic pathway.240, 241 FLC is one of the most important members of the
azole family. FLC is well absorbed and exhibits high oral bioavailability. However, its
fungistatic nature renders FLC inefficient against invasive fungal diseases. Consequently,
second-generation analogues such as POS, VRC, and ITC were developed to help
overcome some of these deficiencies. However, the extensive use of azoles has caused an
increase in the number of azole-resistant fungi, which in combination with toxicity
concerns, created a need to improve on the existing azole scaffolds.

Our and other groups previously reported that alkylation of various drug scaffolds can
result in derivatives with promising antifungal properties.199,
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220-223

For example,

kanamycin B (KANB) and tobramycin (TOB) analogues with linear alkyl chains
comprised of 12 and 14 carbons (C12 and C14),199 an n-alkylated ebsulfur derivative with a
linear C5 alkyl chain,242 as well as 2,4-difuoro-2-(1H-1,2,4-triazo-1-yl)acetophenone
analogues with linear C5-C8 alkyl chains221 displayed strong antifungal activity against C.
albicans and Aspergillus spp. It is also well known that tridemorph, a morpholine-based
compound containing a linear C13 alkyl chain attached to the nitrogen atom, is a useful
fungicide against plant fungal pathogens.243 Inspired by the promise shown by KANB and
TOB (C12 and C14), ebsulfur (C5), and 2,4-difuoro-2-(1H-1,2,4-triazo-1-yl)acetophenone
(C5-C8) as antifungals, as well as the proven efficacy of tridemorph against plant
pathogenic fungi, we decided to generate two new families of antifungal compounds: (1)
alkylated piperazine analogues, and (2) alkylated piperazine-azole hybrids. We opted for
the piperazine moiety containing a nitrogen atom in place of the oxygen of the morpholine
of tridemorph, as a morpholine-based linear alkyl chain could not be attached to the azole
scaffold via its oxygen atom. In an effort to develop novel azole analogues, we decided to
replace the triazole on the carbon alpha to the dihalophenyl ring of FLC by a linear
alkylated piperazine.

Herein, we report the synthesis of nine piperazine derivatives (1-9) as well as that of eleven
alkylated piperazine-azole hybrids (16-26) (Figure 5.1). We also report the synthesis of
one alkylated morpholine derivative (10) and two morpholine-azole hybrids (27 and 28).
We evaluate the antifungal activity of these compounds against a variety of C. albicans,
non-albicans Candida, and Aspergillus strains by in vitro MIC determination as well as by
time-kill studies. We also explore the hemolytic activity as well as cytotoxicity of these
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compounds against mouse erythrocytes and three mammalian cell lines, respectively.
Finally, we investigate the potential mechanism of action of selected compounds by
probing their ability to disrupt fungal membrane and/or the ergosterol biosynthetic
pathway.
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Figure 5.1. Synthetic scheme for the preparation of A. piperazine derivatives 1-9 and morpholine derivative
10, and B. novel azole analogues 16-28.

5.3 RESULTS AND DISCUSSION
5.3.1. Design and synthesis of two families of antifungal compounds
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We synthesized the alkylated piperazine derivatives 1-9 and morpholine derivative 10 in a
single step. The nucleophilic substitution reactions of piperazine and morpholine with
linear alkyl chain halides generated derivatives 1-10 (Figure 5.1A). The alkylated
piperazines 1-9 were used in the preparation of alkylated piperazine-azole hybrids 16-26,
which proceeded in two steps from either the commercially available fluorinated
compound 12 or its synthesized chlorinated counterpart 13244 (Figure 5.1B). The carbonyl
group of compounds 12 and 13 was first converted to an epoxide by using
trimethylsulfoxonium iodide in the presence of a strong base and a surfactant to yield the
oxirane intermediates 14 and 15, respectively, which were then reacted under mild basic
conditions with piperazines 1-9 to afford hybrids 16-26. Two additional hybrids, 27 and
28, were also synthesized by reacting intermediate 14 with morpholine and 4-(2aminoethyl)morpholine, respectively.

5.3.2. Antifungal activity in the absence or presence of serum
The antifungal activity of the newly prepared alkylated piperazine/morpholine-azole
hybrids 16-28, of intermediate 14 that we used to verify that only final compounds exert
antifungal activity, as well as that of alkylated piperazine/morpholine derivatives 1-10 were
first evaluated against a panel of seven C. albicans (ATCC 10231 (A), ATCC 64124(R)
(B), ATCC MYA-2876(S) (C), ATCC 90819(R) (D), ATCC MYA-2310(S) (E), ATCC
MYA-1237(R) (F), and ATCC MYA-1003(R) (G)), three non-albicans Candida (C.
glabrata ATCC 2001 (H), C. krusei ATCC 6258 (I), and C. parapsilosis ATCC 22019
(J)), and three Aspergillus (A. flavus ATCC MYA-3631 (K), A. nidulans ATCC 38163
(L), and A. terreus ATCC MYA-3633 (M)) strains using a concentration range of 0.03-

242

31.3 µg/mL (Table 5.1). Commercially available antifungal agents such as AmB, CAS,
FLC, and VRC were used as positive controls for comparison. For final compounds 1-10
and 16-28, intermediate 14, as well as the reference drugs AmB and CAS, we reported
MIC-0 values, which correspond to no visible growth of the thirteen fungal strains tested.
We reported MIC-2 values (i.e., 50% growth inhibition) for FLC and VRC against all
fungal strains tested with the exception of strain A by VRC. Out of the seven C. albicans
strains; two were classified as sensitive (strains C and E), one as intermediate (strain A),
and four as resistant (strains B, D, F, and G) against FLC and ITC as defined by American
Type Culture Collection (ATCC). Henceforth, we define antifungal activity as excellent
(0.03-1.95 µg/mL), good (3.9 µg/mL), moderate (7.8-15.6 µg/mL), or poor (≥31.3 µg/mL)
based on MIC values. It is important to note that all comparisons to follow will be done by
using the MIC values reported in µg/mL as the data were collected that way. However, we
also present in parentheses in Table 5.1 the corresponding values in micromolar.

Table 5.1: MIC valuesa (in µg/mL) (Note: MIC values in micromolar are presented in
parentheses) determined for compounds 1-10, 14, and 16-28, as well as for four control
antifungal agents (AmB, CAS, FLC, and VRC) against various yeast strains and
filamentous fungi.
Cpd A
#
1
>31.3
(>312.5)
2
>31.3
(>200.3)
3
>31.3
(>157.8)
4
31.3
(147.4)
5
15.6
(68.9)
6
7.8
(32.4)

Yeast strains
F

B

C

D

E

>31.3
(>312.5)
>31.3
(>200.3)
>31.3
(>157.8)
>31.3
(>147.4)
15.6
(68.9)
7.8
(32.4)

>31.3
(>312.5)
>31.3
(>200.3)
>31.3
(>157.8)
>31.3
(>147.4)
15.6
(68.9)
15.6
(64.8)

>31.3
(>312.5)
>31.3
(>200.3)
>31.3
(>157.8)
31.3
(147.4)
15.6
(68.9)
7.8
(32.4)

>31.3
(>312.5)
>31.3
(>200.3)
>31.3
(>157.8)
31.3
(147.4)
15.6
(68.9)
7.8
(32.4)

>31.3
(>312.5)
>31.3
(>200.3)
>31.3
(>157.8)
31.3
(147.4)
15.6
(68.9)
7.8
(32.4)

Filamentous fungi
L
M

G

H

I

J

K

>31.3
(>312.5)
>31.3
(>200.3)
>31.3
(>157.8)
>31.3
(>147.4)
15.6
(68.9)
15.6
(64.8)

>31.3
(>312.5)
>31.3
(>200.3)
>31.3
(>157.8)
31.3
(147.4)
7.8
(34.5)
7.8
(32.4)

>31.3
(>312.5)
>31.3
(>200.3)
>31.3
(>157.8)
31.3
(147.4)
7.8
(34.5)
7.8
(32.4)

>31.3
(>312.5)
>31.3
(>200.3)
>31.3
(>157.8)
>31.3
(>147.4)
15.6
(68.9)
7.8
(32.4)

>31.3
(>312.5)
>31.3
(>200.3)
>31.3
(>157.8)
31.3
(147.4)
31.3
(138.2)
31.3
(129.6)
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>31.3
(>312.5)
>31.3
(>200.3)
>31.3
(>157.8)
>31.3
(>147.4)
15.6
(68.9)
15.6
(64.8)

>31.3
(>312.5)
>31.3
(>200.3)
>31.3
(>157.8)
>31.3
(>147.4)
15.6
(68.9)
15.6
(64.8)

Table 5.1 continued
7

1.95
(7.7)
0.975
(3.6)
0.975
(3.5)
>31.3
(>110.4)
>31.3
(>132.0)
7.8
(23.1)
>31.3
(>79.5)
3.9
(9.0)

7.8
(30.7)
0.975
(3.6)
0.975
(3.5)
>31.3
(>110.4)
>31.3
(>132.0)
31.3
(92.8)
>31.3
(>79.5)
31.3
(71.9)

3.9
(15.3)
1.95
(7.2)
0.975
(3.5)
>31.3
(>110.4)
>31.3
(>132.0)
7.8
(23.1)
>31.3
(>79.5)
31.3
(71.9)

7.8
(30.7)
0.975
(3.6)
1.95
(6.9)
>31.3
(>110.4)
>31.3
(>132.0)
31.3
(92.8)
31.3
(79.5)
15.6
(35.8)

3.9
(15.3)
1.95
(7.2)
0.975
(3.5)
>31.3
(>110.4)
>31.3
(>132.0)
7.8
(23.1)
>31.3
(>79.5)
>31.3
(>71.9)

3.9
(15.3)
1.95
(7.2)
1.95
(6.9)
>31.3
(>110.4)
>31.3
(>132.0)
31.3
(92.8)
>31.3
(>79.5)
31.3
(71.9)

3.9
1.95
1.95
1.95
3.9
1.95
7.8
(15.3)
(7.7)
(7.7)
(7.7)
(15.3)
(7.7)
(30.7)
8
1.95
0.48
0.975
1.95
1.95
0.975
1.95
(7.2)
(1.8)
(3.6)
(7.2)
(7.2)
(3.6)
(7.2)
9
1.95
0.975
0.975
0.975
0.975
0.975
0.975
(6.9)
(3.5)
(3.5)
(3.5)
(3.5)
(3.5)
(3.5)
10
>31.3
>31.3
>31.3
>31.3
>31.3
>31.3
>31.3
(>110.4) (>110.4) (>110.4) (>110.4) (>110.4) (>110.4) (>110.4)
14
>31.3
>31.3
>31.3
>31.3
>31.3
>31.3
>31.3
(>132.0) (>132.0) (>132.0) (>132.0) (>132.0) (>132.0) (>132.0)
16
31.3
31.3
15.6
0.975
31.3
0.975
31.3
(92.8)
(92.8) (46.2)
(2.9)
(92.8)
(2.9)
(92.8)
17
>31.3
>31.3
>31.3
15.6
>31.3
>31.3
>31.3
(>79.5) (>79.5) (>79.5) (39.6) (>79.5) (>79.5) (>79.5)
18
0.975- 15.6
7.8
0.03
1.95
3.9
3.9
31.3
(35.8) (17.9)
(0.1)
(4.5)
(9.0)
(9.0)
(2.271.9)
19
0.975
7.8
3.9
7.8
15.6
15.6
15.6
3.9
0.975
0.24
0.48
0.975
1.95
(2.2)
(17.6)
(8.8)
(17.6)
(35.2)
(35.2)
(35.2)
(8.8)
(2.2)
(0.55) (1.1)
(2.2)
(4.4)
20
0.975
3.9
7.8
3.9
7.8
7.8
3.9
>31.3
1.95
0.015
0.24
0.975
0.975
(2.1)
(8.4)
(16.8) (8.4)
(16.8)
(16.8)
(8.4)
(>67.5) (4.2)
(0.03) (0.5)
(2.1)
(2.1)
21
1.95
15.6
7.8
15.6
15.6
15.6
15.6
3.9
1.95
0.24
1.95
1.95
1.95
(4.1)
(32.8)
(16.4) (32.8)
(32.8)
(32.8)
(32.8)
(8.2)
(4.1)
(0.50) (4.1)
(4.1)
(4.1)
22
1.95
7.8
3.9
3.9
7.8
7.8
15.6
0.975
0.48
0.015
1.95
3.9
3.9
(3.9)
(15.9)
(7.9)
(7.9)
(15.9)
(15.9)
(31.7)
(2.0)
(0.98)
(0.03) (3.9)
(7.9)
(7.9)
23
1.95
7.8
1.95
1.95
3.9
3.9
3.9
0.975
0.975
<0.24
0.975
0.975
0.975
(3.9)
(15.4)
(3.9)
(3.9)
(7.7)
(7.7)
(7.7)
(1.9)
(1.9)
(<0.47) (1.9)
(1.9)
(1.9)
24
1.95
31.3
7.8
1.95
3.9
3.9
1.95
>31.3
0.975
>31.3
0.48
1.95
0.975
(3.8)
(60.2)
(15.0) (3.8)
(7.5)
(7.5)
(3.8)
(>60.2) (1.9)
(>60.2) (0.9)
(3.8)
(1.9)
25
1.95
15.6
7.8
3.9
7.8
7.8
7.8
0.975
1.95
0.24
3.9
3.9
3.9
(3.9)
(31.4)
(15.7) (7.9)
(15.7)
(15.7)
(15.7)
(2.0)
(3.9)
(0.48) (7.9)
(7.9)
(7.9)
26
1.95
7.8
3.9
3.9
3.9
3.9
1.95
0.975
1.95
0.24
3.9
1.95
1.95
(3.7)
(14.9)
(7.4)
(7.4)
(7.4)
(7.4)
(3.7)
(1.9)
(3.7)
(0.46) (7.4)
(3.7)
(3.7)
27
>31.3
>31.3
>31.3
3.9-31.3 7.8-31.3 >31.3
31.3
31.3
>31.3
31.3
7.8
1.95
15.6
(>96.5) (>96.5) (>96.5) (12.0(24.0(>96.5) (96.5)
(96.5) (>96.5) (>96.5) (24.0)
(6.0)
(48.1)
96.5)
96.5)
28
31.3
31.3
31.3
>31.3
>31.3
31.3
>31.3
31.3
>31.3
31.3
>31.3
>31.3
>31.3
(85.2) (85.2)
(85.2) (>85.2) (>85.2) (85.2)
(>85.2) (85.2) (>85.2) (85.2) (>85.2) (>85.2) (>85.2)
AmB 3.9
3.9
1.95
0.975
1.95
3.9
3.9
1.95
3.9
1.95
15.6
3.9
3.9
(4.2)
(4.2)
(2.1)
(1.1)
(2.1)
(4.2)
(4.2)
(2.1)
(4.2)
(2.1)
(15.6)
(4.2)
(4.2)
CAS 0.975
0.24
0.06
0.12
0.12
0.24
0.48
0.06
0.48
1.95
>31.3
>31.3
>31.3
(0.8)
(0.2)
(0.05) (0.1)
(0.1)
(0.2)
(0.4)
(0.05) (0.4)
(1.6)
(>25.8) (>25.8) (>25.8)
FLC 62.5
>125
15.6
>125
>125
62.5
62.5
>31.3
>31.3
1.95
62.5
62.5
62.5
(204.1) (>408.1) (50.9) (>408.1) (>408.1) (204.1) (204.1) (>102.2) (>102.2) (6.4)
(204.1) (204.1) (204.1)
VRC 0.24
3.9
1.95
1.95
0.975
7.8
1.95
0.06
0.12
<0.03
0.24
0.12
0.12
(0.69) (11.2)
(5.6)
(5.6)
(2.8)
(22.3)
(5.6)
(0.17) (0.34)
(<0.06) (0.69)
(0.34) (0.34)
Yeast strains: A = Candida albicans ATCC 10231, B = C. albicans ATCC 64124(R), C = C. albicans ATCC MYA-2876(S), D = C.
albicans ATCC 90819(R), E = C. albicans ATCC MYA-2310(S), F = C. albicans ATCC MYA-1237(R), G = C. albicans ATCC
MYA-1003(R), H = Candida glabrata ATCC 2001, I = Candida krusei ATCC 6258, J = Candida parapsilosis ATCC 22019. NOTE:
Here, the (S) and (R) indicate that ATCC reports these strains to be susceptible (S) and resistant (R) to ITC and FLC.
Filamentous fungi: K = Aspergillus flavus ATCC MYA-3631, L = Aspergillus nidulans ATCC 38163, M = Aspergillus terreus ATCC
MYA-3633.
Known antifungal agents: AmB = amphotericin B, FLC = fluconazole, VRC = voriconazole.
a
For yeast strains: MIC-0 values are reported for FLC analogues 1-10, 14, 16-28, AmB and CAS, whereas MIC-2 values are reported
for FLC and VRC. For filamentous fungi (strains K-M), MIC-0 values are reported for all compounds.

From a quick glance at the MIC data reported in Table 5.1, we could rapidly make the
following observations. The inactivity of 14 confirmed that the intermediates generated
during the synthesis of our target compounds did not exert any antifungal activity. In the
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case of the alkylated piperazines, the longer chains displayed better antifungal activity.
Compounds 1-4 displayed poor activity against all fungal strains tested. Compounds 5 and
6 were found to be moderately active against all strains tested, with the exception of
Aspergillus flavus (strain K). Compound 7 was found to display good activity against five
(strains A, C, and E-G) of the seven C. albicans strains tested, all three non-albicans
Candida (strains H-J), and two (strains K and L) of the three Aspergillus strains tested.
Among the alkylated piperazines, compounds 8 and 9 were found to be the best. It exhibited
an excellent and broad spectrum of activity. Surprisingly, the corresponding morpholine
analogue of 9, compound 10, displayed poor activity against all of the tested strains.

Overall, we found the morpholine-azole hybrids 27 and 28 to be inactive as antifungal
agents, with the exception of compound 27 against strains K (7.8 µg/mL) and L (1.95
µg/mL). In general, for the alkylated piperazine-azole hybrids 16-26, we observed better
activity against non-albicans Candida and Aspergillus strains than against C. albicans.
Overall, compounds 20-26 displayed good to excellent antifungal activity against most
strains tested. Compounds 16 and 18, although generally not as efficient as 20-26, also
displayed good to excellent activity against a few fungal strains. However, compound 17
was found to basically be inactive against all fungal strains tested.

When focusing on Aspergillus strains, we observed that compounds 19-21, 23, and 24
displayed excellent activity against strains K-M. Compounds 18, 22, 25, and 26 were good
against strains K-M, whereas compounds 16 and 17 were completely inactive, with the
exception of compound 16 against strain L (0.975 µg/mL). When looking at the non-
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albicans Candida, we found that the three strains tested were susceptible to the majority of
the alkylated piperazine-azole hybrids, with strain J being the most susceptible. Indeed,
compounds 16, 18-23, 25, and 26 showed excellent activity against strain J. In most cases,
compounds 18-26 displayed moderate to excellent activity against strains H and I. When
examining the MIC values against C. albicans strains A-G, we observed that compounds
19-26 exhibited good to moderate activity, whereas compounds 16-18 generally displayed
poor activity. From all of these observations made on compounds 1-28, we can conclude
that compounds 7-9, 20, 22, 23, 25, and 26 displayed better overall activity. It is important
to point out that these compounds maintained activity against the azole-resistant C.
albicans strains.

As it is known that some of the azole antifungals on the market tend to bind to proteins and
be less efficient in intracellular matrices, we tested the best compounds 7, 9, 20, 22, 25,
and 26 against strains A, J, and L in presence and absence of fetal bovine serum (FBS)
(Table 5.2), in order to test the potential effect of protein binding to our compounds. We
found that the alkylated piperazine-azole hybrids 20, 22, 25, and 26 retained their full
antifungal activity in the presence of FBS, whereas the alkylated piperazine derivatives 7
and 9 exhibited a 2 to 8-fold decrease in activity in the presence of this agent. It is important
to note that even with this small loss in activity, compounds 7 and 9 remained good
antifungals.
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Table 5.2: MIC valuesa (in µg/mL) determined for compounds 7, 9, 20, 22, 25, and 26, as
well as for two control antifungal agents (AmB and VRC) against various yeast strains and
filamentous fungi.
Yeast strains
Filamentous fungi
Cpd # Candida albicans Candida albicans Candida
Candida
Aspergillus nidulans Aspergillus nidulans
ATCC 10231 (A) ATCC 10231 (A) parapsilosis
parapsilosis
ATCC 38163 (L) (no ATCC 38163 (L)
ATCC 22019 (J) ATCC 22019 (J) FBS)
(no FBS)
(+10% FBS)
(+10% FBS)
(no FBS)
(+10% FBS)
7
1.95
3.9
1.95
7.8
1.95
7.8
9
0.975
7.8
0.975
7.8
0.975
7.8
20
0.975
0.975
0.015
0.06
0.975
0.975
22
1.95
1.95
0.015
0.06
3.9
3.9
25
1.95
1.95
0.24
0.24
3.9
3.9
26
1.95
1.95
0.24
0.24
1.95
3.9
AmB 3.9
7.8
1.95
15.6
3.9
15.6
VRC 0.48
0.48
0.015
0.015
0.12
0.12

5.3.3. Structure-activity relationship (SAR) summary
From a deeper analysis of the antifungal MIC data (Table 5.1), we could answer the five
following questions: (i) Which chain length confers better activity to the alkylated
piperazine derivatives 1-9? (ii) Which chain length confers superior activity to the
alkylated piperazine-azole hybrids 16-26? (iii) Which scaffold (alkylated piperazine versus
alkylated piperazine-azole hybrid) produces the best antifungal activity? (iv) Does the
identity of the halogen atoms on the phenyl ring play a role in antifungal activity? (v) How
do the compounds generated compare to antifungals currently used in the clinic?

For the alkylated piperazine derivatives 1-9, the optimal chain lengths for maximal activity
were found to be C14, C13, and C12, and the general trend for activity versus chain length
was C14 = C13 > C12 > C10 > C9 = C8 = C5 = C1. For the alkylated piperazine-azole hybrids
16-26, the optimal chain lengths were found to be C13, C12, and C10, and the general trend
for activity versus chain length was C13 > C12 > C10 > C14 > C11 > C9 > C8 > C1 > C5. By
performing pairwise comparisons of the activity of alkylated piperazine derivatives 1-9 to
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that of their direct azole hybrid counterparts 16-24 (e.g., 1 versus 16, 2 versus 17, etc), we
determined that the hybrids conferred superior antifungal activity, with the exception of
compounds 8 and 9, which displayed overall superior antifungal activity than hybrids 23
and 24. By investigating the activity of the dichlorinated hybrids 25 and 26, and comparing
them to those of the difluorinated counterpart 20 and 22, respectively, we observed that the
identity of the halogen atoms on the phenyl ring did not greatly influence the antifungal
activity of the compounds. For the C10-containing hybrids (20 and 25) a slightly superior
activity was observed with the difluorinated compound 20, whereas for C12-containing
hybrids (22 and 26) comparable antifungal activity was observed with both compounds
against all strains tested. In general, we found that the most potent antifungal compounds
synthesized (7-9, 20, 22, 23, 25, and 26) displayed better activity than FLC and similar or
better activity than AmB against all fungal strains tested, as well as better activity than
CAS against the three Aspergillus strains tested. For the reminder of the study, we decided
to use active compounds with alkyl chains containing an even number carbons are
representatives.

5.3.4. Antibiofilm activity of synthetic compounds
Biofilms are complex functional communities of one or more species of microorganisms
that are encased in extracellular polymeric substances and attached to both a solid surface
and to each other. Being complex matrices, antifungal agents have difficulty reaching the
pathogens embedded in these difficult-to-treat networks. The antibiofilm activity of
compounds 7, 9, 20, 22, 25, and 26, as well as that of VRC were evaluated against biofilms
of C. albicans ATCC 64124 (strain B) by XTT reduction assay (Table 5.3). The SMIC50
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and SMIC80 values (SMIC50 and SMIC80 are defined as the drug concentration required to
inhibit the metabolic activity of the biofilm by 50% and 80%, respectively) for all tested
compounds ranged between 7.8-15.6 µg/mL and 31.3-62.5 µg/mL, respectively, and were
both 62.5 µg/mL for VRC, indicating the superiority of the alkylated piperazine-azole
hybrids as C. albicans antibiofilm agents. Although it has been reported that Candida
biofilms can exhibit higher degree of resistance (with 30 to 2,000-times higher MIC values
than their corresponding planktonic MIC values) to current antifungals such as AmB and
azoles,245 we found the MIC values of alkylated piperazine-azole hybrids to not be greatly
affected in biofilms. By comparing the SMIC50 and SMIC80 values to the MIC values in
liquid cultures for each compound, we found that compounds worked best in biofilms in
the following order: 22 and 25 (0 to 2-fold increase in MIC in biofilms) > 7 (1 to 4-fold
increase) > 26 (2 to 4-fold increase) > 20 (4 to 16-fold increase) > 9 (16 to 64-fold increase).
Our results suggested that all hybrids tested, with the exception of 9, could eliminate preformed biofilms of C. albicans ATCC 64124 (strain B), at least in vitro.

Table 5.3: Antibiofilm activity of compounds 5, 6, 16, 17, 19, and 20, as well as VRC
against C. albicans ATCC 64124 (strain B) biofilms.
Cpd #
SMIC50 (µg/mL) SMIC80 (µg/mL)
5
7.8
31.3
6
15.6
62.5
16
15.6
62.5
17
7.8
15.6
19
15.6
31.3
20
15.6
31.3
VRC
62.5
62.5
SMIC50 = sessile minimum inhibitory concentration that
reduced the metabolic activity of biofilms by 50%.
SMIC80 = sessile minimum inhibitory concentration that
reduced the metabolic activity of biofilms by 80%.

5.3.5. Time-kill assays
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To determine if the antifungal activity of the alkylated piperazine-azole hybrids is
fungistatic or fungicidal, we performed time-kill assays over 24-hour periods by using
compounds 20 and 22, each against two fungal strains (strains A and J for 20; H and J for
22) (Figure 5.2). We found compounds 20 and 22 to be fungicidal at 4× their respective
MIC values against strains A and H, respectively. With their fungicidal activity,
compounds 20 and 22 appear to be better antifungals than the control FDA-approved drug
VRC, which displayed fungistatic activity against these two fungal strains. However, when
tested against strain J, both compounds displayed fungistatic activity at up to 8× their MIC
values. Although fungistatic against strain J, at 1× their respective MIC values, compounds
20 and 22 displayed a larger reduction in fungal growth than VRC, confirming their
superiority as antifungals.

Figure 5.2. Representative time-kill curves for compound 20 against A. C. albicans ATCC 10231 (strain A)
and B. C. parapsilosis ATCC 22019 (strain J), as well as for compound 22 against C. C. glabrata ATCC
2001 (strain H), and D. strain J. Fungal strains were treated with no drug (black circles), 1× MIC (white
circles), 4× MIC (inverted black triangles), or 8× MIC (white triangles) of compounds 20 or 22, or with 1×
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MIC (black squares) or 4× MIC (white squares) of VRC (previously published as VOR). The detection limit
of this assay was 100 CFU/mL (represented by the red line in panels A and C).

5.3.6. Hemolysis assay
Since our synthetic hybrids exhibited promising antifungal activity, we wanted to confirm
that they would display none or reasonable (<50% hemolysis at 10× MIC) hemolytic
activity against murine red blood cells (mRBCs). We first investigated the alkylated
piperazine derivatives 7 and 9 and found them to exhibit 52% and 93% hemolysis of
mRBCs at 7.8 µg/mL (1 to 8-fold higher concentration than their overall antifungal MIC
values), potentially indicating that very long alkyl chains might not be optimal for the
development of these compounds as antifungals. We next tested all of the alkylated
piperazine-azole hybrids generated, with the exception of compound 17 that we had found
to be inactive. Compounds 16 (C1) and 18 (C8) displayed <10% hemolysis at a
concentration 62.5 µg/mL, which is 2 to 1024-fold higher than their overall MIC values.
Similarly, compound 20 induced only 23% lysis at 31.3 µg/mL, which is 1 to 1024-fold
higher than the MIC values reported for this compound. Since compound 20 is one of the
best molecules in terms of MIC values, the low hemolytic activity for this analogue is
highly encouraging. However, similarly to their counterparts 7 and 9, hybrids 22 and 24
with C12 and C14 alkyl chains were found to display >50% hemolysis at 7.8 µg/mL,
confirming that very long alkyl chains are not optimal. Subsequently, we analyzed the
hemolytic activity of the dichlorinated compounds 25 and 26 and compared them with their
difluorinated counterparts 20 and 22. Similarly to compounds 20 and 22, hybrids 25 and
26 showed chain-dependent hemolytic activity in the order of 26 (C12) > 25 (C10).
Compound 25 showed only 22% hemolysis at 7.8 µg/mL (1 to 65-fold higher concentration
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than its antifungal MIC values). However, at that same concentration of 7.8 µg/mL,
compound 26 displayed 85% hemolysis of mRBCs. Overall, the difluorinated analogues
20 and 22 displayed lower or equal hemolytic activity when compared to their dichlorinated
counterparts 25 and 26. Importantly, the newly synthesized compound 20 displayed less
hemolytic effect than the FDA-approved control drug VRC.

5.3.7. In vitro cytotoxicity assay
Since fungi are eukaryotes with similar biological properties, the drugs that are designed
to target fungal cells may cause unwanted toxicity to mammalian cells. Therefore, a crucial
parameter to consider when developing antifungal drugs is their selectivity for fungal over
mammalian cells. To determine the selectivity of the synthetic hybrids towards fungi, we
tested the most active compounds 7, 9, 18, 20, 22, 25, and 26 against three different cell
lines, HEK-293, A549, and BEAS-2B, along with the FDA-approved antifungal agent
VRC as a positive control (Figure 5.3). We observed that the alkylated piperazine
derivatives 7 and 9 were toxic to all three cell lines tested, with the longer alkyl chains
resulting in higher toxicity to mammalian cells. Compound 18 (C8) was non-toxic to A549
at up to 15.5 µg/mL, but exhibited some toxicity against HEK-293 and BEAS-2B at 7.8
µg/mL (1 to 1024-fold higher concentration than its overall antifungal MIC values).
Similarly, hybrid 20 displayed no toxicity at up to 7.8 µg/mL against A549, and also
exhibited some toxicity against HEK-293 and BEAS-2B at 7.8 µg/mL, which is 1 to 2048fold higher than the MIC values reported for this compound. As we postulated, for
compound 22 with the longer alkyl chain, less than 40% cell survival was reported against
all three cell lines when tested at a concentration of 7.8 µg/mL (1 to 2048-fold higher
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concentration than its overall antifungal MIC values). The dichlorinated compounds 25 and
26 exhibited similar trends and the cytotoxicity values were 1 to 128-fold higher
concentration than the overall antifungal MIC values reported for these compounds.
Overall, when considering the very low MIC values for hybrids 18, 20, 22, 25, and 26
against specific fungal strains, these cytotoxicity data are encouraging.

Figure 5.3. Representative cytotoxicity assays of piperazine and azole analogues against three mammalian
cell lines: A. HEK-293, B. A549, and C. BEAS-2B. Cells were treated with various concentrations of
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compounds 7 (yellow bars), 9 (orange bars), 18 (green bars), 20 (turquoise bars), 22 (blue bars), 25 (purple
bars), 26 (hot pink bars), and VRC (previously published as VOR, light pink bars). The positive control
consisted of cells treated with Triton X-100® (TX, 12.5% v/v). The negative control consisted of cells treated
with DMSO (no drug).

5.3.8. Membrane permeabilization assay
Previous studies from our group have demonstrated that amphiphilic molecules can cause
membrane disruption to result in fungal cell death. Based on these findings, we assumed
that the hybrids generated in this study could also potentially cause fungal death by
disrupting the fungal membrane. To investigate this possible mechanism of action, we
evaluated the effect of compounds 20 and 26 on fungal cell membrane integrity by using
propidium iodide (PI) dye as a probe (Figure 5.4). The PI dye can only enter the cells with
compromised membrane. Afterwards, the dye binds to nucleic acid and fluoresces, which
can be observed under a fluorescence microscope. We used compounds 20 and 26 with C10
and C12 linear alkyl chains to determine the impact of chain length on membrane disruption.
The KANB (C14) derivative with a 14-carbon linear alkyl chain, and FLC were used as
positive and negative controls, respectively. At 2× MIC, the positive control KANB (C14)
significantly increased PI dye uptake by C. albicans ATCC 10231 (strain A). As expected,
at 7.8 µg/mL, the highest concentration achievable in this assay, the negative control FLC
did not allow for PI uptake by the fungal cells. Regardless of their chain length, neither
compound 20 nor 26 (at 4× MIC) induced cellular uptake of PI dye into C. albicans ATCC
10231 (strain A). From this study, we concluded that the possible mechanism of action of
our compounds is not membrane disruption.
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Figure 5.4. Effect of FLC and compounds 20 and 26 on the cell membrane integrity of C. albicans ATCC
10231 (strain A). From the top to bottom: Propidium iodide (PI) dye uptake by yeast cells without drug, with
FLC (7.8 µg/mL), KANB (C14) (15.6 µg/mL), compound 20 (4× MIC), and compound 26 (4× MIC).

5.3.9. Determination of sterol composition in C. albicans in the presence and absence
of drugs
Since our synthetic hybrids did not cause membrane disruption of C. albicans ATCC 10231
(strain A) in the membrane permeabilization assay, we predicted they could potentially act
like the other conventional azoles, and decided to explore their effect on sterol composition.
By using gas chromatography-mass spectrometry (GC-MS), we investigated the potential
of the synthetic compounds to exert their antifungal activity by inhibiting the sterol 14αdemethylase enzyme of the ergosterol biosynthetic pathway (Figure 5.5). We selected two
of the best compounds, 20 and 26, and evaluated their effect on sterol composition in C.
albicans ATCC 10231 (strain A) at sub-MIC levels of 0.48 µg/mL (Figure 5.5E) and 0.975
µg/mL (Figure 5.5F), respectively. We also used FLC and VRC at 1.95 µg/mL and 0.12
µg/mL, respectively, for comparison studies (Figure 5.5C and 5.5D). A no drug control
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was also performed (Figure 5.5A). The sterol profile results are summarized in Figure
5.5G. The sterol profile in the absence of drug indicated that strain A accumulated 100%
ergosterol (2), suggesting that the sterol biosynthesis was fully functional in this fungal
strain. When treated with FLC, we found predominance of ergosterol (2, 95.90%) in strain
A, which indicated that FLC had no effect on ergosterol biosynthesis in this specific fungal
strain. This observation could be easily explained by the fact that we have used FLC
concentration that corresponds to 32-fold lower than the antifungal MIC value (62.5
μg/mL) for FLC against this strain. When treating strain A with VRC, we detected a lower
amount of ergosterol (2, 64.93%), and an increased amount of lanosterol (1, 18.49%) and
eburicol (3, 2.14%) in comparison to what we observed with FLC. However, when strain
A was treated with compound 26, we observed a relatively low amount of ergosterol (2,
50.64%), as well as a higher quantity of lanosterol (1, 29.49%), eburicol (3, 1.15%), and
the fungistatic metabolite 14α-methyl ergosta-8,24(28)-diene-3β,6α-diol (4, 11.05%).
Interestingly, when strain A was treated with compound 20, we detected a greater reduction
in the amount of ergosterol (2, 30.15%) along with a related increase in lanosterol (1,
33.37%), eburicol (3, 1.25%) and the fungistatic metabolite 14α-methyl ergosta-8,24(28)diene-3β,6α-diol (4, 15.40%). Finally, both compounds inhibited the ergosterol
biosynthesis better than the azole drug controls FLC and VRC. These results indicated that
the synthetic analogues 20 and 26 act by inhibiting 14α-demethylase enzyme present
fungal cells, thereby affecting the ergosterol biosynthetic pathway.
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Figure 5.5. A. A simplified ergosterol biosynthetic pathway and products resulting from inhibition of
ERG11. B-F. GC-MS chromatograms of the sterols extracted from untreated and antifungal-treated C.
albicans ATCC 10231 (strain A). The fungal strain was treated with DMSO (no drug control, panel B), FLC
at 1.95 µg/mL (panel C), VRC (previously published as VOR) at 0.12 µg/mL (panel D), compound 20 at
0.48 µg/mL (panel E), and compound 26 at 0.975 µg/mL (panel F). The peaks in these chromatograms are
for lanosterol (1), ergosterol (2), eburicol (3), 14α-methyl ergosta-8,24(28)-dien-3β,6α-diol (4), and three
unknown sterols (5-7). G. A table summarizing the percentage of each sterol from panels B-F.

5.3.10. Molecular docking study
To provide further confirmation of the inhibition of sterol 14α-demethylase with the new
FLC derivatives, we performed docking studies of analogue 20 with the C. albicans
CYP51. The synthetic analogue 20 was docked based on the crystal structure of VT-1161
with C. albicans CYP51 (PDB ID: 3P99246) (Figure 5.6). The pharmacophore of 20 was
unambiguously positioned based on VT-1161 and the rest of the molecule was positioned
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isosterically with the features of the inhibitor VT-1161. The difluorophenyl ring, triazole,
and piperazine ring of the synthetic analogue 20 are isosteric with the difluorophenyl ring,
tetrazole, and pyridine ring of VT-1161. The alkyl chain of 20 is isosteric with the 4-(2,2,2trifluoroethoxy)phenyl ring of VT-1161. Even though the alkyl chain is longer, it fits
perfectly in to the hydrophobic region. The triazole ring is coordinated to the iron (Fe) of
the heme and the difluorophenyl ring is largely occupying the hydrophobic environment of
Phe126, Ile131, Phe228, and on the other side Tyr132. The hydroxyl group of 20 makes
water molecule mediated hydrogen bonding with the hydroxyl of Tyr132 and carboxylate
group of the heme. The piperazine ring is surrounded by Leu121, Met508, and Leu376,
which is favored hydrophobically. Additional hydrophobic interactions with the phenyl
ring of Tyr118 was observed for the piperazine ring. Similarly to the 4-(2,2,2trifluoroethoxy)phenyl group of VT-1161, the alkyl chain of compound 20 occupies a large
solvent accessible predominantly hydrophobic pocket surrounded by Tyr64, Leu87, Leu88,
Pro230, Val234, and His377. In sum, the synthetic analogue 20 exhibited many favorable
interactions with the CYP51 enzyme, which further support the results observed by the
determination of sterol composition experiments.
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Figure 5.6. A. Docking of compound 20 to the C. albicans sterol 14α-demethylase CYP51 (PDB ID:
3P99246). B. Co-crystal structure of VT-1161 bound to the C. albicans sterol 14α-demethylase CYP51 (PDB
ID: 3P99246). In both panels the residues interacting with the bound molecules are shown as orange sticks. A
water molecule is depicted as a purple sphere. The heme is shown as green sticks with its iron in dark orange.
Compounds 20 and VT-1161 as depicted as turquoise sticks with their oxygen, nitrogen, and fluorine atoms
in red, blue, and dark turquoise.

5.3.11. Chemical and physical properties
FLC is known for its bioavailability, but in bulk form, it appears crystalline and is only
slightly soluble in water compared to organic solvents such as DMSO where it is highly
soluble. Our best compounds, 7, 8, 9, 20, 22, 23, 25, and 26, displayed similar solubility
behaviors to that of FLC. The Lipinski’s rule of five is often used as a starting point to
evaluate drug likeness or determine if a compound with a certain pharmacological or
biological activity has properties that would make it a likely active drug in humans. We
calculated the LogP values of all the compounds (Table 5.4). In general, an orally active
drug is allowed no more than one violations of the rule of five. We investigated compound
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7, 8, 9, 20, 22, 23, 25, and 26 for potential violations of the rule of five. In the case of the
alkylated piperazines 7, 8, and 9, we observed only one violation (their LogP values was
greater than 5), but their molecular weight <500, not more than 5 hydrogen bond donors,
and 10 hydrogen bond acceptors were in line with the rule of five. Similar results were
observed for the alkylated piperazine-azole hybrids 20, 22, 23, 25, and 26. Compounds 20,
22, 23, and 25 exhibited < 500, < 5 hydrogen bond donors and < 10 hydrogen bond
acceptors with Log P values higher than 5. Only compound 26 displayed two violations
with greater than 500 molecular weight and LogP value greater than 5. From these
observations, we can conclude that these compounds will be, in the future (outside the
scope of this study), be investigated in animal studies.

Table 5.4: LogPa values of all the compounds tested.
Cpd #
LogP
1
-0.38 (-0.36)
2
1.28 (1.58)
3
2.53 (3.10)
4
2.95 (3.60)
5
3.37 (4.11)
6
3.78 (4.61)
7
4.20 (5.12)
8
4.62 (5.62)
9
5.04 (6.13)
10
5.26 (6.68)
16
1.07 (0.66)
17
2.73 (2.60)
18
3.98 (4.12)
19
4.40 (4.62)
20
4.81 (5.13)
21
5.23 (5.63)
22
5.65 (6.14)
23
6.07 (6.64)
24
6.48 (7.15)
25
5.61 (6.16)
26
6.45 (7.17)
27
0.91 (0.61)
28
0.54 (0.05)
a
Calculated from ChemDraw and from
Molinspiration (in parenthesis)

5.4 CONCLUSION
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In summary, we have synthesized nine novel alkylated piperazine derivatives (1-9) as well
as eleven alkylated piperazine-azole hybrids (16-26) along with an alkylated morpholine
derivative (10) and two morpholine-azole hybrids (27-28) with alkyl chains of various
lengths (C1, C5, C8-C14). We did not detect any antifungal activities with the alkylated
morpholine derivative and the two morpholine-azole hybrids. We observed that the
antifungal activity of alkylated piperazines and alkylated piperazine-azole hybrids
depended on the length of the alkyl chains. We identified compounds 7, 9, 20, 22, 25, and
26 as promising antifungal agents with low hemolytic activity, low cytotoxicity, and great
activity against C. albicans, non-albicans Candida, and Aspergillus strains. In most cases,
compounds 7-9, 20, 22, 23, 25, and 26 displayed enhanced or comparable antifungal
activity against fungal strains when compared to the commercial antifungal drugs AmB,
CAS, and FLC. These compounds also exhibited superior activity compared to the control
drug VRC against Candida biofilms. Contrary to the mechanism of action (i.e., membrane
disruption) previously reported for molecules containing long alkyl chains, the compounds
in this study did not disrupt the fungal membrane. Instead, the molecules studied killed the
fungal cells by disrupting ergosterol biosynthesis by targeting the sterol 14α-demethylase
enzyme of the ergosterol biosynthetic pathway. In the future, it will be interesting to see
how these promising molecules will fare in in vivo studies.

5.5. EXPERIMENTAL SECTION
5.5.1. Chemistry
5.5.1.1. Materials and instrumentation
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All the chemicals used in this study (including compounds 1 and 12) were purchased from
Sigma-Aldrich (St. Louis, MO) or AK Scientific (Union City, CA) and used without any
further purification. DMF and THF were freshly distilled prior to use. Chemical reactions
were monitored by TLC (Merck, Silica gel 60 F254). Visualization was achieved using one
of the following methods: Iodine stain (I2 in SiO2 gel) or UV light. Compounds were
purified by SiO2 flash chromatography (Dynamic Adsorbents Inc., Flash SiO2 gel 32-63µ).
1

H and 13C NMR spectra were recorded on a Varian 400 MHz spectrometer. Mass spectra

were recorded using an Agilent 1200 series Quaternary LC system equipped with a diode
array detector, and Eclipse XDB-C18 column (250 mm × 4.6 mm, 5 µm), and an Agilent
6120 Quadrupole MSD mass spectrometer. Further confirmation of purity for the final
azole molecules was obtained by RP-HPLC, which was performed on an Agilent
Technologies 1260 Infinity HPLC system by using the following general method 1: Flow
rate = 1 mL/min; λ = 254 nm; column = Vydac 201SPTM C18, 250 × 4.6 mm, 90 Å, 5 µm;
Eluents: A = H2O + 0.1% TFA, B = MeCN; gradient profile: starting from 1% B, increasing
from 1% B to 100% B over 20 min, holding at 100% B from 20-25 min, decreasing from
100% B to 1% B from 25-30 min. Prior to each injection, the HPLC column was
equilibrated for 15 min with 1% B. All compounds synthesized were determined to be
≥96% pure. For compounds 19, 21, and 23, the following general method was used: Flow
rate = 1 mL/min; λ = 254 nm; column = Apollo C18, 250 × 4.6 mm, 5 µm; Eluents: A =
H2O + 0.1% formic acid, B = MeCN 0.1% formic acid; gradient profile: starting from 95%
B, increasing from 95% B to 100% B over 16 min, holding at 100% B from 16-20 min,
decreasing from 100% B to 5% B from 20-30 min. All reactions were carried out under
nitrogen atmosphere and all yields reported represent isolated yields. Known compounds
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were characterized by 1H NMR and are in complete agreement with samples reported in
the literature. Compounds 2 and 7 was synthesized as previously reported.220

5.5.1.2. Experimental protocols for the preparation of compounds 3, 4, 6-8, and 10-22
1-Octyl piperazine (3). To a solution of piperazine (669 mg, 7.77 mmol) in MeCN (15
mL), 1-bromooctane (300 mg, 1.55 mmol) was added. The reaction mixture was stirred at
room temperature for 12 h and progress of the reaction was monitored by TLC
(1:1/MeOH:CH2Cl2, Rf 0.20). The organic layer was removed under reduced pressure and
the residue was purified by flash column chromatography (SiO2, 1:4/MeOH:CH2Cl2) to
afford compound 3 (260 mg, 85%) as a white solid: 1H NMR (400 MHz, CD3OD, Figure
D1) δ 2.96 (t, J = 5.1 Hz, 4H), 2.53 (very br s, 4H), 2.37 (m, 2H), 1.53-1.47 (p, J = 7.2 Hz,
2H), 1.32-1.26 (m, 10H), 0.88 (t, J = 6.6 Hz, 3H); 13C NMR (100 MHz, CD3OD, Figure
D2) δ 58.4, 51.8, 44.0, 31.6, 29.1, 29.0, 27.1, 25.8, 22.3, 13.0; LRMS m/z calcd for
C12H26N2: 198.2; found 199.2 [M+H]+.

1-Nonyl piperazine (4). To a solution of piperazine (1.01 g, 12.1 mmol) in MeCN (10
mL), 1-bromononane (500 mg, 2.41 mmol) was added. The reaction mixture was stirred at
room temperature for 12 h and progress of the reaction was monitored by TLC
(1:1/MeOH:CH2Cl2, Rf 0.21). The organic layer was removed under reduced pressure and
the residue was purified by flash column chromatography (SiO2, 1:4/MeOH:CH2Cl2) to
afford compound 4 (301 mg, 59%) as a white solid: 1H NMR (400 MHz, CD3OD, Figure
D3) δ 2.83 (t, J = 5.0 Hz, 4H), 2.43 (very br s, 4H), 2.35-2.27 (m, 2H), 1.55-1.45 (m, 2H),
1.34-1.23 (m, 12H), 0.88 (t, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CD3OD, Figure D4) δ
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59.0, 53.3, 44.5, 31.6, 29.3, 29.2, 29.0, 27.3, 25.8, 22.3, 13.0; LRMS m/z calcd for
C13H28N2: 212.2; found 213.2 [M+H]+.

1-Decyl piperazine (5). To a solution of piperazine (1.95 g, 22.6 mmol) in MeCN (15 mL),
1-bromodecane (1.00 g, 4.52 mmol) and Cs2CO3 (736 mg, 2.26 mmol) were added. The
reaction mixture was stirred at room temperature for 12 h and progress of the reaction was
monitored by TLC (1:1/MeOH:CH2Cl2, Rf 0.10). The organic layer was removed under
reduced pressure and the residue was purified by flash column chromatography (SiO2,
1:4/MeOH:CH2Cl2) to afford compound 5 (690 mg, 67%) as a white solid: 1H NMR (400
MHz, CD3OD, Figure D5) δ 2.91 (t, J = 5.1 Hz, 4H), 2.50 (very br s, 4H), 2.36 (m, 2H),
1.51 (p, J = 6.4 Hz, 2H), 1.32-1.26 (m, 14H), 0.90 (t, J = 6.7 Hz, 3H); 13C NMR (100 MHz,
CD3OD, Figure D6) δ 58.8, 52.9, 44.4, 31.6, 29.28, 29.26, 29.2, 29.0, 27.2, 25.8, 22.3,
13.0; LRMS m/z calcd for C14H30N2: 226.2; found 227.2 [M+H]+.

1-Undecyl piperazine (6). To a solution of piperazine (883 mg, 10.6 mmol) in MeCN (10
mL), 1-bromoundecane (500 mg, 2.13 mmol) was added. The reaction mixture was stirred
at room temperature for 12 h and progress of the reaction was monitored by TLC
(1:1/MeOH:CH2Cl2, Rf 0.24). The organic layer was removed under reduced pressure and
the residue was purified by flash column chromatography (SiO2, 1:4/MeOH:CH2Cl2) to
afford compound 6 (363 mg, 71%) as a white solid: 1H NMR (400 MHz, CD3OD, Figure
D7) δ 2.89 (t, J = 5.0 Hz, 4H), 2.48 (very br s, 4H), 2.36-2.32 (m, 2H), 1.54-1.46 (m, 2H),
1.35-1.22 (m, 16H), 0.88 (t, J = 6.6 Hz, 3H); 13C NMR (100 MHz, CD3OD, Figure D8) δ
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58.7, 52.4, 44.2, 31.6, 29.30 (2C), 29.27, 29.2, 29.0, 27.2, 25.8, 22.3, 13.0; LRMS m/z
calcd for C15H32N2: 240.3; found 241.2 [M+H]+.

1-Tridecyl piperazine (8). To a solution of piperazine (788 mg, 9.49 mmol) in MeCN (10
mL), 1-bromotridecane (500 mg, 1.90 mmol) was added. The reaction mixture was stirred
at room temperature for 12 h and progress of the reaction was monitored by TLC
(1:1/MeOH:CH2Cl2, Rf 0.28). The organic layer was removed under reduced pressure and
the residue was purified by flash column chromatography (SiO2, 1:4/MeOH:CH2Cl2) to
afford compound 8 (301 mg, 59%) as a white solid: 1H NMR (400 MHz, CD3OD, Figure
D9) δ 2.83 (t, J = 5.0 Hz, 4H), 2.44 (very br s, 4H), 2.34-2.29 (m, 2H), 1.55-1.45 (m, 2H),
1.35-1.22 (m, 20H), 0.88 (t, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CD3OD, Figure D10) δ
59.0, 53.3, 44.5, 31.7, 29.4, 29.34 (2C), 29.29, 29.27, 29.2, 29.0, 27.3, 25.8, 22.3, 13.0;
LRMS m/z calcd for C17H36N2: 268.3; found 269.2 [M+H]+.

1-Tetradecyl piperazine (9). To a solution of piperazine (1.55 g, 18.0 mmol) in MeCN
(15 mL), 1-bromotetradecane (1.00 g, 3.61 mmol) and Cs2CO3 (588 mg, 1.81 mmol) were
added. The reaction mixture was stirred at room temperature for 12 h and progress of the
reaction was monitored by TLC (1:1/MeOH:CH2Cl2, Rf 0.20). The organic layer was
removed under reduced pressure and the residue was purified by flash column
chromatography (SiO2, 1:4/MeOH:CH2Cl2) to afford compound 9 (650 mg, 64%) as a
white solid: 1H NMR (400 MHz, CD3OD, Figure D11) δ 2.93 (t, J = 5.1 Hz, 4H), 2.52
(very br s, 4H), 2.37 (m, 2H), 1.52 (p, J = 7.4 Hz, 2H), 1.32-1.26 (m, 20H), 0.90 (t, J = 6.5
Hz, 3H); 13C NMR (100 MHz, CD3OD, Figure D12) δ 58.7, 52.6, 44.3, 31.7, 29.37, 29.35,
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29.33 (2C), 29.28, 29.27, 29.2, 29.1, 27.2, 25.8, 22.3, 13.0; LRMS m/z calcd for C18H38N2:
282.3; found 283.3 [M+H]+.

4-Tetradecyl morpholine (10). To a solution of morpholine (200 mg, 2.30 mmol) in
MeCN (8 mL), 1-bromotetradecane (1.3 mL, 4.59 mmol) was added. The reaction mixture
was stirred at room temperature for 12 h and progress of the reaction was monitored by
TLC (1:1/MeOH:CH2Cl2, Rf 0.50). The organic layer was removed under reduced pressure
and the residue was purified by flash column chromatography (SiO2, 1:9/MeOH:CH2Cl2)
to afford compound 10 (320 mg, 49%) as a colorless liquid: 1H NMR (400 MHz, CD3OD,
Figure D13) δ 3.67 (t, J = 4.7 Hz, 4H), 2.43 (br s, 4H), 2.31 (m, 2H), 1.53-1.45 (m, 2H),
1.38-1.21 (m, 22H), 0.88 (t, J = 7.0 Hz, 3H); 13C NMR (100 MHz, CD3OD, Figure D14) δ
66.1, 58.8, 53.4, 31.7, 29.40, 29.38, 29.37 (2C), 29.31, 29.30, 29.2, 29.1, 27.2, 25.8, 22.3,
13.1; LRMS m/z calcd for C18H37NO: 283.3; found 284.3 [M+H]+.

2,4-Dichloro-2-(1H-3-amino-1,2,4-triazo-1-yl)acetophenone (11). To a solution of
2,2',4'-trichloroacetophenone (2.60 g, 11.6 mmol) in 2-propanol (15 mL), 4-amino-1,2,4triazole (783 mg, 9.31 mmol) was added and the resulting mixture was refluxed for 12 h.
The solvent was evaporated, and to the residue CH2Cl2 (15 mL) was added and the solution
was stirred for 30 min at room temperature and filtered. The solid was washed with CH2Cl2
(2×10 mL) to afford compound 11 (3.2 g, 89%) as a white solid: 1H NMR (400 MHz,
CD3OD, which matches the lit.,221 Figure D15) δ 9.04 (s, 1H), 8.77 (s, 1H), 7.92 (d, J =
8.5 Hz, 1H), 7.69 (d, J = 2.0 Hz, 1H), 7.53 (dd, J1 = 7.8 Hz, J2 = 2.0 Hz, 1H), 4.84 (s, 2H).
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2,4-Dichloro-2-(1H-1,2,4-triazo-1-yl)acetophenone (13). A solution of compound 11
(1.50 g, 4.88 mmol) in H2O (15 mL) was cooled to 0 °C followed by the addition of conc.
HCl (0.5 mL) and sodium nitrite (370 mg, 5.36 mmol). The reaction mixture was then
stirred at room temperature for 2 h and the completion of the reaction was observed by
TLC (1:9/MeOH:CH2Cl2, Rf 0.70). The reaction mixture was neutralized with a saturated
NaHCO3 solution and the solid formed was filtered. The residue was purified by flash
column chromatography (SiO2, 1:9/MeOH:CH2Cl2) to afford compound 13 (960 mg, 80%)
as a yellow solid: 1H NMR (400 MHz, CDCl3 which matches the lit.,221 Figure D16) δ
8.28 (s, 1H), 7.98 (s, 1H), 7.64 (d, J = 8.4 Hz, 1H), 7.49 (d, J = 2.0 Hz, 1H), 7.36 (dd, J1 =
8.4 Hz, J2 = 2.0 Hz, 1H), 5.62 (s, 2H).

1-[[2-(2,4-Difluorophenyl)-2-oxiranyl]methyl]-1H-1,2,4-triazole (14). To a solution of
2,4-difuoro-2-(1H-1,2,4-triazo-1-yl)acetophenone (1.00 g, 4.48 mmol) in toluene (10 mL),
trimethylsulfoxonium iodide (1.08 g, 4.93 mmol), hexadecyltrimethylammonium bromide
(163 mg, 0.45 mmol) and 1.5 mL 20% (v/v) sodium hydroxide was added. The reaction
mixture was stirred at 60 °C for 1 h and progress of the reaction was monitored by TLC
(3:2/EtOAc:Hexanes, Rf 0.35). The reaction mixture was diluted with EtOAc (20 mL) and
washed with H2O (20 mL). The organic layer was removed under reduced pressure and the
residue was purified by flash column chromatography (SiO2, 3:2/EtOAc:Hexanes) to
afford compound 14 (720 mg, 68%) as a yellow gummy liquid: 1H NMR (400 MHz,
CDCl3, Figure D17) δ 8.08 (s, 1H), 7.86 (s, 1H), 7.20-7.11 (m, 1H), 6.86-6.75 (m, 2H),
4.82 (d, J = 14.8 Hz, 1H), 4.49 (d, J = 14.8 Hz, 1H), 2.93 (d, J = 4.6 Hz, 1H), 2.87 (d, J =
4.6 Hz, 1H); 13C NMR (100 MHz, CDCl3, Figure D18) δ 164.4, 164.3, 161.9, 161.8, 161.7,
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159.4, 159.2, 151.8, 144.1, 129.64, 129.59, 129.55, 129.49, 111.90, 111.87, 111.69,
111.65, 104.3, 104.1, 103.8, 56.3, 53.59, 53.55, 52.2; LRMS m/z calcd for C11H9F2N3O:
237.1; found 238.1 [M+H]+.

1-[[2-(2,4-Dichlorophenyl)-2-oxiranyl]methyl]-1H-1,2,4-triazole (15). To a solution of
2,4-dichloro-2-(1H-1,2,4-triazo-1-yl)acetophenone (2.00 g, 7.81 mmol) in toluene (20
mL), trimethylsulfoxonium iodide (1.89 g, 8.59 mmol), hexadecyltrimethylammonium
bromide (94 mg, 0.26 mmol), and 20% (w/w) sodium hydroxide (344 mg) were added. The
reaction mixture was stirred at 60 °C for 2 h and progress of the reaction was monitored by
TLC (3:2/EtOAc:Hexanes, Rf 0.74). The reaction mixture was diluted with EtOAc (60 mL)
and washed with H2O (20 mL) and brine (30 mL), and then dried over MgSO4. The organic
layer was removed under reduced pressure and the residue was purified by flash column
chromatography (SiO2, 1:1/EtOAc:Hexanes) to afford compound 15 (620 mg, 29%) as a
brown liquid: 1H NMR (400 MHz, CDCl3, Figure D19) δ 8.10 (s, 1H), 7.88 (s, 1H), 7.38
(d, J = 1.8 Hz, 1H), 7.16 (dd, J1 = 8.2 Hz, J2 = 1.8 Hz, 1H), 7.10 (d, J = 8.2 Hz, 1H), 4.86
(d, J = 14.9 Hz, 1H), 4.48 (d, J = 14.9 Hz, 1H), 2.96 (d, J = 4.3 Hz, 1H), 2.88 (d, J = 4.3
Hz, 1H); 13C NMR (100 MHz, CDCl3, Figure D20) δ 151.8, 144.1, 135.5, 133.2, 132.7,
130.2, 129.2, 127.5, 58.5, 53.0, 52.4; LRMS m/z calcd for C11H9Cl2N3O: 269.0; found
270.0 [M+H]+.

2-(2,4-Difluorophenyl)-1-(1H-1,2,4-triazo1-yl)-3-(4-methylpiperazine)propan-2-ol)
(16). To a solution of compound 14 (50 mg, 0.21 mmol) in EtOH (3 mL), Nmethylpiperazine (31 mg, 0.32 mmol) and Et3N (0.04 mL, 0.32 mmol) were added. The
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reaction mixture was stirred at 80 °C for 12 h and progress of the reaction was monitored
by TLC (1:9/MeOH:CH2Cl2, Rf 0.30). The organic layer was removed under reduced
pressure and the residue was purified by flash column chromatography (SiO2,
1:19/MeOH:CH2Cl2) to afford compound 16 (55 mg, 77%) as a colorless liquid: 1H NMR
(400 MHz, CDCl3, Figure D21) δ 8.08 (s, 1H), 7.77 (s, 1H), 7.55-7.46 (m, 1H), 6.82-6.75
(m, 2H), 4.53 (d, J = 15.0 Hz, 1H), 4.49 (d, J = 15.0 Hz, 1H), 3.06 (d, J = 13.6 Hz, 1H),
2.68 (d, J = 13.6 Hz, 1H), 2.48 (m, 8H), 2.32 (m, 3H); 13C NMR (100 MHz, CDCl3, Figure
D22) δ 164.0, 163.9, 161.5, 161.4, 160.1, 160.0, 157.7, 157.6, 151.0, 144.6, 129.33, 129.27,
129.23, 129.18, 126.2, 126.1, 126.03, 125.00, 111.64, 111.61, 111.43, 111.41, 104.5,
104.28, 104.26, 104.0, 72.01, 71.96, 62.2, 62.1, 56.3, 56.2, 54.9, 54.0, 45.7; LRMS m/z
calcd for C16H21F2N5O: 337.2; found 338.1 [M+H]+. Purity of the compound was further
confirmed by RP-HPLC by using method 1: Rt = 3.39 min (99% pure; Figure D23).

2-(2,4-Difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-3-(4-pentylpiperazine)

propan-2-ol

(17). To a solution of compound 14 (35 mg, 0.15 mmol) in EtOH (3 mL), Npentylpiperazine (34 mg, 0.22 mmol) and Et3N (0.03 mL, 0.22 mmol) were added. The
reaction mixture was stirred at 80 °C for 12 h and progress of the reaction was monitored
by TLC (1:9/MeOH:CH2Cl2, Rf 0.40). The organic layer was removed under reduced
pressure and the residue was purified by flash column chromatography (SiO2,
1:19/MeOH:CH2Cl2) to afford compound 17 (42 mg, 71%) as a colorless liquid: 1H NMR
(400 MHz, CD3OD, Figure D24) δ 8.30 (s, 1H), 7.78 (s, 1H), 7.50-7.44 (m, 1H), 6.97-6.84
(m, 2H), 4.70 (d, J = 14.3 Hz, 1H), 4.65 (d, J = 14.3 Hz, 1H), 3.06 (dd, J1 = 13.9 Hz, J2 =
1.5 Hz, 1H), 3.05-2.86 (m, 4H), 2.83 (d, J = 13.9 Hz, 1H), 2.80-2.62 (m, 4H), 1.63 (p, J =
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7.6 Hz, 2H), 1.40-1.29 (m, 6H), 0.93 (t, J = 6.9 Hz, 3H); 13C NMR (100 MHz, CD3OD,
Figure D25) δ 164.0, 163.9, 161.5, 157.6, 149.7, 129.51, 129.45, 129.41, 129.35, 125.6,
125.5, 110.7, 110.5, 103.7, 103.5, 103.2, 73.84, 73.79, 62.92, 62.88, 57.9, 56.00, 55.95,
53.2, 52.6, 29.2, 25.2, 22.1, 12.8; LRMS m/z calcd for C20H29F2N5O: 393.2; found 394.2
[M+H]+. Purity of the compound was further confirmed by RP-HPLC by using method 1:
Rt = 3.46 min (96% pure; Figure D26).

2-(2,4-Difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-3-(4-octylpiperazine)propan-2-ol
(18). To a solution of compound 14 (50 mg, 0.21 mmol) in EtOH (3 mL), compound 3 (63
mg, 0.32 mmol) and Et3N (0.04 mL, 0.32 mmol) were added. The reaction mixture was
stirred at 80 °C for 12 h and progress of the reaction was monitored by TLC
(1:9/MeOH:CH2Cl2, Rf 0.45). The organic layer was removed under reduced pressure and
the residue was purified by flash column chromatography (SiO2, 1:19/MeOH:CH2Cl2) to
afford compound 18 (48 mg, 53%) as a colorless liquid: 1H NMR (400 MHz, CD3OD,
Figure D27) δ 8.30 (s, 1H), 7.74 (s, 1H), 7.48-7.41 (m, 1H), 6.94-6.81 (m, 2H), 4.67 (d, J
= 14.3 Hz, 1H), 4.60 (d, J = 14.3 Hz, 1H), 2.99 (dd, J1 = 13.9 Hz, J2 = 1.5 Hz, 1H), 2.79
(d, J = 13.9 Hz, 1H), 2.70-2.42 (m, 10H), 1.51 (m, 2H), 1.30-1.20 (m, 10H), 0.87 (t, J =
6.7 Hz, 3H);
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C NMR (100 MHz, CD3OD, Figure D28) δ 164.0, 163.9, 161.5, 161.4,

160.5, 160.4, 158.1, 158.0, 149.7, 144.6, 129.54, 129.48, 129.44, 129.38, 125.60, 125.56,
125.47, 125.43, 110.72, 110.69, 110.51, 110.48, 103.7, 103.47, 103.45, 103.2, 74.0, 73.9,
62.9, 62.8, 57.7, 56.0. 55.92, 52.88, 52.5, 31.5, 29.0, 28.9, 26.9, 25.2, 22.3, 13.0; LRMS
m/z calcd for C23H35F2N5O: 435.3; found 436.2 [M+H]+. Purity of the compound was
further confirmed by RP-HPLC by using method 1: Rt = 3.39 min (98% pure; Figure D29).
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2-(2,4-Difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-3-(4-nonylpiperazine)propan-2-ol
(19). To a solution of compound 14 (100 mg, 0.42 mmol) in EtOH (5 mL), compound 4
(134 mg, 0.63 mmol) and Et3N (0.09 mL, 0.63 mmol) were added. The reaction mixture
was stirred at 80 °C for 12 h and progress of the reaction was monitored by TLC
(1:19/MeOH:CH2Cl2, Rf 0.35). The organic layer was removed under reduced pressure and
the residue was purified by flash column chromatography (SiO2, 1:19/MeOH:CH2Cl2) to
afford compound 19 (147 mg, 78%) as a yellow liquid: 1H NMR (400 MHz, CD3OD,
Figure D30) δ 8.31 (s, 1H), 7.72 (s, 1H), 7.48-7.39 (m, 1H), 6.93-6.78 (m, 2H), 4.66 (d, J
= 14.2 Hz, 1H), 4.57 (d, J = 14.2 Hz, 1H), 2.97 (dd, J1 = 13.8 Hz, J2 = 1.6 Hz, 1H), 2.77
(d, J = 13.8 Hz, 1H), 2.50-2.42 (m, 4H), 2.42-2.32 (m, 4H), 2.29-2.24 (m, 2H), 1.48-1.41
(m, 2H), 1.33-1.22 (m, 12H), 0.87 (t, J = 6.7 Hz, 3H); 13C NMR (100 MHz, CD3OD, Figure
D31) δ 164.0, 163.9, 161.5, 161.4, 160.5, 160.4, 158.1, 158.0, 149.6, 144.6, 129.5, 129.41,
129.38, 129.3, 125.83, 125.80, 125.7, 110.7, 110.6, 110.5, 110.4, 103.7, 103.4, 103.2, 73.6,
73.5, 63.04, 63.0, 58.3, 56.1, 56.0, 53.8, 52.8, 31.6, 29.20, 29.18, 28.9, 27.2, 25.9, 22.3,
13.0; LRMS m/z calcd for C26H41F2N5O: 449.3; found 450.2 [M+H]+. Purity of the
compound was further confirmed by RP-HPLC by using method 1: Rt = 15.41 min (99%
pure; Figure D32).

2-(2,4-Difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-3-(4-decylpiperazine)propan-2-ol
(20). To a solution of compound 14 (50 mg, 0.21 mmol) in EtOH (3 mL), compound 5 (72
mg, 0.32 mmol) and Et3N (0.04 mL, 0.32 mmol) were added. The reaction mixture was
stirred at 80 °C for 12 h and progress of the reaction was monitored by TLC

271

(1:9/MeOH:CH2Cl2, Rf 0.40). The organic layer was removed under reduced pressure and
the residue was purified by flash column chromatography (SiO2, 1:19/MeOH:CH2Cl2) to
afford compound 20 (71 mg, 73%) as a yellow liquid: 1H NMR (400 MHz, CD3OD, Figure
D33) δ 8.33 (s, 1H), 7.75 (s, 1H), 7.49-7.43 (m, 1H), 6.95-6.81 (m, 2H), 4.68 (d, J = 14.3
Hz, 1H), 4.59 (d, J = 14.3 Hz, 1H), 2.98 (dd, J1 = 13.8 Hz, J2 = 1.6 Hz, 1H), 2.79 (d, J =
14.3 Hz, 1H), 2.52-2.45 (m, 4H), 2.45-2.35 (m, 4H), 2.31-2.27 (m, 2H), 1.50-1.44 (m, 2H),
1.33-1.28 (m, 14H), 0.89 (t, J = 6.7 Hz, 3H); 13C NMR (100 MHz, CD3OD, Figure D34) δ
164.0, 163.9, 161.5, 161.4, 160.6, 160.4, 158.1, 158.0, 149.6, 144.6, 129.5, 129.42, 129.39,
125.82, 125.79, 125.70, 125.66, 110.68, 110.65, 110.5, 110.4, 103.7, 103.4, 103.2, 73.6,
73.5, 63.04, 63.01, 58.3, 56.1, 56.0, 53.7, 52.8, 31.6, 29.26, 29.24, 29.18, 29.0, 27.2, 25.9,
22.3, 13.0; LRMS m/z calcd for C25H39F2N5O: 463.3; found 464.3 [M+H]+. Purity of the
compound was further confirmed by RP-HPLC by using method 1: Rt = 3.32 min (96%
pure; Figure D35).

2-(2,4-Difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-3-(4-undecylpiperazine)propan-2-ol
(21). To a solution of compound 14 (100 mg, 0.42 mmol) in EtOH (5 mL), compound 6
(152 mg, 0.63 mmol) and Et3N (0.09 mL, 0.63 mmol) were added. The reaction mixture
was stirred at 80 °C for 12 h and progress of the reaction was monitored by TLC
(1:19/MeOH:CH2Cl2, Rf 0.44). The organic layer was removed under reduced pressure and
the residue was purified by flash column chromatography (SiO2, 1:19/MeOH:CH2Cl2) to
afford compound 21 (146 mg, 73%) as a yellow liquid: 1H NMR (400 MHz, CD3OD,
Figure D36) δ 8.31 (s, 1H), 7.72 (s, 1H), 7.47-7.41 (m, 1H), 6.93-6.78 (m, 2H), 4.66 (d, J
= 14.2 Hz, 1H), 4.57 (d, J = 14.2 Hz, 1H), 2.97 (dd, J1 = 13.8 Hz, J2 = 1.6 Hz, 1H), 2.77
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(d, J = 13.8 Hz, 1H), 2.50-2.43 (m, 4H), 2.42-2.32 (m, 4H), 2.29-2.24 (m, 2H), 1.48-1.40
(m, 2H), 1.33-1.22 (m, 16H), 0.87 (t, J = 6.7 Hz, 3H); 13C NMR (100 MHz, CD3OD, Figure
D37) δ 164.0, 163.9, 161.5, 161.4, 160.5, 160.4, 158.1, 158.0, 149.6, 144.6, 129.5, 1289.41,
128.38, 129.32, 125.8, 125.7, 110.7, 110.6, 110.4, 110.0, 103.7, 103.4, 103.2, 73.6, 73.5,
63.04, 62.99, 58.3, 56.1, 56.0, 53.7, 52.8, 31.6, 29.28, 29.27, 29.23, 29.17, 29.0, 27.2, 25.9,
22.3, 13.0; LRMS m/z calcd for C26H41F2N5O: 477.3; found 478.3 [M+H]+. Purity of the
compound was further confirmed by RP-HPLC by using method 1: Rt = 16.06 min (96%
pure; Figure D38).

2-(2,4-Difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-3-(4-dodecylpiperazine)propan-2-ol
(22). To a solution of compound 14 (50 mg, 0.21 mmol) in EtOH (3 mL), compound 7 (81
mg, 0.32 mmol) and Et3N (0.04 mL, 0.32 mmol) were added. The reaction mixture was
stirred at 80 °C for 12 h and progress of the reaction was monitored by TLC
(1:9/MeOH:CH2Cl2, Rf 0.50). The organic layer was removed under reduced pressure and
the residue was purified by flash column chromatography (SiO2, 1:19/MeOH:CH2Cl2) to
afford compound 22 (80 mg, 80%) as a colorless liquid: 1H NMR (400 MHz, CDCl3, Figure
D39) δ 8.10 (s, 1H), 7.76 (s, 1H), 7.53-7.46 (m, 1H), 6.83-6.74 (m, 2H), 4.50 (s, 2H), 3.05
(d, J = 13.6 Hz, 1H), 2.65 (d, J = 13.6 Hz, 1H), 2.60-2.28 (m, 8H), 1.45-1.43 (m, 2H), 1.281.19 (m, 20H), 0.85 (t, J = 6.6 Hz, 3H); 13C NMR (100 MHz, CDCl3, Figure D40) δ 164.0,
163.9, 161.5, 161.4, 160.1, 160.0, 157.7, 157.6, 151.0, 144.6, 129.34, 129.28, 129.24,
129.19, 126.19, 126.16, 126.1, 126.0, 111.62, 111.59, 111.41, 111.38, 104.5, 104.3, 104.2,
104.0, 72.01, 71.95, 62.22, 62.18, 58.5, 56.31, 56.26, 54.0, 53.1, 31.9, 29.59, 29.57, 29.53,
29.49, 29.4, 29.3, 27.4, 26.5, 22.6, 14.1; LRMS m/z calcd for C27H43F2N5O: 491.3; found
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492.3 [M+H]+. Purity of the compound was further confirmed by RP-HPLC by using
method 1: Rt = 3.12 min (97% pure; Figure D41).

2-(2,4-Difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-3-(4-tridecylpiperazine)propan-2-ol
(23). To a solution of compound 14 (100 mg, 0.42 mmol) in EtOH (5 mL), compound 8
(169 mg, 0.63 mmol) and Et3N (0.09 mL, 0.63 mmol) were added. The reaction mixture
was stirred at 80 °C for 12 h and progress of the reaction was monitored by TLC
(1:19/MeOH:CH2Cl2, Rf 0.48). The organic layer was removed under reduced pressure and
the residue was purified by flash column chromatography (SiO2, 1:19/MeOH:CH2Cl2) to
afford compound 23 (132 mg, 62%) as a yellow liquid: 1H NMR (400 MHz, CD3OD,
Figure D42) δ 8.31 (s, 1H), 7.72 (s, 1H), 7.47-7.40 (m, 1H), 6.93-6.79 (m, 2H), 4.66 (d, J
= 14.2 Hz, 1H), 4.57 (d, J = 14.2 Hz, 1H), 2.97 (d, J = 13.8 Hz, 1H), 2.77 (d, J = 13.8 Hz,
1H), 2.50-2.45 (m, 4H), 2.45-2.32 (m, 4H), 2.30-2.24 (m, 2H), 1.48-1.39 (m, 2H), 1.331.20 (m, 20H), 0.87 (t, J = 6.6 Hz, 3H); 13C NMR (100 MHz, CD3OD, Figure D43) δ 164.0,
163.9, 161.5, 161.4, 160.6, 160.4, 158.1, 158.0, 149.6, 144.6, 129.5, 129.42, 129.38,
129.32, 125.83, 125.79, 125.70, 125.67, 110.7, 110.6, 110.5, 110.4, 103.7, 103.44, 103.42,
103.2, 73.6, 73.5, 63.04, 63.00, 58.3, 56.1, 56.0, 53.8, 52.8, 31.6, 29.32, 29.30, 29.24,
29.21, 29.15, 29.0, 27.2, 25.9, 22.3, 13.0; LRMS m/z calcd for C28H45F2N5O: 505.4; found
506.3 [M+H]+. Purity of the compound was further confirmed by RP-HPLC by using
method 1: Rt = 16.82 min (97% pure; Figure D44).

2-(2,4-Difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-3-(4-tetradecylpiperazine)propan-2ol (24). To a solution of compound 14 (50 mg, 0.21 mmol) in EtOH (3 mL), compound 9
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(89 mg, 0.32 mmol) and Et3N (0.04 mL, 0.32 mmol) were added. The reaction mixture was
stirred at 80 °C for 12 h and progress of the reaction was monitored by TLC
(1:9/MeOH:CH2Cl2, Rf 0.40). The organic layer was removed under reduced pressure and
the residue was purified by flash column chromatography (SiO2, 1:19/MeOH:CH2Cl2) to
afford compound 24 (91 mg, 83%) as a yellow solid: 1H NMR (400 MHz, CD3OD, Figure
D45) δ 8.33 (s, 1H), 7.75 (s, 1H), 7.49-7.43 (m, 1H), 6.95-6.81 (m, 2H), 4.68 (d, J = 14.3
Hz, 1H), 4.59 (d, J = 14.3 Hz, 1H), 2.98 (dd, J1 = 13.8 Hz, J2 = 1.6 Hz, 1H), 2.79 (d, J =
13.8 Hz, 1H), 2.55-2.45 (m, 4H), 2.45-2.32 (m, 4H), 2.31-2.27 (m, 2H), 1.46 (p, J = 7.4
Hz, 2H), 1.34-1.28 (m, 22H), 0.90 (t, J = 7.0 Hz, 3H); 13C NMR (100 MHz, CD3OD, Figure
D46) δ 164.0, 163.9, 161.5, 161.4, 160.6, 160.4, 158.1, 158.0, 150.7, 149.6, 144.6, 129.5,
129.42, 129.39, 129.3, 125.83, 125.80, 125.70, 125.67, 110.69, 110.65, 110.5, 110.4,
103.7, 103.5, 103.2, 73.6, 73.5, 63.1, 63.0, 58.3, 56.1, 56.0, 53.8, 52.8, 31.7, 29.36, 29.34,
29.32, 29.26, 29.24, 29.20, 29.18, 29.06, 27.2, 26.0, 22.3, 13.0; LRMS m/z calcd for
C29H47F2N5O: 519.4; found 520.3 [M+H]+. Purity of the compound was further confirmed
by RP-HPLC by using method 1: Rt = 3.47 min (96% pure; Figure D47).

2-(2,4-Dichlorophenyl)-1-(1H-1,2,4-triazol-1-yl)-3-(4-decylpiperazine)propan-2-ol
(25). To a solution of compound 15 (50 mg, 0.19 mmol) in EtOH (3 mL), compound 5 (55
mg, 0.24 mmol) and Et3N (0.03 mL, 0.24 mmol) were added. The reaction mixture was
stirred at 80 °C for 12 h and progress of the reaction was monitored by TLC
(1:9/MeOH:CH2Cl2, Rf 0.40). The organic layer was removed under reduced pressure and
the residue was purified by flash column chromatography (SiO2, 1:19/MeOH:CH2Cl2) to
afford compound 25 (48 mg, 52%) as a yellow liquid: 1H NMR (400 MHz, CD3OD, Figure
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D48) δ 8.31 (s, 1H), 7.74 (s, 1H), 7.61 (d, J = 8.6 Hz, 1H), 7.42 (d, J = 2.2 Hz, 1H), 7.20
(dd, J1 = 8.6 Hz, J2 = 2.2 Hz, 1H), 4.97 (d, J = 14.3 Hz, 1H), 4.67 (d, J = 14.3 Hz, 1H),
3.41 (d, J = 14.0 Hz, 1H), 2.83 (d, J = 14.0 Hz, 1H), 2.75-2.35 (m, 10H), 1.55-1.45 (m,
2H), 1.35-1.21 (m, 14H), 0.87 (t, J = 6.6 Hz, 3H); 13C NMR (100 MHz, CD3OD, Figure
D49) δ 149.7, 144.8, 138.4, 133.9, 131.5, 130.3, 130.0, 126.8, 74.9, 61.2, 57.5, 54.9, 52.3,
31.6, 29.3, 29.2, 29.1, 29.01, 28.97, 26.8, 24.9, 22.3, 13.0; LRMS m/z calcd for
C25H39Cl2N5O: 495.3; found 496.3 [M+H]+. Purity of the compound was further confirmed
by RP-HPLC by using method 1: Rt = 3.45 min (97% pure; Figure D50).

2-(2,4-Dichlorophenyl)-1-(1H-1,2,4-triazol-1-yl)-3-(4-dodecylpiperazine)propan-2-ol
(26). To a solution of compound 15 (50 mg, 0.19 mmol) in EtOH (3 mL), compound 7 (61
mg, 0.24 mmol) and Et3N (0.03 mL, 0.24 mmol) were added. The reaction mixture was
stirred at 80 °C for 12 h and progress of the reaction was monitored by TLC
(1:9/MeOH:CH2Cl2, Rf 0.50). The organic layer was removed under reduced pressure and
the residue was purified by flash column chromatography (SiO2, 1:19/MeOH:CH2Cl2) to
afford compound 26 (44 mg, 45%) as a yellow liquid: 1H NMR (400 MHz, CD3OD, Figure
D51) δ 8.31 (s, 1H), 7.74 (s, 1H), 7.60 (d, J = 8.6 Hz, 1H), 7.42 (d, J = 2.1 Hz, 1H), 7.20
(dd, J1 = 8.6 Hz, J2 = 2.1 Hz, 1H), 4.98 (d, J = 14.3 Hz, 1H), 4.68 (d, J = 14.3 Hz, 1H),
3.43 (d, J = 14.0 Hz, 1H), 2.86 (d, J = 14.0 Hz, 1H), 2.78-2.43 (m, 10H), 1.58-1.51 (m,
2H), 1.35-1.18 (m, 18H), 0.87 (t, J = 6.4 Hz, 3H); 13C NMR (100 MHz, CD3OD, Figure
D52) δ 149.8, 144.7, 138.3, 133.9, 131.5, 130.3, 130.1, 126.8, 75.1, 61.2, 57.3, 54.9, 52.1,
52.0, 31.6, 29.3 (2C), 29.2, 29.1, 29.0, 28.9, 26.6, 24.6, 22.3, 13.0; LRMS m/z calcd for
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C27H43Cl2N5O: 523.3; found 524.3 [M+H]+. Purity of the compound was further confirmed
by RP-HPLC by using method 1: Rt = 3.46 min (98% pure; Figure D53).

2-(2,4-Difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-3-(mopholine)propan-2-ol (27). To a
solution of compound 14 (50 mg, 0.21 mmol) in EtOH (3 mL), morpholine (0.073mL, 0.32
mmol) and Et3N (0.04 mL, 0.32 mmol) were added. The reaction mixture was stirred at 80
°C for 12 h and progress of the reaction was monitored by TLC (1:10/MeOH: CH2Cl2, Rf
0.02). The organic layer was removed under reduced pressure and the residue was purified
by column chromatography (SiO2, 1:20/MeOH: CH2Cl2) to afford compound 27 (60 mg,
88%) as a white solid: 1H NMR (400 MHz, CDCl3, Figure D54) δ 8.12 (s, 1H), 7.77 (s,
1H), 7.55-7.53 (m, 1H), 6.82-6.76 (m, 2H), 5.11 (d, J = 8.2 Hz, 1H), 4.55 (d, J = 14.2 Hz,
1H), 4.48 (d, J = 14.2 Hz, 1H), 3.55 (m, 4H), 3.07 (d, J = 13.6 Hz, 1H), 2.61 (d, J = 12.8
Hz, 1H), 2.32 (m, 4H), 1.60 (br s, 1H); 13C NMR (100 MHz, CDCl3, Figure D55) δ 164.0,
163.9, 161.6, 161.4, 160.1, 160.0, 157.7, 157.6, 151.1, 144.7, 129.35, 129.29, 129.26,
129.20, 111.8, 111.7, 111.6, 111.5, 104.6, 104.3, 104.1, 72.2, 72.1, 66.8, 63.0, 62.9, 56.2,
56.1, 54.7; LRMS m/z calcd for C15H18F2N4O2: 324.1; found 325.1 [M+H]+. Purity of the
compound was further confirmed by RP-HPLC by using method 1: Rt = 2.85 min (99%
pure; Figure D56).

2-(2,4-Difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-3-(4-(2aminoethyl)morpholine)propan-2-ol (28). To a solution of compound 14 (50 mg, 0.21
mmol) in EtOH (3 mL), 4-(2-aminoethyl)morpholine (41 mg, 0.32 mmol) and Et3N (0.04
mL, 0.32 mmol) were added. The reaction mixture was stirred at 80 °C for 12 h and
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progress of the reaction was monitored by TLC (1:9/MeOH:CH2Cl2, Rf 0.20). The organic
layer was removed under reduced pressure and the residue was purified by flash column
chromatography (SiO2, 1:19/MeOH:CH2Cl2) to afford compound 28 (60 mg, 78%) as a
colorless liquid: 1H NMR (400 MHz, CD3OD, Figure D57) δ 8.32 (s, 1H), 7.75 (s, 1H),
7.51-7.44 (m, 1H), 6.96-6.81 (m, 2H), 4.66 (d, J = 14.3 Hz, 1H), 4.61 (d, J = 14.3 Hz, 1H),
3.62 (t, J = 4.7 Hz, 4H), 3.22 (d, J = 12.8 Hz, 1H), 2.97 (d, J = 12.8 Hz, 1H), 2.70 (td, J1 =
12.5 Hz, J2 = 6.1 Hz, 1H), 2.66 (td, J1 = 12.5 Hz, J2 = 6.1 Hz, 1H), 2.42-2.36 (m, 4H); 13C
NMR (100 MHz, CD3OD, Figure D58) δ 164.1, 163.9, 161.6, 161.5, 160.6, 160.5, 158.2,
158.1, 149.8, 144.6, 130.1, 130.04, 130.00, 129.9, 124.9, 124.84, 124.75, 124.7, 110.8,
110.7, 110.6, 110.5, 103.8, 103.57, 103.55, 103.3, 74.2, 74.1, 66.30, 66.25, 57.0, 55.9, 55.8,
54.53, 54.49, 53.2, 53.1, 45.3; LRMS m/z calcd for C17H23F2N5O2: 367.2; found 368.1
[M+H]+. Purity of the compound was further confirmed by RP-HPLC by using method 1:
Rt = 3.14 min (96% pure; Figure D59).

5.5.2. Biological studies
5.5.2.1. Antifungal agents
Azole derivatives 1-28 were purchased or chemically synthesized as described in section
5.5.1.2 above. A 5 mg/mL stock solution of compounds 1-28 was prepared in DMSO and
stored at -20 °C in the dark (foiled wrapped). The antifungal agents amphotericin B (AmB),
fluconazole (FLC), and voriconazole (VRC) were obtained from AK Scientific Inc
(Mountain View, CA). The antifungal agent caspofungin (CAS) was purchased from
Sigma-Aldrich (St. Louis, MO). AmB, FLC, VRC, and CAS were dissolved in DMSO at
final concentrations of 5 mg/mL and were stored at -20 °C.
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5.5.2.2. Organisms and culture conditions
Candida albicans ATCC 10231 (A), C. albicans ATCC 64124 (B), and C. albicans ATCC
MYA2876 (C) were kindly provided by Dr. Jon Y. Takemoto (Utah State University,
Logan, UT, USA). C. albicans ATCC MYA90819 (D), C. albicans ATCC MYA2310
(E), C. albicans ATCC MYA1237 (F), C. albicans ATCC MYA1003 (G), Candida
glabrata ATCC 2001 (H), Candida krusei ATCC 6258 (I), Candida parapsilosis ATCC
22019 (J), Aspergillus flavus ATCC MYA-3631 (K), and Aspergillus terreus ATCC
MYA-3633 (M) were obtained from the American Type Culture Collection (Manassas,
VA, USA). Aspergillus nidulans ATCC 38163 (L) was received from Dr. Jon S. Thorson
(University of Kentucky, Lexington, KY, USA). Filamentous fungi and yeasts were
cultivated at 35 °C in RPMI 1640 medium (with

L-glutamine,

without sodium

biocarbonate, Sigma-Aldrich, St. Louis, MO) buffered to a pH of 7.0 with 0.165 M
morpholinepropanesulfonic acid (MOPS) buffer (Sigma-Aldrich).

The human embryonic kidney cell line HEK-293 (ATCC CRL-1573), the human bronchus
normal cell line BEAS-2B (ATCC CRL-9609), and the human lung carcinoma cell line
A549 (ATCC CRL-185) were kind gifts from the laboratories of Dr. Matthew S. Gentry
(University of Kentucky, Lexington, KY, USA) and Dr. David K. Orren (University of
Kentucky, Lexington, KY, USA). The mammalian cells were grown in Dulbecco’s
Modified Eagle’s Medium (DMEM) (ATCC, Manassas, VA, USA) with 10% fetal bovine
serum (FBS) (ATCC, Manasas, VA, USA) and 1% Pen/Strep (ATCC, Manassas, VA,
USA). Cell lines were cultured at 37 °C with 5% CO2 and passaged by trypsinization with
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0.05%-trypsin-0.53 mM EDTA (ATCC, Manassas, VA, USA). Cell confluency was
determined by using a Nikon Eclipse TS100 microscope (Minato, Tokyo, Japan).

5.5.2.3. MIC value determination by in vitro antifungal assay
The MIC values of compounds 1-10, 14, and 16-28 against yeast cells were determined in
96-well plates as described in the CLSI document M27-A3 with minor modifications.224 A
single colony of freshly prepared yeast cells was used to inoculate 5 mL of yeast extract
peptone dextrose broth (YPD) and incubated overnight with shaking at 200 rpm at 35 °C.
100 µL of actively growing yeast culture was then transferred to 900 µL of sterile ddH2O
and re-adjusted to achieve OD600 of 0.12 (~1×106 CFU/mL). The cell suspension was
further diluted to achieve 2-4×103 CFU/mL in RPMI 1640 medium. 100 µL of cells (to
achieve a final concentration of 1-2×103 CFU/mL) were added to the wells of a 96-well
microtiter plates that contained 0.015-31.3 µg/mL of compounds 1-10, 14, and 16-28,
0.975-62.5 µg/mL of FLC, 0.03-31.3 µg/mL of VRC, 0.48-31.3 µg/mL of AmB, or 0.0331.3 µg/mL of CAS, and incubated for 48 h at 35 °C. Each test was performed in triplicate.
The final concentration of DMSO was ensured to be <1.25% in all experiments. The MIC
values for compounds 1-10, 14, and 16-28, AmB, and CAS were defined as the minimum
drug concentration that yielded complete inhibition (also known as MIC-0). For FLC and
VRC, the minimum drug concentration that yielded at least 50% growth inhibition (MIC2) when compared with the growth control well was reported. One exception for the
reporting of the MIC of the azoles was that of VRC against C. albicans ATCC 10231 (strain
A), where the MIC-0 (indicating complete inhibition) was reported. These data are
presented in Table 5.1.
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Similarly, the MIC values of compounds 1-10, 14, and 16-28, as well as that of all control
drugs against filamentous fungi (strains K, L, and M) were determined as previously
described in CLSI document M38-A2.224 Spores were harvested from sporulating cultures
growing on potato dextrose agar (PDA) by ﬁltration through sterile glass wool and
enumerated by using a hemocytometer to obtain the desired inoculum size. Serial dilutions
of compounds 1-10, 14, and 16-28, as well as VRC and CAS were made in sterile 96-well
microplates in the ranges of 0.03-31.3 µg/mL in RPMI medium. The concentration ranges
for FLC and AmB were 0.975-62.5 µg/mL and 0.48-31.3 µg/mL, respectively. Spore
suspensions were added to the wells to afford a ﬁnal concentration of 5×105 CFU/mL. The
plates were incubated at 35 °C for 48 h. The MIC values of compounds 1-10, 14, and 1628, azoles, AmB, and CAS against filamentous fungi were based on the complete inhibition
of growth when compared to the growth control (MIC-0). Each test was performed in
triplicate. These data are also presented in Table 5.1.

5.5.2.4. MIC value determination by in vitro antifungal assay in the presence of FBS
To investigate the effect of presence of serum on the MIC values of our novel azole
derivatives, we selected compounds 7, 9, 20, 22, 25, and 26, with an even number of
carbons in their side chain as representatives from here onwards as they displayed strong
activity in MIC assays and provide coverage of the range of chain lengths utilized. The
procedures described in section 5.5.2.3 were utilized and the RPMI 1640 medium or RPMI
medium was supplemented with 10% fetal bovine serum (FBS) in parallel against C.
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albicans ATCC 10231 (strain A), C. parapsilosis ATCC 22019 (strain J), and A. nidulans
ATCC 38163 (strain L). These data are presented in Table 5.2.

5.5.2.5. Time-kill assays
The time-kill curve analyses were performed using a previously published protocol.247 The
Candida cell lines, C. albicans ATCC 10231 (strain A), C. glabrata ATCC 2001 (strain
H), and C. parapsilosis ATCC 22019 (strain J) were grown in culture tubes with YPD
broth overnight. Afterwards, from the culture tubes, volumes of 10-20 µL of cells were
added to Eppendorf tubes and diluted with the appropriate amounts of RPMI 1640 medium
(990-980 µL) to make up the working stocks with final volume of 1,000 µL and OD600 of
0.12-0.13. The cell suspension working stocks were then thoroughly vortexed and 300 µL
of cells were added to new culture tubes, which were used for the time-kill experiments.
The sterile controls consisted of culture tubes with 4,000 µL RPMI 1640 medium and no
fungal cell. The untreated or growth controls were added to the aforementioned 300 µL of
cell suspensions from the working stocks and 3,700 µL of RPMI 1640 medium. Due to the
low MIC values (0.015-0.975 µg/mL) of the tested compounds, the stock solutions of
compounds 20 and 22 were prepared at 5,000 or 1,000 µg/mL. To perform the time-kill
experiments with the drugs, tubes contained 300 µL of cells, the appropriate amounts of
RPMI medium, and compounds 20 and 22 at concentrations of 1×, 4×, and 8× their
respective MIC values to make up final volumes of 4000 µL. For the VRC controls,
contained 300 µL of cells, the appropriate amount of RPMI medium, and VRC at
concentrations of 1× and 4× its MIC values. Once the culture tubes were prepared, they
were incubated at 35 °C and agitated at 200 rpm for 24 h. At 0, 3, 6, 9, 12, and 24 h time
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points, 100 µL of cells from each tube were serially diluted with RPMI 1640 medium to
the appropriate dilutions, which ranged from 102-107 dilutions depending on the turbidity
and incubation time of each culture tube. After serial dilutions, the cells were plated onto
PDA plates. The initial inoculum (at time 0 h) was determined to be between 1-4×105
CFU/mL. After 48 h incubation, fungal colonies on the plates were visible, counted, and
reported. It is important to note that strain A was unique in the sense that the colonies grew
very rapidly and thus, these plates were counted after 24 h incubation. The experiments
were performed in duplicate. The detection limit of this assay was 100 CFU/mL. These
data are presented in Figure 5.2.

5.5.2.6. Biofilm assays
We investigated the biofilm reduction activity of our compounds against the azole-resistant
C. albicans ATCC 64124 (strains B) by XTT [2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)2H-tetrazolium-5-carboxanilide] reduction assay with minor modification.248 Briefly, C.
albicans ATCC 64124 (strain B) was grown overnight in yeast peptone dextrose broth
(YPDB) at 35 °C with agitation at 200 rpm. The culture was then diluted to an OD600 of
0.1 (~106 CFU/mL) and 100 µL was transferred into each well of a 96-well plate. The cells
were grown statically at 37 °C for 24 h. The following day, all the spent medium containing
planktonic cells were aspirated and each well was carefully washed thrice with sterile PBS
buffer (10 mM phosphate buffered saline, pH 7.2). Freshly prepared RPMI 1640 medium
(100 µL) was added into each well containing serially diluted compounds 7, 9, 20, 22, 25,
and 26 and a positive control (VRC) at the final concentrations of 0.12-62.5 µg/mL, except
for the wells that contains medium only (no drug and no biofilms) and biofilms alone (no
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drug). The plates were further incubated at 37 °C statically for an additional 24 h. After 24
h, the plates were carefully washed with sterile PBS. 100 µL of XTT (0.5 mg/mL) /
menadione (1 µM) solution was added to each well of the plates, covered with aluminum
foil, and incubated for 2 h at 37 °C. Then, 80 µL of the colored supernatant from each well
was transferred to a new microtiter plate and the absorbance was read at 490 nm. The
percent inhibition of metabolic activity of biofilms for each well containing drug was
calculated by comparing the metabolic activity of biofilms formed in the absence of drug
(growth control). The sessile minimum inhibitory concentrations, SMIC50 and SMIC80
were defined as the drug concentrations at which a 50% and 80% decrease in optical
density was observed when compared to the growth control. The experiments were
performed in duplicate. These data are presented in Table 5.3.

5.5.2.7. Hemolytic activity assays
The hemolytic activity of compounds 7, 9, 16, 18, 20, 22, and 25-26 was determined by
using previously described methods with minor modifications.199 Murine red blood cells
(mRBCs) (1 mL) were suspended in 3 mL of PBS and centrifuged at 1,000 rpm for 5 min
to obtain the mRBCs. The mRBCs were washed four times in PBS and resuspended in the
same buffer to a final concentration of 107 erythrocytes/mL. Serial dilution of compounds
7, 9, 16, 18, 20, 22, and 25-26 were prepared in Eppendorf tubes containing 100 µL of
milliQ-H2O, and 100 µL of mRBC suspension was added to achieve a final concentration
of compounds ranging from 0.48-62.5 µg/mL and 5×106 erythrocytes/mL of RBC. The
tubes were incubated at 37 °C for 60 min. Tubes with milliQ-H2O (200 µL) and Triton X100 (1% v/v, 2 µL) served as negative (blank) and positive controls, respectively. The
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percentage of hemolysis was calculated using the following equation: % hemolysis =
[(absorbance of sample) – (absorbance of blank)] ×100/(absorbance of positive control).
These data are presented in Table 5.5 and Figure 5.7.

Table 5.5: Percentage of hemolysis caused by azole derivatives and VRC against mouse
erythrocytes with the error bars (± SDEV).
Cpd #
7
9
16
18
20
22
24
25
26
VRC

0.48
2.0 ± 0.2
3.0 ± 0.9
0.4 ± 2.0
0
2.0 ± 1.0
3.0 ± 0.3
4.0 ± 0.3
4.0 ± 0.5
4.0 ± 0.6
9.0 ± 5.0

0.975
0
8.0 ± 3.0
0
0
5.0 ± 2.0
4.0 ± 0.2
4.0 ± 0.2
9.0 ± 1.0
8.0 ± 0.5
10.0 ± 2.0

1.95
2.0 ± 0.3
8.0 ± 10.0
0
0
4.0 ± 2.0
5.0 ± 0.2
7.0 ± 2.0
13.0 ± 1.0
12.0 ± 0.2
6.0 ± 2.0

Concentration (µg/mL)
3.9
7.8
9.0 ± 0.3
52.0 ± 3.0
25.0 ± 7.3
93.0 ± 0.5
0
2.0 ± 3.0
0
2.0 ± 1.0
6.0 ± 0.3
5.0 ± 2.0
10.0 ± 2.0
77.0 ± 8.0
33.0 ± 2.0
98.0 ± 5.0
19.0 ± 0.3
22.0 ± 2.0
24.0 ± 2.1
85.0 ± 1.4
7.0 ± 0.5
11.0 ± 11.0

15.6
100.0 ± 4.2
100 ± 0.5
1.0 ± 3.0
0
7.0 ± 1.0
91.0 ± 2.0
100.0 ± 8.0
100.0 ± 4.0
100.0 ± 0.2
3.0 ± 1.2

31.3
100.0 ± 3.0
100.0 ± 5.0
9.0 ± 9.0
2.0 ± 0.2
23.0 ± 2.0
100.0 ± 5.0
100.0 ± 5.0
100.0 ± 1.4
100.0 ± 12.5
83.0 ± 5.0

62.5
100.0 ± 1.0
100.0 ± 0
12.0 ± 6.0
4.0 ± 0.2
92.0 ± 8.0
100.0 ± 0
100.0 ± 3.0
100.0 ± 6.0
100.0 ± 8.4
100.0 ± 2.3

Figure 5.7. 3D bar graph depicting the dose-dependent hemolytic activity of azole derivatives against mouse
erythrocytes. Mouse erythrocytes were treated and incubated for 1 h at 37 °C with compounds 7, 9, 16, 18,
20, 22, and 24-26, and VRC at concentrations ranging from 0.48-62.5 µg/mL. Triton X-100® (1% v/v) was
used as a positive control (100% hemolysis, not shown).

285

5.5.2.8. In vitro cytotoxicity assays
Mammalian cytotoxicity assays were performed as previously described with minor
modifications.242 HEK-293, BEAS-2B, and A549 mammalian cell lines were cultured as
mentioned above. Once cell lines were about 80% confluent, cells were counted by a
hemacytometer (Hausser Scientific, Horsham, PA, USA) and plated in 96-well microtiter
plates at concentrations of 10,000 cells per well for HEK-293 and 3,000 cells per well for
BEAS-2B and A549. The 96-well microtiter plates were allowed to incubate at 37 °C with
5% CO2 for 16 h, after which the medium was replaced with 200 µL of fresh medium with
0.1% DMSO to make up the negative controls. For the piperazine analogues 7 and 9, the
DMSO concentrations used were 0.2% and 0.4% due to their low solubility, respectively.
Please note that 0.1-0.4% DMSO was previously determined to be non-toxic to these cell
lines. Additionally, the positive controls were prepared by adding 200 µL of medium
containing Triton X-100® (12.5% v/v) to the cells. The sterile or background controls
contained 200 µL of medium without any cells. Stock solutions of compounds 7, 9, 18, 20,
22, 25, 26, and VRC were initially prepared at 31 mg/mL or 1,000× the tested
concentrations and serially diluted with biological DMSO in Eppendorf tubes to achieve
15.5, 7.8, 3.9, 1.9, 1.0, 0.5, 0.25, 0.13 mg/mL. For each concentration, 1 µL of each 1,000×
stock solution was added to 999 µL fresh medium in new Eppendorf tubes to achieve final
concentrations of 31, 15.5, 7.8, 3.9, 1.9, 1.0, 0.5, 0.25, 0.13 µg/mL. Afterwards, each tested
well was removed of old medium by vacuum suction and added 200 µL of the prepared
medium containing the appropriate concentrations of compounds and 0.1-0.4% DMSO.
The 96-well microtiter plates were then incubated for an additional 24 h. After the
incubation period, cell survival was assessed via addition of resazurin (10 µL of 25 mg/L
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solution) for 6-10 h. Live cells produced the fluorescent pink compound resorufin, which
was measured at λ560 absorption and λ590 emission by a SpectraMax M5 plate reader. Dead
cells remained to be purple. The percentage survival rates were calculated by using the
following formula: % cell survival = [(fluorescence of sample) – (fluorescence of
background)] × 100/[(fluorescence of negative control) – (fluorescence of background)].
The experiments were performed in duplicate. These data are presented in Figure 5.3.

5.5.2.9. Membrane permeabilization assay using propidium iodide staining
A fresh culture of C. albicans ATCC 10231 (strain A) was prepared in 5 mL of YPD broth
in a Falcon tube and was grown overnight at 35 °C at 200 rpm. An overnight culture (40
µL) was transferred to RPMI 1640 medium (1 mL) containing no drug (negative control)
or compounds 20 at a concentration of 3.9 µg/mL (4× MIC) or compound 26 at a
concentration of 7.8 µg/mL (4× MIC). FLC (7.8 µg/mL) and KANB derivative C14 (15.6
µg/mL)199 were used as a negative and positive controls, respectively. The cell suspensions
were then treated for 1 h at 35 °C with continuous agitation (200 rpm). The cells were then
centrifuged and resuspended in 500 µL of PBS buffer (pH 7.2). Subsequently, cells were
treated with propidium iodide (9 µM, final concentration) and incubated for 20 min at room
temperature in the dark. Glass slides prepared with 10 µL of each mixture were observed
in bright field and fluorescence modes (using Texas red filter set, excitation and emission
wavelengths of 535 and 617 nm, respectively) using a Zeiss Axiovert 200M fluorescence
microscope. Data were obtained from at least two independent experiments. The images
were also post-processed utilizing automatic contrast and brightness setting in Microsoft
PowerPoint 2013 to eliminate background noise. These data are presented in Figure 5.4.
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5.5.2.10. Determination of sterol composition in C. albicans
A single colony of C. albicans ATCC 10231 (strain A) was picked from a fresh culture
plate to inoculate 3 mL of yeast peptone dextrose broth (YPDB) and was incubated at 35
°C for ~18 h with continuous agitation (180 rpm). The overnight yeast culture was used to
inoculate RPMI 1640 medium (15 mL) and the final inoculum concentration was adjusted
to 1×106 CFU/mL (~OD600 = 0.12) by using spectrophotometric method. Afterwards, the
yeast cells were treated with compounds 20 (0.48 µg/mL), 26 (0.975 µg/mL), and VRC
(0.12 µg/mL) at their sub-MIC values, except for FLC (1.95 µg/mL; NOTE: C. albicans
ATCC 10231 (strain A) is resistant to FLC249). An equivalent amount of DMSO without
drug (untreated control) was also prepared. Cells were harvested by centrifugation (5,000
rpm) for 10 min at room temperature, and cell pellets were saponified at 80 °C for 2 h with
3 mL of MeOH, 2 mL of pyrogallol dissolved in MeOH (0.5%, wt/v) (CAS # 87-66-1,
Sigma-Aldrich, St. Louis, MO.), and 2 mL of KOH (60%, wt/v). The non-saponifiable
sterols were then extracted three times with 5 mL of heptane. The extracts were evaporated
under a stream of nitrogen to dryness and resuspended in 500 µL of heptane. The sterol
suspension was then transferred to a GC-MS vial and derivatized with 250 µL of N-methylN-(trimethylsilyl) trifluoroacetamide (MSTFA, CAS # 24589-78-4, Sigma-Aldrich, St.
Louis, MO) at 70 °C for 20 min. GC-MS analyses were performed on an Agilent 7890A
gas chromatograph with splitless injection, coupled to an Agilent 5970C inert XL mass
spectrometer with a triple-axis detector and an Agilent 19091S-433 capillary column (30
m x 250 µm). The oven temperature was programmed to hold at 70 °C for 2 min and then
ramped to 270 °C at a rate of 20 °C/min. Helium (10 psi) was used as the carrier gas, the
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electron ionization energy was 70 eV, and the inlet temperature 250 °C. Identification of
sterols was achieved using the NIST (the National Institute of Standards and Technology)
reference database. These data are presented in Figure 5.5.

5.5.2.11. Molecular docking study
The remarkable depletion of ergosterol content in C. albicans ATCC 10231 (strain A) by
sub-MIC concentration of compounds 20 and 26 indicated that the potential target of these
compounds could be the cytochrome P450 sterol 14α-demethylase. A molecular docking
study was performed using Crystallographic Object Oriented Toolkit (COOT) software,250
in order to investigate the possible interactions and binding mode of compound 20 with the
enzyme C. albicans CYP51 (PDB ID: 3P99246). VT-1161, a known inhibitor of cytochrome
P450 sterol 14α-demethylase sterol, was also used as a positive control.
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Chapter 6
Conclusions and future directions

Disclaimer: This chapter presents unpublished work that is ongoing as well as future
direction ideas for the projects presented in this dissertation.

6.1. CONCLUSIONS
In this dissertation, I have developed novel synthetic methodologies, rationally designed
novel antibacterial and antifungal agents, and successfully performed the biological
evaluation of these compounds. For my main dissertation project comprising Chapters 13, my efforts to understand how the structure of the ZAF derivatives effects the
antibacterial activity have led to the development of over 45 published and unpublished
ZAF derivatives including 15 2nd generation and 14 3rd generation compounds with highly
selective activity against P. gingivalis 381 and ATCC 33277. In Chapters 2 and 3, the
antibacterial activity of ZAF derivatives was evaluated including mono-species biofilm
testing. Future experiments will focus on important dual- and tri-species biofilm testing to
determine the ZAF derivatives’ ability to inhibit multi-species biofilms. In addition, the
most active compounds will be evaluated against P. gingivalis mouse models. The
mechanism of action responsible for the selective anti-P. gingivalis activity of the ZAF
derivatives remains unknown. Therefore, ongoing research efforts are to generate biotintagged ZAF derivatives to perform pull-down assays with streptavidin to identify the
target(s) of these compounds in P. gingivalis.
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6.2. ONGOING AND FUTURE DIRECTIONS
6.2.1. ZAF derivatives as potential thiol isomerase inhibitors
In addition to the antibacterial activity of these compounds we are also actively looking for
other applications of this scaffold. Recent collaborations with Professor Daniel R. Kennedy
from Western New England University (MA, USA) revealed that ZAF and its derivatives
could potentially be used as thiol isomerase inhibitors for the prevention of thrombosis.251
We are working closely with the Kennedy laboratory to further investigate the most active
ZAF derivatives as potential thiol isomerase inhibitors, all studies are ongoing in Prof.
Kennedy and Prof. Garneau-Tsodikova’s laboratories in which current laboratory members
are continuing this research. The goal of this “future directions” section is to provide people
who will keep working on this project with all of the details necessary to successfully
complete this research.

6.2.1.1. Abstract
Thiol isomerases (TIs), including protein disulfide isomerase (PDI), ERp5, ERp57, and
ERp72,252-254 play essential and non-redundant roles in the initiation of thrombus
formation. Thiol isomerase inhibitors have the potential to overcome the two major
drawbacks of current antithrombotic therapies, as they target both arterial and venous
thrombosis without enhancing bleeding risks. Recently, the FDA-approved drug
zafirlukast (ZAF) was shown to be a promising thiol isomerase inhibitor and, unlike other
agents, inhibited PDI, ERp5, ERp57, and ERp72, which provided enhanced therapeutic
activity.251 Herein, we report the preliminary screening of 35 ZAF derivatives (synthesis
previously published)62,

103, 255

to further optimize ZAF’s inhibitory effects of thiol
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isomerases, platelet aggregation, cancer cell generated Factor Xa, as well as platelet
aggregation and thrombus formation in mice.

6.2.1.2. Introduction
In 2010, the Global Burden of Disease Study documented that thrombosis was the
underlying pathology that caused 1 in 4 deaths worldwide.256 Thrombosis is the most
common underlying pathology related to heart diseases such as stroke, venous
thromboembolism (VTE), myocardial infarction, ischemic heart disease, and deep vein
thrombosis.251, 257, 258 Current antithrombotic agents from aspirin to warfarin (Figure 6.1)
do not have the ability to inhibit both platelet pathways (e.g., heart attacks, strokes, or
arterial thrombosis)259,

260

and coagulation pathways (e.g., deep vein thrombosis and

pulmonary embolism)261, 262 for thrombosis treatment. Additionally, the other major issues
with current treatment options are a risk of bleeding, which is a potential side effect of
antithrombotic therapy that limits their use.263
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Figure 6.1. Structures depicting seven representative antithrombotic agents including aspirin, warfarin,
clopidogrel, prasugrel, rivaroxaban, heparin, and bacitracin.

Current antithrombotic agents are categorized for the treatment of either arterial thrombosis
or venous thrombosis. The most widely studied class of arterial thrombosis agents are
clopidogrel and prasugrel, which are antiplatelet drugs that inhibit the cell-surface receptor
P2Y12 (Figure 6.1).264, 265 For the treatment of venous thrombosis, there are a few classes
of anticoagulant drugs used such as vitamin K antagonists (e.g., warfarin),261 indirect
inhibitors of Factor Xa (e.g., heparins),266 and direct inhibitors of Factor Xa that are
currently undergoing clinical trials (e.g., rivaroxaban) (Figure 6.1).267-269 There are other
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drug candidates in the pipeline for the treatment of thrombosis, none of these candidates or
current drugs on the market however, can prevent both platelet activation and coagulation,
and additionally they cannot prevent coagulation without promoting bleeding.251, 267, 270-273

TI inhibitors are promising molecules to enhance antithrombotic therapy, as they have the
ability to target both arteriole and venous thrombosis without effecting bleeding times.251,
274

In fact, a clinical study of patients with advanced cancer taking a TI inhibitor

demonstrated no enhanced bleeding.272 TIs are oxidoreductases that serve a critical role in
protein folding and have extracellular activity that initiates thrombus formation, fibrin
formation, and platelet aggregation.275-277 These enzymes include protein disulfide
isomerase (PDI), and closely related enzymes ERp5,252 ERp57,253 and ERp72,254 which
have important roles in both arterial and venous thrombosis through the propagation of
platelet activation.252 Inhibition of these enzymes has been shown to decrease platelet
activation, aggregation, adhesion in addition to inhibiting thrombus formation.278,

279

Interestingly, each of these enzymes are non-redundant, meaning that inhibition of one TI
blocks thrombosis. Although the inhibition of one enzyme seems sufficient with a broadly
similar impact on platelet activation and thrombosis, the effects are not identical because
each of the enzymes may have different mechanisms of action and/or substrates. Therefore,
it is important to develop novel compounds that are more potent and selective as broadspectrum TI inhibitor antithrombotic agents without compromising hemostasis. Currently
the antibiotic bacitracin (topical use only) (Figure 6.1) is the only known broad-spectrum
TI inhibitor.280 An inhibitor of any one of the thiol isomerases or pan-thiol isomerase
inhibitor would be valuable to potentially result in the inhibition of multiple pathways for
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the prevention and treatment of both arteriole and venous thrombosis such as modulating
platelet aggregation, platelet thrombus formation, cell migration, and fibrin generation.281,
282

Previously, we have identified a new powerful family-wide (pan) inhibitor of TI activity,
zafirlukast (ZAF, Figure 6.2A), which was shown to modulate platelet function and
integrin function in vitro and inhibit thrombosis in mice.251 ZAF is a cysteinyl LT (CysLT)
receptor antagonist FDA-approved as an oral tablet for the treatment of asthma.283 Multiple
studies have shown the wide-range use of ZAF repurposed or derivatized as a potential
treatment option for Mycobacterium tuberculosis infections and West Nile virus
infections.176, 177 Recently, ZAF displayed potent activity as an inhibitor of Porphyromonas
gingivalis growth as a potential treatment for periodontal diseases.62, 103, 104 The structure
offers a unique opportunity for structure-activity relationship (SAR) studies as ZAF has a
cyclopentyl carbamate attached to an N-methylindole and an arylsulfonamide scaffold
linked via a decorated benzoyl ring. These functional groups offer various points of SAR
studies focused on bioisosteric replacement of the types of substituents/positions on each
of these aromatic and heterocyclic ring systems with the goal of increasing the inhibition
of TIs. ZAF has previously been shown to display no cytotoxicity to mammalian cell lines,
as well as no hemolytic activity, but it does display the ability to enter the blood cells and
its potency could be improved. Therefore, we want to further investigate the potential to
improve activity, selectivity, minimize the risk of potential bleeding, and modify the
various structural aspects of ZAF to determine if we can develop more potent TI inhibitors.
Inspired by the findings, we have developed ZAF derivatives (synthesis of all derivatives
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previously reported)62,

103, 255

as potential drug candidates for targeting TI inhibitors.

Herein, we report the testing of a preliminary library of 35 ZAF derivatives (Figure 6.2B
and 6.2C), along with their biological evaluation as inhibitors of TIs. Overall, compound
21 was found to inhibit TIs and was found to be more potent and selective as a TI inhibitor
compared to the parent ZAF.
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Figure 6.2. A. Chemical structure of zafirlukast (ZAF) and overview of the R1, R2, and R3 substituents present
in the 35 previously published ZAF derivatives biologically evaluated herein. B and C. Synthesized
derivatives of ZAF. The molecules can be divided into two scaffold variations: scaffold 1 (B) and scaffold
2a (C).

6.2.1.3. Inhibition of platelet aggregation with a library of 35 ZAF derivatives with
structure-activity relationship (SAR) analysis
The 35 ZAF derivatives evaluated in this study have all been previously published and
include the 1st generation of ZAF derivatives,62 as well as the ZAF derivatives synthesized
in Chapters 2 and 3 of this dissertation (Figure 6.2, compounds 1-35).103, 255 In this study
two different scaffolds of ZAF derivatives (1 and 2; Figure 6.2A) were evaluated: scaffold
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1 where the organization of the substituents on the benzoyl group (ring B) was kept the
same as that found in the parent ZAF (3-methoxy-4-indoyl organization), and scaffold 2
where the organization of the substituents on ring B was different than that found in ZAF
(2-methoxy-5-indoyl organization). The use of two different ZAF scaffolds offered an ideal
opportunity for initial SAR studies (all IC50 data for all compounds tested are presented in
Table 6.1 below).

Table 6.1: The structure-activity relationship (SAR) of all 35 previously published ZAF
derivatives and their IC50 values when tested against PDI and ERp57. Note: ND means
activity was not detected at concentrations up to 100 µM.
Active compounds
Cpd
R1
ZAF
21
NO2
22
NO2
23
NO2
24
NO2
32
NO2
2
Me
14
H
26

NO2

27
NO2
31
NO2
35
NO2
Inactive compounds
Cpd
R1
1
Me
3
H
4
H
5
Me
6
H
7
H
8
H
9
H
10
NO2
11
NO2
12
H
13
H
15
H
16
H
17
H
18
H
19
H
20
H

R2

R3

Me
Me
Me
Me
CH2Me
OMe
H

2-F
3-F
4-F
3-NO2
2-F
Me
2-naphthalene in place
of benzene
2-naphthalene in place
of benzene
2-Cl
3,4-diF
2-F

Me
Me
Me
CH2CH(CH3)2
R2
OMe
H
H
H
H
H
Me
Me
Me
Me
H
H
Me
Me
Me
Me
Me
Me

R3
H
H
Me
H
H
2-Me
H
2-Me
H
2-Me
2-F
4-F
2-F
3-F
4-F
3-NO2
4-NO2
2-naphthalene in place
of benzene
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IC50 (µM)
10-30
10
30
30
30
50
100
100
100
100
100
100
IC50 (µM)
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND

Table 6.1 continued
25
28
29
30
33
34
35

NO2
NO2
NO2
NO2
NO2
NO2
NO2

Me
Me
Me
Me
(CH2)2Me
(CH2)3Me
CH2CH(CH3)2

4-NO2
2-Br
2,6-diF
2,4-diF
2-F
2-F
2-F

ND
ND
ND
ND
ND
ND
ND

With these 35 ZAF derivatives aimed at increasing TI inhibition, the goal was to answer
the following five questions in terms of SAR. The compound numbers used to answer these
questions are provided into parenthesis following the questions. The five questions are: (i)
is the cyclopentyl carbamate group on ZAF necessary for activity as TIs inhibitors?
(scaffold 1, compounds 1-5); (ii) is the N-methyl R2 group necessary for TI inhibition
activity? (compounds 6 vs 8, 7 vs 9, 12 vs 15, 13 vs 17, and 14 vs 20); (iii) is an electronwithdrawing group (e.g., R1 = NO2) on the indole ring beneficial for TI inhibition when R2
= Me? (compounds 9 vs 11, 15-20 (R1 = H) vs 21-26 (R1 = NO2)); (iv) what is the effect of
varying the R3 electron-withdrawing group(s) or bulkiness on the arylsulfonamide ring
when R1 = NO2 and R2 = Me? (R3 = 2-F (21), 3-F (22), 4-F (23), 3-NO2 (24), 4-NO2 (25),
2-naphthyl (26), 2-Cl (27), 2-Br (28), 2,6-diF (29), 2,4-diF (30), and 3,4-diF (31); and (v)
what is the effect of adding a longer linear or larger branched R1 group to the nitrogen of
the indole ring when R1 = NO2 and R3 = 2-F? (compounds 21 vs 32-35).

To answer the five questions posed and to determine the potential of the 35 ZAF derivatives
(1-35) as TI inhibitors compared to the parent ZAF, we first tested them against TIs PDI
and ERp57 (Table 6.1). The parent compound ZAF (used as a control as it was previously
shown to display activity as a broad-spectrum TI inhibitor)251 along with the 35 ZAF
derivatives were assayed for their ability to inhibit PDI and ERp57 activity by insulin
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turbidity assay (see methods section 6.2.1.7.2). The assay was used to determine the
activity of their ability to inhibit enzyme activity in a time-dependent manner from 0-90
min through the reduction of insulin catalyzed by TIs in the presence of dithiothreitol
(DTT) resulting in the aggregation of insulin chains. The insulin-based turbidometric assay
was adapted to a 384-well format and light absorbance for the turbidity of insulin
aggregation was monitored by measuring at 650 nm.103, 284, 285 All compounds were tested
for activity at 1, 3, 10, 30, and 100 µM from 0-90 min with the positive control being wells
with ERp57 or PDI alone (Figure 6.3A) to show the kinetic inhibition of insulin turbidity
by the compounds. The most active ZAF derivative was compound 21 (Figure 6.3A),
which was able to entirely inhibit the enzyme activity of PDI and ERp57 (IC50 = 10 µM).
Additionally, compound 21 was further tested in comparison to ZAF (IC50 = 10-30 µM,
(Figure 6.3B)) tested at 1, 3, 10, 30, and 100 µM. In Figure 6.3B, the data were collected
at the 50-min time point and the kinetic data was converted to endpoint format, which
determined that compound 21 displayed increased potency compared to ZAF. The negative
control for this assay was vehicle plates with purple circles for ERp57 alone (Figure 6.3A)
and the positive control for this assay was the commercially available ZAF (pale blue bars
Figure 6.3B).

300

Figure 6.3. All 35 ZAF derivatives presented in this study were screened for inhibitory effects on the redox
reactivity of thiol isomerase (TI) ERp57 assayed at 10 µg/mL, data presented depict the representative
compound 21 as this displayed the most activity. A. Shows the kinetic inhibition of insulin turbidity by
compound 21, B. converts the kinetic data to endpoint format at the 50-min time point to determine a percent
inhibition of compound 21 and compares it to the parent compound ZAF. The ability of compound 21 to
inhibit TI activity and its specificity was measured by insulin turbidity assay in which insulin chain
precipitation through disulfide bond reduction was measured at a wavelength of 650 nm in a
spectrophotometer at 37 °C. The positive control was enzyme assay performed in the absence of enzyme.
Compound 21 and ZAF concentrations dependently inhibits ERp57 activity.

When looking broadly at the data presented in Table 6.1, the most active compounds were
presented at the top with IC50 values ranging from 10-100 µM, and the inactive compounds
at the bottom where no inhibitory activity was seen when tested against PDI and ERp57 at
concentrations up to 100 µM. In general, when tested for activity as inhibitors of PDI and
ERp57, compounds belonging to scaffold 1 displayed poor activity, while those with
scaffold 2 displayed similar or increased activity as inhibitors when compared to the parent
ZAF. The higher potency of compounds with scaffold 2 indicates that in the context of a
substitution pattern distinct from that of ZAF, a cyclopentyl carbamate group at the R1 of
ZAF is not required for TI inhibition. In fact, scaffold 2a (Figure 6.2C), with its 2-methoxy5-indoyl substituents on ring B, yielded the most active compound 21, which was ~4-fold
more potent than ZAF (Figure 6.3).

By taking a deeper look into the data, we aimed to answer the five questions posed above.
Question i: Is the cyclopentyl carbamate group on ZAF necessary for activity as TIs
inhibitors? To answer this question, we first evaluated the ZAF derivatives 1-5 of scaffold
1 (Figure 6.2B), which all lacked the cyclopentyl carbamate group at the C5 position of the
indole (ring A) of ZAF. Each compound either had a hydrogen or methyl group at R1 or R3
and either a methoxy or hydrogen for the R2 group. Overall, it was found that compounds
1-5 displayed no activity against TIs PDI and ERp57 at concentrations up to 100 µM. The
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dispensability of the cyclopentyl carbamate group in the context of scaffold 2 is
encouraging, because this group or a lipidic “tail” at this position are required for both high
potency and selectivity of ZAF towards leukotriene receptors.255 For this reason,
compounds lacking the cyclopentyl carbamate group may not have this off-target binding
activity.

To investigate if the N-methyl R2 group is necessary for TI inhibition activity when R1 =
H (question ii), we compared compounds 6 (R3 = H), 7 (R3 = 2-Me), 12 (R3 = 2-F), 13 (R3
= 4-F), and 14 (R3 = 2-naphthylene in place of benzene) that had R2 = H and their respective
counterparts that had the same R3 groups with R2 = Me for compounds 8, 9, 15, 17, and
20. When tested for inhibitory activity against TIs, derivatives 6, 7, 12, and 13 displayed
no activity up to the highest concentration tested of 100 µM, along with their respective
counterparts of 8, 9, 15, and 17. Compound 14 displayed minimal activity at 100 µΜ while
its counterpart 20 with the naphthalene ring at R3 displayed no activity. As these
compounds were found to be inactive a conclusion could not be made if the R2 methyl
group was necessary for activity when answering question ii, but a conclusion is made
when answering question v later on in the discussion.

Therefore, for the next set of compounds we kept the N-methyl R2 group on the nitrogen
of the indole (ring A) constant while investigating if an electron-withdrawing group (e.g.,
R1 = NO2) on the C5 position of the indole ring was beneficial for TI inhibition (question
iii). Overall, we discovered that the electron-withdrawing group (R1 = NO2) on the indole
(ring A) resulted in increased TI inhibition activity and yielded derivatives 22 (R3 = 3-F),
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23 (R3 = 4-F), and 24 (R3 = 3-NO2) with moderate activity (IC50 = 30 µM), and the most
active compound 21 (R3 = 2-F) with an IC50 value of 10 µM. By performing a pairwise
comparison we observed that compounds with N-methyl R2 group and methyl on the C2
position of the arylsulfonamide ring, such as 9 (R1 = H) and 11 (R1 = NO2) were found to
be inactive. Additionally, for compounds 15-20 (R1 = H) vs compounds 21-26 (R1 = NO2)
where compounds 15-20 were found to be inactive, compounds 21-26 overall displayed
the best activity out of any of the compounds tested. Additionally, from this data we
discovered that the methyl at the C2 position of the arylsulfonamide ring of compound 11
decreased activity when compared to compound 21 that had an electron-withdrawing group
such as fluorine at that position. Therefore, the future compounds tested did not have the
R3 = 2-Me on the arylsulfonamide ring C.

Having confirmed the importance of the electron-withdrawing group on the C5 position of
the indole (ring A) along with the increased activity with N-methyl R1 group on the nitrogen
of the indole ring, the next set of derivatives kept these two R1 and R2 groups constant
while varying the R3 groups. We wanted to know (question iv) what is the effect of varying
the R3 electron-withdrawing group(s) or bulkiness on the aryl sulfonamide ring when R1 =
NO2 and R2 = Me? We observed that replacing the benzene ring of the arylsulfonamide
(ring C) to a bulky 2-naphthalene ring (26) resulted in almost complete loss of activity.
Thus, the naphthylated derivatives were not further pursued in the study. For compounds
21-25, we observed that substitution of the R3 group with electron-withdrawing groups
such as fluorine and nitro groups yielded significant increase in activity for TI inhibition
(IC50 = 10-30 µM for R3 = 2-F, 3-F, 4-F, and 3-NO2) with the exception of the inactive
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compound 25 (R3 = 4-NO2). As compound 21 was the most active compound, the
importance of the 2-F on the arylsulfonamide (ring C) was investigated by the replacement
of the fluorine with other mono- and di-halogenated groups for compounds 27-31 that
contained R3 = 2-Cl, 2-Br, 2,6-diF, 2,4-diF, and 3,4-diF. All compounds 27-31 were found
to be inactive, therefore, R3 = 2-F remained constant for the remaining compounds tested
in the experiments. Overall, it was found that compound 21 (R3 = 2-F) displayed better
activity (>) than 22 (R3 = 3-F), which was similar to (≈) 23 (R3 = 4-F), (≈) 24 (R3 = 3-NO2),
which displayed better activity (>) than 26 (R3 = 2-naphthalene in place of benzene), (≈)
27 (R3 = 2-Cl), (≈) 31 (R3 = 3,4-diF), (>) 25 (R3 = 4-NO2), (≈) 28 (R3 = 2-Br), (≈) 29 (R3
= 2,6-diF), and (≈) 30 (R3 = 2,4-diF).

Having determined the importance of the R1 = NO2 group at the C5 position of the indole
(ring A), along with the importance of the electron-withdrawing R3 = 2-F group on the
arylsulfonamide (ring C) these two groups were kept constant while using a different
method to investigate the importance of the N-methyl R2 group on the nitrogen of the
indole. Question v: What is the effect of adding a longer linear or larger branched R1 group
to the nitrogen of the indole ring when R1 = NO2 and R3 = 2-F? To answer this question
and investigate the importance of the N-methyl indole (ring A) on the most active
compound 21, we compared it to compounds 32-35 with varying chain lengths that led to
compounds that were completely inactive (IC50 = 100 µM or not detected at concentrations
up to 100 µM). As the most active ZAF derivative was 21, this compound was chosen for
further investigation. In addition to increased potency against TIs, the most active
compound 21 was previously tested in mammalian cell lines HEK-293, BEAS-2B, and
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HepG2 and was found to display no cytotoxicity at concentrations up to 62.6 µg/mL
(Figure 3.10 in section 3.3.7).255

6.2.1.4. Platelet aggregation assays of the most active ZAF derivatives
Platelet aggregation was measured in washed platelet suspensions in the presence of either
DMSO, ZAF (0.1-40 µM, Figure 6.4A), or compound 21 (0.1-20 µM, Figure 6.4B), and
were stimulated for 180 s with collagen with decreasing platelet aggregation in a dose
dependent manner. Endpoint readings for compound 21 at 180 s from three respective
independently replicated runs from Figure 6.4B are displayed in Figure 6.4C to present the
% aggregation at the 180 s endpoint. Overall, compound 21 resulted in the most potent
inhibitor of platelet aggregation, which was more potent than the parent compound ZAF.

Figure 6.4. A. ZAF and B. the most active ZAF derivative (21) inhibit platelet aggregation. C. Endpoint
readings at 180 s of three respective replicate runs used to produce B to show the percent error for the
replicates at a specific time point. The vehicle, ZAF, and compound 21 were each incubated with washed
human platelets (4×108 cells/mL) for 5 min prior to stimulation with collagen (1 µg/mL) for 180 s and
measured by an optical aggregometer.

6.2.1.5. Inhibition of platelet aggregation and thrombus formation in mice with ZAF
derivatives
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Ongoing research efforts will comprise the investigation of the ability of the most active
ZAF derivatives to inhibit platelet aggregation and thrombus formation in mice. These
studies are currently being designed for future experiments to be performed. In this
experiment, the ability of the most active ZAF derivatives to inhibit mouse platelet
aggregation (in animal) and thrombus formation will be investigated through methods
described in section 6.2.1.7.4.

6.2.1.6. Conclusions
In summary, we provide evidence that testing of a library of 35 ZAF derivatives led to the
discovery of the most active ZAF derivative 21 that displayed potent thiol isomerase
inhibition against TIs PDI and ERp57, which modulates platelet function and thrombosis.
Through these studies we have discovered that: (i) at the C5 position of the indole (ring A)
the presence of the cyclopentyl carbamate group is not needed for activity, but its complete
removal with a hydrogen at that position decreased activity, while replacement with an
electron-withdrawing group of NO2 increased activity of the derivatives compared to the
parent ZAF; (ii) removal of the N-methyl group on the nitrogen of the indole (ring A) by
replacement with a hydrogen, longer linear or branched alkyl chain decreased activity; (iii)
modification of the 3-methoxy-4-indoyl organization of ZAF to a 2-methoxy-5-indoyl
arrangement increased TI inhibition activity of the ZAF derivatives; (iv) replacement of
the R3 hydrogen on the arylsulfonamide (ring C) by electron-withdrawing groups (e.g., R3
= 2-F, 3-F, 4-F, and 3-NO2) resulted in increased activity, while the addition of bulky
groups, halogens (e.g., Br or Cl) or di-halogenated groups resulted in decreased activity
compared to the parent ZAF. Investigation into various SAR studies through the synthesis
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of novel ZAF derivatives will be further explored and are described in detail in section
6.2.2.1 where ZAF derivatives will be designed and synthesized for testing as TI inhibitors
by keeping the most active R3 substituent on ring C as 2-F constant for the future ZAF
derivatives. Further investigation of the most active ZAF derivatives, along with synthesis
of the novel ZAF derivatives for future investigations as potential TI inhibitors are ongoing
in Prof. Kennedy and Prof. Garneau-Tsodikova’s laboratories in which current laboratory
members are continuing this research.

6.2.1.7. Biological experimental section
6.2.1.7.1. Materials and instrumentation
Recombinant ERp57 was purchased from Abcam (Cambridge, MA). Zafirlukast was
purchased from TCI America (Portland, OR). Recombinant insulin (bovine), bacitracin,
DTT buffers and all other chemicals were purchased from Sigma Aldrich (St. Louis, MO);
while 96- and 384-well clear bottom plates were purchased from Corning (Corning, NY).

6.2.1.7.2. Insulin-based turbidometric assay
The ability of ZAF derivatives 1-35 to inhibit PDI and ERp57 was determined by an insulin
turbidity assay, performed as previously described,251 to measure TI inhibitory activity of
the derivatives (Figure 6.3A). The disulphide bonds in insulin were reduced by a TI, which
results in the separation of the A and B chains and precipitation, which was measured by
spectrophotometry at a wavelength of 650 nm. A 384-well clear bottom Corning plate was
used. In each well a 30 µL cocktail consisting of 1.75 mg/mL insulin and an optimized
concentration (0.5 µg/well of PDI and ERp57) in 100 mM K2PO4, 0.2 mM EDTA with a
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pH of 7.2. The reduction was initiated by the addition of 0.3 mM DTT after incubation for
10 min to propagate enzyme activity. Then the absorbance was measured at 650 nm at
every minute for 90 min using a PerkinElmer Envision plate readers (PerkinElmer,
Waltham, MA). The negative controls comprised wells that contained no inhibitors and
wells that contained no TIs. Positive controls were wells that contained ZAF. All
compounds were tested in duplicate.

The IC50 values were obtained using a 6-point dose curve with a minimum of three
independent replicates (Figure 6.3B). The lead compound 21 was diluted in a 6-point dose
curve with concentrations of 0, 1, 3, 10, 30, and 100 µM and insulin turbidity was measured
at the 50-min time point using a SpectraMax M3 microplate reader (Molecular Devices,
Sunnyvale, CA).

6.2.1.7.3. Platelet preparation and stimulation
To determine the activity of ZAF and select ZAF derivatives as inhibitors of ex vivo platelet
aggregation, ZAF and compound 21 were selected for further investigation by testing their
ability to prevent the induction of arterial and venous thrombosis (Figure 6.4). The
examination of platelet aggregation was performed by the collection of washed human
platelets from consenting, drug-free donors using standard venipuncture techniques. The
washed human platelets were prepared by differential centrifugation as previously
described254 and suspended to a density of 4×108 cells/mL in Tyrodes-HEPES buffer that
comprised 134 mM NaCl, 2.9 mM KCl, 0.34 mM Na2HPO4, 20 mM HEPES, 1 mM MgCl2,
and 5 mM glucose at pH 7.3. The platelets were incubated with vehicle (DMSO, 0.1% v/v)
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or ZAF for 5 min prior to stimulation. Then agonists were used to stimulate platelets for
180 s in a lumi-aggregometer (Chronolog, Havertown, PA, USA) with continuous stirring.
In the presence of 100 ng/mL PGI2 platelets were pelleted by centrifugation at 1,000 g for
5 min and were re-suspended to a density of 2×108 cells/mL in Tyrodes-HEPES buffer.
The positive control ZAF was tested at 1.25, 2.5, 5, 10, 20, and 40 µM. ZAF derivative 21
was tested at 1.25, 2.5, 5, 10, and 20 µM.

6.2.1.7.4. Assessment of platelet aggregation and thrombus formation in mice
In order to assess the most active ZAF derivatives (21) ability to inhibit arterial thrombus
formation, a tail bleeding assay using laser injury will be performed. Male C57BL/6J mice
(RRID:IMSR_JAX:000664) which will be bred in house, and at age 4-5 weeks will be
anaesthetized with a weight range of 19-25 g by intraperitoneal injection of ketamine (125
mg/kg), xylazine (12.5 mg/kg), and atropine (0.25 mg/kg). Platelets will be labelled by
intravenous infusion of DyLight 649-conjugated anti-GPIb platelet labelling antibody (0.2
µg/g of body weight) as previously reported.251 After the exposure of the testicular
cremaster muscle, the vehicle of DMSO (0.1% v/v) or ZAF derivative will be infused
intravenously and following a 5-min incubation period, the arteriole wall injury will be
induced by laser ablation (Micropoint, Andor Technology, Belfast, UK). Then thrombus
formation will be observed using an Olympus BX microscope (Olympus, Essex, UK) and
a Hamamatsu (Hamamatsu Photonics, Hertfordshine, UK) CCD camera, with the data
analyzed using Slidebook Software 5.0 (Intelligent Imaging Innovations, Denver,
USA).253, 254, 286 Mice will be killed using Schedule 1 approved methods at the end of the
experiment. All animal experiments will be blinded for both the experimental treatment
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and the analysis. Animal experiments have previously been approved by the University of
Reading Local Ethical Review Panel and authorized by the UK Home Office. Animal
studies are reported in compliance with the ARRIVE guidelines287 and with the
recommendations made by the British Journal of Pharmacology.288
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6.2.2. Future studies for ZAF derivatives active against P. gingivalis
6.2.2.1. Design and synthesis of novel 4th generation ZAF derivatives
Based on the current data showing inhibition of P. gingivalis growth activity, there are
currently many compounds that we could envision preparing as ZAF derivatives. Thus, we
need to rationally design batches of 10-20 derivatives to be synthesized. In general, future
studies should focus on modifying the types and the positions of substituents on rings A,
B, and C for the next generations of ZAF derivatives (Figure 6.5).

Representative current and future SAR options:
(Bold substituents are synthesized or in progress)
O
O S
O
NH

= H, Me, CH

R1
2Me, MeO,
NH2, NO2, CH2OH,
carbamates
R1

A

B

C

R3

R3

= 2-F, 4-NO

2

OMe

- Modify position of substituents
- Replace methoxy group with other
alkoxy groups (varying chain lengths
and branched chains)
- Replace indole ring with
= alkyl (CH
other heterocycles
R2
2Me, (CH2)3Me, CH(CH3)2), amino
(containing N, O, or S)
(CH2NH2), alkoxy (CH2OH), aryl (phenyl)
N
R2

Figure 6.5. Representative structure of current and future SAR options for modification of rings A, B, and
C. Along with modifications of the positions and substituents of R1, R2, and R3.

For scaffold 2, we know that for R1 the cyclopentyl carbamate at the C5 position of indole
(ring A) of ZAF was not essential for the inhibition of P. gingivalis growth. However,
substituting with different types of carbamates, alkyl chains varying in length, electrondonating groups (e.g., alkyl, alkoxy, and amino), and electron-withdrawing groups (e.g.,
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halogen, nitrile, carbonyl, and nitro) could be valuable for activity, which is what we will
investigate in future generations of ZAF derivatives. We also will expand the N-R2 on
indole (ring A) by replacement of N-methyl with various short chains of amino and alkoxy
groups to determine the effect of polarity on activity. In order to determine the optimal
conformation of the substituents on ring B, the methoxy and amide bond will be places at
different positions in relation to ring A such as ortho-, meta-, and para-positions. Once we
have identified the optimal substitution pattern on ring B, we will replace the methoxy by
various alkyl, alkoxy, and halogen groups. The importance of the indole ring will also be
investigated by replacing indole (ring A) with various heterocycles containing N, O, or S.
We have started the preliminary synthesis of these heterocyclic derivatives and we have
designed the synthesis for other 5- and 6-membered heterocyclic derivatives for scaffold
2b (Figure 6.6, compounds 36-39).

A. Scaffold
2b:ZAF derivatives)
generation
th
(4
R3
O
C
O S
O
NH
B

OMe

B. Scaffold 2b:
R1
Y
R1
Y
R1
Y
g
a, b, c
a, b, c
f, g
R1
R1
R1
X
X
X
N
N
N
d, or e
= H d, or e
R = MgI, MgBr
= I, Br, Li
R2
R2
R2
R1
R1
= I, Br, Li
R = MgI, MgBr
1
R1
X = N, O, S
1
Y ==C,
a. NIS, TFA, THF; b. NIH, CH2Cl2; c. NBS, Al2O3, Et3N, THF, hexanes; d. NBS,
HN
R1 = Me, alkylsDMF; e. n-BuLi, THF, hexanes; f. I2, hexanes, Et2O, H2O; g. Mg, I2, THF.
R2
Y

R1
O
O
O
O
A X R2
X
OMe
OMe
OMe
OMe
Y
= Me; R = 2-F
R
2
36: X = N; Y = CH; R2 = Me; R3 = 4-NO
h
i
j,
k,
l
OMe
OMe
OMe
OMe + or
O
37: X = N; Y = CH; R2 = 2-F 3
2
R1
38: X = O; Y = CH; R3 = 4-NO
m, n
HO
H
Br
39: X = O; Y = CH; R3
o, or p Z
2
h. NaBH4, THF; i. PBr3, Et2O; j. n-BuLi, THF; k. n-BuLi, ZnBr2,
N
Z = heterocycles
n
dba
-BuLi,
Et
Pd(PPh3)4, THF; l.
2O; m. Zn, I2, S-Phos, Pd2
3,
X = N, O, S
DMF; n. Zn, P(Ph)3, Pd(OAc)2, TMSCl, 1,2-dibromoethane,
Y ==C,
I, N
Br, MgI,
THF; o. Zn, Cl2Pd(PPh3)2, DMA, benzene; p. THF. NOTE: Final
R1 MgBr, Li
compounds of Scaffold 2b will be prepared by synthetic
methodology shown in Scheme 2.1 with b. KOH,
= Me, alkyls
.
R2
MeOH/THF/H2O; c. arylsulfonamide, EDC•HCl, DMAP, CH2Cl2

Figure 6.6. A. Examples of ZAF derivatives with scaffold 2b compounds (36-39) that I synthesized for the
4th generation ZAF derivatives along with B. representative synthetic schemes, where the indole ring was
replaced by various 5- and 6-membered heterocyclic rings.
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In Chapters 2 and 3, we investigated novel 2nd and 3rd generation ZAF derivatives that were
selectively active against the periodontal pathogen P. gingivalis.103,

255

For all 3rd

generation ZAF derivatives we focused on keeping the most active R3 groups on the
arylsulfonamide ring C constant with the two most active groups of 2-F (for the project of
thiol isomerase inhibition and for the project of activity with P. gingivalis) and 4-NO2. In
addition to 3rd generation ZAF derivatives (Figure 3.1, section 3.2) where we investigated
the importance of the N-methyl R2 group, we designed scaffold 2b (Figure 6.6) and started
synthesizing 4th generation ZAF derivatives 36-39 (Figure 6.6) to investigate the
importance of indole (ring A) by replacing ring A with various heterocycles containing N,
O, or S. Note: We are in the preliminary steps of designing and synthesizing additional
scaffold 2b compounds and compounds 36-39 have not been tested yet. For the synthesis
of compounds with various substituents on rings B and C for scaffold 2 I do not anticipate
the need for other alternative synthetic routes. However, the preliminary investigation into
the importance of the indole ring A by replacement of the indole ring with other
heterocycles (containing N, O, or S) has shown that the typical synthetic route will not
work for the 5- and 6-membered heterocyclic rings for the condensation reaction “a” seen
with scaffold 2a (Scheme 3.1 in section 3.3.1). Therefore, we developed novel synthetic
schemes to overcome the problem by including reactions to activate the heterocyclic rings
to push the condensation reactions forward. For scaffold 2b the step that will differ from
that of scaffold 2a (shown in Scheme 3.1 in section 3.3.1) is the first step in the
condensation reaction (labeled as reaction “a” from Scheme 3.1 in section 3.3.1), while
reactions “b” and “c” will remain the same for scaffold 2b in terms of the hydrolysis of the
ester to the carboxylic acid and amide coupling as the final two steps of the synthesis. For
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scaffold 2b the 5- and 6-membered heterocyclic rings will first undergo iodination,
bromination, or undergo the addition of lithium at the C2 position for 5-membered rings
and the C3 position for 6-membered rings (using one of the reactions a-e). These
compounds will either be taken directly to the next step (with R1 = iodine, bromine, or
lithium) or they will undergo reaction “f” or “g” to synthesize a Grignard reagent to further
push the reaction forward (with R1 = magnesium iodide or magnesium bromide). This
synthesis is a convergent synthesis where methyl-5-formyl-2-methoxybenzoate undergoes
a reduction “h” of the aldehyde to a primary alcohol, followed by “i” bromination, the
addition of the heterocycle with R1 = iodine, bromine, lithium, magnesium iodide, or
magnesium bromide (using one of the reactions j-p) to yield the ester which undergoes the
same hydrolysis of the ester to the carboxylic acid (reaction “b” from Scheme 3.1 in section
3.3.1). These reactions should allow for the 5- and 6-membered heterocycles to be more
reactive in order to push the reactions to go to completion to move forward in making the
final compounds.

6.2.2.2. Design and synthesis of 5th generation ZAF derivatives for mechanism of action
studies
As the mechanism of action of these compounds have not been elucidated, future studies
should investigate the mechanism of action through various approaches. This section will
highlight the approach through synthesizing biotinylated compounds. We rationally
designed the synthesis of novel 5th generation ZAF derivatives with scaffold 2c (Figure
6.7, 40-42) to be used to determine the mechanism of action through pull-down assays.
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Scaffold 2c: A synthetic scheme for compound 40 (similar
mechanism used for compound 41)
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Figure 6.7. A synthetic scheme for scaffold 2c (40-42) 5th generation biotinylated ZAF derivatives to use for
mechanism of action studies.

For the synthesis of the 5th generation ZAF derivatives an alternative synthetic scheme was
designed to yield biotinylated ZAF derivatives with biotin attached to scaffold 2c at the C5
of the indole 40, nitrogen of the indole 42, or C4 of the arylsulfonamide ring 41 (Figure
6.7). For the synthesis of 5th generation ZAF derivatives we do not anticipate the need for
another alternative synthetic route as we have already tried various reactions of all novel
steps and we have performed and optimized all of these steps. For scaffold 2c, 5th
generation ZAF derivative 40 (similar reaction scheme used for 41) a linear synthesis will
be used. The indole ring A will undergo reaction “e” amine protection using tertbutyloxycarbonyl, followed by reactions “a-c” from Scheme 3.1 in section 3.3.1. Next the
Boc-protected amine will undergo reaction “f” deprotection under acidic conditions using
trifluoroacetic acid and finally it will be biotinylated with reaction “g”. For scaffold 2c
ZAF derivative 42 a convergent synthesis will be used. First the alcohol of tert-butyl-(2315

hydroxyethyl)carbamate is treated with methanesulfonyl chloride reaction “h” in the
presence of triethylamine, which creates a good leaving group. Then 5-nitroindole
undergoes condensation reaction “a” from Scheme 3.1 in section 3.3.1. Problem solving
and optimization had to be performed for reaction “i” as using a method we previously
published for alkylation with sodium hydride and dimethylformamide was not ideal as
sodium hydride was too strong of a base leading to many side products. To optimize these
conditions, using a weaker, but still somewhat strong base of sodium carbonate with
dimethylformamide worked for reaction “i”. Then previously described reactions “b-c”
from Scheme 3.1 in section 3.3.1, followed by reaction “f” and “g” from compound 40,
were used to yield 5th generation ZAF derivative 42. These reactions were performed as
small-scale trial reactions. The 5th generation ZAF derivatives 40-42 will be scaled up by
current graduate students and used in pull-down assays.

6.2.2.3. Multi-species biofilm studies with oral bacterial species
To further test the specificity of the most active ZAF derivatives, future studies need to
focus on performing dual- and tri-species biofilm studies. Multi-species biofilm studies
will be performed using the same protocol presented in the experimental section 3.5.2.4
and 3.5.2.5. Important multi-species biofilms to test are the dual species of F. nucleatum
and P. gingivalis as well as the tri-species biofilms of S. sanguinis, P. gingivalis, and A.
actinomycetemcomitans. These bacterial species have important synergistic (F. nucleatum
enhances the growth of P. gingivalis by providing a carbon dioxide rich
microenvironment)17,
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and antagonistic interactions (S. sanguinis produces hydrogen
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peroxide to inhibit the growth of P. gingivalis and A. actinomycetemcomitans)3 that are
vital to the progression or the regression of periodontal diseases.

As this project is ongoing, current laboratory members in Professors Gonzalez and
Garneau-Tsodikova’s laboratories will be continuing this research. Ongoing research
efforts will look into the design, synthesis, and biological evaluation of novel ZAF
derivatives through multiple studies such as mechanism of action, % growth inhibition
assays with P. gingivalis and other oral bacterial species, cytotoxicity studies in
mammalian cells, CFU assays, and multi-species biofilm studies.
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APPENDIX A
1H

and 13C NMR spectra as well as HPLC traces A1-A48 for Chapter 2

Figure A1: 1H NMR spectrum for compound 12a (SGT1735) in (CD3)2SO (400 MHz).
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Figure A2: 13C NMR spectrum for compound 12a (SGT1735) in (CD3)2SO (100 MHz).

Figure A3: HPLC trace for compound 12a (SGT1735). Rt = 18.45 min.

Figure A4: 1H NMR spectrum for compound 12c (SGT1734) in (CD3)2SO (400 MHz).
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Figure A5: 13C NMR spectrum for compound 12c (SGT1734) in (CD3)2SO (100 MHz).

Figure A6: HPLC trace for compound 12c (SGT1734). Rt = 18.66 min.
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Figure A7: 1H NMR spectrum for compound 12f (SGT1739) in (CD3)2SO (400 MHz).

Figure A8: 13C NMR spectrum for compound 12f (SGT1739) in (CD3)2SO (100 MHz).
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Figure A9: HPLC trace for compound 12f (SGT1739). Rt = 19.26 min.

Figure A10: 1H NMR spectrum for compound 13a (SGT1617) in CDCl3 (400 MHz).
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Figure A11: 13C NMR spectrum for compound 13a (SGT1617) in CDCl3 (100 MHz).

Figure A12: HPLC trace for compound 13a (SGT1617). Rt = 19.30 min.
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Figure A13: 1H NMR spectrum for compound 13b (SGT1618) in CDCl3 (400 MHz).

Figure A14: 13C NMR spectrum for compound 13b (SGT1618) in CDCl3 (100 MHz).
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Figure A15: HPLC trace for compound 13b (SGT1618). Rt = 19.51 min.

Figure A16: 1H NMR spectrum for compound 13c (SGT1619) in CDCl3 (400 MHz).
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Figure A17: 13C NMR spectrum for compound 13c (SGT1619) in CDCl3 (100 MHz).

Figure A18: DEPT NMR spectrum for compound 13c (SGT1619) in CDCl3 (100 MHz).
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Figure A19: HPLC trace for compound 13c (SGT1619). Rt = 19.48 min.

Figure A20: 1H NMR spectrum for compound 13d (SGT1620) in CDCl3 (400 MHz).
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Figure A21: 13C NMR spectrum for compound 13d (SGT1620) in CDCl3 (100 MHz).

Figure A22: HPLC trace for compound 13d (SGT1620). Rt = 19.32 min.
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Figure A23: 1H NMR spectrum for compound 13e (SGT1621) in CDCl3 (400 MHz).

Figure A24: 13C NMR spectrum for compound 13e (SGT1621) in CDCl3 (100 MHz).

329

Figure A25: DEPT NMR spectrum for compound 13e (SGT1621) in CDCl3 (100 MHz).

Figure A26: HPLC trace for compound 13e (SGT1621). Rt = 20.20 min.
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Figure A27: 1H NMR spectrum for compound 13f (SGT1622) in CDCl3 (400 MHz).

Figure A28: 13C NMR spectrum for compound 13f (SGT1622) in CDCl3 (100 MHz).
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Figure A29: DEPT NMR spectrum for compound 13f (SGT1622) in CDCl3 (100 MHz).

Figure A30: HPLC trace for compound 13f (SGT1622). Rt = 19.32 min.
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Figure A31: 1H NMR spectrum for compound 14a (SGT1623) in CDCl3 (500 MHz).

Figure A32: 13C NMR spectrum for compound 14a (SGT1623) in (CD3)2SO (100 MHz).
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Figure A33: HPLC trace for compound 14a (SGT1623). Rt = 19.11 min.

Figure A34: 1H NMR spectrum for compound 14b (SGT1624) in CDCl3 (500 MHz).
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Figure A35: 13C NMR spectrum for compound 14b (SGT1624) in (CD3)2SO (100 MHz).

Figure A36: HPLC trace for compound 14b (SGT1624). Rt = 19.22 min.
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Figure A37: 1H NMR spectrum for compound 14c (SGT1625) in CDCl3 (500 MHz).

Figure A38: 13C NMR spectrum for compound 14c (SGT1625) in (CD3)2SO (100 MHz).
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Figure A39: HPLC trace for compound 14c (SGT1625). Rt = 17.65 min.

Figure A40: 1H NMR spectrum for compound 14d (SGT1626) in CDCl3 (500 MHz).
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Figure A41: 13C NMR spectrum for compound 14d (SGT1626) in (CD3)2SO (100 MHz).

Figure A42: HPLC trace for compound 14d (SGT1626). Rt = 19.09 min.

338

Figure A43: 1H NMR spectrum for compound 14e (SGT1627) in CDCl3 (500 MHz).

Figure A44: 13C NMR spectrum for compound 14e (SGT1627) in (CD3)2SO (100 MHz).

339

Figure A45: HPLC trace for compound 14e (SGT1627). Rt = 19.07 min.

Figure A46: 1H NMR spectrum for compound 14f (SGT1628) in CDCl3 (500 MHz).
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Figure A47: 13C NMR spectrum for compound 14f (SGT1628) in (CD3)2SO (100 MHz).

Figure A48: HPLC trace for compound 14f (SGT1628). Rt = 15.17 min.
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APPENDIX B
1H

and 13C NMR spectra as well as HRMS and HPLC traces B1-B86 for Chapter 3

Figure B1: 1H NMR spectrum for compound 2 (SGT1629) in CDCl3 (500 MHz).
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Figure B2: 13C NMR spectrum for compound 2 (SGT1629) in CDCl3 (100 MHz).

Figure B3: 1H NMR spectrum for compound 3 (SGT1630) in CDCl3 (500 MHz).
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Figure B4: 13C NMR spectrum for compound 3 (SGT1630) in CDCl3 (100 MHz).

Figure B5: 1H NMR spectrum for compound 4 (SGT1631) in CDCl3 (500 MHz).
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Figure B6: 13C NMR spectrum for compound 4 (SGT1631) in CDCl3 (100 MHz).

Figure B7: 1H NMR spectrum for compound 5 (SGT1633) in CDCl3 (500 MHz).
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Figure B8: 13C NMR spectrum for compound 5 (SGT1633) in CDCl3 (100 MHz).

Figure B9: 1H NMR spectrum for compound 6 (SGT1632) in CDCl3 (500 MHz).
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Figure B10: 13C NMR spectrum for compound 6 (SGT1632) in CDCl3 (100 MHz).

Figure B11: 1H NMR spectrum for compound 9 (SGT1639) in CDCl3 (500 MHz).
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Figure B12: 13C NMR spectrum for compound 9 (SGT1639) in CDCl3 (100 MHz).

Figure B13: 1H NMR spectrum for compound 10 (SGT1640) in CDCl3 (500 MHz).
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Figure B14: 13C NMR spectrum for compound 10 (SGT1640) in CDCl3 (100 MHz).

Figure B15: 1H NMR spectrum for compound 11 (SGT1641) in CDCl3 (500 MHz).
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Figure B16: 13C NMR spectrum for compound 11 (SGT1641) in CDCl3 (100 MHz).

Figure B17: 1H NMR spectrum for compound 12 (SGT1660) in CDCl3 (500 MHz).
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Figure B18: 13C NMR spectrum for compound 12 (SGT1660) in CDCl3 (100 MHz).

Figure B19: 1H NMR spectrum for compound 13 (SGT1642) in CDCl3 (500 MHz).
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Figure B20: 13C NMR spectrum for compound 13 (SGT1642) in CDCl3 (100 MHz).

Figure B21: 1H NMR spectrum for compound 15 (SGT1644) in CDCl3 (500 MHz).
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Figure B22: 13C NMR spectrum for compound 15 (SGT1644) in CDCl3 (100 MHz).

Figure B23: 1H NMR spectrum for compound 16 (SGT1645) in CDCl3 (500 MHz).
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Figure B24: 13C NMR spectrum for compound 16 (SGT1645) in CDCl3 (100 MHz).

Figure B25: 1H NMR spectrum for compound 17 (SGT1646) in CD3OD (500 MHz).

354

Figure B26: 13C NMR spectrum for compound 17 (SGT1646) in CD3OD (100 MHz).

Figure B27: 1H NMR spectrum for compound 18 (SGT1648) in (CD3)2SO (500 MHz).
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Figure B28: 13C NMR spectrum for compound 18 (SGT1648) in CDCl3 (100 MHz).

Figure B29: 1H NMR spectrum for compound 19 (SGT1647) in CD3OD (500 MHz).
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Figure B30: 13C NMR spectrum for compound 19 (SGT1647) in CDCl3 (100 MHz).

Figure B31: 1H NMR spectrum for compound 21b (SGT1649) in CDCl3 (500 MHz).
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Figure B32: 13C NMR spectrum for compound 21b (SGT1649) in (CD3)2SO (100 MHz).

Figure B33: HRMS spectrum for compound 21b (SGT1649). m/z found 515.4124 [M+H]+.
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Figure B34: HPLC trace for compound 21b (SGT1649). Rt = 13.03 min.

Figure B35: 1H NMR spectrum for compound 21c (SGT1650) in CDCl3 (500 MHz).
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Figure B36: 13C NMR spectrum for compound 21c (SGT1650) in (CD3)2SO (100 MHz).

Figure B37: HRMS spectrum for compound 21c (SGT1650). m/z found 559.1314 [M+H]+.
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Figure B38: HPLC trace for compound 21c (SGT1650). Rt = 13.03 min.

Figure B39: 1H NMR spectrum for compound 21d (SGT1662) in CDCl3 (500 MHz).
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Figure B40: 13C NMR spectrum for compound 21d (SGT1662) in (CD3)2SO (100 MHz).

Figure B41: HRMS spectrum for compound 21d (SGT1662). m/z found 516.1034 [M+H]+.
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Figure B42: HPLC trace for compound 21d (SGT1662). Rt = 13.03 min.

Figure B43: 1H NMR spectrum for compound 21e (SGT1663) in CDCl3 (500 MHz).
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Figure B44: 13C NMR spectrum for compound 21e (SGT1663) in (CD3)2SO (100 MHz).

Figure B45: HRMS spectrum for compound 21e (SGT1663). m/z found 516.1027 [M+H]+.
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Figure B46: HPLC trace for compound 21e (SGT1663). Rt = 17.41 min.

Figure B47: 1H NMR spectrum for compound 21f (SGT1651) in CDCl3 (500 MHz).
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Figure B48: 13C NMR spectrum for compound 21f (SGT1651) in (CD3)2SO (100 MHz).

Figure B49: HRMS spectrum for compound 21f (SGT1651). m/z found 516.1763 [M+H]+.
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Figure B50: HPLC trace for compound 21f (SGT1651). Rt = 13.03 min.

Figure B51: 1H NMR spectrum for compound 22a (SGT1652) in (CD3)2SO (500 MHz).
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Figure B52: 13C NMR spectrum for compound 22a (SGT1652) in (CD3)2SO (100 MHz).

Figure B53: HRMS spectrum for compound 22a (SGT1652). m/z found 512.1273 [M+H]+.
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Figure B54: HPLC trace for compound 22a (SGT1652). Rt = 13.03 min.

Figure B55: 1H NMR spectrum for compound 22g (SGT1653) in (CD3)2SO (500 MHz).
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Figure B56: 13C NMR spectrum for compound 22g (SGT1653) in (CD3)2SO (100 MHz).

Figure B57: HRMS spectrum for compound 22g (SGT1653). m/z found 539.1226 [M+H]+.
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Figure B58: HPLC trace for compound 22g (SGT1653). Rt = 17.77 min.

Figure B59: 1H NMR spectrum for compound 23a (SGT1654) in (CD3)2SO (500 MHz).
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Figure B60: 13C NMR spectrum for compound 23a (SGT1654) in (CD3)2SO (100 MHz).

Figure B61: HRMS spectrum for compound 23a (SGT1654). m/z found 526.1448 [M+H]+.
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Figure B62: HPLC trace for compound 23a (SGT1654). Rt = 17.86 min.

Figure B63: 1H NMR spectrum for compound 23g (SGT1655) in CDCl3 (500 MHz).
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Figure B64: 13C NMR spectrum for compound 23g (SGT1655) in CDCl3 (100 MHz).

Figure B65: HRMS spectrum for compound 23g (SGT1655). m/z found 553.1369 [M+H]+.
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Figure B66: HPLC trace for compound 23g (SGT1655). Rt = 17.82 min.

Figure B67: 1H NMR spectrum for compound 24a (SGT1657) in CDCl3 (500 MHz).
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Figure B68: 13C NMR spectrum for compound 24a (SGT1657) in CDCl3 (100 MHz).

Figure B69: HRMS spectrum for compound 24a (SGT1657). m/z found 540.1576 [M+H]+.
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Figure B70: HPLC trace for compound 24a (SGT1657). Rt = 18.26 min.

Figure B71: 1H NMR spectrum for compound 24g (SGT1656) in CDCl3 (500 MHz).
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Figure B72: 13C NMR spectrum for compound 24g (SGT1656) in CDCl3 (100 MHz).

Figure B73: HRMS spectrum for compound 24g (SGT1656). m/z found 567.1532 [M+H]+.
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Figure B74: HPLC trace for compound 24g (SGT1656). Rt = 13.02 min.

Figure B75: 1H NMR spectrum for compound 25a (SGT1659) in (CD3)2SO (500 MHz).
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Figure B76: 13C NMR spectrum for compound 25a (SGT1659) in (CD3)2SO (100 MHz).

Figure B77: HRMS spectrum for compound 25a (SGT1659). m/z found 540.1599 [M+H]+.
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Figure B78: HPLC trace for compound 25a (SGT1659). Rt = 13.03 min.

Figure B79: 1H NMR spectrum for compound 25g (SGT1661) in CD3OD (500 MHz).
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Figure B80: 13C NMR spectrum for compound 25g (SGT1661) in (CD3)2SO (100 MHz).

Figure B81: HRMS spectrum for compound 25g (SGT1661). m/z found 567.1539 [M+H]+.
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Figure B82: HPLC trace for compound 25g (SGT1661). Rt = 18.11 min.

Figure B83: 1H NMR spectrum for compound 26g (SGT1658) in CDCl3 (500 MHz).
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Figure B84: 13C NMR spectrum for compound 26g (SGT1658) in CDCl3 (100 MHz).

Figure B85: HRMS spectrum for compound 26g (SGT1658). m/z found 601.1373 [M+H]+.
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Figure B86: HPLC trace for compound 26g (SGT1658). Rt = 17.81 min.
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APPENDIX C
1H

and 13C NMR spectra as well as HPLC traces C1-C32 for Chapter 4

Figure C1: 1H NMR spectrum for compound 1 in CD3OD (400 MHz).
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Figure C2: 13C NMR spectrum for compound 1 in CD3OD (100 MHz).

Figure C3: 1H NMR spectrum for compound 2 in CD3OD (400 MHz).
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Figure C4: 13C NMR spectrum for compound 2 in CD3OD (100 MHz).

Figure C5: 1H NMR spectrum for compound 3 in CD3OD (400 MHz).
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Figure C6: 13C NMR spectrum for compound 3 in CD3OD (100 MHz).

Figure C7: 1H NMR spectrum for compound 4 in CDCl3 (400 MHz).

Figure C8: 13C NMR spectrum for compound 4 in CDCl3 (100 MHz).
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Figure C9: 1H NMR spectrum for compound 5 in CDCl3 (400 MHz).

Figure C10: 13C NMR spectrum for compound 5 in CDCl3 (100 MHz).
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Figure C11: 1H NMR spectrum for compound 6 in CDCl3 (400 MHz).

Figure C12: 13C NMR spectrum for compound 6 in CDCl3 (100 MHz).
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Figure C13: 1H NMR spectrum for compound 7 in CD3OD (400 MHz).

Figure C14: 13C NMR spectrum for compound 7 in CD3OD (100 MHz).
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Figure C15: 1H NMR spectrum for compound 8 in CDCl3 (400 MHz).

Figure C16: 13C NMR spectrum for compound 8 in CDCl3 (100 MHz).
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Figure C17: 1H NMR spectrum for compound 9 in CD3OD (400 MHz).

Figure C18: 13C NMR spectrum for compound 9 in CD3OD (100 MHz).
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Figure C19: 1H NMR spectrum for compound 10 in CD3OD (400 MHz).
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Figure C20: 13C NMR spectrum for compound 10 in CD3OD (100 MHz).
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Figure C21: 1H NMR spectrum for compound 11 in CD3OD (400 MHz).

Figure C22: 13C NMR spectrum for compound 11 in CD3OD (100 MHz).
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Figure C23: 1H NMR spectrum for compound 12 in CD3OD (400 MHz).

Figure C24: 13C NMR spectrum for compound 12 in CD3OD (100 MHz).

Figure C25: 1H NMR spectrum for compound 13 in CDCl3 (400 MHz).

398

Figure C26: 13C NMR spectrum for compound 13 in CDCl3 (100 MHz).

Figure C27: 1H NMR spectrum for compound 14 in CD3OD (400 MHz).
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Figure C28: 13C NMR spectrum for compound 14 in CD3OD (100 MHz).

Figure C29: 1H NMR spectrum for compound 15 in CDCl3 (400 MHz).
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Figure C30: 13C NMR spectrum for compound 15 in CDCl3 (100 MHz).

Figure C31: 1H NMR spectrum for compound 16 in CDCl3 (400 MHz).

401

Figure C32: 13C NMR spectrum for compound 16 in CDCl3 (100 MHz).
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APPENDIX D
1H

and 13C NMR spectra as well as HPLC traces D1-D59 for Chapter 5

Figure D1: 1H NMR spectrum for compound 3 in CD3OD (400 MHz).

Figure D2: 13C NMR spectrum for compound 3 in CD3OD (100 MHz).
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Figure D3: 1H NMR spectrum for compound 4 in CD3OD (400 MHz).

Figure D4: 13C NMR spectrum for compound 4 in CD3OD (100 MHz).

Figure D5: 1H NMR spectrum for compound 5 in CD3OD (400 MHz).
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Figure D6: 13C NMR spectrum for compound 5 in CD3OD (100 MHz).

Figure D7: 1H NMR spectrum for compound 6 in CD3OD (400 MHz).

Figure D8: 13C NMR spectrum for compound 6 in CD3OD (100 MHz).
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Figure D9: 1H NMR spectrum for compound 8 in CD3OD (400 MHz).

Figure D10: 13C NMR spectrum for compound 8 in CD3OD (100 MHz).

Figure D11: 1H NMR spectrum for compound 9 in CD3OD (400 MHz).
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Figure D12: 13C NMR spectrum for compound 9 in CD3OD (100 MHz).

Figure D13: 1H NMR spectrum for compound 10 in CD3OD (400 MHz).

Figure D14: 13C NMR spectrum for compound 10 in CD3OD (100 MHz).
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Figure D15: 1H NMR spectrum for compound 11 in CD3OD (400 MHz).

Figure D16: 1H NMR spectrum for compound 13 in CDCl3 (400 MHz).

408

Figure D17: 1H NMR spectrum for compound 14 in CDCl3 (400 MHz).

Figure D18: 13C NMR spectrum for compound 14 in CDCl3 (100 MHz).

Figure D19: 13H NMR spectrum for compound 15 in CDCl3 (400 MHz).

Figure D20: 13C NMR spectrum for compound 15 in CDCl3 (100 MHz).
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Figure D21: 1H NMR spectrum for compound 16 in CDCl3 (400 MHz).

Figure D22: 13C NMR spectrum for compound 16 in CDCl3 (100 MHz).
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Figure D23: HPLC trace for compound 16. Rt = 3.39 min.

Figure D24: 1H NMR spectrum for compound 17 in CD3OD (400 MHz).
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Figure D25: 13C NMR spectrum for compound 17 in CD3OD (100 MHz).

Figure D26: HPLC trace for compound 17. Rt = 3.46 min.
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Figure D27: 1H NMR spectrum for compound 18 in CD3OD (400 MHz).

413

Figure D28: 13C NMR spectrum for compound 18 in CD3OD (100 MHz).

414

Figure D29: HPLC trace for compound 18. Rt = 3.39 min.

Figure D30: 1H NMR spectrum for compound 19 in CD3OD (400 MHz).

415

Figure D31: 13C NMR spectrum for compound 19 in CD3OD (100 MHz).

Figure D32: HPLC trace for compound 19. Rt = 15.41 min.
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Figure D33: 1H NMR spectrum for compound 20 in CD3OD (400 MHz).

Figure D34: 13C NMR spectrum for compound 20 in CD3OD (100 MHz).
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Figure D35: HPLC trace for compound 20. Rt = 3.32 min.

Figure D36: 1H NMR spectrum for compound 21 in CD3OD (400 MHz).

418

Figure D37: 13C NMR spectrum for compound 21 in CD3OD (100 MHz).

Figure D38: HPLC trace for compound 21. Rt = 16.06 min.

419

Figure D39: 1H NMR spectrum for compound 22 in CDCl3 (400 MHz).

Figure D40: 13C NMR spectrum for compound 22 in CDCl3 (100 MHz).
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Figure D41: HPLC trace for compound 22. Rt = 3.12 min.

Figure D42: 1H NMR spectrum for compound 23 in CD3OD (400 MHz).

421

Figure D43: 13C NMR spectrum for compound 23 in CD3OD (100 MHz).

Figure D44: HPLC trace for compound 23. Rt = 16.82 min.
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Figure D45: 1H NMR spectrum for compound 24 in CD3OD (400 MHz).

Figure D46: 13C NMR spectrum for compound 24 in CD3OD (100 MHz).

423

Figure D47: HPLC trace for compound 24. Rt = 3.47 min.

Figure D48: 1H NMR spectrum for compound 25 in CD3OD (400 MHz).

424

Figure D49: 13C NMR spectrum for compound 25 in CD3OD (100 MHz).

Figure D50: HPLC trace for compound 25. Rt = 3.45 min.

425

Figure D51: 1H NMR spectrum for compound 26 in CD3OD (400 MHz).

Figure D52: 13C NMR spectrum for compound 26 in CD3OD (100 MHz).

426

Figure D53: HPLC trace for compound 26. Rt = 3.46 min.

Figure D54: 1H NMR spectrum for compound 27 in CDCl3 (400 MHz).

427

Figure D55: 13C NMR spectrum for compound 27 in CDCl3 (100 MHz).

Figure D56: HPLC trace for compound 27. Rt = 2.85 min.

428

Figure D57: 1H NMR spectrum for compound 28 in CD3OD (400 MHz).

429

Figure D58: 13C NMR spectrum for compound 28 in CD3OD (100 MHz).

430

Figure D59: HPLC trace for compound 28. Rt = 3.14 min.
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